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ABSTRACT 
 
 
The possible presence of veterinary drug residues and other contaminants in 
edible tissues and even food products is one of the key issues for food safety 
which arouses great public concern. The main objective of this thesis was the 
development of sensitive, selective, robust and effective analytical methods for the 
determination of veterinary drugs in food of animal origin using liquid 
chromatography hyphenated with mass spectrometric techniques. 
Initially, an extended review of the veterinary drug classes and the existing 
methodologies  for their determination is presented. The experimental section of 
the thesis is constituted of four parts: (1) Multi-residue determination of seventeen 
sulfonamides and five tetracyclines in fish tissue using a multi-stage LC-ESI-
MS/MS approach based on advanced mass spectometric techniques (Chapter 3), 
(2) Qualitative multi-residue screening methods for 143 veterinary drugs and 
pharmaceuticals in milk and fish tissue using Liquid Chromatography Quadrupole-
Time-Of-Flight Mass Spectrometry (Chapter 4), (3) Multi-residue determination of 
115 veterinary drugs and pharmaceutical residues in milk powder, butter, fish 
tissue and eggs using Liquid Chromatography-Tandem Mass Spectrometry (LC-
MS/MS) (Chapter 5) and Multiresidue / Multiclass Determination Of 76 Veterinary 
Drugs And Pharmaceuticals In Bovine Muscle Tissue By Hydrophilic Interaction 
Liquid Chromatography-Tandem Mass Spectrometry (HILIC-MS/MS) (Chapter 6). 
It is our strong belief that these studies will constitute a step forward in multiresidue 
veterinary drug analysis, providing rapid and reliable analytical results.  
 
 
 
 
 
 
SUBJECT AREA: Analytical Chemistry 
KEYWORDS: Veterinary drugs, LC-MS/MS, LC-QTOF MS, multi-residue methods, food 
matrices  
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ΠΕΡΙΛΗΨΗ 
 
Η πιθανή παρουσία υπολειμμάτων κτηνιατρικών φαρμάκων και άλλων ρυπαντών σε 
βρώσιμους ιστούς  και στα προϊόντα διατροφής είναι ένα από τα βασικά θέματα για την 
ασφάλεια των τροφίμων που προκαλεί μεγάλη ανησυχία στην κοινή γνώμη. Ο κύριος 
στόχος της παρούσας διπλωματικής εργασίας ήταν η ανάπτυξη ευαίσθητων, 
εκλεκτικών, ανθεκτικών και αποτελεσματικών αναλυτικών μεθόδων για τον 
προσδιορισμό κτηνιατρικών φαρμάκων σε τρόφιμα ζωικής προέλευσης με τη χρήση 
υγροχρωματογραφίας συζευγμένης με τεχνικές φασματομετρίας μάζας. 
Αρχικά παρουσιάζεται μια εκτεταμένη ανασκόπηση των κατηγοριών των κτηνιατρικών 
φαρμάκων και των υπάρχοντων μεθόδων για τον προσδιορισμό τους. Το πειραματικό 
μέρος της διατριβής αποτελείται από τέσσερα μέρη: (1) Ανάπτυξη ταχέων μεθόδων 
διαλογής (screening) για τον προσδιορισμό μη στοχευμένων-ενώσεων σε ζωικούς 
ιστούς με χρήση προηγμένων τεχνικών σάρωσης διαδοχικής φασματομετρίας μαζών 
συζευγμένης με υγροχρωματογραφία (Κεφάλαιο 3), (2) Ανάπτυξη πολυ - 
υπολειμματικής μεθόδου ταυτόχρονου προσδιορισμού 143 κτηνιατρικών φαρμάκων 
και φαρμακευτικών προϊόντων σε γάλα και ιστό ψαριού με LC-QTOF-MS (Κεφάλαιο 
4), (3) Ανάπτυξη πολυ - υπολειμματικής μεθόδου ταυτόχρονου προσδιορισμού 115 
κτηνιατρικών φαρμάκων και φαρμακευτικών καταλοίπων σε σκόνη γάλακτος, βούτυρο, 
ιστό ψαριού και αυγό χρησιμοποιώντας υγροχρωματογραφία υψηλής απόδοσης 
συζευγμένης με διαδοχική φασματομετρία μαζών (Κεφάλαιο 5) και Ανάπτυξη πολυ - 
υπολειμματικής μεθόδου προσδιορισμού 76 κτηνιατρικών καταλοίπων και 
φαρμακευτικών ουσιών σε ζωικούς ιστούς με υγροχρωματογραφία υδρόφιλων 
αλληλεπιδράσεων συζευγμένης με διαδοχική φασματομετρία μαζών (HILIC-MS/MS, 
Κεφάλαιο 6). 
 Πεποίθησή μας είναι ότι οι μελέτες αυτές θα αποτελέσουν ένα βήμα προς τα εμπρός 
στην πολυ-υπολειμματική ανάλυση κτηνιατρικών φαρμάκων παρέχοντας γρήγορα και 
αξιόπιστα αναλυτικά αποτελέσματα. 
 
 
ΘΕΜΑΤΙΚΗ ΠΕΡΙΟΧΗ: Αναλυτική Χημεία 
ΛΕΞΕΙΣ ΚΛΕΙΔΙΑ: Κτηνιατρικά φάρμακα, LC-MS/MS, LC-QTOF MS, πολύ-
υπολειμματικές μέθοδοι, τρόφιμα ζωικής προέλευσης 
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CHAPTER 1. 
Veterinary drug residues and the role of analytical chemistry 
 
1.1 Introduction 
Since always, animal breeding and agriculture have been major human activities, 
but nowadays they have been evolved into an important economic activity and they 
have a clear impact on food safety. Over the years, increasing interest has been 
directed toward maximizing the quantity of food product and at the same time 
reducing the cost. It is of vital importance to cover the needs for food supplies of an 
increasing world population, and also comply with legal limits regarding 
contaminants and veterinary drugs used. Thus, new practices in animal breeding 
have been designed by controlling various factors such as genetics, nutrition, 
health, management and the environmental conditions. 
During the last decades, a large number of veterinary drugs has been used at 
therapeutic levels in the systems of livestock breeding in order to improve animal 
health and prevent stress-induced animal death but also as growth promoters for 
intensive animal production [1]. Antibacterials (including sulfonamides, 
tetracyclines, beta-lactams, macrolides etc) are widely used by farmers to fight 
against bacterial infections [2, 3]. Furthermore, other families of veterinary drugs, 
such as anthelmintics and coccidiostats, are used for the treatment of parasitic 
diseases and coccidiosis (an infectious disease caused by a microscopic 
protozoan parasite), respectively [4, 5]. 
Their improper use, non-respect of withdrawal periods, and cross-contamination 
can lead to the presence of residues of veterinary drugs, mainly antimicrobial 
agents, in food of animal origin. These residues may include the non-altered parent 
compound as well as metabolites and/or conjugates, and may have direct toxic 
effects on consumers, e.g. allergic reactions in hypersensitive individuals. 
Moreover, indirect problems in clinical treatment maybe caused through induction 
of resistant strains of bacteria (development of bacterial resistance) [6-8]. 
As a result increasing concern has been expressed for the safeguarding of the 
public health. In that direction, several associations and international systems of 
25 
 
legal control are working on the quality assurance and control of the animal 
products entering the food supply. 
 
1.2 Classification of veterinary drugs 
 
1.2.1 Antibacterials 
Antibacterial agents can be classified based on their mechanism of action, 
chemical structure, spectrum of activity or source. Most commonly, the 
classification is based on the chemical structures, which can provide information on 
chemical, physical and biological properties. The classes are: aminoglycosides, 
amphenicols, β-lactams (cephalosporins & penicillins), lincosamides, macrolides, 
nitrofurans, quinolones, sulfonamides, tetracyclines and miscellaneous. 
 
1.2.1.1 Aminoglycosides 
Aminoglycosides are broad-spectrum antibiotics isolated from Streptomyces and 
Micromonospora bacteria that exert their antibacterial effect by targeting the 
bacterial ribosome, thus inhibiting protein synthesis [9].  Their structure contains 
two or more aminosugars linked by glycosidic bond to an aminocyclitol group, 
which is 2-deoxystreptamine in most aminoglycosides or streptidine in 
streptomycin and dehydrostreptomycin.  Most aminoglycosides are mixtures of 
several very similar components differing only in degree of methylation or 
stereochemistry of the sugar units.  Closely related aminocyclitols, such as 
spectinomycin or apramycin, that also contain an aminocyclitol group but slightly 
differ in structure, are generally considered part of the aminoglycoside class of 
antibiotics. They are administered both therapeutically and prophylatically to treat 
cattle, swine and poultry [10]. Aminoglycosides are not absorbed orally and so are 
usually administered via intramuscular injection. Residues of these drugs tend to 
concentrate in the kidney as they are generally excreted through the urinary tract 
[11]. 
 
1.2.1.2 Amphenicols 
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Amphenicols (chloramphenicol, florfenicol, and thiamphenicol) are broad-spectrum 
antibiotics with a phenylpropanoid structure, active against a variety of pathogens. 
They function by blocking the enzyme peptidyl transferase on a ribosome subunit 
of bacteria [9]. Chloramphenicol was first isolated from cultures of Streptomyces 
venezuelae but is now produced synthetically. It readily forms conjugates with 
glucuronic acid in the liver of treated animals and therefore appears in kidney 
mainly as the corresponding glucuronide [12]. However due to the reports of 
serious side effects (mainly aplastic anemia) in humans, chloramphenicol was 
banned in the EU, the USA and Canada in the 1990s.  Structurally similar 
thiamphenicol and florfenicol, in which the nitro group of chloramphenicol is 
replaced by a methyl sulphonyl group (in florfenicol, a hydroxyl group is also 
replaced by a fluorine), have been permitted as chloramphenicol substitutes. 
 
1.2.1.3 β-Lactams 
β-Lactam antibiotics are probably the most widely applied antimicrobial drugs in 
current veterinary practice.  They are divided into two subcategories: penicillins 
and cephalosporins. These antibacterials have as their basic structure a 
thiazolidine ring, a β-lactam ring and variable side chains that account for the major 
differences in their chemical and pharmacological properties [13]. In penicillins, the 
ring is fused to a five-member thiazolidine ring, while for cephalosporins the ring is 
fused to a six-member ring. The β-lactam ring is responsible for the antimicrobial 
activity and also for a reduced stability of β-lactams.  They are thermolabile, 
unstable in alcohols and acidic conditions [14]. 
Their mode of action is based on inhibiting bacterial cell wall biosynthesis, which 
has lethal effect on bacteria. However, bacteria have shown resistant against β-
lactam antibiotics [15]. Penicillins are derived from Penicillium fungi and are 
historically significant because they are the first drugs that were effective against 
many previously serious diseases. They are used in the treatment of bacterial 
infections caused by susceptible, usually Gram-positive, organisms [16]. 
Cephalosporins are originally derived from the fungus Acremonium, previously 
known as Cephalosporium. First-generation cephalosporins were active 
predominantly against Gram-positive bacteria but successive generations have 
increased activity against Gram-negative bacteria, as well. 
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1.2.1.4 Macrolides and lincosamides 
Macrolides are basic macrocyclic antibiotics that have a common 14-, 16-, or 17-
membered ring in their structure, which is linked by glycoside bonding to one or 
more molecules of deoxy sugars, usually cladinose and desosamine. They are 
widely used in veterinary practice to treat respiratory diseases and to promote 
growth and are usually used against Gram-positive organisms that are resistant to 
penicillin treatment. Erythromycin and tylosin are the drugs most commonly given 
to food-producing animals. Macrolide antibiotics are weak bases readily soluble in 
common organic solvents [17]. Lincosamides (lincomycin, clindamycin, and 
pirlimycin) are monoglycosides with an amino acid side chain. The first lincosamide 
to be discovered was lincomycin, isolated from Streptomyces lincolnensis. They 
are highly effective against a broad spectrum of gram-positive and anaerobic 
bacteria.  Both macrolides and lincosamides target the bacterial ribosome and 
inhibit protein synthesis [13, 14, 17].   
 
1.2.1.5 Nitrofurans 
Nitrofurans are synthetic antibacterial compounds, which contain a characteristic 5-
membered nitrofuran ring in their structure. They are used to treat infections 
caused by protozoa or by certain Gram-positive or Gram-negative bacteria and do 
not contribute to the development of antimicrobial resistance [9, 13]. The precise 
mechanism by which nitrofurans exert their antimicrobial effects is not completely 
clarified, but it is based on inhibition of enzyme systems [18]. They are used in the 
poultry industry as well as for the treatment of cattle and pigs and residues of them 
have also been found in farm-raised shrimp and honey [11]. However due to their 
toxicological effects (carcinogenity and mutagenicity), nitrofurans (nitrofurazone, 
nitrofurantoin, furaltadone, furazolidone and later also nifursol) were banned in 
many countries, including the US, the EU, Japan and Australia, starting in mid-
1990s to early 2000s. 
 
1.2.1.6 Quinolones 
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Quinolones are broad spectrum synthetic antibiotics (derived from 3-
quinolenecarboxylic acid) that are widely used in aquaculture and poultry farming. 
They prevent bacterial DNA from unwinding and duplicating. 
 The first generation of quinolones includes mainly oxolinic acid and nalidixic acid 
that are effective only against Gram-negative bacteria, while the second-generation 
quinolones are fluoroquinolones, such as enrofloxacin, danofloxacin and 
ciprofloxacin. Fluoroquinolones contain a fluorine atom at the C-3 position and a 
piperazinyl group at the C-7 position, which increases the activity against Gram-
positive and Gram-negative bacteria, respectively, and the majority of quinolones 
in clinical use belong to this subclass [19]. Quinolones are also highly important 
human drugs, and their widespread use in food-producing animals is of high 
concern due to the recent evidence of development of bacterial resistance to these 
antibiotics.  
 
1.2.1.7 Sulfonamides 
Sulfonamides are synthetic antibiotics that are used for prophylactic and 
therapeutic treatment of bacterial and protozoal infections. They share a common 
chemical nucleus that comes from sulfanilamide and is responsible for the 
exhibited antimicrobial activity [14]. They have been used clinically for more than 
50 years, and during this time over 5000 derivatives have been tested. 
Sulfonamides show large variations in polarity and exhibit amphoteric properties. In 
bacteria, antibacterial sulfonamides act as competitive inhibitors of the enzyme 
dihydropteroate synthetase (DHPS), an enzyme involved in folate synthesis 
(vitamin B9). As such, the microorganism will be "starved" of folate and die. On the 
contrary, humans, acquire folate through the diet [20]. Sulfonamides are often 
administered together with synthetic diaminopyrimidines, such as baquiloprim, 
ormetoprim or trimethoprim, which act as potentiators of sulfonamides. 
 
1.2.1.8 Tetracyclines 
Tetracyclines are broad-spectrum antibiotics that consist of a substituted 2-
napthacenecarboxamide molecule. They are widely used in veterinary medicine for 
cost-effective prophylactic and therapeutic treatment and also as growth-promoting 
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substances in cattle and poultry but their usefulness has been reduced with the 
onset of bacterial resistance. Tetracycline antibiotics are protein synthesis 
inhibitors, inhibiting the binding of aminoacyl-tRNA to the mRNA-ribosome complex 
[21]. 
 
1.2.1.9 Other antibacterials 
Unlike the compounds in the preceding groups, several individual antibacterials 
have heterogenous nature. A tabulated survey of their properties is not possible. 
However, there are a number of subgroups including diaminopyrimidines 
quinoxalines, pleuromutilins, peptides or novobiocin and dapsone that merit 
discussion. 
Diaminopyrimidines are a class of organic chemical compounds that include two 
amine groups on a pyrimidine ring. They include many dihydrofolate reductase 
inhibitor drugs and the antibiotics iclaprim and trimethoprim. Trimethoprim blocks 
folic acid synthesis in bacteria at a step later than the sulfonamides [22].  
Carbadox and olaquindox are both quinoxaline-1, 4- dioxide antibacterials that are 
synthetically produced. They are light-sensitive compounds and require special 
handling precautions during analysis to prevent their decomposition. Metabolism 
studies have shown that carbadox is rapidly converted into its mono-oxy and 
desoxy metabolites whereas quinoxaline-2-carbonic acid is considered to be the 
last remaining major metabolite and may serve as a marker residue. Both 
carbadox and its desoxy metabolite are carcinogenic compounds [23]. 
Pleuromutilin and its derivatives are antibacterial drugs that inhibit protein 
synthesis in bacteria by binding to the peptidyl transferase component of the 50S 
subunit of ribosomes. This class of antibiotics includes retapamulin, valnemulin and 
tiamulin [24]. Among the peptides, the main antibacterials are avoparcin, 
bacitracin, efrotomycin, polymyxin and virginiamycin. Most are complex 
multicomponent compounds that possess large peptide molecules that often 
contain D-amino acids in contrast to naturally occurring proteins, which are 
composed of L-amino acids.These peptides disrupt both Gram positive and Gram 
negative bacteria by interfering with cell wall and peptidoglycan synthesis [13]. 
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Novobiocin, also known as albamycin or cathomycin, is an aminocoumarin 
antibiotic that is produced by the actinomycete Streptomyces niveus. 
Aminocoumarins are very potent inhibitors of bacterial DNA gyrase, with higher 
potency than fluoroquinolones, but at a different site on the enzyme. Finally, 
dapsone (diamino-diphenyl sulfone), according to its chemical structure, is not 
comprehended in any antibacterial class but according to its mechanism of action, 
it falls onto the sulfonamide group. As an antibacterial, dapsone inhibits bacterial 
synthesis of dihydrofolic acid, via competition with para-aminobenzoate for the 
active site of dihydropteroate synthetase. It is used for the treatment of 
Mycobacterium leprae infections (leprosy) and for a second-line treatment against 
Pneumocystis jirovecii [13]. 
 
1.2.2 Anthelmintics 
Anthelmintics (also called parasiticides, endectocides and nematocides) are drugs 
used to treat parasitic warm infections, including flatworms (tapeworms and flukes) 
and roundworms (nematodes), which usually infect human, livestock and crops, 
affecting food production. 
They are usually classified into several types on the basis of similar chemical 
structure and mode of action. Basically, three main families can be distinguished: 
benzimidazoles, nicotinic receptor agonists and macrocyclic lactones 
(avermectines and milbemycins) [25]. The benzimidazoles consist of a ring system 
composed of a benzene ring fused with an imidazole ring. They exert their effect by 
binding selectively and with high affinity to the beta-subunit of helminth microtubule 
protein. The target site of the nicotinic agonists (e.g. levamisole, 
tetrahydropyrimidines) is a pharmacologically distinct nicotinic acetylcholine 
receptor channel in nematodes. The macrocyclic lactones (e.g. ivermectin, 
moxidectin) are a group of complex compounds isolated from Streptomyces 
avermitilis. They act as agonists of a family of invertebrate-specific inhibitory 
chloride channels that are activated by glutamic acid [26].  
The most frequently used anthelmintic compounds are levamisole, several 
compounds from the benzimidazole group (albendazole, cambendazole, 
fenbendazole, oxfendazole and thiabendazole) and ivermectin [1]. Other important 
anthelmintics are dichlorvos and haloxon (organophosphorus cholinesterase 
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antagonists) and piperazine (gamma-amino-butyric acid agonist at receptors on 
nematode muscles causing flaccid paralysis). Praziquantel has a selective effect 
on the tegument of trematodes and increases permeability of calcium while 
salicylanilides: rafoxanide, oxyclozanide, brotianide and closantel and the 
substituted phenol, nitroxynil, are proton ionophores [27]. 
Anthelmintic resistance is wide-spread and a serious threat to effective control of 
helminth infections and, therefore, new classes of anthelmintics with new new 
modes of action are being proposed. Thus, a new anthelmintic class named 
aminoacetonitrile derivative (AAD) has been developed, which is well tolerated and 
has low toxicity to mammals. The AAD monepantel is effective against some 
nematodes resistant to other drugs because its mode of action, which is based on 
a nematode-specific clade of acetylcholine receptor subunits, is different [24]. 
 
1.2.3 Beta-agonists 
B-agonists are synthetic phenethanolamine compounds and were originally used 
as therapeutic treatments for asthma and preterm labour in humans [28]. However,  
these  compounds  have  also  been  misused  as  nutrient  repartitioning  agents  
in livestock,  where  they  served  to  divert  nutrients  from  fat  deposition in  
animals  to  the  production  of  muscle  tissues [29]. B-agonists have been banned 
as growth promoters in many countries including European Union countries and 
China because of their well-documented adverse effects on human health. 
Because of diversified analogues and rapid metabolism, highly sensitive analytical 
methods for quantification and confirmation of trace residues in cattle tissues are 
necessary for surveillance of feeding processes and food animal origin [30]. 
 
1.2.4 Coccidiostats 
Coccidiostats are antiprotozoal agents that act upon Coccidia parasites by 
inhibiting reproduction and retarding the development of the parasite in a host cell 
[11, 31].  Even  minor lesions  of  the  intestinal  wall  due  to  coccidiosis  can  lead  
to  poorer growth  of  the  animal  and  lower  feed  conversion,  reducing  
economic  viability.  They are most commonly used in poultry populations by 
addition in the feed at the authorized levels and observing the prescribed hygiene 
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requirements. The  disease  can  also  occur  in  other  food  producing animals  
including  pigs, calves, and  lambs  [5]. 
Coccidiostats can be grouped in two major classes: the polyether ionophore 
antibiotics (monensin, lasalocid, maduramycin, narasin, salinomycin and 
semduramycin) and the nonpolyether ionophores (often reffered as synthetic 
compounds or chemicals). Polyether ionophore antibiotics are produced by 
fermentation with several strains of Streptomyces spp. and Actinomadura spp. 
They have both anticoccidial and antibacterial activity and they are also used as 
growth-promoting agents and as an active compound against clostridiosis [31]. 
 
1.2.5 Hormones  
 
1.2.5.1 Anabolic steroids 
Anabolic steroids (ASs) have been extensively used in husbandry practice with 
beneficial effects such as animal growth promotion and feed efficiency. The use of 
anabolic steroids for growth promotion purposes in meat producing animals results 
in an improvement in muscle growth and more lean meat. However, 
toxicological/epidemiological studies show that there are harmful effects to 
consumers; as a result the public health is placed in risk. As a consequence, the 
use of anabolic steroids for fattening purposes has been banned in the European 
Union since 1986 [32]. 
 
1.2.5.2 Corticosteroids 
Endogenous corticosteroids are produced by the adrenal cortex (e.g. cortisol) and 
have important effects on a variety of metabolic events, including glucose and 
protein metabolism. The overall effect is to increase the blood glucose level by 
stimulating hepatic synthesis of glucose from amino acids [33]. Nowadays, several 
exogenous corticosteroids (prednisolone, dexamethasone, betamethasone, 
methylprednisolone) are authorized for therapy in both human and veterinary 
practices. They are widely used to combat inflammatory diseases in food-
producing animals, but they are also frequently employed as growth promoters. 
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The European Union banned their administration for fattening purposes in 1996 
[34]. 
 
1.2.5.3 Thyreostats 
Thyreostats are orally active drugs, which upon administration disturb the normal 
metabolism of the thyroid gland by inhibiting the production of the hormones 
triiodothyronine and thyroxine. This goitrogenic activity may be attributed to the 
presence of athiocarbamidegroup. In livestock,the administration of thyreostats 
results in a considerable live weight gain, mainly caused by increased water 
retention in edible tissue and augmented filling of the gastrointestinal tract [35]. 
Consequently, these growth promoting agents negatively affect the meat quality of 
treated animals. In addition, xenobiotic thyreostats are listed as compounds with 
teratogenic and carcinogenic properties and thus pose a possible human health 
risk. These arguments led in 1981 to a ban on their use for animal production in the 
European Union [36]. 
 
1.2.6 Tranquilizers 
Tranquilizers are administered to animals for sedation prior to anesthesia before 
transport to the market. Stress in animals is known to produce a deterioration of 
meat quality and pigs, in particular, easily become stressed during transport [1]. 
Some tranquilizers have analgesic effects (α2-agonists) but these are the exception 
since analgesia is not a hall mark of tranquilizers [37].  
Tranquilizers are classified into two broad categories in veterinary medicine: major 
and minor tranquilizers. Major tranquilizers include phenothiazides (acepromazine, 
promazine, and chlorpromazine), butyrophenones (azaperone, droperidol) and α2-
agonists (xylazine, detomidine, medetomidine, dexmedetomidine etc.) while minor 
consist of benzodiazepines (diazepam, midazolam, zolazepam) [37]. Most 
tranquillizers are rapidly metabolized in the animal’s body and any residues are 
concentrated in the liver and/or kidney. These organs should be discarded if 
tranquillizers have been administered shortly before slaughter [1]. 
 
 
34 
 
1.3 Residual veterinary drugs in food of animal origin 
Organic contaminants that might be present in food, whether from natural or 
anthropogenic origin, can be divided into four main categories, namely pesticides, 
persistent environmental chemicals, naturally occurring toxins and veterinary 
drugs. In the field of food safety, scientists and regulatory agencies need to identify 
any potential risks to consumers related to the consumption of food [2]. 
Taking into consideration the inevitable use of veterinary drugs and the assurance 
of the public health, there are several measures required in order to eliminate the 
possibility of contamination; extensive analytical control of food, determination of 
the sources of contamination and strict legislation [38]. 
The veterinary drug residues in food are a crucial issue in food safety and thus in 
public health. The concept of zero tolerance, which refers to the total absence of 
residues, is unrealistic, since the power of analytical chemistry is not limitless. For 
quite some time, this concept seemed to guarantee the highest degree of food 
safety as residues could not be found in meat, milk and eggs, due to high detection 
limits. As the power of analytical chemistry increases, the types of chemicals that 
can be detected increase, and the limits of concentration at which they can be 
measured are continually reduced. Analytical Chemistry is the mean to expand and 
refine our ever-changing perspective of food safety. Since it is impossible to 
entirely abandon the use of veterinary drugs, a complete risk assessment must be 
performed in order to evaluate the possible hazards against public health. 
 
1.3.1 Risk evaluation 
Although residues from veterinary drugs in food products of animal origin are 
generally considered safe and well tolerated, they have been associated with a 
wide range of adverse effects and can represent a risk for consumers. However, 
the adverse effects from consuming food of animal origin, like meat, milk and eggs, 
are not very probable since the residues are present at very low concentrations, 
and thus acute human toxicity is rather unlikely [13]. 
The main side-effect of the presence of antibacterial residues in food is the 
development of resistant bacterial strains. Such resistance could be transferred to 
other bacteria, pathogenic or not, and can be related to the appearance of 
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antibacterial-resistant microorganisms [8]. Although increased bacterial resistance 
has several causes, two are the main key factors; the overuse and misuse of 
antibiotics. Such resistant bacteria may enter the human food supply and cause 
infectious diseases that can no longer be successfully treated by the antibacterial 
agent. Furthermore, some substances must receive particular attention due to 
allergic reactions [39]. 
Although prophylactic medication with coccidiostats in the feed remains the major 
way of preventing coccidiosis, the development of resistance by the coccidium to 
all medications available has been the greatest problem associated with this 
control [31]. Also, anthelmintic resistance has become entrenched as a perennial 
programme favourite at any gathering of veterinary parasitologists. Anthelmintic 
resistance is likely to develop wherever anthelmintics are frequently used and be 
detected if it is investigated. Worm count or egg count reduction after treatment are 
useful for the detection of all types of anthelmintic resistances. More economical, 
faster and more sensitive in vitro assays for the detection of anthelmintic resistance 
have been developed [40]. 
Finally, growth promoters (β-agonists, hormones) have been banned in many 
countries, including European Union countries, because of their well-documented 
adverse effects on human health, such as food poisoning and cardiovascular and 
central nervous diseases [16,41], as well as their teratogenic and carcinogenic 
properties [36]. 
Risk assessments of veterinary drugs residing in foods are performed by following 
the integrative steps of hazard identification, hazard characterization, exposure 
assessment, and risk characterization [42]. At the step of hazard identification, 
known or potential adverse health effects in humans are identified, which are 
induced by a veterinary drug or its metabolites that may be present in a particular 
food. 
Toxicological evaluations, toxicokinetic assessments, and cancer/non-cancer 
evaluations are mainly performed for hazard identification. At the hazard 
characterization step, the characteristics of the adverse effects associated with a 
veterinary drug or its metabolites present in food are demonstrated. In addition, the 
levels that clearly do not cause any adverse effects on human health are evaluated 
according to dose-response relationships [43].  
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Maximum acceptable or tolerable levels for chemicals which are neither genotoxic 
nor carcinogenic, such as acceptable daily intake (ADI), reference dose (RfD), 
tolerable daily intake (TDI) and provisional tolerable weekly intake (PTWI) for 
contaminants which may accumulate in the body, are set. Dose–response 
information is essential for quantifying an adverse health effect. NOAEL (No 
Observed Adverse Effect Level) is the highest dose of a substance which causes 
no detectable adverse alteration in line with defined treatment conditions. ADI is 
generated using conservative statistical extrapolation to humans [44]. The ADI is 
an estimate of the residue, expressed in term of mg or mg per kg bodyweight, 
which can be ingested daily over a lifetime with a health risk to the consumer. In 
calculating an MRL, the ADI, the residue depletion patterns of a compound in the 
edible tissues of a particular food-producing animal and the theoretical food intakes 
are taken into account [45]. 
In case the chemical is evaluated as a complete carcinogen, which means a 
genotoxic carcinogen, it is recommended to operate a policy of prohibition and 
control levels “as low as reasonably practicable” [42]. 
Furthermore, toxicity assays involve the determination of acute toxicity, designated 
as LD50 (the dose that will kill 50% of the animals in a test series), subacute 
toxicity, determined by animal feeding tests lasting four weeks and chronic toxicity, 
assessed by animal feeding tests lasting 6 months to 2 years. In chronic toxicity 
tests attention is especially given to the occurrence of carcinogenic, mutagenic and 
teratogenic symptoms [38]. 
 
1.3.2 Legislation 
In order to ensure the safety of the consumers, many agencies worldwide regulate 
the use of antimicrobials, particularly in food-animal species. The US Department 
of Agriculture’s (USDA) Food Safety Inspection Service (FSIS) is responsible for 
the safety of meat, poultry, and egg products in the USA. The European Food 
Safety Authority (EFSA) is the keystone of the European Union’s (EU) risk 
assessment regarding food and animal feed safety. The Codex Alimentarius 
Commission (created by the FAO and WHO) develops food standards, guidelines 
and related texts such as codes of practice under the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA). Moreover, VICH, a trilateral (EU-Japan-
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USA) program aimed at harmonizing technical requirements for veterinary product 
registration was officially launched in April 1996. 
The European Union (EU) has strictly regulated controls on the use of antibacterial 
agents, particularly in food–animal species, by publishing different Regulations and 
Directives. The use of veterinary drugs was regulated through EU Council 
Regulation 2377/90/EC [46], which has been repealed by Council Regulation 
470/2009/EC [47] and describes the procedure for establishing Maximum Residue 
Limits (MRLs) for veterinary medicinal products in foodstuffs of animal origin. 
In 1996, the prohibition of the use of growth promoters is laid down in Council 
Directives 96/22/EC and 96/23/EC, which also contain guidelines for controlling 
veterinary drug residues in animals and their products with all the necessary 
information to set up national monitoring plans [48, 49].  In regulation (EC) No 
1831/2003 the European Union (EU) has prohibited the use of antimicrobials as 
feed additives  but allows the usage of anticoccidial drugs to allow for the 
prevention of coccidiosis, a disease that may cause serious economical 
consequences [50]. EU-wide surveillance conducted during 2009, reported that 
coccidiostats continue to be a problem with non-compliance rates of 2.05 and 
1.19% in poultry meat and eggs, respectively [5]. In response, the European Food 
Safety Authority set maximum levels (MLs) for 11 coccidiostats in edible tissues 
(including eggs) [51].  
Most recently, Regulation 37/2010/EC [52] lists pharmacologically active 
substances and their maximum residue level (MRL) in foodstuffs of animal origin, 
as well as compounds for which no MRL has been set because no hazard for 
public health has been observed. As regards the coccidiostat lasalocid, regulation 
37/2010/EC was amended in 2012 [53].  
The requirements for performance and validation of analytical methods employed 
in the official residues control for screening and confirmatory purposes are 
described in European Decision 2002/657/EC [54]. Validation shall demonstrate 
that the analytical method complies with the criteria applicable for the relevant 
performance characteristics. Different control purposes require different categories 
of methods. The following table determines which performance characteristic shall 
be verified for which type of method [54]. 
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Table 1.1:  European Decision’s 2002/657/EC requirements 
  
Detection 
limit CCß 
Decision 
limit 
CCα 
Trueness
/recovery 
Precision 
Selectivity/
specificity 
Applicability/ 
ruggedness/ 
Qualitative 
methods 
S + - - - + + 
C + + - - + + 
Quantitative 
methods 
S + - - + + + 
C + + + + + + 
S = screening methods; C = confirmatory methods; + = determination is mandatory. 
 
Amending the Decision 2002/657/EC as regards the setting of minimum required 
performance limits (MRPLs) for certain residues in food of animal origin, a 
Commission Decision, 2003/181/EC, was regulated [55].  
 
1.4 Analytical methodologies 
For all the reasons mentioned above, sensitive and reliable analytical methods for 
the determination of veterinary drug and pharmaceutical residues in food of animal 
origin are needed to ensure consumers’ safety. An emerging trend in drug residue 
analysis is the development of generic methods that are capable of monitoring a 
wide variety of compounds, belonging to different drug classes. This appears as a 
considerable challenge due to all the pre-mentioned reasons and, as a result, 
multiclass methods for veterinary drugs are still not so widespread although they 
are strongly required. An overview of the analytical methodologies developed so 
far for the multi-residue analysis of veterinary drugs in food matrices using liquid 
chromatography and mass spectrometric techniques is presented in Table 1.2. 
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Table 1.2: Applications in multi-residue analysis of veterinary drugs in food matrices. 
Compounds Matrix 
Sample preparation 
technique 
Stationary 
phase 
Mobile 
phase 
Detection-
identification 
Recoveries Reference 
 SAs (6), TCs 
(1), Qs (6) and 
other 
contaminants (5) 
shrimp 
extraction with 5% TCA 
in H2O (v/v) and 
cleanup with SPE  
Waters YMC 
Phenyl, 
(50×4mm, 3 
μm) 
A: 5% (v/v) 
ACN/H2O, 
with 0.1% 
formic acid, 
B: 85% (v/v) 
ACN/ H2O 
with 0.05% 
formic acid. 
LC–APCI-QIT-
MS
n
 
>40% (Sulfaquinoxaline) 
- >90% (Sulfamerazine)   
Li 2006b 
[56] 
Antibiotics (19), 
synthetic 
antibacterials 
(42), hormonal 
agents (20), 
ANTHs (35) and 
other 
contaminants 
(14)  
Bovine, 
porcine, 
chicken 
muscle 
extraction with ACN-
MeOH (95:5, v/v) and 
delipidation with n-
hexane saturated with 
ACN 
TSKgel 
ODS-100Z 
(150×2.1mm, 
5 μm) 
A: 10mM 
ammonium 
acetate 
containing 
0.3% acetic 
acid,  
B: ACN / 
MeOH  (2/8, 
v/v) 
LC-ESI-
MS/MS (+) 
and (-) 
46.3% (Ciprofloxacin) - 
117.7% 
(Desoxycarbadox) 
 Yamanda 
[57] 
SAs (15), TCs 
(5), Qs (4) and β-
LACTs (5) 
egg 
Homogeniztion with 
sodium succinate 
buffer and extraction-
phenyl 
cartridge 
column, 
A: 0.1% 
formic acid in 
H2O (v/v), B: 
LC-ESI-
MS/MS (+) 
<25% (Amoxicillin) - 80% 
(SAs) 
Heller 2006 
[58] 
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cleanup with SPE  (50×4mm, 3 
μm  silica) 
ACN  
TCs (7) and Qs 
(14) 
pig tissues 
extraction with EDTA-
McIlvaine buffer and 
cleanup with SPE 
Acquity 
UPLC BEH 
C18 
(100×2.1mm, 
1.7 μm) 
A: 
MeOH/ACN 
(v/v, 40:60), 
B: 0.2% 
formic acid  in 
H2O 
LC-ESI-
MS/MS (+) 
85.6% (Chlortetracycline) 
- 117.8% 
(Demeclocycline) 
[59]  
Shao 2007 
β-LACTs (3), 
LINCs (1), MCs 
(4), Qs (8), Sas 
(10), TCs (3), 
ANTHs (1) and 
other antibiotics 
(2) 
meat 
pre-homogeneization 
of the meat with EDTA 
–washed sand and 
PLE with H2O 
XTerra MS 
C18 
(100×2.1 
mm, 3.5 μm) 
A: 10mM 
formic acid in 
MeOH 
B: 10mM 
formic acid in 
H2O 
LC-ESI-
MS/MS (+) 
73% (Tetracycline) – 
93% (Flumequine)  
[60] 
Carretero 
2008 
TCs (4), Qs (9),  
MCs (4), β-
LACTs (7), SAs 
(14) and other 
antibiotics (1)  
chicken, 
porcine 
muscle 
extraction with MeOH - 
water (70:30, v/v) with 
EDTA, dillution 
Acquity 
UPLC BEH 
C18 
(100×2.1mm, 
1.7 μm) 
A: 1 mM 
oxalic acid 
with 0.2% 
formic acid  in 
H2O B: 0.1% 
formic acid in 
ACN. 
LC-ESI-
MS/MS (+) 
60.5% (Chlortetracycline) 
- 96.5% (Spiramycin) 
[61] Chico 
2008b 
 TCs (5), MCs honey liquid–liquid extraction Zorbax SB- A: 1mM LC-ESI- 24% (Streptomycin) - [62] 
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(7), AMGs (3), β-
LACTs (8), 
AMPs (2) and 
SAs (17) 
with ACN, 10% TCA in 
water (v/v) and NFPA - 
hydrolysis  
C18 
(50×2.1mm, 
1.8 μm) 
NFPA in H2O 
with 0.5% 
formic acid, 
B: 
ACN/MeOH 
(50/50, v/v) 
with 0.5% 
formic acid  
MS/MS (+) 226% (Neomycin) Hammel et 
al. 2008 
Qs (5), TCs (4), 
MCs (2), SAs (1), 
AMPs (1),  
AMGs (1), LINCs 
(1), COCs (1) 
and other 
contaminants (1) 
honey 
dissolution in water and 
cleanup with SPE  
Phenomenex 
Polar-RP 
Synergi 
(50×2mm, 4 
μm) 
ESI (+): A: 
0.1% formic 
acid in H2O, 
B: 0.1% 
formic acid in 
ACN,  
ESI (-): A: 
H2O, B: ACN 
LC-ESI-
MS/MS (+) 
and (-) 
29% (Erythromycin) - 
104% (Streptomycin) 
[63] 
 Lopez et 
al. 2008 
β-LACTs (16), 
SAs (10), MCs 
(10), AMGs (8), 
TCs (4) and Qs 
(10) 
milk 
extraction with ACN 
and 5% TCA aqueous 
solution 
Symmetry  
C18, 
(150×3.9mm, 
5 μm) 
A: 0.1% 
PFPA in H2O, 
B: ACN 
LC-ESI-
MS/MS (+) 
- 
[64] 
Gaugain-
Juhel. 2009 
TCs (4), SAs (4), 
Qs (4), β-LACTs 
(3) and MCs (4) 
muscle 
extraction with MeOH - 
water (70:30, v/v) with 
EDTA, dillution 
Genesis 
C18, 
(50×2.1mm, 
A: 0.2% 
formic acid 
containing 
LC-ESI-
MS/MS (+) 
68% (Ciprofloxacin, 
Difloxacin) - 95% 
(Oxytetracycline) 
[65] 
Granelli 
2009 
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4 μm) 0.1mM oxalic 
acid in H2O, 
B: ACN 
TCs (4), SAs 
(12), Qs (14), 
MCs (10), LINCs 
(3) and other 
antibiotics (1) 
milk 
extraction with 
McIlvaine buffer at pH 
4.0, TCA, cleanup with 
SPE  
C18 AQUA 
(150×2.1 
mm, 3 μm) 
A: 0.2% 
formic acid  in 
H2O, B: 0.2% 
formic acid  in 
ACN 
LC-ESI-
MS/MS (+) 
94% (Doxycycline) – 
112% (Tulathromycin) 
[66]  
Bohm 2009 
MCs (4), TCs (4), 
Qs (5), and SAs 
(4) 
honey 
dissolution in Na2EDTA 
and cleanup with SPE  
Acquity 
UPLC BEH 
C18 
(100×2.1mm, 
1.7 μm) 
A: MeOH, B: 
0.05% (v/v) 
formic acid in 
H2O 
LC-ESI - 
MS/MS (+) 
53 % (Erythromycin) - 
115% (Tylosin) 
[67] 
Martínez 
Vidal. 2009 
TCs (4), MCs (4), 
Qs (5), SAs (4) 
and ANTHs (8)  
egg 
Comparison of SE  - 
QuEChERS - SPE - 
MSPD  
Acquity 
UPLC BEH 
C18 
(100×2.1mm, 
1.7 μm) 
A: MeOH, B: 
0.05% (v/v) 
formic acid in 
H2O 
LC-ESI - 
MS/MS (+) 
 SEs’: 70.4% 
(Tetracycline) to 94.4% 
(Tilmicosin) 
[68]  
Garrido 
Frenich 
2010 
AMGs (3),  β-
LACTs (3),   TCs 
(4), LINCs (2), 
MCs (4), Qs (4), 
and SAs (4) 
chicken 
muscle 
extraction using (1:1, 
v/v) of 2% 
trichloroacetic acid in 
H2O – ACN followed by 
removing fat with 
hexane 
ZIC–HILIC 
(100×2.1 
mm, 3.5 μm) 
A: 50mM 
ammonium 
formate in 
H2O at pH 
2.5, B: ACN 
LC-ESI - 
MS/MS (+) 
57% (Erythromycin) - 
86% (Danofloxacin) 
[69] 
Chiaochan 
et. al 2010 
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Qs (4), TCs (3), 
MCs (9), β-
LACTs (4), SAs 
(9), AMPs (3),  
AMGs (6) and 
NSAIDs (1)  
amimal 
tissue 
solid-liquid extraction 
with ACN / H2O (86:14, 
v/v) and defatting with 
hexane 
Atlantis 
dC18 
(20×3.9 mm, 
3 μm) and 
ZIC–HILIC 
(50×2.1mm, 
5 μm) for 
AMGs 
Reversed 
Phase: A: 
0.1% (v/v) 
formic acid in 
H2O, B: ACN 
HILIC: A: 
0.4% (v/v) 
formic acid in 
H2O, B: ACN 
LC - ESI - 
MS/MS (+) 
and (-) 
- 
[70] 
Martos et 
al. 2010  
SAs (9), Qs (5), 
MCs (1), β-
LACTs (1)  
Bovine 
muscle 
tissue 
Extraction with ACN – 
d-SPE with PSA 
(QuEChERS) 
compared to PLE with 
water 
XTerra MS 
C18  
(100×2.1 
mm, 3.5 μm) 
A:10 mM 
ammonium 
formate in 
H2O, B: 10 
mM 
ammonium 
formate in 
MeOH  
LC-ESI - 
MS/MS (+) 
25% (Ciproflocaxin) – 
93% (Flumequine) 
[71] 
Blasco et 
al. 2011 
TCs (3), SAs 
(16), β-LACTs 
(7), Qs (3), MCs 
(3), LINCs (2) 
porcine 
muscle 
solid–liquid extraction 
with ACN with fast 
partition at very low 
temperature 
Zorbax 
Eclipse XDB 
C-18 
(150×4.6 
mm, 5 μm) 
A: H2O/ACN 
(95 : 5 v/v) 
with formic 
acid 0.1% and 
B: H2O/ACN 
(5 : 95 v/v) 
with formic 
LC - ESI - 
MS/MS (+) 
- 
[72] 
Lopes et al. 
2011 
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acid 0.1%  
SAs (14), TCs 
(4), Qs (9), β-
LACTs (7),  MCs 
(5), LINCs (1) 
and other 
antibiotics (1) 
egg 
PLE with 1:1 (v/v) 
mixture of ACN 
and 0.01 mol L−1 
succinic acid buffer pH 
6.0 
Acquity 
UPLC BEH 
C18 
(100×2.1mm, 
1.7 μm) 
A: oxalic acid 
2-hydrate 
0.13g/L in 
H2O with 
0.02% formic 
acid, B: 0.1% 
(v/v) formic 
acid in ACN 
LC-ESI- 
MS/MS (+) 
47% (Amoxicillin) - 320% 
(Danofloxacin) 
[73] 
Jiménez et 
al. 2011 
TCs (7), Qs (14), 
MCs (12), SAs 
(12), LINCs (3), 
PLMTs (3) and 
other antibiotics 
(3) 
cattle and 
pig muscle 
extraction with EDTA-
McIlvaine buffer and 
cleanup with SPE  
AQUA C18 
(150×2.1 
mm, 3 μm) 
A: 0.2% 
formic acid  in 
H2O, B: 0.2% 
formic acid  in 
ACN 
LC - ESI - 
MS/MS (+) 
99% (Nalidixic acid) - 
114% (Ofloxacin) 
[74] 
Bohm et al. 
2011 
β-LACTs (4), 
SAs (8), TCs (4), 
Qs (3), MCs (3), 
NSAIDs (1), 
ANTHs (1), other 
antibiotics (1) 
and other 
contaminants (1)  
milk 
extraction with ACN, 
cleanup with SPE and 
with an 30 kDa MW 
cutoff filter 
YMC ODS-
AQ (100×2 
mm, 3 μm) 
A: 0.1% (v/v) 
formic acid in 
H2O, B: ACN 
LC - ESI - 
MS/MS (+) 
22% (Ampicillin) - 
143.3% (Enrofloxacin) 
[75] 
Clark et al. 
2011 
Qs (11), SAs 
(20), TCs (4), 
bovine 
kidney 
extraction ACN- H2O 
(4:1, v/v), cleanup with 
Prodigy 
ODS-3 
A: 0.1% (v/v) 
formic acid in 
LC - ESI - 
MS/MS (+) 
53 % (Chlortetracycline) - 
129% (Semicarbazide) 
[76] 
Schneider 
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MCs (9), NFs (7), 
β-LACTs (15), 
AMPs (1), 
QUINOXs (1), 
ANTHs (12), β-
AGONs (9), 
NSAIDs (6), 
CORTs (7), 
THYRs (5), other 
antibiotics (2) 
and other 
contaminants 
(11)  
hexane partitioning  (150×3mm, 5 
μm) 
H2O, B: 0.1% 
(v/v) formic 
acid in ACN 
et al. 2012 
TCs (3), β-
LACTs (5), Qs 
(2), SAs (3) and 
other 
contaminants (8)  
egg 
MeOH:H2O:CH3COOH 
80:20:1 (v/v/v), 0.5 g 
CH3COONa and 2.0 g 
Na2SO4 anhydrous 
(QuEChERS-like 
extraction method) 
ACE C18 
(150×2.1mm, 
3 μm) 
A: 0.1% (v/v) 
formic acid in 
H2O, B: 0.1% 
(v/v) formic 
acid in ACN 
LC - ESI - 
MS/MS (+) 
56% (Oxacillin) - 79% 
(Doxycycline)  
[77] 
Capriotti et 
al. 2012 
SAs (5), Qs (7), 
TCs (4), MCs (4), 
ANTHs (8) and 
other antibiotics 
(1) 
baby food 
and infant 
formula 
modified QuEChERS 
approach 
Acquity 
UPLC BEH 
C18 
(100×2.1mm, 
1.7 μm) 
A: MeOH, B: 
0.05% (v/v) 
formic acid in 
H2O 
LC-ESI-
MS/MS (+) 
baby food: 69.9% 
(Flumequine) to 122.9% 
(Sulfaquinoxaline) -  
infant formula: 70.4% 
(Flumequine) to 119% 
(Sulfadimethoxine) 
[78] 
Aguilera-
Luiz et al. 
2012 
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Qs (2), SAs (6), 
MCs (4), ANTHs 
(7), other 
antibiotics (1) 
and other 
contaminants (1)  
chicken QuEChERS  
Acquity 
UPLC BEH 
C18 
(100×2.1mm, 
1.7 μm) 
A: 0.1% (v/v) 
formic acid in 
ACN, B: 0.1% 
(v/v) formic 
acid in H2O 
LC-ESI-
MS/MS (+) 
69% (Sulfadimidine) to 
118.3% (Oxolinic acid) 
[79] 
Lopes et al. 
2012a 
MCs (11), β-
LACTs (7), 
LINCs (2), Qs 
(1), ANTHs and 
other antibiotics 
(1)                              
milk Extraction with ACN 
HSS T3 
column 
(100×2.1 
mm, 1.8 μm) 
A: 0.05% (v/v) 
formic acid in 
H2O, B: ACN 
UPLC-ESI-
MS/MS (+) 
56.9 % (Cefapirin) – 
127.6% 
(Troleandomycin) 
[80] 
Tang et al. 
2012 
β-LACTs (7), 
TCs (4), Qs (6),  
SAs (6), ANTHs 
(7) and other 
antibiotics (1)                              
gilthead sea 
bream 
modified QuEChERS 
approach 
Acquity 
UPLC BEH 
C18 
(100×2.1mm, 
1.7 μm) 
A: 0.1% (v/v) 
formic acid in 
ACN, B: 0.1% 
(v/v) formic 
acid in H2O 
LC-ESI-
MS/MS (+) 
74% (Penicillin G) to 
117% (Chlortetracycline)  
[81] 
Lopes et al. 
2012b 
MCs (10),  LINCs 
(3), Qs (13), TCs 
(8) and other 
antibiotics (3)                              
honey 
Dillution to McIlvaine 
buffer, pH 4.0 and 
cleanup with SPE  
AQUA C18 
(150×2.1 
mm, 3 μm) 
A: 0.2% (v/v) 
formic acid in  
H2O, B: 0.2% 
(v/v) formic 
acid in ACN 
LC - ESI - 
MS/MS (+) 
92% (Danofloxacin) – 
106% Tylosin A 
[82] Bohm 
et al. 2012 
β-AGONs (17), 
β-LACTs (11), 
THYRs (2), 
Raw milk 
Extraction with ACN- 
Ethanol with addition of 
EDTA  
Acquity 
HSS-T3 
column 
ESI (+): A: 
0.1% formic 
acid in H2O 
LC-ESI-
MS/MS (+) 
and (-) 
62% (Amitraz) to 133% 
(Teridazole) 
[83]  
Zhan et al 
2012 
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QUINOXs (9), 
LINCs (2), 
ANTHs (28), Qs 
(17), SAs (20), 
TCs (10), AMPs 
(4), CORTs (5), 
MCs (10), 
NSAIDs (25), 
COCs (12),  
other antibiotics 
(2)  and  other 
contaminants 
(81)  
(100×2.1 
mm, 1.8 μm) 
with 0.5 
mmol/L 
ammonium 
acetate, B: 
0.1% formic 
acid in MeOH 
 ESI (-): A: 2.5 
mmol/L 
ammonium 
acetate in 
H2O B: MeOH 
SAs (4), Qs (2), 
COCs (7), 
CORTs (3), other 
antibiotics (1) 
and other 
contaminants (1) 
milk 
extraction with ACN - 
cleanup with SPE  
Synergi 
Polar-RP 
100 Å 
(50×2.0 mm, 
2.5 μm) 
A: 0.1% (v/v) 
formic acid in  
H2O, B: 0.1% 
(v/v) formic 
acid in ACN 
LC- ESI-
MS/MS (+) 
65% (Robenidine) – 
119% 
(Sulfamethoxypyridazine) 
[84] 
 Nebot 
2012 
Qs (14), TCs (4), 
MCs (7), β-
LACTs (8), SAs 
(22), ANTHs 
(21), other 
antibiotics (4) 
chicken 
muscle 
solid-liquid extraction 
with EDTA-succinate 
buffer and acetonitrile 
RP-LC 
column PFP 
(100×4.6 
mm, 3 μm) 
A: 0.1% (v/v) 
formic acid in  
H2O, B: 0.1% 
(v/v) formic 
acid in ACN 
LC - ESI - 
MS/MS (+) 
29% (Ofloxacin) - 98% 
(Erythromycin)  
[85] 
Biselli et al. 
2013 
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and  other 
contaminants (4)   
β-AGONs (17), 
THYRs (1), 
QUINOXs (7) 
MCs (10), 
ANTHs (28), Qs 
(17), NSAIDs 
(24), SAs (20), β-
LACTs (6), 
AMPs (3), LINCs 
(1), COCs (13), 
CORTs (1), other 
antibiotics (1) 
and other 
contaminants 
(62)  
infant 
formula 
extraction with ACN, 
clean-up by low 
temperature and water 
precipitation 
Acquity 
HSS-T3 
column 
(100×2.1 
mm, 1.8 μm) 
ESI (+): A: 
0.1% formic 
acid in H2O 
with 0.5 
mmol/L 
ammonium 
acetate, B: 
0.1% formic 
acid in MeOH 
 ESI (-): A: 2.5 
mmol/L 
ammonium 
acetate in 
H2O B: MeOH 
LC-ESI-
MS/MS (+) 
and (-) 
59% (Erythromycin) - 
133% (Nalidixic acid)  
[86] 
Zhan et al. 
2013 
AMGs (2), MCs 
(7), LINC (2), 
SAs (6), TCs (4), 
Qs (14) and 
other antibiotics 
(1)   
chicken 
meat 
extraction with ACN:2% 
trichloroacetic acid 
(45:55, v/v) and on-line 
clean-up using 
turbulent flow 
chromatography 
Betasil 
phenyl hexyl 
(50×2.1 mm, 
3 μm) 
A: 1 mM 
HFBA with 
0.5% formic 
acid in H2O, 
B: 0.5% 
formic acid in 
ACN/ MeOH 
(1:1, v/v). 
LC-ESI-
MS/MS (+) 
71% (Neomycin) - 120% 
(Kanamycin) 
[87] 
Bousova et 
al. 2013 
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SAs (13), TCs 
(4), MCs (4), Qs 
(11) and AMPs 
(1)  
milk 
extraction and protein 
precipitation with ACN -  
Acquity 
HSS-T3 
(100×2.1 
mm, 1.8 μm) 
A: 0.1% (v/v) 
formic acid in  
H2O, B: 0.1% 
(v/v) formic 
acid in ACN 
LC- ESI-
MS/MS (+) 
and (-) 
- 
[88] 
Freitas et 
al. 2013 
TCs (4), Qs (11),  
MCs (8), β-
LACTs (6), SAs 
(15), LINCs (1), 
AMPs (2), 
ANTHs (19), 
TRANQs (8), 
COCs (4), 
NSAIDs (20) and 
other antibiotics 
(3)   
milk 
Protein precipitation 
with ACN, dillution with 
water and cleanup with 
SPE  
Acquity 
UPLC BEH 
C18 
(50×2.1mm, 
1.7 μm) 
A: 0.1% 
formic acid in 
H2O (v/v), B: 
0.1% formic 
acid in 
H2O/ACN 
(1/9, v/v) 
UPLC–TOF-
MS (+) 
76% (Nafcillin) – 186% 
(Ipronidazole) 
[89] 
Stolker et 
al. 2008 
SAs (23), TCs 
(6), Qs (14), β-
LACTs (12), MCs 
(10), LINC (4), 
ANTHs (19), 
TRANQs (7), 
COCs (1) and 
other antibiotics 
(7) 
meat 
liquid–liquid–solid 
extraction (bipolarity 
extraction) and cleanup 
with SPE  
HSS T3 C18,  
(100×2.1 
mm, 1.8 μm) 
A: 0.3% (v/v) 
formic acid 
and 5% ACN 
in H2O, B: 
0.3% (v/v) 
formic acid 
and 5% H2O 
in ACN  
UPLC - ESI - 
TOF (+) 
13% (Fenbendazole) - 
144% (Cefoperazon) 
[90] 
Kaufmann 
et al. 2008 
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SAs (15), TCs 
(4), Qs (11), β-
LACTs (7),  MCs 
(10), AMPs (2), 
ANTHs (19), 
TRANQs (8), 
COCs (6), 
NSAIDs (23) and 
other antibiotics 
(2) 
egg, fish, 
meat 
extraction with ACN - 
water  and cleanup 
with SPE  
Acquity 
UPLC BEH 
C18 
(100×2.1mm, 
1.7 μm) 
A: 0.1% (v/v) 
formic acid in 
H2O, B: 
ACN/0.1% 
(v/v) formic 
acid in H2O 
9/1 
HRLC–ESI 
TOF-MS (+) 
32% (Phenylbutazone) – 
1274 (Piroxycam) 
[91] 
Peters et 
al. 2009 
SAs (25), TCs 
(6), Qs (14), MCs 
(10) β-LACTs 
(25), QUINOXs 
(2), LINC (1), 
ANTHs (34), 
COCs (2), 
CORTs (5), β-
AGONs (7), 
NSAIDs (5), 
TRANQs (2), 
other antibiotics 
(3) and other 
contaminants (8)  
milk 
extraction and protein 
precipitation with ACN - 
ultrafiltration 
Acquity 
UPLC BEH 
C18 
(100×2.1mm, 
1.7 μm) 
A: 0.1% (v/v) 
formic acid in  
H2O, B: 0.1% 
(v/v) formic 
acid in ACN 
UPLC - ESI - 
TOF (+) 
1% (Eprinomectin) - 807 
% (Danofloxacin) 
[92] 
Ortelli et al. 
2009 
Sas (8), TCs (4), milk extraction with ACN, YMC ODS- A: 0.1% (v/v) UHPLC-Q- 42% (Chlortetracycline) – [93] 
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β-LACTs (4), 
MCs (3), Qs (3), 
ANTHs (1) and 
other 
contaminants (2) 
cleanup with 3000 Da 
molecular weight cutoff 
centrifuge filter 
AQ, 
(100×2.1 
mm, 3 μm) 
formic acid in  
H2O, B: ACN 
TOF-MS 154% 
(Sulfachloropyridazine). 
Turnipseed 
et al. 2011 
Qs (14), 
Sas (18), TCs 
(5), CORTs (7), 
ANTHs (23), β-
AGONs (14), 
other antibiotics 
(1) and other 
contaminants 
(23) 
Meat, milk, 
egg 
extraction with acidified 
ACN, cleanup with 
SPE  
Zorbax 
Eclipse 
XDB C18 
(100×3.0 
mm, 1.8 μm) 
A: 5 mmol L
-1
 
ammonium 
formate in 
H2O with0.1% 
formic acid,  
B: 0.1% (v/v) 
formic acid in 
ACN 
UHPLC-Q-
TOF-MS  
41.1–120.9% (meat), 
52.4–91.9% (milk) and 
57.3–118.9% (egg) 
[94] 
Deng et al. 
2011 
SAs (7), ANTHs 
(1), other 
antibiotics (1) 
and other 
contaminants (5)  
shrimp  QuEChERS 
RR Zorbax 
Eclipse XDB-
C18 (50×4.6 
mm, 1.8 μm) 
A: 0.1% (v/v) 
formic acid in  
H2O, B: 0.1% 
(v/v) formic 
acid in ACN 
LC - ESI - 
TOF (+) 
33% (Sulfamethizole) - 
118% (Mebendazole) 
[95] 
Villar-
Pulido et al. 
2011 
β-LACTs (15), 
Sas (12), MCs 
(10), TCs (7), 
AMGs (10) and 
Qs (10) 
Muscle 
tissues 
Two protocols: 
extraction with ACN 
and extraction with  
acidified ACN, cleanup 
with SPE  
RP18 
Purospher 
column 
(125×3 mm, 
5 μm) 
A: 1mM HFBA 
in H2O  with 
0.5% formic 
acid, B: 
0.5% formic 
acid in MeOH 
LC- orbitrap 
H-ESI MS (+ 
and -) 
- 
 
[96] 
Hurtaud-
Pessel et 
al. 2011 
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/ ACN 
(50:50; v/v) 
β-LACTs (5), 
Sas (8), Qs (1), 
MCs (2), ANTHs 
(5), COCs (4) 
and other 
contaminants 
(93) 
Meat, milk, 
liver, corn 
silage 
Extraction with acidified 
ACN - QuEChERS 
Hypersil 
Gold AQ 
(50×2.1mm, 
1.9 μm) 
A: 0.1% (v/v) 
formic acid in  
H2O, B: 0.1% 
(v/v) formic 
acid in ACN 
LC- orbitrap 
H-ESI MS (+) 
- 
[97] 
Filigenzi et 
al. 2011 
Sas (24), Qs 
(16), MCs (16), 
TCs (6), β-
LACTs (12), 
ANTHs (18), 
COCs (2), 
TRANQs (7), 
other antibiotics 
(1) and other 
contaminants (3) 
muscle, 
kidney, liver, 
fish and 
honey 
extraction with ACN 
and EDTA-succinate 
buffer, cleanup with 
SPE  
Kinetex 
Core–Shell, 
C18 
(150×2.1 
mm, 2.6 μm) 
A: 0.3% (v/v) 
formic acid 
and 5% ACN 
in H2O, B: 
0.3% (v/v) 
formic acid 
and 5% H2O 
in ACN  
LC- orbitrap 
H-ESI MS (+ 
and -) 
Kidney: 11.9% 
(Cephalexin) – 97.5% 
(Ofloxacin), Honey: 1.2% 
(Sulfanilamide) -89.6% 
(Nalidixic acid)  
[98] 
Kaufmann 
et al. 2011 
 Qs (5), SAs (1), 
AMPs (1) and 
other antibiotics 
(1) 
frog legs,  
aquacultured 
Species 
extraction with H2O 1% 
acetic acid - ACN (1:4, 
v/v) 
YMC ODS-
AQ (100×2 
mm, 3 μm) 
A: 0.1% (v/v) 
formic acid in  
H2O, B: ACN 
LC - ESI - Q-
TOF (+ and -) 
58% (Ciprofloxacin) - 
128.8% (Nalidixic acid) 
[99] 
Turnipseed 
et al. 2012 
ANTHs (20) and 
COCs (14) 
feed, milk 
Extraction with ACN 
with NH4OH - 
- - 
DART- 
orbitrap MS (+ 
- [100] 
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QuEChERS and -) 
MCs (6), SAs (4), 
TCs (4), Qs (12), 
β-LACTs (5), 
NFs (2), LINCs 
(1), ANTHs (1), 
other antibiotics 
(1) and other 
contaminants 
(46) 
feed, fish 
Extraction with 
ACN/H2O (80:20) 
HCOOH 0.1% &  
ultrasonic extraction -
clean-up by low 
temperature (freezer 
for 2h) 
Acquity 
UPLC BEH 
C18 
(100×2.1 
mm, 1.7 μm) 
A: 0.01% (v/v) 
formic acid 
and 0.1 nM 
NH4Ac in 
H2O,  
B: 0.01% (v/v) 
formic acid 
and 0.1 nM 
NH4Ac in 
MeOH 
UHPLC-Q-
TOF-MS (+) 
- [101] 
TCs (2), β-
LACTs (2) and 
AMPs (1)  
milk QuEChERS 
Gemini C18  
(50×2.1 mm, 
3 μm) 
A: H2O, B: 
MeOH 
LC-IT-TOF 
MS (+ and -) 
83% (Ampicillin) – 92% 
(Tetracycline) 
[102] 
AMGs (12), β-
AGONs (4), MCs 
(12), β-LACTs 
(27), Ts (6), Sas 
(22), Qs (27), 
AMPs (4), COCs 
(14), NSAIDs 
(10), ANTHs 
(26), TRANQs 
(3), other 
antibiotics (6) 
milk 
extraction with ACN, 
cleanup with 3000 Da 
molecular weight cutoff 
centrifuge filter 
YMC ODS-
AQ, 
(100×2.1 
mm, 3 μm) 
A: 0.1% (v/v) 
formic acid in  
H2O, B: ACN 
UHPLC-Q-
TOF-MS (+ 
and -) 
- [103] 
54 
 
and other 
contaminants 
(22)  
Abbreviations: TCA: Trichloroacetic acid, ACN: Acetonitrile, MeOH: Methanol, QuEChERS: Quick Easy Cheap Effective Rugged Safe, SE: Solvent Extraction, SPE: Solid 
Phase Extraction, PLE: Pressurized Liquid Extraction, MSPD: Matrix Solid Phase Extraction, ANTHs: Anthelmintics, AMGs: Aminoglycisides, AMPs: Amphenicols, β-AGONs: 
Beta-agonists,  β-LACTs: β-Lactams, COCs: Coccidiostats, CORTs: Corticosteroids, LINC: Lincosamides, MCs: Macrolides, NFs: Nitrofurans, NSAIDs: Non Steroidal Anti 
inflammatory Drugs, PLMTs: Pleuromutullins, Qs: Quinolones, QUINOXs: Quinoxalins, SAs: Sulfonamides, TCs: Tetracyclines, , THYRs: Thyreostats, TRANQs: Tranquilizers 
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1.4.1 Sample preparation 
Sample preparation is the process which includes the isolation and/or 
preconcentration of compounds of interest from various matrices, the removal of 
any matrix interferences that may affect the detection system as well as making the 
analytes more suitable for separation and detection. Even with the advances in the 
development of highly efficient analytical instrumentation for their final 
determination, sample preparation is a vital part of the analytical procedure and 
effective sample preparation is essential for obtaining accurate quantitative results 
and maintaining instrument performance. 
A typical sample preparation technique consists of an extraction step of the 
analytes from the matrix and a subsequent purification step of the extract. 
 
1.4.1.1 Sample extraction techniques 
 
A. Liquid extraction (LE) 
Liquid extraction is a very popular sample treatment technique. LE entails 
conventional liquid–liquid extraction (LLE) of target compounds from liquid 
matrices, such as milk, and the liquid extraction of homogenized tissues such as 
liver, kidney, and meat, referred to as solvent extraction (SE). To obtain optimal 
results, the extraction solvent has to be selected in such way that efficient 
extraction of the target compounds is obtained, whereas the extraction of matrix 
constituents remains limited in order to prevent excessive matrix effects (ME). The 
selection of the solvent therefore depends not only on the target compounds, but 
also on the matrix.  
Simple extraction with aqueous buffers (e.g. McIlvaine buffer or succinate buffer) is 
advantageous for highly polar residues because they reduce non-polar matrix 
components (e.g. lipids) and extracts can be enriched on reversed phase SPE [56, 
59, 66, 74, 82]. A disadvantage is that strongly protein-bound residues are not fully 
extracted and polar matrix components are co-extracted. Complexing agents are 
reported to be essential for the extraction of tetracyclines, quinolones and some 
macrolides, because these compounds have a strong tendency to form chelates 
with divalent metallic cations present in food samples [56, 85].  
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In general, the majority of methods employ more efficient organic solvents as 
extracting agents. Methanol (MeOH) and acetonitrile (ACN) are more adequate as 
extraction solvents as they can simultaneously precipitate the proteins and extract 
the target analytes. Many authors, as it is shown by the collected applications 
presented in Table 1.2, prefer ACN over MeOH or ethyl acetate as extraction 
solvent, because MeOH and ethyl acetate extract too many matrix compounds, 
complicating the following clean-up steps. However, ACN does not sufficiently 
extract polar analytes.  
A great number of multi-residue analytical methods developed use a combination 
of water or aqueous buffer and organic solvent as the extraction mixture of the 
target compounds from the matrix (Table 1.2). Kaufmann et al. proposed a bipolar 
extraction, combining an extraction with ACN and one using a McIlvain buffer-
containing complexing agent [90]. With one of the greater challenges in sample 
preparation being the development of a generic extraction method which should 
not only cover a vast number of target analytes, but should also be applicable to 
different types of food and feed matrixes, Mol et al. reported a thorough research 
comparing the use of ACN, MeOH and acetone (ACE) for the extraction of 
veterinary drugs, pesticides and toxins from honey, milk, eggs and muscle [104]. 
However, in the area of multi-residue analysis there is always a compromise 
between recovery and purity of sample extracts. 
Liquid–liquid extraction (LLE) is a widely applied extraction procedure in residue 
analysis due to its high selectivity compared to simple solvent extraction (SE). LLE 
applications can also include polar ionisable compounds, which can be extracted 
by non polar organic solvents using the ion-pair technique: transforming positively 
charged substances into non-polar neutral compounds in the presence of organic 
anions, or vice versa [105, 106].  
Anastassiades et al. developed a variation of LLE, called QuEChERS sample 
preparation procedure (standing for Quick, Easy, Cheap, Effective, Rugged and 
Safe), which has been successfully applied to the analysis of hundreds of pesticide 
residues [107]. In QuEChERS approach, the high-moisture sample (H2O is added 
to dry foods) is extracted with an organic solvent (mainly ACN, but also ethyl 
acetate or acetone) in the presence of salts (MgSO4, NaCl and/or buffering 
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agents). The addition of salts induces phase separation of the solvent from the 
aqueous phase. The residues of interest and matrix co-extractives are separated 
into the relevant liquid phase based on their polarity with the residues partitioning 
into the organic phase and matrix co-extractives into the aqueous phase. The 
extract is subjected to further purification using dispersive-SPE (d-SPE), which 
entails mixing sorbents with the extract.  
Although veterinary drugs present greater diversity in the chemical properties 
compared to pesticides, making their simultaneous extraction more difficult, many 
methods have been developed for antibacterial determination using this technique, 
as shown in Table 1.2. The majority of methods based on the QuEChERS 
approach involve SE with acidic ACN in the presence or absence of EDTA followed 
by phase separation using anhydrous magnesium sulfate as drying agent. A few 
methods include a subsequent d-SPE procedure using C18, primary secondary 
amine (PSA) or a combination of both as sorbent. A thorough optimization of the 
QuEChERS procedure for the extraction of antibactrerials from animal tissues was 
performed from Stubbings & Bigwood [108]. QuEChERS flexibility, coupled to low 
cost and ease of use will undoubtedly result in an increase in its application to 
residue analysis.  
 
B. Pressurised liquid extraction (PLE) 
The use of automated extraction techniques leads to a reduction in uncertainty. 
Automated methods are generally more reproducible than manual ones and they 
also decrease the time spent on sample preparation, which is often the bottleneck 
in analysis. However, their disadvantage is additional extraction cost and 
instrumental downtime. Pressurised liquid extraction (PLE) is the most widely used 
instrumental extraction technique in food and feed analysis [109]. 
Pressurised liquid extraction has received numerous names, such as accelerated 
solvent extraction (ASE), pressurized fluid extraction (PFE), pressurised hot 
solvent extraction (PHSE), subcritical solvent extraction (SSE) and hot H2O 
extraction (HWE). PLE is carried out at temperatures above the boiling point of the 
solvent and uses high pressure to maintain the solvent in the liquid phase and 
achieve fast and efficient extraction of analytes from the solid matrix. HWE has 
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gained interest during the last years [110]. PHWE is cheaper, cleaner and more 
environmentally friendly than conventional PLE. Moreover, the dielectric constant 
(polarity) of water can be significantly reduced with increasing temperature, so 
under pressure, heated water can behave like an organic solvent, thus making 
more selective the extraction of moderately polar compounds. Thus, at 100–200 
°C, water can act as a medium/non-polar solvent. However, due to the high 
temperatures involved, the thermal stability of the analytes should always be 
checked before extraction. For instance, degradation of macrolides has been 
observed at temperatures above 100 °C [111]. 
Several authors have demonstrated the feasibility of using PLE for sample 
preparation in the multi-residue determination of veterinary drug residues in 
different types of foods (Table 1.2). Herranz et al. report a PLE analytical method 
for the determination of quinolones in table eggs [112]. Berrada et al. determine 
macrolides in meat and fish using PLE with MeOH [113] while Tao et all determine 
macrolides and avermectines with PLE with ACN/MeOH [114].  A method for the 
determination of tetracyclines using trichloracetic acid/acetonitrile as extraction 
solvents was developed by Yu et al. [115]. PLE was also used for the extraction of 
sulfonamides from meat samples [116], aminoglycosides from milk [117] and 
corticosteroids from bovine liver [34]. 
 
C. Microwave-assisted extraction 
Microwave-assisted extraction (MAE) is a technique which uses microwave energy 
to heat a solvent in contact with a sample, in order to partition analytes from the 
sample matrix into the solvent. Using microwave energy allows the solvent to be 
heated rapidly: an average extraction takes 15–30 min. MAE offers high sample 
throughput (several samples can be extracted simultaneously) with low solvent 
consumption (10–30 mL). However, solvent choice is limited, care must be taken 
not to overheat the sample, additional clean-up of the samples is generally 
necessary prior to analysis and MAE is not amenable to automation (on-line 
extraction and detection) [118,119]. 
 Although MAE is established as a routine, well-developed method for sample 
preparation in environmental analysis (soils, sediments, etc.), only few papers have 
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been found in the literature for the application of MAE to the extraction of veterinary 
drugs from solid foodstuffs [120-122]. This is generally due to the limited diffusion 
of the solvent in samples containing more than 30% of water (as it is the case in 
food samples), resulting in low analyte recovery. This problem can be 
circumvented by prior drying of samples by lyophilisation [123]. 
 
D. Supercritical fluid extraction 
Supercritical fluids (SCFs) include properties of both liquids and gases while their 
density correlates with temperature and pressure. They offer a considerable 
promise as a media for selective isolation of target compounds for complex 
matrices. Carbon dioxide (CO2) is the most widely used supercritical fluid, because 
of its inertness, low cost, high purity, low toxicity and low critical parameters (CO2: 
Tc = 31.3 ◦C, Pc = 72.9 atm). Apart from CO2, other potential SCF solvents are 
N2O, xenon, C2H6, C3H8, n-C5H12, NH3, CHF3, SF6 and water [124]. Sometimes, 
the relatively low polarity of CO2 may be a major problem. By adding a polar 
modifier (MeOH, EtOH or H2O), its polarity can be changed to make separation 
more selective but it also leads to more co-extractants. 
Two of the main problems with SFE are the robustness of the method compared to 
other techniques and that conditions must be consistent for reproducible 
extractions. This has resulted in reduced interest in the area of residue analysis in 
the last 10 years [123]. 
Very few SFE applications have been reported in peer reviewed literature for 
selective isolation of veterinary drug residues from food samples [125-127]. 
 
E. Matrix Solid Phase Dispersion (MSPD) 
Matrix solid-phase dispersion (MSPD) is a sample pretreatment procedure that is 
increasingly used for extracting/purifying analytes from a variety of solid and semi-
solid foodstuffs. It is a sample preparation strategy that consists of a manual 
blending of samples with a bulk dispersing agent, to produce complete disruption 
of the original matrix structure, thus providing an enhanced surface area for 
subsequent sample extraction. Usually, the blended material is then transferred 
60 
 
and packed into a column to perform sequential extraction and eventual clean-up 
with an appropriate solvent or a sequence of solvents. MSPD’s biggest advantage 
is that it can combine the procedures of homogenization, disruption, extraction and 
clean-up into one simple process. 
Since its introduction, it has been widely applied to the isolation of veterinary drugs 
from samples of animal origin. Milk and its derivates were the most investigated 
matrices [128-132], but eggs and animal and fish tissues, were also analyzed [133 
– 136]. It has been applied in the extraction of coccidiostats [132], tetracyclines 
[131], cephalosporins [128], macrolides [129], penicillins [130], sulfonamides [134, 
136], quinolones [133] and amphenicols [129, 135]. Different bulk materials have 
been used as matrix dispersing agents, being C18- and C8-bonded silica the most 
popular by far. Cephalosporins, penicillins and amphenicols were extracted from 
milk by a polar/non-polar polymer (Abselut Nexus) [128] and Strata X [129] while 
Kishida used normal-phase MSPD with alumina N–S for the extraction of 
sulfonamides from meat samples [137]. MSPD with hot water extraction has been 
employed in some cases for the extraction of antibacterials in food, using a home-
made like-PLE apparatus [138-140]. Finally, the use of molecularly imprinted 
polymers (MIPs), as selective dispersing media for sample clean-up (MI-MSPD) 
has been reported [133, 135]. The use of MIPs enhances the selectivity and 
sensitivity of the MSPD procedure, allowing higher recoveries of the target 
analytes. 
 
1.4.1.2 Sample clean-up/purification techniques 
 
A. Solid-Phase Extraction (SPE) 
SPE is the most important sample purification technique in residue analysis and 
has gradually replaced liquid-liquid extraction and liquid-liquid partitioning. A 
number of books and review papers have already been written on this topic and 
can be consulted for more detail [141-144]. 
 A wide choice of sorbents is available which rely on different mechanisms for 
extraction/retention of analytes. Alumina, amino or strong cation exchangers (SCX) 
have been proposed for ionic antibacterials, while C18 or polymeric sorbents, 
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especially Hydrophilic-Liphophilic Balance (HLB) polymeric reversed phases are 
used for neutral or ionisable compounds working at a pH lower than the pKa of the 
analytes. HLB sorbent consists of a copolymer of N-vinylpyrrolidone and 
divinylbenzenes. The hydrophilic N-vinyl pyrrolidone increases the water wettability 
of the polymer and the lipophilic divinylbenzene provides the reversed-phase 
retention necessary to retain analytes. 
 For compounds with varied chemical properties, mixed-mode sorbents are 
recommended (e.g., Bond Elut SCX cartridges for multiresidue of basic drugs 
[145]. SPE can be directly used for the extraction of veterinary drugs from liquid 
food only (e.g., milk, or honey, which can be dissolved in aqueous media). 
Applications of SPE in multi-residue analysis of veterinary drugs in food matrices 
are presented in Table 1.2.  
 
B. Dispersive SPE (d-SPE) 
Dispersive-SPE (d-SPE) is a clean-up technique that involves mixing sorbent with 
a sample that has been pre-extracted with an appropriate solvent. It is typically part 
of the QuEChERS method where it follows the extraction step. The appropriate 
sorbent adsorbs matrix co-extractives onto its surface, leaving analytes of interest 
in the solvent. C18 sorbents remove highly lipophilic compounds and other 
sorbents, like amino- or carbon-based phases, are employed mainly for the 
removal of fatty acids and pigments, respectively. MgSO4 is added to provide 
additional clean-up by removing residual H2O and some other compounds via 
chelation. It is an extremely fast, simple and inexpensive process that provides 
high recovery and reproducibility for many LC- and GC-amenable analytes. 
 Several analytical methods have used d-SPE as a clean-up step in veterinary 
residue analysis, mainly using C18 as a sorbent [146-148]. PSA, amine (NH2) and 
silica have also been reported [71, 95, 108, 149, 150]. d-SPE does not provide the 
same degree of clean-up as SPE. However, it does provide good recovery and 
reproducibility, coupled with practical (speed) and cost advantages. 
 
C. Molecularly imprinted polymers (MIPs) 
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Molecularly imprinted polymers (MIPs) are engineered cross-linked polymers that 
exhibit high affinity and selectivity towards a target compound or class of 
structurally related compounds. The use of MIPs as selective sorbents in SPE, so-
called molecularly imprinted solid phase extraction (MISPE), is an emerging clean-
up procedure for complex matrices such as food. Currently, MIPs are not employed 
very much for food analysis, in comparison to other methods, but, thanks to their 
high specificity, reduction in the time of analysis in on-line approaches and 
reduction in the costs of analysis, rapid increase in the number of applications is 
foreseeable. Different works reported the use of MIPs for extraction and clean-up 
in β-agonist [151], tetracycline [152], sulfonamide [153], quinolone [154] and 
chloramphenicol [155] residue analysis. 
 
D. Turbulent flow chromatography (TFC) 
A relatively new technique used for sample preparation is the so-called turbulent 
flow chromatography (TFC) that has shown a great potential for on-line sample 
pretreatment, in terms of both, high sample throughput and high reproducibility 
linked to automation. Columns packed with large particle size sorbents (typically 60 
μm) allow on-line extraction using high solvent flow rates (typically 4–6 mL min−1), 
without significant back-pressure. Molecules with low molecular weight diffuse 
faster than molecules with high molecular weight. Therefore, the small analytes 
diffuse into the particle pores, whereas the high flow of the mobile phase quickly 
flushes the large sample compounds (e.g. proteins) into the waste, before they 
have the opportunity to diffuse into the particle pores. Once trapped the analytes 
on the turbulent flow column, a back-flushing elution desorbs the analytes and 
focuses them onto the analytical column for chromatographic separation [2].  The 
number of TFC applications in food analysis is scarce [87, 156, 157]. 
 
E. Molecular weight cut-off devices – Ultra-filtration 
The development of multi-residue assays using LC–MS/MS detection has resulted 
in the alternative purification systems in the field of residue analysis such as ultra-
filtration (UF). In residue analysis of food, UF is primarily used to separate analytes 
of interest from macromolecules, such as proteins, peptides, lipids and sugars, 
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which may interfere with analysis, particularly affecting ionisation in mass 
spectrometry. Molecular weight cut-off devices or spin filters coupled to 
microcentrifuge tubes are the most commonly used formats [123]. Examples of 
applications include sulfonamides in milk [158], eggs [159] and edible tissues 
[160], tetracyclines in egg [161] and penicillin G in muscle, kidney and liver [162]. 
Goto et al. compared several types of membranes for ultra-centrifugation and 
showed the difference in recoveries of the antibiotics, because some membranes 
sometimes adsorb tetracycline and penicillins irreversibly [163]. Lately, three multi 
residue method for the determination of 27, 25 and >150 veterinary drugs in milk, 
respectively, using extraction with ACN, were reported [75, 93, 103]. Clark et al. 
[75] used a 30 kDa MW cut-off centrifuge filter while Turnipseed et al. [93, 103] a 3-
kD cut-off filter. Moreover, a multi residue method for the analysis of 150 veterinary 
drugs in milk using a 3-kD cut-off filter has been presented. In this study it was 
shown that ultrafiltration removes more lipophilic matrix interferences than SPE, 
but that the removal of hydrophilic interferences is worse [92]. 
 
F. Restricted access materials (RAMs) 
RAM sorbents are porous chromatographic supports partially based on size-
exclusion mechanisms that have been specifically developed for protein removal 
[164]. RAMs are suitable for on-line SPE, allowing direct injection of complex 
samples into LC-MS. Macromolecules are excluded from the stationary phase and 
eluted with the mobile phase and the small molecules are able to permeate 
through the pores of the RAM sorbent and interact with it by diverse mechanisms. 
RAMs are frequently used as pre-columns in column switching LC systems, using 
two pumps and a selection valve with a synchronization unit. These systems allow 
automate on-line protein removal and analyte preconcentration on the RAM pre-
column, and afterwards separation of the target compounds in the analytical 
column, avoiding or reducing sample pretreatment. However, high fat and protein 
contents may block the efficient elimination of interferences and decrease column 
lifetime. Different examples have been published, reporting the application of 
RAMs in extract purification of food samples e.g. the clean-up of trace levels of 
tetracycline antibiotics in food [165]. 
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G. Porous monolithic microextraction materials 
Thanks to their structure, monoliths have a number of potential advantages like low 
cost, mechanical robustness and high stability, no void volumes forming at 
conventional LC flow rates, high hydraulic permeability and dominance of 
convection over diffusion of mass-exchange under dynamic conditions, which allow 
the separation of target analytes at extremely high flow rates [166]. 
They are widely used as sorbents in in-tube solid phase microextraction (SPME). 
Basically, monolithic materials are divided into two groups: polymer- and silica-
based. Up till now, organic polymer and silica-based monoliths have been 
introduced as extraction media for the microextraction. Generally, the most 
commonly used organic polymer monoliths can be grouped into one of several 
broad categories [167]. Poly (methacrylic acid-co-ethylene glycol dimethacrylate) 
(poly (MAA-co-EGDMA)) monoliths are the most widely reported type to veterinary 
residue analysis. They have been used for the microextraction of sulfonamides in 
milk and eggs [168, 169], quinolones in milk, egg, chicken and fish muscles [170, 
171], tetracyclines in fish muscle [172] and chlorampenicol in honey, milk, eggs 
[173]. A hybrid organic-inorganic silica monolith with hydrophobic and strong 
cation-exchange functional groups was prepared and used for in-tube 
microextraction of sulfonamides in milk [174]. Also, Stir Bar Sorptive Extraction 
(SBSE) based on poly (vinylimidazole-co-divinylbenzene) (VIDB) monolithic 
material as coating was used to directly extract sulfonamide antibacterial residues 
in milk without de-fats and de-proteins step [175]. SBSE is based on sorptive 
extraction, whereby the solutes are extracted into a polymer coating on a magnetic 
stirring rod. The extraction is controlled by the partitioning coefficient of the solutes 
between the polymer coating and the sample matrix and by the phase ratio 
between the polymer coating and the sample volume [176]. 
 
H. Nanoparticles as sorbent materials 
The excellent properties of new nanomaterials were recently exploited for 
extraction and new clean-up technologies. Carbon nanotubes (CNTs) can be 
considered excellent materials for SPE because of their large adsorption surface 
and high affinity for organic compounds. Multi-walled CNTs (MWCNTs) are 
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preferred over the single-walled CNTs (SWCNTs), as the presence of concentric 
sheets results in enhanced interaction with the analytes. One of the advantages of 
carbon-based adsorbent materials is that their sorbent capacity is maintained even 
in organic media. Recent examples have reported the successful use of CNTs in 
preparing food samples [166, 177, 178]. 
 
1.5 Instrumental analysis 
 
1.5.1 Screening tests 
Very popular and quite often used methods for residue screening are methods 
based on microbial or immunological assay or bioassays [179, 180]. Screening 
methods usually can provide semi-quantitative or quantitative results, with low rate 
of false compliant samples. They can also assure high throughput, ease of use, 
short analysis time, good selectivity, and low cost. It is common practice for routine 
laboratories to apply screening methods, covering families of antibiotics, and 
samples found to be non-compliant are then analyzed by confirmatory methods 
[181]. However, this approach would not be sufficient itself. Positive responses 
from the rapid tests would need to be correlated with an actual presence of 
residues in the samples. Thus, very often, screening tests are accompanied by 
confirmatory methods [182]. 
 
1.5.2 Confirmatory methods 
Separation techniques, for example gas chromatography (GC), high-performance 
liquid chromatography (LC), and capillary electrophoresis, have been widely used 
for the analysis of veterinary drugs residues in food samples. Historically, the 
control of veterinary drug residues was based on chromatography coupled to non-
specific technologies such as fluorimetric detector (FLD), ultra violet detector (UV) 
and electron capture detector (ECD). However, these techniques suffer some 
inherent drawbacks: each antibiotic class has to be tested separately, confirmation 
of the target analytes is based mainly on retention-time comparison to standards 
and some analytes have to be derivatized to obtain an appropriate limit of 
detection (LOD). 
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The first introduction of mass spectrometry (MS) in the 1980s was immediately 
considered as a revolution in the domain due to its outstanding specificity and 
sensitivity. Compared with older chromatographic methods based on the use of 
conventional detectors, the use of separation techniques coupled to very selective 
MS detector systems, besides supplying precious information about the identity of 
a specific compound, offers the additional advantage that older laborious and time-
consuming sample treatment procedures can be greatly simplified, thereby 
resulting in faster and low-handling methodologies. 
Public Health Agencies in many countries rely on detection by mass spectrometry, 
which, being a specific detector, affords unambiguous confirmation of 
contaminants in foodstuff. Commission Decision 2002/657/EC states that “Methods 
based only on chromatographic analysis without the use of molecular 
spectrometric detection are not suitable for use as confirmatory methods” [54]. 
 
1.5.2.1 Capillary electrophoresis  
Capillary electrophoresis (CE) is a separative analytical technique which is widely 
accepted due to its ability to simultaneously determine different analytes with both 
high efficiency and resolution, low consumption of samples and electrolytes and 
the possibility of rapid method development [183]. CE is an adequate alternative to 
chromatographic techniques, mainly when only small sample amounts are 
available. 
The physicochemical properties of some veterinary drugs, their ionizable nature, 
multiple ionization sites and different water solubilities, make them highly suitable 
for electrophoretic analysis. Also, CE, as HPLC, allows automation, injection of 
smaller volumes of samples and multiple modes of detection (ECL, UV, DAD, FLD, 
MS etc).  For these reasons, CE is an analytical tool that has gain importance and 
today broadens its scope of applications, mainly in the food and drug analysis 
areas [184,185]. 
The coupling of CE with MS combines the excellent separation capabilities of CE 
and the power of MS in analyte identification, with MS/MS being additionally used 
in structure elucidation or for additional selectivity in order to gain sensitivity by 
reducing the background noise. CE-MS and CE-MS/MS methods have been 
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reported for the analysis of quinolones in chicken muscle [186], sulfonamides in 
pork [116], and sulfonamides and trimethoprim in meat samples [187]. 
Nevertheless, a small number of applications have been presented describing the 
simultaneous determination of different groups of veterinary drugs [188,189]. 
 
1.5.2.2 Gas chromatography – mass spectrometry 
GC is rarely used for the determination of veterinary drugs, due to the polar nature, 
low volatility and thermal instability of these drugs. Derivatization of polar 
compounds is advisable to improve peak shape and sensitivity of the method, 
acetylation being most widely used, since the reaction can be carried directly in 
aqueous phase. Once again, MS detection offers the major advantage of the 
qualitative identification of the analytes by their mass spectrum. 
 In the case of chlorampenicol the high sensitivity of the GC-NCI-MS technique 
may be advantageous and justify the time necessary for derivatization (silylation) of 
the antibiotic to enhance its volatility. GC-MS methods based on electron ionization 
(EI) have historically been used for this purpose [190], but the resulting sensitivity 
sometimes remains insufficient. Negative chemical ionization (NCI) is more 
commonly used since it is particularly well adapted for these halogenated 
substances which exhibit intense electronic capture properties [191]. The same 
strategy can be successfully applied for measuring other related compounds such 
as thiamphenicol or florfenicol [192]. 
A similar approach is also effective for β-agonists for which positive chemical 
ionization (PCI) is indeed an interesting option providing a wide panel of different 
mass spectra by varying the nature of the reagent gas in the ionization source. 
Τhese approaches provide excellent detectability, down to 0.1 μg kg-1 (ppb) for 
chloramphenicol in tissues and at sub-ppb levels for most β-agonists on the basis 
of one single ion. [191]. 
In conclusion, there is a downward trend in utilizing GC for the determination of 
antibacterials in food matrices, due to long analysis time and the additional step of 
derivatization, as demonstrated by the very small number of recent publications.  
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1.5.2.3 Liquid Chromatography – mass spectrometry 
LC-MS techniques provide a universal approach applicable to the widest number of 
veterinary drugs and this is the reason why they have today become the technique 
of choice in the field of the analysis of antibacterial residues in food stuffs. 
The combination of atmospheric pressure ionization tandem mass spectrometry 
(API-MS/MS), with liquid chromatography (LC) and ultra-performance LC (UPLC) 
is currently the most frequently used technique in antibacterial analysis. The most 
used atmospheric pressure interfaces are atmospheric pressure chemical 
ionization (APCI), and electrospray ionization (ESI). For compounds of moderate to 
high polarity, ESI constitutes the most important ionization technique in MS 
coupled to LC for the analysis of organic contaminants, and it dominates the 
application area of antibacterial analysis (Table 1.2). 
Among the different mass analyzers usually applied for target analysis, triple 
quadrupole (QqQ) is the most widely used for measuring and quantifying residues 
of veterinary drugs. Hybrid quadrupole-linear ion trap (Q-LIT) system combines 
fully functional quadrupole and linear ion trap-MS within the same instrument and 
thus, apart from great sensitivity, is capable of producing MSn spectral information, 
useful for structure elucidation. Q-LIT has been used in fewer applications than 
simple triple quadruple formats. 
However, a recent trend towards the high-resolution mass spectrometry (HR-MS; 
i.e. time-of-flight, TOF; Orbitrap; Fourier Transform-Ion Cyclotron Resonance, FT–
ICR) is undoubtedly observed. High resolution mass analyzers and hybrid mass 
analyzers, such as Q-TOF, LIT-Orbitrap, open a new era in food analysis, together 
with holistic sample preparation and retrospective analysis. Due to their high 
resolving power, mass accuracy, fragmentation and isotopic pattern elucidation 
can provide tentative identification of non-target and unknown compounds in food 
samples. Full scan acquisition mode and MSn mode are useful tools of these new 
generation instruments. 
The main source of analytical problems encountered by LC-MS users is related to 
matrix effect problems, particularly when studying complex samples, such as food. 
It represents certainly one of the main sources of pitfall for the analyst, affecting 
many aspects of the method performance, such as detection capability, 
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repeatability and accuracy. Matrix effect mainly appears as ion suppression and it 
corresponds to the decrease of the evaporation efficiency of the ions of the analyte 
due to competition effects with co-extracted and co-eluted matrix components. 
Another proposed mechanism is the competition between analytes and interfering 
compounds regarding the maximal ionization efficiency of the technique [193-195]. 
Much less frequently and by a process not yet fully understood, the presence of 
endogenous compounds in the nanodroplets of the electrosprayed solution can 
result in an increased ion signals for the analytes compared to those of a reference 
standard solution. 
To overcome matrix effects when quantifying, two practicable approaches can be 
used. The use of adequate isotope-labeled internal standards and/or analyte 
quantitation by matrix-matched calibration standards should eliminate the analytical 
systematic errors (bias) caused by ion suppression or ion enhancement [196]. 
 
A. LC-MS/MS Techniques (QqQ and Q-LIT) 
Triple quadrupole MS analyzers (QqQ) present the highest sensitivity and 
selectivity when working in selected reaction monitoring (SRM) or multiple reaction 
monitoring (MRM), by selection of at least two precursor ion-to-product ion 
transition reactions. The fragmentation of the target compounds in order to detect 
only specific product ions rather than the entire molecule permits to considerably 
increase the signal to noise ratio of the target diagnostic signal by decreasing to a 
major extent the interferences due to other compounds present in the final extract 
with the same - or very close - molecular weight as the analyte of interest [191]. 
Under this condition, QqQ MS analyzers are best suited to achieve the strict 
tolerance levels regulated in various countries for antibacterials in different food 
matrices. 
The large number of veterinary drugs that have to be monitored in order to ensure 
food safety has caused a steady increase of the number of multi-analyte analytical 
methods developed in recent years. Applications of multi-analyte methods related 
to LC coupled to MS/MS are presented in Table 1.2.  
The application range of MS/MS is today extremely wide, both in terms of target 
compounds and in terms of possible different acquisition modes. This last 
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capability authorizes not only very sensitive and specific quantitative target 
measurements, but also powerful untargeted “fishing” approaches based on 
advanced scanning techniques like precursor ion scanning or neutral loss 
scanning, applicable to a class of substances with similar fragmentation patterns 
[197,198]. 
A drawback of the QqQ MS arrangement is its relatively long duty cycle (slow scan 
speed) that limits the number of scans that can be acquired simultaneously. As a 
result, SRM methods are typically limited to ~100 or 150 target analytes, 
depending on the chromatographic separation, resulting in a loss of sensitivity. 
Furthermore, for reliable quantification, two selected reaction monitoring transitions 
are required and some analytes present only one transition while some transitions 
are unspecific. In spite these disadvantages, QqQ still remains the analyzer of 
choice, coupled to liquid chromatography, for the determination of veterinary drugs 
in food matrices.  
 
B. High-resolution MS Techniques 
To overcome the drawbacks associated with QqQ and IT mass analyzers, as well 
as to meet with the challenge of monitoring drug metabolites that are either more 
stable of higher toxicological concern than the parent compound [199], high-
resolution mass analyzers (Q-TOF, Orbitrap and FT-ICR) are increasingly 
becoming more popular in analytical laboratories. 
The introduction of the reflectron TOF MS which is used to compensate for energy 
spread from the initial ion velocities has resulted in mass resolving power 
approaching Δm/m∼10,000 [Δm = full-width half-maximum (FWHM)]. Mass 
accuracy can currently reach values better than 10 ppm in routine conditions with 
external calibration. The ability of a time-of-flight (TOF) mass spectrometer to 
assign a mass to compounds with high accuracy (±0.005 Da) enables it to collect 
full scan data and still detect low levels (ng/g) of contaminants in complex food 
matrices with sufficient selectivity. A hybrid quadrupole TOF detector (Q-TOF) has 
the additional ability to obtain MS/MS spectra that can be used to further 
characterize drug residues. Fourier transform ion cyclotron resonance (FT-ICR) is 
one of the most sensitive ion-detection methods with mass accuracy of <1 ppm 
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[200], but the high cost of instrumentation currently restricts their application. An 
alternative to these techniques is the Orbitrap mass analyzer, launched in 2005. 
However, it suffers from a slower data acquisition rate than Q-TOF instruments, so 
it is not fully appropriate for fast chromatography [201]. This system provides 
outstanding mass accuracy, mass resolution and reliable high-sensitivity MSn 
performance, much higher resolving power (R = 100,000) than TOF-MS, which is 
important when analyzing complex matrices in order to avoid both false positive 
and false negative results [166].  
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CHAPTER 2 
Scope and Objectives 
 
2.1 The analytical problem 
There are three main difficulties that constitute the analytical problem in the residue 
analysis of veterinary drugs in food. First, there is the large number of compounds 
with diverse physico-chemical characteristics. In addition, the definition of 
‘‘residue’’ of many contaminants includes known metabolites of toxicological 
interest since many drugs administered to food-producing animals are oxidized, 
reduced and biotransformed to water-soluble conjugates, primarily by 
glucuronidation, sulfatation or conjugation with glycine. Such metabolites cannot 
be ignored, particularly when they are even more hazardous and more persistent 
than the parent compounds (e.g., nitrofurans are rapidly biochemically transformed 
into toxic metabolites, which are highly bound to the proteins, so they are stable for 
longer periods in food-producing animals) [202].  
The second problem is the very low concentration levels at which a veterinary drug 
residue should be analysed, since most of the MRLs and MRPLs established are 
at the ppb level (parts per billion or μg kg-1). Therefore, analytical methods for the 
determination of veterinary drug residues in food matrices at trace levels are 
necessary and the procedures used for selective and quantitative extraction of the 
analytes, cleanup and enrichment of sample, as well as the sensitive and specific 
detection should meet the requirements of this challenge. 
Finally, the complexity of the matrix should also be taken into consideration. 
Several edible tissues from food producing animals can be selected for residue 
surveillance including muscle, liver, kidney, skin and fat, which are normally 
collected at slaughter houses. In addition, further sample matrix types can be taken 
on-farm or at production sites, including milk, honey, eggs and fish. All these foods, 
except honey, are protein rich (from 3% in milk to 20% in meat), which is important 
for those drugs that bind easily to proteins. They also contain significant amounts 
of divalent and trivalent cations that form complexes with some antibacterials, 
increasing their retention in different tissues. In general, many residues are present 
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in conjugated forms and require liberation through enzymatic or chemical 
hydrolysis prior to extraction [13]. 
Due to all the aforementioned reasons and the desire of improving the cost-
effectiveness of analytical procedures, the development of multiclass methods 
which are able to detect, confirm and quantify as many compounds as possible, 
has become a significant trend in the analysis of residues and contaminants in food 
samples. Liquid chromatography hyphenated to mass spectrometric techniques 
dominates in the field of multi-residue determination of veterinary drugs in complex 
matrices, since it permits excellent sensitivity and selectivity. 
 
2.2 Research Objectives and Scope 
The experimental part of this thesis is consisted of 4 individual studies.  
In the first study performed a strategy was newly developed to rapidly screen 
seventeen sulfonamides and five tetracyclines in a single run from the fish tissue 
using ultra-high performance liquid chromatography (UHPLC) coupled with 
comprehensive mass spectrometric approaches including precursor ion scan and 
data dependent scan. The product ions for precursor-ion scanning were selected 
by studying the MS/MS fragmentation of the analytes. All sulphonamides share the 
same diagnostic product ion at m/z 156 in positive MS/MS scan, while for 
tetracycline antibiotics the diagnostic product ion was proved to be at m/z 154. 
Further characterization of each compound was performed using a data dependent 
scan.  
Separation was performed on a Zorbax Eclipse Plus C18 column with a gradient 
elution using acetonitrile - 0.1% formic acid mobile phase at a flow rate of 0.1 mL 
min-1. A comparison of extraction solvents has been performed in order to optimise 
the extraction procedure for both groups of antibiotics and develop an effective 
generic extraction procedure.Validation was performed according to Commission 
Decision 2002/657/EC and satisfactory method performance characteristics were 
achieved. 
In the second study, two wide-scope screening methods have been developed for 
the identification of veterinary drugs and pharmaceuticals in fish and milk using 
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liquid chromatography quadrupole time-of-flight (LC-QTOF-MS). The methods 
were validated using a qualitative approach at two concentration levels. The 
detection of the residues was accomplished by retention time, accurate mass and 
the isotopic fit using an in-house database. Product-ion spectra were used for 
unequivocal identification of the compounds. Generic sample treatments were 
applied. For fish tissues, a solid-liquid extraction with a mixture of aqueous 0.1% 
(v/v) formic acid and 0.1 (w/v) EDTA – acetonitrile – methanol (1:1:1, v/v) and 
cleanup with hexane was performed. Milk was treated with aqueous TCA 5% (w/v) 
- ACN (3:1, v/v) and then subjected to clean-up with Oasis HLB cartridges. The 
majority of the compounds were successfully detected and identified at the highest 
concentration level (more than 80% of the compounds in both matrices). 
Satisfactory results were obtained at the lowest level as well (more than 60 % of 
the compounds detected and identified). 
In the third study, a simple and sensitive multi-residue method for the 
determination of 115 veterinary drugs and pharmaceuticals, belonging in more than 
20 different classes, in butter, milk powder, egg and fish tissue has been 
developed. The method involves a simple generic solid-liquid extraction step 
(solvent extraction, SE) with 0.1% formic acid in aqueous solution of EDTA 0.1% 
(w/v) – acetonitrile (ACN) – methanol (MeOH) (1:1:1, v/v) with additional ultrasonic-
assisted extraction. Precipitation of lipids and proteins was promoted by subjecting 
the extracts at very low temperature (-23 ºC) for 12 hours. Further cleanup with 
hexane ensures fat removal from the matrix. Analysis was performed by liquid 
chromatography coupled with electrospray ionization and tandem mass 
spectrometry (LC–ESI–MS/MS). Two separate runs were performed for positive 
and negative ionization in multiple reaction monitoring mode (MRM). Particular 
attention was devoted to extraction optimization: different sample-to-extracting 
volume ratios, different concentrations of formic acid in the extraction solvent and 
different ultrasonic extraction temperatures were tested in butter, egg and milk 
powder samples. The method was also applied in fish tissue samples. It was 
validated, on the basis of international guidelines, for all four matrices and 
quantitative analysis was performed using standard addition method.  
Finally, in the fourth study performed, a rapid, sensitive and efficient multiresidue 
analytical method for the simultaneous determination of 76 veterinary drugs and 
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pharmaceuticals in bovine muscle tissue by HILIC–MS/MS has been developed. 
The multi-class method includes aminoglycoside determination which has been 
rarely reported in multiresidue methods due to aminoglycosides’ very different 
physicochemical properties comparing to other veterinary drugs.The analytical 
method includes ACN extraction followed by an acidic aqueous buffer extraction,  
cleanup with HLB cartridges and HILIC-MS/MS determination using bare silica 
stationary phase (BEH HILIC). The method was thoroughly optimized and 
validated according to the European Commission Decision 2002/657, 
demonstrating its good performance and its great potential value in the veterinary 
drug and pharmaceutical analysis field. 
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CHAPTER 3 
Multi-residue determination of seventeen sulfonamides and five 
tetracyclines in fish tissue using a multi-stage LC-ESI-MS/MS 
approach based on advanced mass spectrometric techniques. 
 
3.1 Introduction 
In this study, a strategy was newly developed to rapidly screen seventeen 
sulfonamides and five tetracyclines in a single run from the fish tissue using ultra-
high-performance liquid chromatography (UHPLC) coupled with comprehensive 
mass spectrometric approaches including precursor ion scan and data dependent 
scan. The product ions for precursor-ion scanning were selected by studying the 
MS/MS fragmentation of the analytes. All sulphonamides share the same 
diagnostic product ion at m/z 156 in positive MS/MS scan, while for tetracycline 
antibiotics the diagnostic product ion was proved to be at m/z 153.8. Further 
characterization of each compound was performed using a data dependent scan. 
Separation was performed on a Zorbax Eclipse Plus C18 column with a gradient 
elution using acetonitrile - 0.1% formic acid mobile phase at a flow rate of 0.1 mL 
min-1. 
This approach has proven to be a powerful, highly selective, and sensitive tool for 
rapid screening and detection of non targeted components in fish tissue and 
requires a minimum sample preparation such as one generic extraction step with 
MeOH:ACN 50:50 v/v acidified with 0.05% formic acid. A single UHPLC run is 
required for the confirmation of all 22 compounds and validation data is presented 
for all analytes in fish tissue according to Commission Decision 2002/657/EC. The 
method has also been applied successfully to porcine and poultry meat. With this 
method also non-target compounds of these two groups of veterinary drugs can be 
determined due to their common fragmentation pattern. 
 
3.2 Experimental section 
 
3.2.1 Chemicals and Reagents 
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Acetonitrile and methanol LC–MS grade were purchased from Fisher Scientific 
(Fair Lawn, NJ) and formic acid 99% from Fluka (Buchs, Switzerland). Distilled 
water was provided by a MilliQ purification apparatus (Millipore Direct-Q UV, 
Bedford, MA, USA). Oxytetracycline (OTC), tetracycline (TC), demeclocycline 
(DMTC), chlortetracycline (CTC), doxycycline (DC), sulfadiazine (SDZ), 
sulfathiazole (STZ), sulfamerazine (SMR), sulfadimidine (SDD), 
sulfamethoxypyridazine (SMP), sulfamonomethoxine (SMM), sulfachloropyridazine 
(SCP), sulfadimethoxine (SDM), sulfamethizole (SMT), sulfamethoxazole (SMTX), 
sulfisoxazole (SIX), sulfaguanidine (SGN), sulfapyridine (SPD), sulfamoxole (SMX) 
and sulfaquinoxaline (SQX) were provided from Sigma–Aldrich (Athens, Greece), 
while sulfadoxine (SDX) and sulfaclozine (SClZ) were donated by the National 
Laboratory of Residue Analysis of Food of Animal Origin of the Hellenic Ministry of 
Rural Development and Food. The structures of all the examined compounds are 
presented in Figures 3.1 and 3.2. 
Standards stock solutions (500 μg mL−1) of all veterinary drugs were prepared in 
methanol and were stored at -20 ºC. A multi component solution of the 22 
compounds was obtained by diluting the stock solution in methanol to a final 
concentration of 2 μg mL−1. These solutions were stored at 4 ºC for up to one 
month. Matrix-matched standards were prepared in the same way as the other 
samples. 
 
Figure 3.1. Chemical structure of tetracyclines. 
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Figure 3.2. Chemical structure of sulfonamides. 
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3.2.2 Samples 
Negative fish (sea bass and sea bream), porcine and poultry tissue samples were 
used during these experiments. All fish samples were obtained from aquaculture 
and were confirmed to be free of targeted analyte residues by LC-MS/MS after 
sample preparation with the procedure developed and optimized. Porcine and 
poultry tissue samples were obtained by local supermarket and were also 
evaluated for the survey analysis. All tissue samples were homogenized and 
stored at −20 ºC until analysis. 
 
3.2.3  UHPLC–MS/MS conditions 
A Thermo UHPLC Accela system was connected to a Thermo Scientific TSQ 
Quantum Access Triple Quadrupole Instrument (Thermo, San Jose, CA, USA). A 
Zorbax Eclipse plus C18 (2.1 mm × 50 mm, 1.8 μm, Agilent, CA, USA) column 
protected by a guard column was used at a constant flow rate of 100 μL min−1. 
Mobile phase consisted of water containing 0.1% formic acid (v/v) (solvent A) and 
acetonitrile (solvent B). The gradient used was: 0–12 min linear gradient from 5 to 
50% B; 12–13 min from 50 to 5% B and 13–21 min held at 5% B in order for the 
column to reequilibrate before the next injection. The full loop injection volume of 
the tissue extract was set at 10 μL.  
The quadrupole instrument was operated in the positive-ion mode under the 
following conditions: Spray Voltage, 4000 V; Capillary temperature 270 ºC; Sheath 
gas 60 psi; Auxiliary (drying) gas 20 a.u. Two MS runs were done for each sample: 
one in the precursor ion scan mode and one in data dependent-scan mode. 
Different scan events were created for sulfonamides and tetracyclines in both MS 
modes. For SAs in the precursor-ion scan mode m/z 156 was selected as the 
product ion, collision energy was set at 22 eV, scan time of 1 s was used in both 
quadrupoles Q1 and Q3, and the Q1 scan range was set at m/z 210–315. For TCs 
the product ion was m/z 153.8, collision energy 30 eV, scan time for Q1 and Q3 1 s 
and the Q1 scan range was set at m/z 440–480. This experiment is used as a 
survey experiment to trigger a data dependent (DD) scan of the most abundant ion 
when exceeding a certain threshold, set at 1×104 counts for SAs and at 0.1×104 
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counts for TCs. The data dependent scan was performed with a collision energy of 
30 and 28 eV for SAs and TCs, respectively. 
 
3.2.4 Sample preparation 
Homogenised tissue (1.0 g) was weighed in a 15 mL polypropylene Falcon tube. 
Samples were fortified as appropriate with the targeted compounds. For method 
development each experiment consisted of one blank and three fortified blank 
samples (spikes) in the MRL level. Fortification at a concentration of 100 μg kg−1 
for each analyte was performed by adding 50 μL of the multi-analyte working 
solution (concentration 2 μg mL−1). After that the samples were mixed and allowed 
to stand in the dark for at least 15 min.  
Various extraction solvents were tested (acetonitrile, methanol, acetone) as well as 
two concentrations of formic acid (0.05, 0.1%, v/v) in order to conclude to the most 
efficient mixture which would provide the highest recovery and the lowest signal 
suppression for most of the analytes. Signal suppression states the peak ratio of 
analyte response in matrix extract over the equal concentration of analyte in pure 
standard solution. Addition of 5mL of acetonitrile, 5mL of methanol and 5 μL of 
formic acid was followed by vortex shaking for 30 s and a 15-min ultrasonic 
extraction of the antibiotics from the tissue. Subsequently, the samples were 
centrifuged (3000 rpm, 10min) and a 4mL aliquot of supernatant sample extract 
was transferred to a test tube. The extract was evaporated to dryness under a light 
stream of nitrogen (at 40 ºC). The dry sample was reconstituted in 0.40 mL of 
aqueous formic acid 0.2%, vortexed and ultrasonicated for 1min. After filtration by 
a 0.2 μm RC filter into a polypropylene vial (Mini-UniPrep syringeless filters, 
Whatman, Kent, UK), an aliquot of 10 μL of the extract was analyzed by LC–ESI–
MS/MS. 
 
3.2.5 Validation 
Validation of the developed procedure was performed according to Commission 
Decision 2002/657/EC [54] which indicates that for quantitative screening methods 
the performance characteristics that have to be determined are the detection limit, 
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CCβ, precision, selectivity/specificity and applicability/ruggedness/stability at the 
level of interest. SAs and TCs have common Maximum Residue Limit (MRL) in 
animal tissue, set at 100 μg kg−1 and this concentration was selected to be the 
spiking level for the methods’ validation. The validation was performed using fish 
tissue as the major matrix. Method detection limit (LOD), method quantitation limit 
(LOQ), precision, selectivity, decision limit (CCα) and detection limit (CCβ), were 
estimated based on the analysis of spiked blank fish samples. Ruggedness of the 
method was estimated by analysing spiked poultry and porcine samples. Method 
precision was expressed as relative standard deviation (%RSD). 
 
3.3 Results and discussion 
 
3.3.1 LC–MS/MS method 
Precursor-ion scanning is a powerful approach, since the only knowledge required 
is the fragmentation pattern of the compound. Searching for common fragment 
ions can also provide vital information about the putative structure of a metabolite. 
By fixing the third quadrupole Q3 on selected ion, and scanning the first 
quadrupole Q1 over an appropriate range, the resulting spectra contain all of the 
precursor ions that produce the common fragment ion selected at Q3. The pseudo-
molecular ions of all the examined compounds are summarized in Table 3.1. 
 
 
 
 
 
 
 
 
 
 
82 
 
Table 3.1: Pseudo-molecular ions ([M+H]+), retention times (RT with their SD, n = 18) and 
characteristic product ions of sulfonamides and tetracyclines. 
 [M+H]+ RT ± S (min) 
Characteristic 
ions 
 [M+H]+ RT ± S (min) 
Characteristic 
ions 
SDZ 251 6.42 ± 0.10 156, 92, 108 SGN 215 2.55 ± 0.15 156, 92, 108 
STZ 256 7.13 ± 0.11 156, 92, 108 SIX 268 8.21 ± 0.15 156, 92, 108 
SMR 265 7.64 ± 0.07 156, 92, 108 SMX 268 11.00 ± 0.09 156, 92, 108 
SDD 279 8.43 ± 0.09 156, 92, 108 SQX 301 11.94 ± 0.08 156, 92, 108 
SMP 281 8.81 ± 0.12 156, 92, 108 SMTX 254 10.59 ± 0.12 156, 92, 108 
SPD 250 7.24 ± 0.07 156, 92, 108 SMT 271 8.74 ± 0.08 156, 92, 108 
SMM 281 9.63 ± 0.14 156, 92, 108 OTC 461 7.72 ± 0.09 154, 443, 426 
SCP 285 9.99 ± 0.10 156, 92, 108 CTC 479 9.57  ± 0.08 154, 462, 444 
SDX 311 10.33 ± 0.12 156, 92, 108 DC 445 9.96  ± 0.07 154, 428, 410 
SClZ 285 11.82 ± 0.06 156, 92, 108 TC 445 8.15 ± 0.10 154, 427, 410 
SDM 311 11.93 ± 0.06 156, 92, 108 DMTC 465 8.84 ± 0.07 154, 448, 430 
 
Each sulfonamide and tetracycline standard was diluted in methanol and infused at 
a flow rate of 10 μL min−1 in order to establish the pseudo-molecular ion in a 
positive ESI mode and check the presence of potential impurity or adduct ions. 
Only protonated species [M+H]+ were observed for all the compounds and from 
these experiments, breakdown curves were recorded under different collision 
energy conditions to select the main characteristic fragments for quantification and 
analyte confirmation purposes.  
Sulfonamides show a very typical fragmentation pattern, which includes ions with 
m/z 156, 92 and 108, as shown in Figure 3.3. As the first ion was found to be the 
most intense for the majority of sulfonamides, it was selected for our precursor-ion 
scan experiment to increase the overall sensitivity of such method. Precursor-ion 
scan survey of m/z 156 was optimized at collision energies of 22 and 30 eV, with 
the first being the optimum, as the collision energy of 30 eV proved to disassemble 
the fragment of m/z 156 in the other two characteristic fragments of SAs (m/z 92 
83 
 
and 108), decreasing the sensitivity of the method. This scan was performed in a 
m/z range of 210–315 within 1 s. 
 
Figure 3.3: Fragmentation pattern of sulfonamides. 
 
The fragmentation patterns of protonated tetracyclines have been reported 
previously  and [203-205] and in general, they show an array of common fragment 
ions such as ions at m/z 154, 126, 98, and 58 that are identified as characteristic of 
the whole class of molecules. Possible structures for these common fragment ions 
are shown in Figure 3.4 but numerous other resonance structures and other 
isomers could be proposed [206].  
 
Figure 3.4 Possible structures of the fragment ions with m/z 154, 126, 98, 86, 58 [33]. 
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The fragment ion that was chosen for the precursor-ion scan experiment was the 
most intense common fragment at m/z 153.8, as it was found from the breakdown 
curves obtain for each compound. Optimization for the collision energy was 
performed at 25 and 30 eV and the optimum value was proved to be 30 eV, 
because the precursor ion was not sufficiently produced at the lower collision 
energy, resulting in low sensitivity of the detection of tetracyclines. This scan was 
performed in a different scan event than the precursor-ion scan for sulfonamides 
and in a m/z range of 440–480, also within 1 s. 
The precursor ions chosen for both sulfonamides and tetracyclines not only 
present the highest intensity, but were also the most selective ones (highest m/z). 
A chromatogram of all 22 compounds in the precursor-ion scan mode is presented 
in Figure 3.5. 
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Figure 3.5 Precursor-ion scan chromatograms of a fish tissue spiked with 
seventeen sulfonamides and five tetracyclines at the MRL level (100 μg kg−1). 
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Experiments were performed in order to reduce the chromatographic analysis time, 
but the results showed that when higher flow rates and steeper gradient were 
used, chromatographic separation was not adequate. There are five pairs of 
isobaric compounds (Table 3.1) that should be separated, namely SMP and SMM, 
SCP and SClZ, SDZ and SDM, SIX and SMX, and DC and TC and determined 
independently. In addition, for shorter chromatographic runs, there was a 
significant loss of sensitivity, especially for the first eluting compounds. These 
drawbacks lead to choose a chromatographic run that was probably more time-
consuming than previously described UHPLC methods, however, it produced the 
best and most reliable results and permitted the determine all the analytes (22 
compounds in total) in one chromatographic run and in concentrations as low as 
possible. 
Τhis experiment was used to trigger a data dependent (DD) scan of the most 
abundant ion when exceeding a certain threshold. The appearance in this scan of 
characteristic ions for each group of compounds confirms that the determined 
compound belongs either to TCs or to SAs. For SAs the characteristic ions are the 
ions with m/z 92 and 108, while for protonated tetracyclines, in addition to the 
characteristic series of fragment ions at m/z 154, 126, 98 and 58, their pseudo-
molecular ions typically lose water, ammonia, or a combination of both, as noted 
previously [203-205]. DC and DMCTC undergo loss of ammonia instead of 
dehydration, whereas the other three may undergo dehydration first [203-204]. The 
three tetracyclines that undergo dehydration (TC, OTC, and CTC) have the 
common feature that they possess a hydroxyl group at the C6 position, whereas 
the others do not. The confirmation of tetracycline compounds was performed by 
monitoring these neutral losses than monitoring the fragment ions cited above 
since it was proved that it is the fragment ion at m/z 154 which is dissociated to m/z 
126 and 98 and this cannot occur in a simple MS/MS mode, but it needs a MSn in 
order to obtain the small fragments in a full-scan spectra [206]. 
Two scan events were added in the method, one for sulfonamides and one for 
tetracyclines, including different signal thresholds and different collision energies. 
Sulfonamides were more sensitive than tetracyclines in the precursor-ion scan 
mode and for that the chosen signal threshold was 1 × 104 counts whereas for 
tetracyclines was 0.1 × 104. The collision energies for the data dependent-scan 
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mode were also optimized for both groups of veterinary drugs and the optimum 
values were 30 eV for SAs and 28 eV for TCs. The choice of the optimum collision 
energy was made based on the appearance in the full-scan spectra of the 
characteristic fragment ions for each compound, as well as on the repeatability of 
the spectra obtained. In Figure 3.6 and  Figure 3.7 two chromatographs are 
presented, one for SAs and one for TCs, in both precursor-ion scan and data 
dependent-scan mode, along with the obtained full-scan spectra. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Total ion chromatogram and full-scan spectra of sulfamerazine (SMR) 
spiked in fish tissue at the MRL level. 
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Figure 3.7: Total ion chromatogram and full-scan spectra of chlortetracycline 
(CTC) spiked in fish tissue at the MRL level. 
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(pseudo-molecular ion: 1 point) and three product ions (3 × 1.5 = 4.5 points). Thus, 
the identification points earned using the precursor-ion scan–data dependent-scan 
technique are more than the SRM technique with two product ions (in total 5.5 
identification points in comparison to 4 points of the SRM method) and therefore it 
fulfils the required criteria for a reliable identification of the compounds [54]. 
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3.3.2 Sample preparation – extraction procedures 
Sulfonamides, which are amphoteric compounds, are readily extracted by organic 
solvents when they are present in molecular form. Sulfonamides are not very 
soluble in non-polar solvents, but have good solubility in polar solvents. Therefore, 
the extraction is generally done with acetonitrile [207,208], chloroform, methylene 
chloride, acetone, or ethyl acetate [209]. The solubility of tetracyclines is higher in 
alcohols such as methanol (MeOH) and ethanol, while varied in other organic 
solvents, as ethyl acetate (EtOAc), acetone, and acetonitrile (ACN). Organic based 
extractions have been performed with EtOAc, ACN, and methanolic trichloroacetic 
acid (TCA) [210-212]. 
The pH value can change the form of analytes in the solvent system and greatly 
affect the extraction efficiency. In general, the compounds interaction with the 
matrix could be avoided by extracting at low pH. A possible explanation for this 
could be that, at neutral conditions, acidic analytes are in their deprotonated state 
and can interact with (protonated) amino functionalities on matrix material. Vice 
versa, basic analytes can interact with deprotonated acidic functionalities on the 
matrix material. At low pH the acidic groups are protonated and exist in their 
neutral state, while basic functionalities are either neutral or protonated (cationic). 
As a consequence, no or less interactions take place, the analytes do not bind to 
the matrix and remain dissolved in the extract solution [104]. 
When most of sulfonamides are extracted in basic conditions, the H+ dissociation 
of secondary amino group increases, so that the extraction efficiency of 
sulfonamides is obviously lower than the extraction process using acidic or neutral 
conditions. However, there is only a slight difference between using the acidified or 
non- acidified extraction solution, although there is a great pKa value discrepancy 
for SAs [208]. 
Acidification of the extraction solvent was mostly beneficial to the extraction of 
tetracyclines. The pKa1 values for OTC, TC, CTC, DMTC and DC vary from 3 to 3.6 
[213] and is associated with the deprotonation of C3 hydroxyl. Loss of protons from 
O12 and dimethylammonium constitutes pKa2 (from 7.5 to 8) and pKa3 (from 8.9 to 
9.8), although the exact assignment of these dissociation constants remains 
controversial [213, 214]. As indicated by their acid dissociation constants, the TCs 
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contain localized charges across all pH values and only achieve an overall neutral 
state as zwitterions. As a result, tetracyclines achieve high molar solubility and best 
extraction to the organic phase at pKa1 < pH < pKa2, where they are in equilibrium 
favouring the zwitterionic state over the fully protonated species [215]. 
Although a wide range of analytes need to be extracted as efficiently as possible, 
the co-extraction of bulk matrix constituents like fat, proteins, and carbohydrates is 
undesirable. They may reduce the lifetime of the UHPLC column and affect the 
ionization process in LC–MS analysis causing a suppression or enhancement of 
analyte response [194,195]. Therefore, besides recoveries, such effects were also 
taken in consideration during evaluation of the extraction procedure. 
For method development and optimization of the extraction procedure each 
experiment consisted of one blank and three fortified blank samples (spikes) in the 
MRL level. Among all the extraction solvents tested, ACN consistently was the 
most favourable with respect to matrix effects, but was not suitable for the 
extraction of tetracyclines. When methanol and acetone were compared, overall 
matrix effects for sulfonamides were less abundant for acetone, but it caused a 
sever signal suppression as far as tetracyclines are concerned. However, 50% 
methanol, giving a relatively high recovery of TCs along with lower signal 
suppression was chosen along with acidification of the extraction solvent with 
0.05% formic acid. The results of the extraction procedure optimization are shown 
schematically in Figures 3.8 – 3.11. 
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Figure 3.8: Recoveries (%) of 17 sulfonamides from fish tissue in different extraction solvents. 
 
 
Figure 3.9: Recoveries (%) of 5 tetracyclines from fish tissue in different extraction solvents. 
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Figure 3.10: Ion suppression after post-extraction spike of sulfonamides in fish tissue extract. 
 
 
Figure 3.11: Ion suppression after post-extraction spike of tetracyclines in fish tissue extract. 
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No clean-up was performed in order to make the method fast and simple. This 
enabled the analysis of a large number of samples (20–30) within a working day. 
Sensitivity achieved by this simple process was sufficient to determine the 
analytes at the concentration levels of interest. The use of matrix-matched 
standards ensured correct quantification of the samples, as ion suppression 
effects were automatically corrected. 
 
3.3.3 Validation 
The applicability of the developed method was tested following the accepted 
criteria for analytical method validation, as indicated in the Commission Decision 
2002/657/EC for quantitative screening methods [54]. Method detection limit 
(LOD), quantitation limit (LOQ), precision, selectivity, decision limit (CCα) and 
detection capability (CCβ) were determined for all compounds in fish tissue and 
precision was also determined for poultry and porcine tissue. All 22 compounds 
presented very similar behaviour in the three matrices examined, a fact that leads 
to the conclusion that sensitivity as well as CCα and CCβ are approximately at the 
same levels as the values that estimated for the fish tissue samples. 
 
3.3.3.1 Limit of detection and limit of quantification 
The calibration curves for detection of the analytes were obtained by performing a 
linear regression analysis on samples spiked with the analytes before the 
extraction. The linearity obtained for all analytes were good in the investigated 
interval (20–150 μg kg−1) with correlation coefficients higher than 0.98. The limit of 
detection of the method was calculated as 3.3 times the standard error of the 
intercept (Sa) divided to the slope of the calibration curve and the limit of 
quantification as 10 times the Sa divided to the slope. The results are presented in 
Table 3.2. In every case, LOD was found to be much lower than the MRL. 
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Table 3.2: LOD, LOQ, CCα and CCβ values for the developed multi-analyte, multi-
stage LC–MS/MS method. 
Sas LOD (μg Kg-1) LOQ (μg Kg-1) CCα (μg Kg-1)  CCβ (μg Kg-1) 
SDZ 22 67 16 27 
STZ 13 39 9.2 16 
SMR 5.7 17 4.0 6.8 
SDD 16 49 12 20 
SMP 5.9 18 4.1 7.1 
SPD 7.4 23 5.0 8.5 
SMM 7.0 21 11 19 
SCP 16 47 7.0 12 
SDX 9.9 30 7.4 13 
SClZ 11 32 5.8 9.9 
SDM 8.3 25 25 37 
SGN 24 73 5.0 8.5 
SIX 9.7 29 6.8 12 
SMX 7.4 23 5.2 8.9 
SQX 16 47 11 19 
SMTX 14 44 10 17 
SMT 12 36 8.4 14 
OTC 26 78 18 31 
CTC 15 45 10 18 
DC 15 47 11 19 
TC 10 31 7.3 12 
DMTC 15 46 11 18 
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3.3.3.2 Decision limit (CCα) and detection capability (CCβ) 
For the calculation of CCα and CCβ, all compounds were treated as banned 
substances since the goal of the developed method is to quantitatively screen for 
sulfonamides and tetracyclines in the lowest possible level. Decision limit and 
detection capability of the method where calculated based on the matrix matched 
calibration curve of samples spiked with the analytes before the extraction [54], 
according to the following equations: CCα (μg kg−1) = a/b + 2.33Sa/b (α = 1%) and 
CCβ (μg kg−1) = CCα + 1.64Sa/b (β = 5%), where a is the intercept of the matrix-
matched curve (20–150 μg kg−1), b is the slope of the matrix-matched curve and 
Sa is the standard error of the intercept. The results are presented in Table 3.2. 
CCβ values range from 6.8 μg kg−1(SMR) to 37 μg kg−1 (SDM). It is concluded that 
the developed method has a very good applicability for detecting the selected 
antibiotics with a statistical certainty of 95% in fish tissue since all CCβ values are 
more than three times below the established MRL (100 μg kg−1). 
 
3.3.3.3 Precision 
The repeatability of the analytical method for each matrix was calculated from the 
analysis of 18 blank fish, poultry and porcine tissue samples (at sets of six) spiked 
each with the 22 veterinary drugs at the MRL level before the extraction. The 
analysis was performed by the same operator on three separate occasions in a 
week period (six experiments per day) and the %RSD of the concentrations 
determined for each compound were calculated. For the reproducibility of the 
method three sets of two spiked samples were analysed in three separate 
occasions and the %RSD of the concentrations determined was calculated. The 
same methodology was followed for all three matrices. All the results are 
summarised in Table 3.3. It can be observed that the RSDs were always lower 
than 20% for all the antibiotics, indicating the good performance of the developed 
method. 
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Table 3.3: Precision values (as %RSDs) for all analytes in all matrices analysed. 
 Fish  Poultry  Porcine  
 % RSDr % RSDR % RSDr % RSDR % RSDr % RSDR 
SDZ 8.4 13 5.2 19 8.6 15 
STZ 6.8 11 7.5 11 11 11 
SMR 12 13 7.3 15 5.4 10 
SDD 9.4 11 9.8 12 5.0 11 
SMP 8.4 9.6 12 13 6.8 8.0 
SPD 4.3 8.8 9.2 15 8.2 11 
SMM 8.5 12 14 16 9.3 11 
SCP 5.3 11 6.5 8.2 5.3 10 
SDX 3.5 8.1 9.0 12 3.9 5.9 
SClZ 13 18 13 18 10 16 
SDM 7.1 12 6.5 8.4 4.1 5.6 
SGN 16 21 15 16 7.6 13 
SIX 8.3 8.7 8.0 10 5.0 8.8 
SMX 8.4 11 11 12 6.9 8.6 
SQX 13 15 7.1 10 8.8 14 
SMTX 8.8 11 4.2 7.8 6.1 11 
SMT 6.7 11 10 12 11 12 
OTC 15 17 18 18 15 18 
CTC 9.2 12 9.2 13 9.1 18 
DC 12 14 11 13 11 19 
TC 5.7 11 7.3 14 6.9 14 
DMTC 11 19 16 17 13 18 
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3.3.3.4 Specificity/selectivity 
The specificity of the method is also good. Analysis of blank samples did not show 
any peaks in the area of interest. Six sets of compounds, tetracycline/doxycycline, 
sulfamethoxypyridazine/sulfamonomethoxine, sulfachloropyridazine/sulfaclozine, 
sulfado-xine/sulfadimethoxine, sulfamoxole/sulfisoxazole and 
sulfadiazine/sulfapyridine have very similar molecular weights at 445 and 281, 
285, 311, 268 and 251–250, respectively. However, these compounds can be 
easily distinguished on the basis of retention time as it is shown in the 
chromatogram of the veterinary drugs (Figure 3.5). 
In addition, 20 fish tissue samples were spiked in the MRL level, randomly with 
one out of three different standard mixtures, and were analysed. This study 
showed no false positive or false negative results. The concentration of the 
antibiotics determined was in every case inside the limits of ± the standard 
deviation that was calculated in the reproducibility experiments. All these 
parameters indicate the good performance of the proposed analytical method. 
 
3.3.3.5 Ruggedness 
In order to evaluate the ruggedness of the method, three sets of spiked samples at 
the MRL level were analyzed. Each set consisted of seven samples of fish, poultry 
and porcine tissue, respectively, spiked randomly with one out of three different 
standard mixtures. The results showed no false positive or false negative results in 
every case and they were again consistent with the results of the reproducibility 
experiments performed for each matrix. 
 
3.3.4 Analysis of real samples 
This method has been used to analyze 30 sea bream and sea bass samples 
available from a local market. Among the 30 samples analyzed, only SIX was 
found in one of them at a concentration of 45 μg kg−1. Antibiotics were considered 
as positively identified in fish samples when all the confirmation criteria were met: 
(i) identical retention time (±2.5% of the one observed for the matrix-matched 
calibrants) and (ii) actual pseudo-molecular ion ([M + H]+) and characteristic 
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product ions as shown in Table 3.1. Figure 3.12 shows the chromatogram of the 
sea bass sample in which SIX was detected and identified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Total ion chromatogram and full-scan spectra of sulfisoxazole (SIX) 
found in a sea bass sample using the developed method. 
 
3.3.5 Conclusions 
A multi-stage LC–ESI–MS/MS method for the simultaneous determination of 
seventeen sulfonamides and five tetracyclines in fish tissue was developed and 
validated. The determined CCα and CCβ were adequate for SAs and TCs residue 
analysis, at levels well below the established MRL (100 μg kg−1). This method can 
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be applied also for the determination of unknown SAs and TCs due to the common 
fragmentation pattern of all the compounds in each category. Experiments were 
performed for the optimization of a generic solvent extraction. MeOH–ACN 
acidified with 0.05% (v/v) of formic acid was finally chosen due to the highest 
recoveries and the lowest ion suppression, especially for tetracyclines. 
The developed method has two main advantages in comparison to current SRM 
methods. The sample preparation procedure consists of a single generic 
extraction of the analytes from the matrix, requiring no cleanup step, a fact that 
makes the method fast and permits the screening analysis of a large number of 
samples. In addition, it could be applied for the determination of all compounds 
that belong to the groups of sulfonamides and tetracyclines, which, due to their 
common fragmentation pattern, provide the same precursor ion. Therefore, also 
unknown non-targeted compounds belonging to these groups of antibiotics can be 
determined, something that is not possible with a SRM method, which is used to 
determine only specific compounds. 
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CHAPTER 4 
Qualitative multi-residue screening methods for 143 veterinary 
drugs and pharmaceuticals in milk and fish tissue using Liquid 
Chromatography Quadrupole-Time-Of-Flight Mass Spectrometry 
 
4.1 Introduction 
The objective of this work was the development of a reliable, sensitive and modern 
screening methodology for the rapid detection and identification of 143 veterinary 
drugs and pharmaceuticals in milk and fish samples based on the use of advanced 
UHPLC–QTOF–MS technique. Generic sample extraction procedures were used 
and their efficiency was evaluated. A qualitative method validation of the screening 
method was performed and subsequently the method was applied to the analysis 
of different milk and fish samples to test its applicability. Experimental data, 
including retention times and product ion spectra were obtained for all target 
compounds and measured exact mass data are presented. The majority of the 
compounds were successfully detected and identified at the highest concentration 
level (more than 80% of the compounds in both matrices). Very satisfactory results 
were obtained in the lowest level as well (more than 60 % of the compounds 
detected and identified). 
 
4.2 Experimental section 
 
4.2.1 Chemicals and Reagents 
All veterinary drug and pharmaceutical standards were of high purity grade (>90%) 
The vast majority of them were purchased from Sigma-Aldrich (Steinheim, 
Germany). Sulfadoxine (SDX) and sulfaclozine (SClZ) were donated by the 
National Laboratory of Residue Analysis of Food of Animal Origin of the Hellenic 
Ministry of Rural Development and Food. Bacitracin, halofuginone, arprinocid, 
salinomycin, semduramicin, manduramycin, nigericin, narasin, albendazole 
sulfone, carprofen, diclofenac, flunixin, mefenamic acid, meloxicam, niflumic acid 
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and tolfenamic acid were donated by the Veterinary Drug Residues Laboratory of 
the State General Laboratory of Cyprus. 
Acetonitrile (ACN) and methanol (MeOH) LC–MS grade were purchased from 
Merck (Darmstadt, Germany), while 2-propanol LC-MS grade from Fisher 
Scientific (Geel, Belgium). Sodium hydroxide monohydrate (NaOH) for trace 
analysis 99.9995% and formic acid 99% were purchased from Fluka (Buchs, 
Switzerland). Hexane (pesticide analysis grade, 95%) was purchased from Carlo 
Erba (Milan, Italy) and distilled water was provided by a MilliQ purification 
apparatus (Millipore Direct-Q UV, Bedford, MA, USA). The 
ethylenediaminetetraacetic acid disodium salt (EDTA) and the trichloroacetic acid 
(TCA) were of analytical grade and were purchased from Panreac (Barcelona, 
Spain) and Fisher Scientific (Loughborough, UK), respectively. RC (Regenerated 
Cellulose) syringe filters (15 mm diameter, 0.22 μm pore size) were provided from 
Phenomenex (Torrance, CA, USA). Solid phase extraction cartridges were Oasis 
HLB 3 cc (60 mg) and 6 cc (200 mg) from Waters (Millford, MA). 
Stock standard solutions of individual compounds (1000 μg ml -1) were prepared in 
methanol and stored at −20 ºC in brown glass to prevent the photodegradation. 
Penicillins, cefalosporines and metformin were dissolved in MilliQ-water and 
stored at 4 ºC. In quinolone standard solutions, 100 μL of formic acid were added 
to enhance solubility. Four intermediate standard solutions containing the analytes 
grouped according to their classification and stability were prepared by dilution of 
the stock solutions with methanol. The final concentration of these multi-
component solutions was 10 μg mL-1 and they were also stored at −20 ºC. New 
ones were prepared every month. All working solutions and calibration standards, 
containing all the target analytes, were obtained by gradient dilution of the 
intermediate solutions, in concentrations varying from 1 μg mL-1 to 1 ng mL-1. The 
working solutions were kept at −20 ºC and renewed weekly. 
 
4.2.2 Samples 
Pasteurized whole bovine and ovine milk samples were purchased from local retail 
food outlets and supermarkets. Samples were stored at 4 ºC before analysis 
(within 10 days). Cultured fish samples, consisting of gilthead sea bream (Sparus 
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aurata) and sea bass (Dicentrarchus labrax) samples, were obtained from 
aquaculture and local fish markets. The fillets (denuded from skin and bone) were 
homogenized with a high-speed blender and stored at -23 ºC until analysis. One 
sample of each matrix was tested to ensure that it did not contain any analytes 
and it was used for negative control and was fortified with target compounds. 
 
4.2.3 Instrumentation 
An ultra-performance liquid chromatography (UHPLC) system (Dionex UltiMate 
3000 RSLC, Thermo Fisher Scientific, Germany) interfaced to a QTOF mass 
spectrometer (Maxis Impact, Bruker Daltonics, Bremen, Germany) was used for 
the screening analysis.  
The chromatographic separation was performed on an ACQUITY UPLC BEH C18 
column (2.1 × 50 mm, 1.7 µm) from Waters (Ireland), thermostated at 30 ºC. The 
mobile phases were (A) MeOH and (B) aqueous solution with 0.01% formic acid 
and, with a flow rate of 0.1 mL min-1. The gradient elution program started with 5% 
MeOH (A), increased to 100% in 7 min, and kept constant for 3 min. Then, the 
initial conditions were restored and the system was allowed to re-equilibrate for the 
next injection for 7 min. The injection volume was set up to 5 µL. 
The QTOF system was equipped with an electrospray ionization interface (ESI), 
operating in positive mode, with the following operation parameters: capillary 
voltage, 2500 V, end plate offset, 500 V, nebulizer pressure, 2 bar (N2), drying 
gas, 8 L min−1 (N2) and drying temperature, 200 °C. 
The QTOF system was operating in bbCID (broadband collision-induced 
dissociation) acquisition mode and recorded spectra over the range 40–1000 m/z 
with a scan rate of 2 Hz. Two acquisition functions with different collision energies 
were performed: the low-energy (LE) function with a collision energy of 4 eV, and 
the high energy (HE) function with a nominal collision energy of 25 eV.  
A QTOF external calibration was daily performed with a sodium formate solution 
and a segment (0.1-0.25 min) in every chromatogram was used for internal 
calibration, using a calibrant injection at the beginning of the run. The sodium 
formate calibration mixture consists of 10 mM sodium formate in a mixture of 
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water/isopropanol (1:1). The theoretical exact masses of calibration ions with 
formulae Na(NaCOOH)1-14 in the range of 40-1000 Da were used for calibration. 
The instrument provided a typical resolving power of over 40,000 at 365 m/z.  
 
4.2.4 Sample preparation 
Two different sample preparation protocols were developed and used for the 
extraction of veterinary drugs and pharmaceuticals from fish and milk samples. A 
schematic representation of the extraction and clean-up procedures is presented 
in Figure 4.1.  
The sample preparation method for the fish tissue samples has been developed 
and presented in the third study of this thesis which predates this work. Briefly, a 
1-g portion of fish tissue sample is weighed and placed into a 15 mL polypropylene 
centrifuge tube. For spiked samples appropriate volumes of the working standard 
mix solutions are added and they are allowed to stand for 10-15 minutes. 2 mL of 
H2O containing 0.1 % formic acid (v/v) and 0.1 % EDTA (w/v), 2 mL of MeOH and 
2 mL of ACN are added in all samples, subsequently. After the addition of each 
solvent the tube is vortex-mixed for 30 sec. The sample set is placed in an 
ultrasonic bath at 60 ºC for 20 min, the samples are centrifuged at 4000 rpm for 10 
min and the supernatant is decanted into a new polypropylene centrifuge tube. 
The tubes are placed in -20 ºC for 12 h in order to precipitate the lipids and 
remaining proteins. After centrifuging and discarding the precipitate, defatting with 
hexane completes the sample clean-up. The extracts are evaporated to dryness 
under a nitrogen stream and reconstituted in 0.5 mL of methanol/aqueous solution 
of formic acid, 0.05% (25:75 v/v), achieving a two-time pre-concentration of the 
analytes in the samples. Finally the extracts are filtered through a 0.22-μm RC 
filter to remove matrix interferences. 
Milk samples are allowed to thaw and a quick homogenization of the fat is 
performed by shaking before taking up the test portion of 2 g for the analysis. The 
samples were extracted with a mixture of aqueous TCA 5% (w/v) - ACN (3:1, v/v) 
and were then subjected to clean-up with HLB (Hydrophilic-Lipophilic Balance) 
solid phase extraction cartridges. In particular, 2 mL of whole milk are transferred 
in a 50 mL polypropylene centrifuge tube. For fortified milk samples, aliquots of 30 
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and 300 μL of a working solution standard containing all the analytes at a 
concentration of 1 μg mL-1 were added to 2 mL milk samples. Spiked levels 
obtained were 15 and 150 ng mL-1 respectively. When fortified, the samples are 
vortex-mixed for 30 s and allowed to stand for 10 – 15 min. After addition of 12 ml 
of aqueous TCA solution 5% (w/v) and 4 ml of ACN the samples are vortexed for 1 
min and shaken for 60 minutes using a mechanical shaker in medium speed. 
Then, the sample tube is centrifuged at 4000 rpm for 5 min and the supernatant is 
decanted in a new polypropylene tube and diluted to 50 mL with Milli-Q water. The 
diluted sample extract is adjusted to pH 5.5 by adding ammonia hydroxide 15% 
(w/v) and afterwards is loaded onto an OASIS HLB (60 mg, 3 mL) cartridge 
previously conditioned sequentially with 6 mL of MeOH and 6 mL of H2O. The 
sample is passed through the cartridge at a flow no faster than 1 drop/2 s and, 
then, it is vacuum-dried for 30 min. No washing step was applied in order to 
minimize analytes loss. The elution is carried out with 2 × 3 mL of MeOH and the 
eluent is collected and evaporated to dryness under a stream of nitrogen at 40 ºC. 
The residue is redissolved in 0.5 mL of MeOH /aqueous solution of formic acid, 
0.05% (25:75 v/v) and filtered through a 0.22-μm RC filter. The pre-concentration 
factor achieved with this method is four-fold and it is very valuable in improving the 
sensitivity of the analytical method. 
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Figure 4. 1: Overall scheme of the screening methods applied 
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A. 1 min vortex stirring 
B. centrifugation 10 min in 
4000 rpm 
C. discard hexane layer 
 
 
Evaporation of the extract under N2 
stream (45 °C) to dryness 
Re-dissolution with 1 mL formic acid 
0.05% (v/v) - MeOH (75/25) 
centrifugation 10 min in 
4000 rpm 
 
 
Addition of 5 mL hexane (defatting) 
 
Supernatant transferred in -20 °C for 12 h 
 
C. centrifugation 10 
min in 4000 rpm 
 
 
 B. 15 min in room temp 
 
1 g fish tissue sample 
 
2 mL ACN 
 
Spike of analytes at 
20 and 200 μg kg-1 
(spiked samples) 
 
30 sec vortex 
stirring 
 
A. 30 sec vortex stirring 
supernant transfer in 
new tube 
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4.2.5 Qualitative Method Validation 
Validation of the screening method was performed for qualitative purposes 
following the strategy described in the literature [101, 216, 217]. A total of twelve 
fish samples (6 sea bream and 6 sea bass) and twelve milk samples (6 bovine 
milk and 6 ovine milk samples) were spiked at two concentration levels (20 and 
200 μg kg-1 for fish samples and 15 and 150 ng ml-1 for milk samples). The 
samples were analyzed together with their respective blanks (non-spiked) and with 
four reagent blanks to ensure that no laboratory contamination was held during the 
analysis. 
The screening detection limit (SDL) and limit of identification (LOI) were 
investigated as the main validation parameters to estimate the threshold 
concentration at which detection and identification, respectively, become reliable 
(false negative rate: zero). The screening detection limit (SDL) was established as 
the lowest concentration level tested for which a compound was detected in all the 
samples, using the most abundant ion (most frequently, the protonated molecule). 
The limit of identification (LOI) was established as the lowest concentration tested 
for which a compound was satisfactorily identified in all spiked samples. The 
identification criterion was the presence of, at least, two m/z ions in either the LE 
or HE function, at the expected retention time (2.5% Retention Time deviation 
tolerance) measured at their exact mass (i.e. two peaks in the respective narrow-
window extracted ion chromatograms, nw-XIC, ±0.002 mDa) with a maximum 
mass error of 2 mDa. According to Commission Decision 2002/657/EC, a 
minimum of three identification points (IPs) is required for authorized substances 
and four for banned compounds [54].  
For HRMS, 2 IPs are earned for the precursor and 2.5 IPs for each product ion. 
Consequently, when a compound is successfully identified (at LOI) 4.5 IPs are 
earned, in agreement with the EU requirements.  The terms SDL and LOI would 
be equivalent to the definition of ‘‘screening target concentration’’ and ‘‘detection 
capability’’, respectively [216], parameters which are being described in the CRL’s 
2010 guideline [218]. 
 
4.3 Results and Discussion 
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4.3.1 UPLC-QTOF-MS method development 
Data analysis and evaluation was processed with Datanalysis 4.1 and 
TargetAnalysis 1.3 (Bruker Daltonics, Bremen, Germany). The TOF data were 
evaluated against an in-house database of 143 pharmaceutical compounds and 
veterinary drugs. Empirical data were obtained after injection into the UHPLC-
QTOF MS of solvent standard solutions for all target analytes in a concentration of 
0.5 μg mL-1. The database includes information over the analytes’ retention time, 
molecular formula (in order to extract the accurate mass of the corresponding 
pseudo-molecular ion and adducts [M+H]+, [M+Na]+, [M+NH4]+), isotopic fit and 
qualifier ions.  
By adding retention time and product ion data for most compounds in the 
database, the analysis of samples becomes much more efficient as many false 
detects can be ruled out quickly based initially on retention time matching followed 
by product ion comparison, if needed. Elemental compositions of the product ions 
were proposed using the experimental m/z and generating formulas (using 
Brucker’s Data Analysis Smart Formula Tool), restraining the number and type of 
atoms to those found in the precursor ion. When possible, these structures were 
compared to fragmentation patterns reported in the literature [219-221]. Table 4.1 
shows the compound name, retention time (min) and exact mass and elemental 
compositions for precursor and their main fragment ions. 
For some compounds, the [M+H]+ did not appear to be the most abundant ion. 
Ionophores, such as monensin, narasin, nigericin and salinomycin formed 
ammonium adducts; the same applied for amphenicols and some non-steroidal 
anti-inflammatory drugs (tolfenamic acid and vedaprofen). Erythromycin presented 
a very abundant [M-H2O+H]
+ ion, since it is very unstable in acidic conditions and 
is rapidly subjected to a loss of H2O. Finally, penicillins were monitored as their 
[(M+H2-CO)+H]
+ degradation products. The degradation of penicillin G and 
cloxacillin is presented in Figure 4. 2 and the same pattern applies to dicloxacillin, 
oxacillin and penicillin V, as well. Amoxicillin and ampicillin, due to their structure (-
NH2 at the R ring) are not subjected in a β-lactam ring-opening even in very acidic 
conditions [222]. 
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Figure 4.2: Degradation products of penicillin G (R=benzyl) and cloxacillin (R=3-
(2-chlorophenyl)-5-methyl-4-isoxazolyl) (from reference 222). 
 
After internal calibration, specific criteria – thresholds were set in order to screen 
the chromatograms for identified compounds, optimized to prevent false negative 
results, but also with an acceptable percentage of false positive results. Initially, 
retention time tolerance should be below 0.25 min, which is lower than 2.5 % RT 
deviation tolerance, for all the compounds. The mass accuracy of the precursor 
ion, as well as of the qualifiers, should be below 2 mDa [217]. This threshold is 
quite strict comparing to ones reported in the literature (e.g. 10 ppm [89, 91, 103], 
5 ppm [94]), but it contributes significantly to reduce the number of false positive 
results. The compliance of ion intensity ratios was not used as a criterion since in  
large  screening  methods,  the  measurement  of  the ion  ratios  becomes  non-
suitable  or  much  more  tedious  than  in target  quantitative  methods  where  a  
limited  number  of  analytes is  included  in  the  scope [217]. The isotopic fit is an 
additional criterion for the identification of a compound [91]. The isotope pattern 
matching algorithm (SigmaFit) is a feature of Bruker Daltonics software; smaller 
values show better isotopic fit, however in less abundant peaks, the mSigma 
values are relatively high, and thus no filtering is carried out for this parameter. 
Moreover, thresholds for the area and the intensity of the chromatographic peak 
are set, according to validated experiments, at the level of 2000 and 500, 
respectively. These thresholds were set, as a compromise of false positive and 
false negative results, bearing in mind the total number of features of a full-scan 
chromatogram.
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Table 4.1: Retention time, elemental formulas and exact masses for precursor and fragment ions of veterinary drugs and pharmaceuticals. 
Compounds 
Elemental 
composition 
Monoiso-
topic mass 
Precursor ion 
Precursor 
ion mass 
RT 
(min) 
Fragment  ion 1 
m/z 
 (fragm 1) 
Fragment  ion 2 
m/z 
 (fragm 2) 
Fragment  ion 
3 
m/z  
(fragm 3) 
Quinolones 
Ciprofloxacin C17H18FN3O3 331.1332 [M+H]+ 332.1405 8.8 C17H17FN3O2
+
 314.1299 C16H19FN3O
+
 288.1507   
Danofloxacin C19H20FN3O3 357.1489 [M+H]+ 358.1561 8.8 C19H19FN3O2
+
 340.1456     
Difloxacin C21H19F2N3O3 399.1394 [M+H]+ 400.1467 9.0 C21H18F2N3O2
+
 382.1362 C20H20F2N3O
+
 356.1569 C17H13F2N2O
+
 299.099 
Enrofloxacin C19H22FN3O3 359.1645 [M+H]+ 360.1718 8.8 C18H23FN3O
+
 316.182 C19H21FN3O2
+
 342.1612 C17H19FN3O3
+
 332.1405 
Flumequine C14H12FNO3 261.0801 [M+H]+ 262.0874 10.6 C14H11FNO2
+
 244.0768     
Marbofloxacin C17H19FN4O4 362.1390 [M+H]+ 363.1463 8.2 C15H15FN3O4
+
 320.1041 C17H18FN4O3
+
 345.1353 C4H10N
+
 72.0786 
Norfloxacin C16H18FN3O3 319.1332 [M+H]+ 320.1405 8.7 C16H17FN3O2
+
 302.1299 C15H19FN3O
+
 276.1507 C13H14FN2O
+
 233.1085 
Ofloxacin C18H20FN3O4 361.1438 [M+H]+ 362.1511 8.5 C17H21FN3O2
+
 318.1612 C14H14FN2O2
+
 261.1034   
Oxolinic acid C13H11NO5 261.0637 [M+H]+ 262.0710 10.1 C13H10NO4
+
 244.0604     
Sarafloxacin C20H17F2N3O3 385.1238 [M+H]+ 386.1311 9.0 C20H16F2N3O2
+
 368.1205 C19H18F2N3O
+
 342.1412   
Tetracyclines 
Chlortetracycline C22H23ClN2O8 478.1143 [M+H]+ 479.1216 9.8 C22H19ClNO7
+
 444.0845 C22H21ClNO8
+
 462.095   
Doxycycline C22H24N2O8 444.1533 [M+H]+ 445.1605 10.3 C22H22NO8
+
 428.1350 C16H22NO2
+
 260.1648   
Minocycline C23H27N3O7 457.1849 [M+H]+ 458.1922 9.4 C23H25N2O7
+
 441.1662 C23H23N2O6
+
 423.1551   
Oxytetracycline C22H24N2O9 460.1482 [M+H]+ 461.1555 9.0 C22H20NO8
+
 426.1183 C22H22NO9
+
 444.1289   
Tetracycline C22H24N2O8 444.1533 [M+H]+ 445.1605 9.0 C22H20NO7
+
 410.1234 C22H20NO8
+
 426.1183 C7H8NO3
+
 154.0499 
Cefalosporines 
Cefaclor C15H14Cl1N3O4S 367.0394 [M+H]+ 368.0466 8.6 C7H8N
+
 106.0651 C10H8NO2
+
 174.0550   
Cefadroxil C16H17N3O5S 363.0889 [M+H]+ 364.0962 7.0 C4H4NOS
+
 114.0008 C10H11O3N2
+
 208.0842 C10H8NO3
+
 190.0499 
Cefalexin C16H17N3O4S 347.0940 [M+H]+ 348.1013 8.7 C7H8N
+
 106.0651 C6H8NO2S
+
 158.027 C4H4NOS
+
 114.0008 
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Cefapirin C17H17N3O6S2 423.0553 [M+H]+ 424.0632 1.5 C13H14N3OS2
+
 292.0573 C7H6NOS
+
 152.0165   
Cefazolin C14H14N8O4S3 454.0300 [M+H]+ 455.0373 11.3 C11H11N6O4S 
+
 353.0557     
Ceftiofur C19H17N5O7S3 523.0290 [M+H]+ 524.0363 10.4 C16H5N2O
+
 241.0396     
Penicillins 
Amoxicillin C16H19N3O5S 365.1045 [M+H]+ 366.1118 5.2 C9H10N3
+
 160.0869 C4H4NOS
+
 114.0008 C16H17N2O5S
+
 349.085 
Ampicillin C16H19N3O4S 349.1096 [M+H]+ 350.1169 7.2 C7H8N
+
 106.0651 C6H10NO2S
+
 160.0427 C10H8NO2
+
 174.055 
Cloxacillin C19H18ClN3O5S 435.0656 [(MH2-CO)+H]+ 410.0936 10.7 C7H12NO2S
+
 174.0583 C6H10NS
+
 128.0528   
Dicloxacillin C19H17Cl2N3O5S 469.0266 [(MH2-CO)+H]+ 444.0546 10.8 C6H10NO2S
+
 160.0427 C13H9Cl2N2O3
+
 310.9985   
Oxacillin C19H19N3O5S 401.1045 [(MH2-CO)+H]+ 376.1326 10.6 C6H10NO2S
+
 160.0427     
Penicillin G C16H18N2O4S 334.0987 [(MH2-CO)+H]+ 309.1267 10.3 C6H10NS
+
 128.0522 C7H12NO2S
+
 174.0583 C7H7
+
 91.0542 
Penicillin V C16H18N2O5S 350.0936 [(MH2-CO)+H]+ 325.1217 10.5 C10H13N2O2
+
 193.0972 C6H10NS
+
 128.0528 C14H19N2O2S
+
 279.1152 
Macrolides 
Azithromycin C38H72N2O12 748.5085 [M+H]+ 749.5158 9.7 C8H16NO2
+
 158.1176 C6H14NO
+
 116.107 C30H59N2O9
+
 591.4215 
Clarithromycin C38H69NO13 747.4769 [M+H]+ 748.4842 10.8 C8H16NO2
+
 158.1176 C30H56NO10
+
 590.3899   
Erythromycin-H2O C37H67NO13 733.4612 [M-H2O+H]+ 716.4579 10.6 C29H52NO9
+
 558.3637 C8H16NO2
+
 158.1174 C29H50NO8
+
 540.3538 
Tiamulin C28H47NO4S 493.3226 [M+H]+ 494.3299 10.5 C8H18NO2S
+
 192.1053     
Tilmicosin C46H80N2O13 868.5660 [M+2H]
2+
 435.2894 9.9 C38H67N2O9
+
 695.4841 C8H16NO3
+
 174.1125 C5H7O2
+
 99.0441 
Sulfonamides 
Dapsone C12H12N2O2S 248.0619 [M+H]+ 249.0692 8.6 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Sulfachloro-
pyridazine 
C10H9ClN4O2S 284.0135 [M+H]+ 285.0208 9.0 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Sulfaclozine C10H9ClN4O2S 284.0135 [M+H]+ 285.0208 9.8 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Sulfadiazine C10H10N4O2S 250.0524 [M+H]+ 251.0597 7.3 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Sulfadimethoxine C12H14N4O4S 310.0736 [M+H]+ 311.0809 9.9 C4H4N4OS
+
 156.0114 C6H6NO
+
 108.0444   
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Sulfadimidine C12H14N4O2S 278.0837 [M+H]+ 279.091 8.8 C6H10N3
+
 124.0869 C6H8N3O2S
+
 186.0332 C12H4N4
+
 204.043 
Sulfadoxine C12H14N4O4S 310.0736 [M+H]+ 311.0809 9.3 C4H4N4OS
+
 156.0114 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 
Sulfaguanidine C7H10N4O2S 214.0524 [M+H]+ 215.0597 2.8 C6H6N
+
 92.0495 C6H6NO
+
 108.0444 C4H4N4OS
+
 156.0114 
Sulfamerazine C11H12N4O2S 264.0681 [M+H]+ 265.0754 8.2 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Sulfameter C11H12N4O3S 280.0630 [M+H]+ 281.0703 8.6 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Sulfamethizole C9H10N4O2S2 270.0245 [M+H]+ 271.0318 8.7 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Sulfamethoxazole C10H11N3O3S 253.0521 [M+H]+ 254.0594 9.1 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Sulfamethoxy- 
pyridazine 
C11H12N4O3S 280.0630 [M+H]+ 281.0703 8.9 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Sulfamono-
methoxine 
C11H12N4O3S 280.0630 [M+H]+ 281.0703 9.2 C6H6NO
+
 108.0444 C4H4N4OS
+
 156.0114 C6H6N
+
 92.0495 
Sulfamoxole C11H13N3O3S 267.0678 [M+H]+ 268.075 9.3 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Sulfapyridine C11H11N3O2S 249.0572 [M+H]+ 250.0645 8.0 C6H6NO
+
 108.0444 C4H4N4OS
+
 156.0114 C6H6N
+
 92.0495 
Sulfaquinoxaline C14H12N4O2S 300.0681 [M+H]+ 301.0754 10.1 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Sulfathiazole C9H9N3O2S2 255.0136 [M+H]+ 256.0209 7.8 C6H6NO
+
 108.0444 C4H4N4OS
+
 156.0114 C6H6N
+
 92.0495 
Sulfisoxazole C11H13N3O3S 267.0678 [M+H]+ 268.075 8.5 C6H6NO
+
 108.0444 C6H6N
+
 92.0495 C4H4N4OS
+
 156.0114 
Quinoxalines 
Carbadox C11H10N4O4 262.0702 [M+H]+ 263.0775 9.2 C10H7N4O3
+
 231.0513 C8H5N2
+
 129.0447   
Olaquindox C12H17N3O4 267.1219 [M+H]+ 268.1292 6.9 C12H11N3O2
+
 229.0846 C10H9N2O4
+
 221.0553 C9H8N2O
+
 160.0631 
Amphenicols 
Florfenicol C12H14Cl2FNO4S 357.0005 [M+NH4]+ 375.0343 9.3 C11H9Cl2NO
+
 241.0053     
Thiampenicol C12H15Cl2NO5S 355.0048 [M+NH4]+ 373.0386 8.5 C11H18ClN2O3
+
 261.1     
Diaminopyrimidines 
Baquiloprin C17H20N6 308.1749 [M+H]+ 309.1822 6.2 C16H18N6
+
 294.1587 C11H11N2
+
 171.0917   
Trimethoprim C14H18N4O3 290.1379 [M+H]+ 291.1452 8.3 C12H14N4O
+
 230.1176 C5H7N4
+
 123.0665 C12H12N4O3
+
 261.0957 
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Other antibiotics 
Lincomycin C18H34N2O6S 406.2138 [M+H]+ 407.221 8.3 C8H16N
+
 126.1277 C17H31N2O6
+
 359.2177   
Novobiocin C31H36N2O11 612.2319 [M+H]+ 613.2392 11.7 C12H13O2
+
 189.091 C22H22NO6
+
 396.1442 C9H16NO5
+
 218.1023 
Rifaximin C43H51N3O11 785.3524 [M+H]+ 786.3596 11.1 C42H48N3O10
+
 754.3334     
Althenmintics 
Albendazole C12H15N3O2S 265.0885 [M+H]+ 266.0958 11.0 C11H12N3OS
+
 234.0696 C8H5N3OS
+
 191.0148 C8H5N3O
+
 159.0427 
Albendazole oxide C12H15N3O3S 281.0834 [M+H]+ 282.0907 9.9 C8H6N3O2S
+
 208.0175 C9H10N3O3S
+
 240.0437 C9H9N3O2
+
 191.0689 
Albendazole 
sulfone 
C12H15N3O4S 297.0783 [M+H]+ 298.0856 11.5 C11H12N3O3S
+
 266.0594 C8H6N3O3S
+
 224.0124   
Dimetridazole C5H7N3O2 141.0538 [M+H]+ 142.0611 7.9 C5H7N2
+
 95.0604 C4H5N2
+
 81.0447   
Febantel C20H22N4O6S 446.1260 [M+H]+ 447.1333 11.3 No fragments 
Fenbendazole C15H13N3O2S 299.0728 [M+H]+ 300.0801 11.3 C14H10N3OS
+
 268.0539 C10H7O2
+
 159.0441   
Flubendazole C16H12FN3O3 313.0863 [M+H]+ 314.0935 10.8 C15H9FN3O2
+
 282.0673 C7H4FO
+
 123.0241   
Levamisol C11H12N2S 204.0721 [M+H]+ 205.0794 7.7 C10H12NS
+
 178.0685 C10H12N
+
 146.0964 C7H7S
+
 123.0263 
Mebendazole C16H13N3O3 295.0957 [M+H]+ 296.103 10.7 C15H10N3O2
+
 264.0768     
Metronidazol C6H9N3O3 171.0644 [M+H]+ 172.0717 7.2 C4H6N3O2
+
 128.0455 C4N2H5
+
 82.0525 C11H11O
+
  
Morantel C12H16N2S 220.1034 [M+H]+ 221.1107 9.0 C6H7S
+
 111.0263 C7H7S
+
 123.0263   
Oxfendazole C15H13N3O3S 315.0678 [M+H]+ 316.075 10.4 C11H11O3 
+
 191.0703 C14H10N3O2S
+
 284.0488   
Piperazine C4H10N2 86.0844 [M+H]+ 87.0917 1.3 C4H7N
+
 70.0651     
Ronidazole C6H8N4O4 200.0546 [M+H]+ 201.0618 7.2 C2H4N2
+
 56.0369     
Ternidazole C7H11N3O3 185.0800 [M+H]+ 186.0873 8.3 C4H6N3O2
+
 128.0455 C4H6N2
+
 82.0525 C6HN2
+
 101.0134 
Thiabendazole C10H7N3S 201.0361 [M+H]+ 202.0433 9.1 C9H7N2S
+
 175.0324 C8H7N2
+
 131.0604   
Triclabendazole C14H9Cl3N2OS 357.9501 [M+H]+ 358.9574 11.8 C13H7Cl3N2OS
+
 343.9334 C13H7Cl3N2OS
+
 345.931 C12H11Cl3N
+
 273.9952 
Coccidiostats 
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Arprinocid C12H9ClFN5 277.0531 [M+H]+ 278.0603 10.3 C7H5ClF
+
 143.0058     
Clopidol C7H7Cl2NO 190.9905 [M+H]+ 191.9977 8.3 C5H6Cl
+
 101.0153 C4H4Cl
+
 86.9996   
Decoquinate C24H35NO5 417.2515 [M+H]+ 418.2588 12.4 C22H32NO5
+
 390.2275 C22H30NO4
+
 372.2169   
Diaveridine C13H16N4O2 260.1273 [M+H]+ 261.1346 8.2 C12H13N4O2
+
 245.1033 C5H7N4
+
 123.0665 C11H13N4O
+
 217.1084 
Ethopabate C12H15NO4 237.1001 [M+H]+ 238.1074 10.4 C7H6NO2
+
 136.0393 C9H10NO2
+
 164.0706 C11H12NO3
+
 206.0812 
Halofuginone C16H17BrClN3O3 413.0142 [M+H]+ 414.0215 10.3 C5H10NO
+
 100.0757 C8H10N
+
 120.0808 C6H14NO
+
 116.107 
Imidocarb C19H20N6O 348.1699 [M+H]+ 349.1771 7.7 C10H10N3O
+
 188.0818 C9H12N3
+
 162.1026   
Lasalocid C34H54O8 590.3819 [M+H]+ 591.3891 10.3 C23H37O4
+
 377.2686     
Monensin C36H62O11 670.4291 [M+NH4]+ 688.4630 12.6 C31H43NO2
+
 461.3288 C25H41O5
+
 421.2949   
Narasin C43H72O11 764.5074 [M+NH4]+ 782.5413 12.4 C23H36O6NH4
+
 426.2850 [M+Na]
 +
 787.4967   
Nigericin C40H68O11 724.4761 [M+NH4]+ 742.5100 12.9 [M+Na]
 +
 747.4654     
Robenidine C15H13Cl2N5 333.0548 [M+H]+ 334.0621 11.0 C7H5ClN
+
 138.0105 C7H8ClN2
+
 155.0371 C8H5ClN3
+
 178.0167 
Salinomycin C42H70O11 750.4918 [M+NH4]+ 768.5256 12.3 C23H36O6 NH4
+
 426.2850     
NSAIDs 
5-Hydroxy-flunixin C14H11F3N2O3 312.0722 [M+H]+ 313.0795 11.3 C14H10F3N2O2
+
 295.0689 C5H8F3
+
 125.0573   
Aceclofenac C16H13Cl2NO4 353.0222 [M+H]+ 354.0294 11.7 C7H15Cl2NO2
+
 215.0474 C13H10Cl2N
+
 250.0185   
Diclofenac C14H11Cl2NO2 295.0167 [M+H]+ 296.024 11.5 C13H10ClN
+
 215.0496 C13H10Cl2N
+
 250.0185   
Flunixin C14H11F3N2O2 296.0773 [M+H]+ 297.0845 11.5 C14H10F3N2O
+
 279.0748 C13H8F3N2O
+
 265.0579   
Ketoprofen C16H14O3 254.0943 [M+H]+ 255.1016 11.0 C7H5O
+
 105.0335 C15H13O
+
 209.0961 C10H9O3
+
 177.0546 
Mefenamic acid C15H15NO2 241.1103 [M+H]+ 242.1176 11.9 C15H14NO
+
 224.107 C14H11NO
+
 209.0827 C7H13O2
+
 129.091 
Meloxicam C14H13N3O4S2 351.0347 [M+H]+ 352.042 11.0 C4H7N2S
+
 115.0324 C5H5N2OS
+
 141.0117   
Naproxen C14H14O3 230.0943 [M+H]+ 231.1016 11.1 C13H13O
+
 185.0961 C10H8N3
+
 170.0713 C12H9
+
 153.0699 
Niflumic acid C13H9F3N2O2 282.0616 [M+H]+ 283.0689 11.6 C13H8F3N2O
+
 265.0583 C13H7F2N2O
+
 245.0521   
Phenylbuntazone C19H20N2O2 308.1525 [M+H]+ 309.1598 11.3 C7H6NO
+
 120.0444 C11H14N
+
 160.1121 C13H11N2O
+
 211.0866 
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Tolfenamic acid C14H12ClNO2 261.0556 [M+NH4]+ 279.0895 8.8 No fragments 
Vedaprofen C19H26NO2 282.1620 [M+NH4]+ 300.1958 12.1 C12H11
+
 155.0855 C18H21
+
 237.1638   
Beta-agonists 
Cimaterol C12H17N3O 219.1372 [M+H]+ 220.1444 6.8 C9H10N3
+
 160.0869 C9H7N2
+
 143.0604 C12H16N3
+
 202.1339 
Clenbuterol C12H18Cl2N2O 276.0796 [M+H]+ 277.0869 9.1 C8H9Cl2N2
+
 203.0137 C12H17Cl2N2
+
 259.0763 C11H6NO
+
 168.0444 
Clenpenterol C13H20Cl2N2O 290.0953 [M+H]+ 291.1025 9.6 C8H9Cl2N3
+
 203.0137     
Mabuterol C13H18ClF3N2O 310.1060 [M+H]+ 311.1133 9.6 C9H9ClF3N2
+
 237.0401 C9H8ClF2N2
+
 217.0339   
Ractopamine C18H23NO3 301.1678 [M+H]+ 302.1751 8.8 C8H9O
+
 121.0648 C7H7O
+
 107.0491 C10H14NO
+
 164.1070 
Salbutamol C13H21NO3 239.1521 [M+H]+ 240.1594 7.2 C9H10NO
+
 148.0757 C8H9O
+
 121.0648   
Terbutaline C12H19NO3 225.1365 [M+H]+ 226.1438 7.1 C8H10NO2
+
 152.0706 C7H9O2
+
 125.0597 C7H7O
+
 107.0491 
Steroids 
Betamethasone C22H29FO5 392.1999 [M+H]+ 393.2072 10.8 C22H27O4
+
 355.1904 C22H29O5
+
 373.201 C22H25O3
+
 337.1798 
Cortisol C21H30O5 362.2093 [M+H]+ 363.2166 10.7 C8H9O
+
 121.0648 C21H27O3
+
 327.1955 C21H25O2
+
 309.1849 
Cortison C21H28O5 360.1937 [M+H]+ 361.201 10.7 C11H15O
+
 163.1117     
Dexamethazone C22H29FO5 392.1999 [M+H]+ 393.2072 7.4 C22H29O5
+
 373.2009     
Methylprednisolone C22H30O5 374.2093 [M+H]+ 375.2166 10.9 C22H29O4
+
 357.206 C22H27O3
+
 339.1955 C22H25O2
+
 321.1849 
Progesteron C21H30O2 314.2246 [M+H]+ 315.2319 11.5 C7H9O
+
 109.0648 C6H9O
+
 97.0648 C8H11O
+
 123.0804 
Thyreostats 
Methyl-thiouracil C5H6N2O2S 158.0150 [M+H]+ 159.0223 3.9 C4H6NO
+
 84.0444 C5H4NOS
+
 126.0008   
Phenyl-thiouracil C10H8N2OS 204.0357 [M+H]+ 205.0430 9.8 C8H7
+
 103.0542 C9H8NO
+
 146.06 C10H6NOS
+
 188.0165 
Propyl-thiouracil C7H10N2OS 170.0514 [M+H]+ 171.0587 8.9 C6H10NO
+
 112.0757 C7H8NOS
+
 154.0321   
Pharmaceuticals 
Ambroxol C13H18Br2N2O2 391.9735 [M+H]+ 392.9808 10.1 C6H6Br2NO
+
 263.8838 C6H14NO
+
 116.1069   
Atenolol C14H22N2O3 266.1630 [M+H]+ 267.1703 7.1 C11H12NO2
+
 190.0863 C11H17N2O3
+
 225.1234 C9H10NO2
+
 164.0706 
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Atorvastatin C33H35FN2O5 558.2530 [M+H]+ 559.2603 11.2 C26H31FNO4
+
 440.2232 C27H29FNO5
+
 466.2024   
Caffeine C8H10N4O2 194.0804 [M+H]+ 195.0877 8.7 C5H7N4
+
 123.0665 C6H8N3O
+
 138.0662 C5H8N3
+
 110.0713 
Carbamazepine C15H12N2O 236.0950 [M+H]+ 237.1022 10.6 C14H12N
+
 194.0964 C14H11N
+
 193.0886   
Cimetidine C10H16N6S 252.1157 [M+H]+ 253.1230 7.4 C5H7N2
+
 95.0604 C5H11N4S
+
 159.0699 C4H9N2S
+
 117.0481 
Gemfibrozil C15H22O3 250.1569 [M+H]+ 251.1642 11.9 C7H13O2
+
 129.091     
Haloperidol C21H23ClFNO2 375.1401 [M+H]+ 376.1474 10.4 C10H10FO
+
 165.071 C21H22ClFNO
+
 358.1368 C7H4FO
+
 123.0241 
Indapamide C16H16ClN3O3S 365.0601 [M+H]+ 366.0674 10.4 C9H10N
+
 132.0808     
Metformin C4H11N5 129.1014 [M+H]+ 130.1087 3.1 C2H5N4
+
 85.0509 C3H7N2
+
 71.0604 CH6N3
+
 60.0556 
Metoprolol C15H25NO3 267.1834 [M+H]+ 268.1907 9.3 C6H12N
+
 98.0964 C6H14NO
+
 116.107 C11H11O
+
 159.0804 
Paracetamol C8H9NO2 151.0633 [M+H]+ 152.0706 7.0 C6H8NO
+
 110.0600 C6H5O
+
 93.0335   
Propranolol C16H21NO2 259.1572 [M+H]+ 260.1645 10.3 C6H14NO
+
 116.1070 C13H11O
+
 183.0804 C12H11
+
 155.0855 
Ranitidine C13H22N4O3S 314.1413 [M+H]+ 315.1485 7.1 C5H10N3O2S
+
 176.0488 C11H12NO2
+
 190.0863   
Simvastatin C25H42NO5 436.3063 [M+NH4]+ 436.3057 12.0 C15H19
+
 199.1481 C19H25O2
+
 285.1850 C17H21
+
 225.1638 
Theophyline C7H8N4O2 180.0647 [M+H]+ 181.0720 8.1 C5H6N3O
+
 124.0505 C4H6N3
+
 96.0556 C3H5N2
+
 69.0447 
Tramadol C16H25NO2 263.1885 [M+H]+ 264.1958 9.2 C3H8N
+
 58.0651     
Triamterene C12H11N7 253.1076 [M+H]+ 254.1149 8.9 C12H9N6
+
 237.0883     
Valsartan C24H29N5O3 435.2270 [M+H]+ 436.2343 11.2 C14H11N4
+
 235.0978 C19H19N2O
+
 291.1492 C14H11N2
+
 207.0917 
Others 
Bromhexine C14H20Br2N2 373.9993 [M+H]+ 375.0066 10.6 C7H6Br2N
+
 261.8861 C7NH16
+
 114.1277   
Chlorpromazine C17H19ClN2S 318.0957 [M+H]+ 319.1030 10.8 C5H12N
+
 86.0964 C13H9ClNS
+
 246.0139   
Colchicine C22H25NO6 399.1682 [M+H]+ 400.1755 10.3 C20H24NO5
+
 358.1649 C20H21O5
+
 341.1384 C22H24NO5
+
 382.1649 
Coumaphos C14H16ClO5PS 362.0145 [M+H]+ 363.0217 11.5 C10H9ClO5PS
+
 306.9591 C12H13ClO5PS
+
 334.9904 C10H7ClO2S
+
 226.9923 
Melamine C3H6N6 126.0654 [M+H]+ 127.0727 2.9 C2H5N4
+
 85.0509 C2H2N3
+
 68.0219   
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4.3.2 Sample Preparation Optimization 
Two different sample preparation procedures were followed for the extraction of 
veterinary drugs and pharmaceuticals from fish and milk samples. The first 
method involves a simple generic solid-liquid extraction step of the analytes from 
fish tissue with 0.1% formic acid in aqueous solution of EDTA 0.1% (w/v) – ACN 
– MeOH (1:1:1, v/v) and additional ultrasonic-assisted extraction. Precipitation of 
lipids and proteins was promoted by subjecting the extracts at very low 
temperature (-23 ºC) for 12 hours and further clean-up with hexane ensures fat 
removal from the matrix. The developed, optimization and validation of this 
method is described in the next chapter (Chapter 5). The second protocol 
consists of a generic extraction of the analytes from milk samples with a 
combination of ACN/5% aqueous TCA solution 5% (1:3, v/v). Further clean-up 
with SPE was performed to remove interfering proteins and provide clean and 
stable extracts. Recoveries were  not  taken  into  account  in  this  study  as  the  
goal  of  the screening  was  to  detect  and  identify  the  compounds,  not  their 
quantification. 
Finding suitable extraction conditions for a large range of target analytes 
displaying different chemical properties (lipophilicity, hydrophilicity, alcaline and 
acidic characteristics, etc), along with keeping the procedure as short and simple 
as possible is a great challenge. Having a look at the literature in the field of 
veterinary drug residues analysis, it becomes apparent that acetonitrile extraction 
is the most common extraction route used for many veterinary drugs including 
antibiotics, anthelmintics and coccidiostats [64, 86, 76, 223]. Acidic extraction 
with trichloroacetic acid was found to be suitable for quinolones, lincomycin, and 
tetracyclines [56, 64, 87]. 
The same difficulties apply in the development of a generic solid-phase extraction 
procedure. If carefully designed, reversed phase SPE can recover most analytes 
from polar extraction solutions but may lead to losses of some (very polar) 
analytes [224, 90, 91]. Mixed-mode materials exhibiting both hydrophobic and 
ion-exchange properties have become a valuable alternative. One of the most 
widely used sorbent is a copolymer of divinylbenzene and vinylpyrrolidone, which 
has been commercialized under the trade name Oasis HLB by Waters. It has 
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become the prime sorbent for multi-residue methods of veterinary drugs and 
pharmaceuticals due to its broad-applicability spectra [89, 90, 91, 94, 224]. 60 mg 
and 200 mg cartridges of equal particle size HLB were assayed in order to 
determine optimum sorbent amount. Slightly better results were obtained with the 
60 mg cartridge over the 200 mg cartridge, and the 60 mg size was chosen for 
further experiments. 
The primary extracts had to be diluted in water in order to decrease the % 
content of ACN (<10%) in the sample that will be loaded in the SPE. This is a 
practice that many researchers employ in order to avoid breakthrough of analytes 
during the SPE step due to a moderate amount of ACN in the extracting solution 
[89, 91, 56]. 
Proper adjustment of sample pH may be necessary to avoid deprotonation of 
acidic compounds or protonation of basic compounds and to enhance extraction 
efficiency of the analytes [224]. As analytes belong to different classes with 
different pKa values, it is extremely difficult to establish a clean-up method that is 
effective for all the compounds. The extract pH was adjusted to 5.5 with 
ammonium hydroxide solution, according to Kaufmann et al. [90] who clearly 
states that this value constitutes a compromise and might not be the optimum for 
some very acidic and strongly basic analytes. Neutral pH values of the extract 
loaded in the SPE have been reported in cases where the extraction was held 
with water [89, 91] while a pH value of 4 was selected by Bohm et al.,[66, 74] 
where McIlvaine buffer was used as extraction solvent.  
Finally, the effectiveness of MeOH and ACN as elution solvents was evaluated. 
When eluting with MeOH, higher recoveries of β-lactams and tetracyclines from 
the milk samples were achieved, since MeOH is a more polar solvent than ACN. 
On the contrary, less polar compounds, like some macrolides (tiamulin, tylosin) 
and some ionophore coccidiostats (semduramycin, narasin), presented better 
results when the elution was performed with ACN. However, MeOH was deemed 
to be the most suitable elution solvent, because it revealed satisfactory results for 
the majority of the target analytes. 
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4.3.3 Qualitative Method Validation  
The  aim  of  a  qualitative  method validation  is  to  ensure  the  presence of  an  
analyte  in  a  sample  at  a  certain  concentration  level.  As  no quantitation  is  
necessary,  method  recovery,  accuracy  and  precision  are  not  considered 
[217]. Two different milk matrices (ovine and bovine) and two different fish 
matrices (sea bream and sea bass) were tested at method validation at two 
concentration levels: 20 and 200 μg kg-1 for fish samples and 15 and 150 ng mL-1 
for milk samples. The method was considered fully validated for a given 
compound, at a certain concentration, when it was detected and identified 
according to the criteria established in all the samples tested (i.e. 6 out of 6 for 
each matrix). Table 4.2 summarizes the SDLs and LOIs obtained for each 
analyte in milk and fish samples. 
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Table 4.2: Validation Results; Detection and identification limits in spiked milk and fish samples at two concentration levels; SDL and LOI obtained. 
Positive/Negative results 
 Milk samples (n=12) Fish Samples (n=12) 
 Detected Identified   Detected Identified   
Compounds 
15 ng mL
-1
 
(n=6) 
150 ng mL
-1
 
(n=6) 
15 ng mL
-1
 
(n=6) 
150 ng mL
-1
 
(n=6) 
SDL 
(ng mL
-1
) 
LOI 
(ng mL
-1
) 
20 μg kg 
-1
 
(n=6) 
200 μg kg 
-
1
 (n=6) 
20 μg kg 
-1
 
(n=6) 
200 μg kg 
-
1
 (n=6) 
SDL 
(μg kg 
-1
) 
LOI 
(μg kg 
-1
) 
Quinolones 
Ciprofloxacin 6/6 6/6 6/6 6/6 15 15 5/6 6/6 5/6 6/6 200 200 
Danofloxacin 6/6 6/6 6/6 6/6 15 15 3/6 6/6 3/6 6/6 200 200 
Difloxacin 6/6 6/6 6/6 6/6 15 15 5/6 6/6 5/6 6/6 200 200 
Enrofloxacin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Flumequine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Marbofloxacin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Norfloxacin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Ofloxacin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Oxolinic acid 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sarafloxacin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Tetracyclines 
Chlortetracycline 6/6 6/6 6/6 6/6 15 15 4/6 6/6 4/6 6/6 200 200 
Doxycycline 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Minocycline 6/6 6/6 6/6 6/6 15 15 4/6 6/6 4/6 5/6 200 >200 
Oxytetracycline 6/6 6/6 5/6 6/6 15 150 4/6 6/6 4/6 6/6 200 200 
Tetracycline 6/6 6/6 6/6 6/6 15 15 4/6 6/6 4/6 6/6 200 200 
Cefalosporines 
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Cefaclor 0/6 0/6 0/6 0/6 >150 >150 0/6 3/6 0/6 2/6 >200 >200 
Cefadroxil 3/6 6/6 1/6 6/6 150 150 0/6 6/6 0/6 6/6 200 200 
Cefalexin 0/6 6/6 0/6 6/6 150 150 0/6 6/6 0/6 6/6 200 200 
Cefapirin 1/6 0/6 0/6 0/6 >150 >150 0/6 0/6 0/6 0/6 >200 >200 
Cefazolin 5/6 5/6 0/6 0/6 >150 >150 0/6 0/6 0/6 0/6 >200 >200 
Ceftiofur 2/6 6/6 1/6 6/6 150 150 0/6 6/6 0/6 3/6 200 >200 
Penicillins 
Amoxicillin 0/6 0/6 0/6 0/6 >150 >150 0/6 6/6 0/6 6/6 200 200 
Ampicillin 3/6 0/6 2/6 0/6 >150 >150 0/6 6/6 0/6 5/6 200 >200 
Cloxacillin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Dicloxacillin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Oxacillin 6/6 6/6 2/6 6/6 15 150 0/6 2/6 0/6 2/6 >200 >200 
Penicillin G 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Penicillin V 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Macrolides 
Azithromycin 0/6 3/6 0/6 3/6 >150 >150 6/6 6/6 6/6 6/6 20 20 
Clarithromycin 0/6 0/6 0/6 0/6 >150 >150 6/6 6/6 6/6 6/6 20 20 
Erythromycin-OH2 2/6 6/6 2/6 6/6 150 150 6/6 6/6 6/6 6/6 20 20 
Tiamulin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Tilmicosin 6/6 6/6 6/6 6/6 15 15 6/6 4/6 6/6 4/6 200 200 
Sulfonamides 
Dapsone 5/6 6/6 5/6 6/6 150 150 1/6 6/6 1/6 6/6 200 200 
Sulfachloropyridazine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sulfaclozine 6/6 6/6 6/6 6/6 15 15 5/6 6/6 5/6 6/6 200 200 
Sulfadiazine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
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Sulfadimethoxine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sulfadimidine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sulfadoxine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sulfaguanidine 5/6 6/6 5/6 6/6 150 150 6/6 6/6 6/6 6/6 20 20 
Sulfamerazine 6/6 6/6 6/6 6/6 15 15 5/6 6/6 5/6 6/6 200 200 
Sulfameter 6/6 6/6 6/6 6/6 15 15 4/6 6/6 4/6 6/6 200 200 
Sulfamethizole 6/6 6/6 6/6 6/6 15 15 2/6 6/6 2/6 6/6 200 200 
Sulfamethoxazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sulfamethoxypyridazine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sulfamonomethoxine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sulfamoxole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sulfapyridine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sulfaquinoxaline 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sulfathiazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Sulfisoxazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Quinoxalines 
Carbadox 6/6 6/6 6/6 6/6 15 15 1/6 6/6 1/6 5/6 200 >200 
Olaquindox 6/6 6/6 6/6 6/6 15 15 0/6 3/6 0/6 1/6 >200 >200 
Amphenicols 
Florfenicol 6/6 6/6 6/6 6/6 15 15 0/6 6/6 0/6 6/6 200 200 
Thiampenicol 6/6 6/6 4/6 2/6 15 >150 0/6 3/6 0/6 2/6 >200 >200 
Diaminopyrimidines 
Baquiloprin 6/6 6/6 6/6 6/6 15 15 5/6 6/6 5/6 6/6 200 200 
Trimethoprim 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Other antibiotics 
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Lincomycin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Novobiocin 0/6 6/6 0/6 6/6 150 150 0/6 6/6 0/6 6/6 200 200 
Rifaximin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Althenmintics 
Albendazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Albendazole oxide 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Albendazole sulfone 2/6 2/6 5/6 4/6 >150 >150 6/6 6/6 6/6 6/6 20 20 
Dimetridazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Febantel 3/6 6/6 0/6 0/6 150 >150 0/6 0/6 0/6 0/6 >200 >200 
Fenbendazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Flubendazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Levamisole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Mebendazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Metronidazol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Morantel 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Oxfendazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Piperazine 0/6 2/6 0/6 2/6 >150 >150 0/6 5/6 0/6 5/6 >200 >200 
Ronidazole 6/6 6/6 6/6 6/6 15 15 0/6 4/6 0/6 3/6 >200 >200 
Ternidazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Thiabendazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Triclabendazole 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Coccidiostats 
Arprinocid 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Clopidol 6/6 6/6 6/6 6/6 15 15 5/6 6/6 5/6 6/6 200 200 
Decoquinate 2/6 6/6 2/6 5/6 150 >150 4/6 6/6 4/6 6/6 200 200 
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Diaveridine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Ethopabate 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Halofuginone 6/6 6/6 6/6 6/6 15 15 0/6 6/6 0/6 6/6 200 200 
Imidocarb 6/6 6/6 6/6 6/6 15 15 5/6 6/6 5/6 4/6 200 >200 
Lasalocid 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Monensin 6/6 6/6 6/6 6/6 15 15 0/6 1/6 0/6 1/6 >200 >200 
Narasin 0/6 6/6 0/6 3/6 150 >150 0/6 6/6 0/6 6/6 200 200 
Nigericin 2/6 6/6 0/6 0/6 150 >150 1/6 6/6 1/6 5/6 200 >200 
Robenidine 0/6 6/6 0/6 6/6 150 150 5/6 5/6 5/6 5/6 >200 >200 
Salinomycin 2/6 6/6 1/6 1/6 150 >150 1/6 6/6 1/6 3/6 200 >200 
NSAIDs 
5-Hydroxy-flunixin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Aceclofenac 6/6 6/6 6/6 6/6 15 15 0/6 6/6 0/6 6/6 200 200 
Diclofenac 0/6 6/6 0/6 6/6 150 150 6/6 6/6 6/6 6/6 20 20 
Flunixin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Ketoprofen 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Mefenamic acid 5/6 6/6 4/6 6/6 150 150 3/6 6/6 3/6 6/6 200 200 
Meloxicam 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Naproxen 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Niflumic acid 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Phenylbuntazone 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Tolfenamic acid 6/6 6/6 0/6 0/6 15 >150 0/6 5/6 0/6 0/6 >200 >200 
Vedaprofen 4/6 6/6 3/6 5/6 150 >150 1/6 1/6 1/6 1/6 >200 >200 
beta-agonists 
Cimaterol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
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Clenbuterol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Clenpenterol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Mabuterol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Ractopamine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Salbutamol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Terbutaline 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Steroids 
Betamethasone 6/6 6/6 2/6 6/6 15 150 2/6 6/6 2/6 6/6 200 200 
Cortisol 6/6 6/6 6/6 6/6 15 15 0/6 6/6 0/6 6/6 200 200 
Cortison 6/6 6/6 6/6 6/6 15 15 4/6 6/6 4/6 6/6 200 200 
Dexamethazone 5/6 6/6 0/6 0/6 150 >150 3/6 5/6 3/6 0/6 >200 >200 
Methylprednisolone 6/6 6/6 5/6 6/6 15 150 5/6 5/6 5/6 4/6 >200 >200 
Progesteron 2/6 6/6 2/6 6/6 150 150 5/6 6/6 5/6 6/6 200 200 
Thyreostats 
Methyl-thiouracil 0/6 2/6 0/6 2/6 >150 >150 5/6 6/6 5/6 6/6 200 200 
Phenyl-thiouracil 3/6 6/6 3/6 6/6 150 150 6/6 6/6 6/6 6/6 20 20 
Propyl-thiouracil 1/6 6/6 1/6 6/6 150 150 6/6 6/6 6/6 6/6 20 20 
Pharmaceuticals 
Ambroxol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Atenolol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Atorvastatin 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Caffeine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Carbamazepine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Cimetidine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Gemfibrozil 6/6 6/6 6/6 6/6 15 15 4/6 6/6 4/6 6/6 200 200 
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Haloperidol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Indapamide 6/6 6/6 6/6 6/6 15 15 1/6 6/6 1/6 6/6 200 200 
Metformin 6/6 6/6 6/6 6/6 15 15 1/6 6/6 1/6 6/6 200 200 
Metoprolol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Paracetamol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Propranolol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Ranitidine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Simvastatin 6/6 6/6 6/6 6/6 15 15 5/6 6/6 5/6 6/6 200 200 
Theophyline 6/6 6/6 6/6 6/6 15 15 0/6 6/6 0/6 6/6 200 200 
Tramadol 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Triamterene 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Valsartan 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Others 
Bromhexine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Chlorpromazine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Colchicine 6/6 6/6 6/6 6/6 15 15 6/6 6/6 6/6 6/6 20 20 
Coumaphos 1/6 6/6 0/6 6/6 150 150 6/6 6/6 6/6 6/6 20 20 
Melamine 6/6 6/6 6/6 6/6 15 15 0/6 4/6 0/6 4/6 >200 >200 
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Milk presented slightly better SDL and LOI values in comparison to fish samples. 
This could be due to the highest pre-concentration achieved with the sample 
preparation protocol used for milk which succeeds to a significant increase in 
sensitivity. The more effective clean-up of milk samples, using SPE, could also 
lead to reduced matrix effects and increased sensitivity.  
The majority of the compounds in both milk and fish samples were detected at 
the lowest concentration level (78% in milk samples and 60% in fish samples). 
What is of great significance is that, practically, the same number of compounds 
were also identified at this level: 74% in milk samples and 60% in fish samples. 
This comes to contrast with methods reported in literature where the number of 
identified compounds is drastically decreased at the low concentration level [101, 
216, 217] indicating the wide effectiveness and applicability of the proposed 
methodology.  
Overall, for milk samples, the reliable identification using two accurate-mass ions 
was feasible for 74% of compounds at 15 ng mL-1 and for 87 % at 150 ng mL-1. 
For the remaining 13% of the compounds, LOIs are >150 ng mL-1 with this 
method. However, only 8% of the compounds presented SDLs >150 ng mL-1. For 
fish samples, as mentioned above, 60% of the compounds were detected and 
identified at 20 μg kg-1. SDLs for the 29% of the compounds and LOIs for the 
24% were calculated at 200 μg kg-1 while 11% could not be detected and 16% 
could not be identified at the concentrations examined. The identification of the 
anthelmintic levamisole in a spiked milk sample (15 ng mL-1) and in a spiked fish 
sample (20 μg kg-1) is shown in Figure 4.2. 
  Two compounds  (tolfenamic acid and febantel)  presented  poor  or none  
fragmentation  as  a  result  of  the  collision  energy  value  applied, which  was  
the  result  of  a  compromise  for  all  compounds. For these compounds no 
fragments could be obtained and, therefore, the  screening  method  was  limited  
for  detection,  since no  identification  could  be  performed.  Cefaclor, amoxicillin 
and clarithromycin were not detected neither identified in any of the spiked milk 
samples while in fish, cefapirin, cefazolin and febantel could be neither detected 
nor identified at the levels tested. One reason is that some analytes are not 
ionized very effectively and their levels of detection, even for solvent standards, 
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are quite high. Many of the cephalosporin compounds fall into this category [103]. 
Another reason is that these compounds might not be stable under the extraction 
conditions assayed and that they are metabolized [225, 226] Matrix effects could 
also highly affect the determination. 
 
Figure 4.3: nw-XICs of Levamisole corresponding to the protonated molecule at LE and to its fragment 
ions at HE for 50 ng ml-1 reference standard, 15 ng ml-1 spiked milk sample and 20 ng g -1 spiked fish 
sample. 
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4.4 Application to milk and fish samples 
To evaluate the applicability of the proposed method in routine analysis, 5 milk 
samples (4 bovine and 1 ovine) and 5 fish samples (3 sea bream and 2 sea 
bass) were tested. No positive results were found in any of these samples. The 
results reported by QTOF MS were confirmed by LC-MS/MS analysis in MRM 
mode, monitoring two transitions per compound, revealing the absence of any of 
the target analytes in the samples examined. This indicates the good selectivity 
of the proposed methodology which presented no false positive results. 
 
4.5 Conclusions 
The  qualitative  validation  of  a  wide-scope  screening  method including  143 
veterinary drugs and pharmaceuticals  has  been  carried  out  in two  types  of  
milk and two types of fish samples. Using this method, data including retention 
times, as well as accurate mass measurements for precursor and product ions, 
have been collected for all analytes. Detection, based mainly on the presence of 
the protonated molecule, as well as identification using a second accurate-mass 
fragment ion, was feasible in most cases at the lowest level tested (20 μg kg-1 for 
fish samples and 15 ng mL-1 for milk samples). Finally, the applicability of the 
method was examined and no false positive results were revealed in blank 
samples.  
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CHAPTER 5 
Multi-residue determination of 115 veterinary drugs and 
pharmaceutical residues in milk powder, butter, fish tissue and 
eggs using Liquid Chromatography-Tandem Mass Spectrometry  
 
5.1 Introduction   
A simple, sensitive and efficient multi-residue and multi-class analytical method 
for the simultaneous determination of 115 veterinary drugs and pharmaceuticals 
in milk powder, butter, egg and fish tissue by HPLC–MS/MS has been 
developed. 
The proposed methodology allows the simultaneous extraction of veterinary 
drugs and pharmaceuticals with very different physicochemical properties from 
various matrices, employing a simple solvent extraction with 0.1% formic acid in 
aqueous solution of EDTA 0.1% (w/v) – acetonitrile (ACN) – methanol (MeOH) 
(1:1:1, v/v) and further ultrasonic-assisted extraction. The extraction procedure 
was fully optimized in terms of recovery for the three out of four matrices 
examined. Two separate runs were performed for positive and negative 
ionization in multiple reaction monitoring mode (MRM) for the determination of all 
analytes. The method was validated in all four matrices and for over 80% of the 
analytes, the recoveries were between 50% and 120% in all matrices studied, 
with RSD values in the range of 1–18%. Limits of detection (LODs) and 
quantification (LOQs) ranged from 0.008 μg kg-1 (oxfendazole in butter) to 3.15 
μg kg-1 (hydrochlorthiazide in egg). The evaluated method provides reliable 
screening, quantification, and identification of 115 veterinary drug and 
pharmaceutical residues in foods of animal origin and has been successfully 
applied in real samples. 
This work was presented at the 5th Int. Symp. On Recent Advances in Food 
Analysis (RAFA 2011, Prague) winning a Poster Award sponsored by Agilent 
Technologies. 
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5.2 Experimental  
 
5.2.1 Chemicals and reagents  
All the analytes studied are presented in Table S5.1. All veterinary drug and 
pharmaceutical standards were of high purity grade (>90%) The vast majority of 
them were purchased from Sigma-Aldrich (Steinheim, Germany). Sulfadoxine 
(SDX) and sulfaclozine (SClZ) were donated by the National Laboratory of 
Residue Analysis of Food of Animal Origin of the Hellenic Ministry of Rural 
Development and Food. Halofuginone, bacitracin, arprinocid, salinomycin, 
semduramicin, carprofen, diclofenac, flunixin, mefenamic acid, meloxicam, 
niflumic acid as well as the internal standards flunixin-d3 and meloxicam-d3 were 
donated by the Veterinary Drug Residues Laboratory of the State General 
Laboratory of Cyprus.  
Acetonitrile and methanol LC–MS grade were purchased from Merck (Darmstadt, 
Germany) while formic acid 99% and ammonium formate from Fluka (Buchs, 
Switzerland). Hexane (pesticide analysis grade, 95%) was purchased from Carlo 
Erba (Milan, Italy) and distilled water was provided by a MilliQ purification 
apparatus (Millipore Direct-Q UV, Bedford, MA, USA). The 
ethylenediaminetetraacetic acid disodium salt (EDTA) was of analytical grade 
and was purchased from Panreac. RC (Regenerated Cellulose) syringe filters (15 
mm diameter, 0.2 μm pore size) were provided from Phenomenex (Torrance, CA, 
USA) 
About 10 mg of each individual standard was accurately weighed and placed in a 
10-mL volumetric flask. Penicillins and cefalosporines were dissolved in MilliQ-
water while all other analytes in methanol. In quinolone standard solutions, 100 
μL of formic acid were added to enhance solubility. Stock solutions of 1000 μg 
ml-1 of each compound were obtained and stored at −20 °C in brown glass to 
prevent the photodegradation. Four intermediate standard solutions containing 
several analytes grouped according to their classification and stability were 
prepared by dilution of the stock solutions with methanol. The final concentration 
of these multi-component solutions was 10 μg ml-1 and they were also stored at 
−20 °C. New ones were prepared every month.  
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All working solutions and calibration standards were obtained by gradient dilution 
of the intermediate solutions, in concentrations varying from 1 μg mL-1 to 1 ng 
mL-1. Working standard solution of internal standards in a concentration of 1 μg 
mL-1 came by subsequent dilutions of their stock solutions in methanol. While not 
in use, the working solutions were kept at −20 °C and renewed weekly. 
 
5.2.2 LC–MS/MS analysis  
A Thermo UHPLC Accela system was connected to a Thermo Scientific TSQ 
Quantum Access Triple Quadrupole Instrument (Thermo, San Jose, CA, USA). 
An Atlantis T3 C18 (100 mm x 2.1 mm, 3 μm, Waters) column protected by a 
guard column was used at a constant flow rate of 100 μL min-1. Two 
chromatographic runs were performed in order to determine all analytes in each 
sample, one in positive ionization mode and one in negative. The mobile phase 
for the positive mode detection consisted of water containing 0.01% formic acid 
(v/v) (solvent A) and methanol (solvent B), while for the negative mode detection 
was modified water (1 mM ammonium formate, A), MeOH (B) and ACN (C)).  
The gradient elution programs for both runs are presented in Tables S5.2 and 
S5.3.  The column was thermostated at 30 °C and the full loop injection volume 
of the extract was set at 10 μL. 
As far as the MS parameters are concerned, the mass spectra and the optimum 
collision energy and tube lens value were obtained for each compound 
separately by direct infusion of individual standard solutions at concentration of 1 
μg mL-1 in formic acid : MeOH (75:25, v/v) or ammonium formate : MeOH (75:25, 
v/v), depending on whether the determination is performed in a positive or a 
negative ionization mode. The ESI parameters (Spray Voltage, Seath Gas, 
Auxiliary Gas, Capillary temperature) for each determination are also presented 
in Tables S5.2 and S5.3. 
Multiple reaction monitoring (MRM) was used and detailed parameters for MRM 
acquisition are presented in Table 5.1. Two transitions were selected for 
identification, but only the most intense one was used for quantification.  
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Table 5.1: MRM parameters and retention times for all compounds determined. 
Compound ESI 
Pseudo 
Molecular Ion 
Product 
Ion 1 
Collision 
Energy (eV) 
Product 
Ion 2 
Collision Energy 
(eV) 
Tube Lens 
RT (SD, n=10) 
(min) 
Quinolones 
Ciprofloxacin + 332 288 18 314 22 85 7.715  (0.029) 
Danofloxacin + 358 96 25 314 20 85 7.776  (0.038) 
Difloxacin + 400 356 20 299 27 85 8.029  (0.022) 
Enrofloxacin + 360 245 25 317 20 85 7.761  (0.032) 
Flumequine + 262 244 20 202 30 85 11.963  (0.024) 
Marbofloxacin + 363 320 15 72 20 85 7.164  (0.025) 
Norfloxacin + 320 276 16 233 23 91 7.613  (0.034) 
Ofloxacin + 362 318 19 261 27 120 7.430  (0.032) 
Oxolinic acid + 262 244 18 158 31 79 10.708  (0.029) 
Sarafloxacin + 386 342 18 299 27 85 8.096  (0.039) 
Ciprofloxacin + 332 288 18 314 22 85 7.715  (0.029) 
Tetracyclines 
Chlortetracycline + 479 444 20 462 15 90 9.407  (0.045) 
Doxycycline + 445 427 19 267 35 90 10.048  (0.034) 
Oxytetracycline + 461 426 19 443 12 90 8.412  (0.018) 
Tetracycline + 445 410 18 426 12 90 8.181  (0.030) 
Cefalosporines 
Cefaclor + 368 174 14 118 32 81 8.070 (0.042) 
Cefadroxil + 364 114 19 134 29 97 5.929  (0.057) 
Penicillins 
Amoxicillin + 366 349 8 114 22 68 5.749  (0.096) 
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Ampicillin + 350 106 20 160 12 87 8.170  (0.029) 
Macrolides 
Azithromycin + 750 591 29 158 37 127 8.378  (0.035) 
Clarithromycin + 749 158 30 590 20 123 11.067  (0.039) 
Erythromycin + 734 158 30 576 20 130 10.381  (0.032) 
Tiamullin + 494 192 21 119 33 101 10.152  (0.031) 
Tilmicosin + 869 174 42 156 44 165 8.892  (0.045) 
Tylosin + 917 174 36 772 28 148 10.252  (0.035) 
Sulfonamides 
Sulfaclozine (SClZ) + 285 92 28 156 15 87 10.072  (0.024) 
Sulfachloropyridazine (SCP) + 285 92 28 156 14 87 8.963  (0.029) 
Sulfadimidine (SDD) + 279 186 17 124 26 87 8.751  (0.029) 
Sulfadimethoxine (SDM) + 311 156 17 108 29 87 10.130  (0.017) 
Suladoxine (SDX) + 311 156 17 108 27 87 9.230  (0.020) 
Sulfadiazine (SDZ) + 251 156 15 92 27 87 7.444  (0.026) 
Sulfaguanidine (SGN) + 215 156 14 92 14 87 4.164  (0.087) 
Sulfisoxazole (SIX) + 268 156 13 92 27 87 8.158  (0.017) 
Sulfamonomethoxine (SMM) + 281 156 13 92 29 87 8.615  (0.028) 
Sulfamethoxypyridazine (SMP) + 281 156 13 92 29 87 9.176  (0.018) 
Sulfamerazine (SMR) + 265 156 16 172 16 87 8.132  (0.032) 
Sulfamethizole (SMT) + 271 156 14 92 28 87 8.340  (0.012) 
Sulfamethoxazole (SMTX) + 254 156 16 108 25 87 8.970  (0.018) 
Sulfamoxole (SMX) + 268 156 13 92 28 87 9.162  (0.024) 
Sulfapyridine (SPD) + 250 156 15 184 17 87 7.623  (0.028) 
Sulfaquinoxaline (SQX) + 301 156 18 92 30 87 10.370  (0.030) 
Sulfathiazole (STZ) + 256 156 15 92 26 87 7.347  (0.031) 
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Dapsone + 249 156 14 108 22 79 8.242  (0.033) 
Other antibiotics 
Bacitracin + 712 199 42 355.5 29 113 9.968  (0.069) 
Lincomycin + 407 126 30 359 17 99 7.027  (0.041) 
Novobiocin + 613 189 31 396 14 108 16.526  (0.050) 
Rifaximin + 786 754 22 361.5 32 114 13.973  (0.027) 
Trimethoprim + 291 230 25 123 30 87 7.059  (0.034) 
Benzimidazoles 
Albendazole + 266 191 31 234 29 85 13.216  (0.028) 
Albendazole sulfone + 298 159 35 266 19 74 10.485  (0.029) 
Febantel + 447 383 17 280 31 110 14.402  (0.017) 
Fenbendazole + 300 268 29 159 33 85 14.019  (0.017) 
Flubendazole + 314 282 31 123 35 90 12.771  (0.028) 
Mebendazole + 296 264 31 105 35 90 12.493  (0.017) 
Oxfendazole + 316 159 30 191 24 87 11.113  (0.024) 
Thiabendazole + 202 131 35 175 35 87 9.121  (0.021) 
Triclabendazole + 359 274 35 171 40 85 16.100  (0.079) 
Nitroimidazoles 
Dimetridazole + 142 96 18 54 30 80 8.230 (0.033) 
Metronidazole + 172 128 13 82 25 69 7.394 (0.028) 
Ternidazole + 186 128 15 82 28 75 8.371 (0.021) 
Ronidazole + 201 140 10 55.5 21 73 7.273 (0.045) 
Coccidiostats 
Aprinocid + 278 143 28 107 48 95 10.927  (0.018) 
Clopidol + 192 101 27 87 31 99 8.628  (0.015) 
Diaveridine + 261 245 26 123 26 93 6.865  (0.025) 
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Ethopabate + 238 206 11 136 27 37 11.291  (0.033) 
Halofuginone + 416 100 26 120 23 73 9.532  (0.045) 
Monensin + 693 461 43 479 51 159 21.119  (0.031) 
Salinomycin + 773 431 48 531 37 138 23.682  (0.073) 
Semduramycin + 895 833 28 851.5 30 116 19.758  (0.053) 
Other Anthelmintics 
Levamisol + 205 178 29 123 30 87 6.501  (0.045) 
Morantel + 221 111 20 177 29 84 7.961  (0.033) 
Nitroxinil - 289 127 34 162 28 87 9.134  (0.032) 
Oxyclozanide - 398 362 25 176 34 79 13.939  (0.065) 
NSAIDs 
Carprofen
a
 - 272 226 28 228 23 85 12.856  (0.041) 
Diclofenac + 296 215 19 250 12 72 14.942  (0.031) 
Flunixin
a
 - 295 251 15 209 30 85 11.793  (0.032) 
Ibuprofen
a
 - 205 161 10 - - 65 13.253  (0.069) 
Ketoprofen + 255 209 13 105 23 106 13.063  (0.044) 
Mefenamic Acid
a
 - 240 196 19 191 26 78 13.491  (0.069) 
Meloxicam
b
 - 350 286 16 146 23 67 9.746  (0.040) 
Naproxen
b
 - 229 169 10 - - 76 11.073  (0.047) 
Niflumic acid + 283 265 22 245 28 97 16.485  (0.077) 
Salicylic acid - 137 93 18 65 32 45 5.369  (0.029) 
Tolfenamic acid
b
 - 260 216 18 180 24 74 6.226  (0.030) 
Amphenicols 
Chloramphenicol - 321 257 13 152 19 90 9.241 (0.023) 
Florfenicol - 356 336 11 185 18 90 7.684 (0.023) 
Thiamphenicol - 354 290 11 185 19 90 8.176 (0.051) 
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beta-agonists 
Clenbuterol + 277 203 26 259 10 82 8.044 (0.032) 
Beta-blockers 
Atenolol + 267 145 26 190 18 94 5.701 (0.032) 
Metropolol + 268 191 17 133 25 96 8.212 (0.034) 
Propanolol + 260 183 19 155 25 99 9.459 (0.031) 
Steroids 
Betamethasone Acetate + 435 415 6 397 10 90 13.365 (0.027) 
Cortisol + 363 309 16 269 21 102 12.267 (0.029) 
Cortison + 361 163 23 145 24 102 11.839 (0.031) 
Dexamethasone + 393 319 17 3369 18 124 13.385 (0.041) 
Methylprednisolone + 375 339 8 357 10 71 12.967 (0.059) 
Prednisolone + 361 343 10 147 24 98 12.210 (0.039) 
Progesteron + 315 109 28 97 24 79 15.361 (0.062) 
Analgetics 
Caffeine + 195 138 18 110 22 87 8.643 (0.018) 
Paracetamol + 152 93 22 110 15 84 7.232 (0.029) 
Tramadol + 264 58 15 246 8 66 8.168 (0.044) 
Diuretics 
Furosemide - 329 285 17 205 25 58 8.176 (0.051) 
Hydrochlorthiazide - 296 269 19 205 22 139 4.977 (0.074) 
Indapamine - 364 189 28 233 21 72 10.426 (0.036) 
Triamterene + 254 237 26 104 36 93 7.945 (0.035) 
Statins 
Atorvastatin + 559 440 22 250 42 123 13.869 (0.031) 
137 
 
Antiepileptic drugs 
Carbamazepine + 237 194 19 193 32 114 12.027 (0.024) 
Antiulcer Drugs 
Cimetidine + 253 159 13 95 29 73 5.860 (0.055) 
Omeprazole + 330 182 23 149 25 90 11.275 (0.028) 
Ranitidine + 315 176 17 102 31 79 5.724 (0.046) 
Fibrates 
Clofibric acid - 213 127 17 85.4 12 64 10.031 (0.018) 
Gemfibrozil - 249 121 19   83 15.611 (0.092) 
Others 
Colchicine + 400 310 26 326 24 110 10.914 (0.035) 
Coumaphos + 363 227 26 307 17 105 15.134 (0.026) 
Theophylline + 181 124 17 96 22 79 8.023 (0.028) 
Valsatran + 436 207 28 291 16 99 14.420 (0.083) 
Internal Standards (IS) 
Flunixin – d3 - 298 254 15   85 11.851 (0.032) 
Meloxicam – d3 - 353 149 23   101 9.769 (0.028) 
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Each chromatographic run was divided into several scan events with a scan time 
of 20 ms for each transition. LC–MS/MS chromatogram of a spiked egg sample, 
at a concentration of 100 ng mL-1 for 115 target compounds, is presented in Fig. 
S5.1. Instrument control and data acquisition were carried out by using the 
Xcalibur software, Version 2.3, from Thermo. 
 
5.2.3 Samples and quality control materials 
Seventy three (73) milk powder, five (5) butter, twenty two (22) fish (gilthead sea 
bream and sea bass) and eight (8) egg samples were obtained from several local 
markets. Upon arrival at the laboratory, milk, butter and egg samples were stored 
at 4 °C. Fish samples were partially thawed at room temperature and muscle 
tissue was taken, homogenized and stored at -20 °C until analysis. Whole egg 
samples (albumen and yolk) were gently homogenized before analysis at room 
temperature under continuous agitation for 5 min. 
 One sample of each matrix was repeatedly measured to confirm that no 
veterinary drugs or pharmaceuticals were present and was used for the 
preparation of matrix-matched calibration standards and fortified samples for the 
validation of the method. 
Spiked samples were prepared by adding the proper amount (from 10 to 200 μL) 
of a working solution containing all the analytes at the suitable concentrations, to 
each 1-g portion of the weighed samples. 50 μL of the Internal Standard working 
solution were added at each sample to achieve a final concentration of 50 μg kg-
1 for each IS. For the evaluation of the different extraction procedures, blank 
samples were spiked at 100 μg kg-1. Afterwards, there was a waiting period of 15 
min for equilibration before starting the extraction step. Blank control samples 
were extracted and run with each analytical run/batch. 
Since there is lack of certified test materials in the examined matrices, and in 
order to establish method accuracy, two Progetto Trieste (Trieste – Italy) test 
materials, MI1320 and MI1321, of lyophilized bovine milk containing a certified 
amount of sulfonamides, tetracyclines and quinolones, were used.   
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5.2.4 Sample Preparation 
A 1-g portion of each properly homogenized sample was weighed and placed 
into a 15 mL polypropylene centrifuge tube. Afterwards, spiking of the samples 
with appropriate volumes of the working standard mix solutions (target 
compounds and IS) was performed. As mentioned above (paragraph 2.3), the 
blank samples fortified with the target compounds were used during the 
optimization and validation of the developed procedure. All spiked samples were 
allowed to stand for 10–15 minutes before proceeding. 
To extract the drug residues and precipitate the proteins, 2 mL of H2O containing 
0.1 % formic acid (v/v) and 0.1 % EDTA (w/v) were added to the samples and 
subsequently 2 mL of MeOH and 2 mL of ACN. The addition of this chelating 
agent improves the extraction recovery of some antibiotics, especially of 
tetracyclines, as it prevents their rapid chelation with metal ions [85]. After the 
addition of each solvent the tube was vortex-mixed for 30 sec. The sample set 
was placed in an ultrasonic bath at 60 ºC for 20 min in order an ultrasonic-
assisted extraction of the veterinary drugs and pharmaceuticals from the matrix 
to take place. 
Thereafter, the samples were centrifuged at 4000 rpm for 10 min and the 
supernatant was decanted into a new polypropylene centrifuge tube. The tubes 
were placed in -20 °C for 12 h in order to precipitate the lipids and remaining 
proteins. The samples were again centrifuged, the precipitate was thrown away 
and the supernant was transferred in another tube were the extracts were 
defatted using 5 mL of hexane, vortexed for 1 min, and then centrifuged for 10 
min 4000 rpm. The hexane layer was aspirated to waste and the final extracts 
were evaporated to dryness under a nitrogen stream at a temperature not 
exceeding 45°C. The resulting residues were reconstituted in 1 mL of 
methanol/aqueous solution of formic acid, 0.05% (25:75 v/v) and then filtered 
through a 0.22-μm RC filter. Appropriate volumes of working multi-analyte 
solutions were added to blank aliquots at this step, to prepare the range of 
matrix-matched standards required. After vortex-mixing for 10 s, each extract 
was then transferred into a vial, and 10 μL was injected into the LC-MS/MS 
system. 
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5.2.5 Method validation  
An in-house validation protocol was carried out, taking into consideration the 
requirements outlined in Commission Decision 2002/657/EC, in order to establish 
the performance characteristics of the method, ensuring the adequate 
identification, confirmation and quantification of the target compounds.  
Identification and confirmation of the analytes were carried out by retention times, 
identification points of each analyte as required by the EU validation criteria, and 
relative ion ratio of selected MRM transitions. For each compound, the MRM 
transition with the highest intensity was used for quantification (quantifier), while 
the other transition was used for confirmation (qualifier). 
The selected solvent extraction procedure was validated in terms of selectivity, 
linearity, trueness, repeatability, inter-day precision, limits of detection (LODs) 
and limits of quantification (LOQs). These validation parameters were evaluated 
in all four matrices examined in this study (milk powder, butter, fish tissue and 
egg). The use of internal standards was only feasible for some NSAIDs 
(carprofen, flunixin, ibuprofen, mefenamic acid, meloxicam, naproxen and 
tolfenamic acid) since it was the only group of analytes for which isotopic labeled 
internal standards were available (flunixin-d3 and meloxicam-d3). The choice of 
the adequate IS was made based on the retention time of the analytes. Flunixin-
d3 was used in the quantification of carprofen, flunixin, ibuprofen and mefenamic 
acid while meloxicam-d3 meloxicam, naproxen and tolfenamic acid.  
Because the aim of the study was the simultaneous quantification of target 
compounds at the lowest achievable level, no focus was put on the decision limit, 
CCα, and the detection capability, CCβ, which are parameters for compliance 
analysis by authorities [40]. 
 
5.2.5.1 Instrument performance 
Calibration curves in pure solvent were constructed for all compounds by plotting 
the peak area against the concentration of the eight corresponding calibration 
standards (1 to 200 ng mL-1). The calibration curves for NSAIDs were 
constructed by calculating the ratio of each peak area relative to the 
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corresponding IS. The linearity of the LC-MS/MS method was evaluated 
assessing the regression coefficient measured for each analyte. Concentrations 
were measured five times for each level (n=5). Instrumental LODs were 
calculated as 3.3 times the standard deviation (SD) of the peak area (or ratio of 
peak areas with the IS) of the analyte in the five replicates of the lowest 
concentration standard solution for each compound (0.1, 0.5, 2 or 10 ng mL-1) 
divided by the slope of the calibration curve. LOQs were calculated as 10 times 
the SD divided by the slope. 
 
5.2.5.2  Method performance 
The selectivity and specificity was assessed by analyzing 10 blank samples from 
each matrix. The absence of background peaks, above a signal-to-noise ratio of 
3, at the retention times of the target compounds showed that the method is free 
of endogenous interferences. 
Standard solution calibration curves in matrix extracts were obtained by addition 
of the target compounds in blank milk powder, butter, fish and egg extracts in 
different concentrations (1 to 200 ng mL-1, eight concentration levels). The 
matrix-matched calibration curve (samples spiked before the extraction)  in milk 
powder was developed by fortifying eight 1 g fractions of blank material with the 
appropriate volumes from two multi-analyte working solutions of 0.1 μg mL-1 and 
1 μg mL-1 (10 μL to 200 μL, 1 to 200 μg kg-1). The exact same fortification was 
performed in eight 1 g fractions of blank butter, fish tissue and egg. 
In order to evaluate the trueness of the method, recovery studies were carried 
out. Overall recoveries for all compounds in each matrix were calculated by 
dividing the matrix-matched calibration curve slope (samples spiked before the 
extraction) to the slope of the standard solution calibration curve in matrix 
extracts. Absolute recoveries were determined by comparing samples spiked at 
the VL (Validation Level, 100 μg kg−1) before and after the extraction. In addition 
to recovery studies, trueness of the method was assessed by analyzing 
proficiency test materials of lyophilized bovine milk for 19 target compounds 
belonging in 3 different groups and having different physicochemical properties. 
The z-score assigned to each laboratory was calculated from the equation: 
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Z - score = (x – X) / σ     (1) 
x is the analyte concentration value reported by the laboratory, X is the assigned 
value and σ is the target value for standard deviation calculated from bX.  
b = %RSD / 100     (2) 
RSD is the relative standard deviation value coming from Horwitz equation [227] 
%RSD = 2(1-0.5 log X)      (3) 
and  X is expressed as a dimensionless concentration. 
The within-day and between-day precision (repeatability and reproducibility, 
respectively) are expressed as RSD% and were evaluated by spiking six blank 
samples (n=6) at the VL for all four matrices. The determination of reproducibility 
was carried out on three different days. 
For the calculation of the method’s LODs and LOQs fortification of six blank 
samples of each matrix was performed in very low concentration of analytes. The 
SD of the peak area of the six replicates (or the peak area ratio for NSAIDs) is 
calculated in the lowest concentration that every analyte is determined in each 
matrix (0.1, 0.5, 2 or 10 μg kg-1). 3.3 times the SD divided to the slope of the 
matrix-matched calibration curve provides method’s LOD for each analyte in 
each matrix while 10 times this ratio provides the method’s LOQs. 
Finally, the matrix effect was studied by evaluating the ionic suppression and 
enhancement effects, comparing standard solution calibration curves for all 
analytes prepared in solvent and in each matrix, separately. 
 
5.3 Results and Discussion 
 
5.3.1 LC-ESI-MS/MS determination  
The aim of the development of this method was to determine a high number of 
substances with sufficient separation on the column and high sensitivity for the 
mass spectrometric measurement.  
At first, the selection and tuning of the precursor and product ions were carried 
out. Direct infusion of individual veterinary drugs and pharmaceutical solutions at 
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concentration of 1 μg mL-1 in formic acid 0.1%: MeOH (75:25, v/v) or ammonium 
formate 1 mM: MeOH (75:25, v/v) was performed, depending on if the 
determination of the analyte is achieved in positive or negative ionization mode, 
respectively. The mass spectra for all analytes were obtained along with analyte 
dependent parameters, such as collision energy and tube lens, which were 
optimized and calculated automatically. For each compound, the MRM transition 
with the highest intensity was used for quantification (quantifier), while the other 
transition was used for confirmation (qualifier). A quantitative data processing 
method was established using the most abundant SRM transition for each 
residue. Table 5.1 gives the specific MS/MS parameters and the retention time of 
all target drugs in the study. 
The protonated ([M+H]+) or deprotonated (M−H]−) molecular ions were selected 
as the precursor ions for the majority of  the compounds. The exceptions were 
the antibiotic bacitracin, where the doubly charged molecule was used as the 
precursor ion, the anti-ulcer drug omeprazole which subjects to a loss of -CH3 
and the coccidiostats monensin, salinomycin and semduramycin for which the 
sodium adducts were chosen for analysis since they are thought to give the most 
reproducible results [228]. 
Electrospray parameters, such as seath gas, auxiliary gas, spray voltage and 
capillary temperature, were studied. The optimization was performed using flow 
injection analysis (FIA) with the carrier solution being the analysis’ mobile phase 
in different proportions of aqueous/organic solvent. MS parameters were 
optimized in both positive and negative ionization modes with variation of a single 
setting at a time and evaluation of the target compounds’ sensitivity. The 
optimum ESI parameters that were chosen for positive and negative ionization 
determination are shown in Tables S5.2 and S5.3.  
The chromatographic analysis was based on a LC–MS/MS methodology. 
Separation was performed in a reversed phase Atlantis T3 C18 (100 mm x 2.1 
mm, 3 μm, Waters) column and the mobile phases chosen were aqueous formic 
acid 0.01% (v/v) and methanol (ESI+) and 1 mM ammonium formate in water, 
MeOH and ACN (ESI-).  
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Due to the very different nature of the analytes, a gradient program from 90% of 
aqueous phase to 100% methanol was performed in ESI+ chromatographic 
analysis in order to elute the analytes in a reasonably short time. In ESI- the 
gradient program starts from 70% aqueous phase to 100 % MeOH and the 
retention times range from 5.4 min (salicylic acid) to 15.6 (gemfibrozil). In positive 
mode determination all analytes were separated and eluted from 4.2 min 
(sulfaguanidine) to 23.7 min (salinomycin) with the ionophore coccidiostats 
monensin, semduramycin and salinomycin being the most strongly retained 
compounds in the analytical column and having, consequently, the highest 
retention times.  
Besides eluting the strongly retained compounds, it is essential to raise the 
content of organic solvent during the gradient profile to avoid an increase of the 
contamination of the column due to poorly eluting matrix constituents such as 
lipids at low concentrations of organic solvent [67]. Furthermore, in the first 3 min 
of the analysis major interferences are presented due to polar matrix constituents 
that are eluted and co-elution with the analytes would lead to large signal 
suppression. Therefore, it was essential that the target analytes began to elute 
after the third minute of the analysis. 
Despite the large number of targeted analytes, complete separation of 
compounds with mass transitions in common was achieved. Seven sets of 
compounds, azithromycin/clarithromycin, oxolinic acid/flumequine, 
tetracycline/doxycycline, sulfamethoxypyridazine/sulfamonomethoxine, 
sulfachloropyridazine/sulfaclozine, sulfadoxine/sulfadimethoxine and 
sulfamoxole/sulfisoxazole have similar pseudomolecular ions at 749, 262, 445, 
281, 285, 311 and 268, respectively. However, these compounds can be easily 
distinguished on the basis of retention time indicating the excellent specificity of 
the developed method. Chromatograms of the veterinary drugs and 
pharmaceuticals obtained for a spiked egg sample with all compounds at the 
validation levels (VL) are shown in Figure S5.1. The long, broad tailing of 
chlortetracycline’s and doxycycline’s chromatographic peaks has been attributed 
to both tautomerization and epimerization conversion processes occurring in the 
LC column, very likely catalyzed by residual silanol groups [77]. 
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Finally, another parameter that affects the chromatographic analysis and needs 
to be taken into consideration is the composition of the re-constitution solvent of 
the extract after the evaporation step. The high content of water (about 90%) in 
the final extract is preferred for the hydrophilic analytes while the high content of 
organic solvent (about 50%) is more suitable for the hydrophobic analytes [86]. In 
the present study the re-constitution solvent consisted of methanol/aqueous 
solution of formic acid, 0.05% (25:75 v/v) and this choice was made after an 
extensive optimization performed for most of the analytes.  
 
5.3.2 Sample Preparation Optimization 
Sample preparation is the process which includes the isolation and/or 
preconcentration of compounds of interest from various matrices, the removal of 
any matrix interferences that may affect the detection system as well as making 
the analytes more suitable for separation and detection. Even with the advances 
in the development of highly efficient analytical instrumentation for their final 
determination, sample preparation is a vital part of the analytical procedure and 
effective sample preparation is essential for obtaining accurate quantitative 
results and maintaining instrument performance. A typical sample preparation 
technique consists of an extraction step of the antibacterials from the matrix and 
a subsequent purification step of the extract [13]. 
To obtain optimal results, the extraction solvent has to be selected in such way 
that efficient extraction of the target compounds is obtained, whereas the 
extraction of matrix constituents remains limited in order to prevent excessive 
matrix effects (ME). The selection of the solvent therefore depends not only on 
the target compounds, but also on the matrix.  
Simple extraction with aqueous buffers (e.g. McIlvaine buffer or succinate buffer) 
is advantageous for highly polar residues because, except from the extraction 
efficiency they also reduce co-extraction of non-polar matrix components (e.g. 
lipids). However, strongly protein-bound residues are not fully extracted and polar 
matrix components are co-extracted. Complexing agents are reported to be 
essential for the extraction of tetracyclines and some macrolides, because these 
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compounds have a strong tendency to form chelates with divalent metallic 
cations present in food samples [85]. 
In general, the majority of methods employ more efficient organic solvents as 
extracting agents. Methanol (MeOH) and acetonitrile (ACN) are more adequate 
as extraction solvents as they can simultaneously precipitate the proteins, 
denature enzymes and extract the target analytes. Many authors, as it is shown 
by the collected applications presented in Table 1.2, prefer ACN over MeOH as 
extraction solvent. Morever, MeOH extracts too many matrix compounds, 
complicating the following clean-up steps and ACN does not sufficiently extract 
polar analytes [13].  
A number of multi-residue analytical methods developed use a combination of 
water or aqueous buffer and organic solvent as the extraction mixture of the 
target compounds from the matrix (see Table 1). In this work a combination of 
0.1% formic acid in aqueous solution of EDTA 0.1% (w/v), acetonitrile (ACN) and 
methanol (MeOH) was used as the extraction solvent and various sample-to-
extracting volume ratios were tested. An organic solvent content of 50% and 67% 
was tested in the first experiment with the aqueous solvent being 1% formic acid 
(v/v) in 0.1% EDTA solution (w/v). As it was expected, the higher content of 
aqueous solvent promoted the extraction of rather polar compounds like b-
lactams, quinolones and tetracyclines (log Kow <2) but more hydrophobic 
compounds like NSAIDs, benzimidazoles, coccidiostats and some anthelmintcs 
(morantel, nitroxinil, oxyclozanide) were not satisfactorily recovered. In addition, 
the higher content of water would make the evaporation step more time-
consuming. Consequently, the 67% of organic solvent content was selected, 
which corresponds to a proportion 1:1:1 of the three solvents of choice. All 
extraction optimization results for butter, egg and milk powder are schematically 
presented in Figures S5.2, S5.3 and S5.4. 
The overall volume of the extraction solvent was then optimized, evaluating the 
difference between 6 mL (2 mL of aqueous solution of EDTA 0.1% (w/v), 2 mL of 
ACN and 2 mL of MeOH) and 9 mL (3 mL of each). Although a slight 
improvement of the recoveries was observed when increasing the volume of the 
extraction solvent, it was not significant enough to compensate for the higher 
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amount of solvents used and the raise of the time needed in the evaporation 
step. These factors would increase the cost and decrease the rapidity of the 
developed method and so a final volume of 6 mL of the extraction solvent was 
chosen. 
Afterwards, the % content of the EDTA solution in formic acid was studied. Since 
some of the target analytes have amphoteric characteristics, we expected the 
extraction yield to be significantly affected by the pH value, and indeed it turned 
out to be a significant factor. Aqueous EDTA solutions (0.1% w/v) with 1%, 0.5% 
and 0.1% were tested and the results, in terms of recovery, were evaluated. 
Coming in accordance to previous reported studies, quinolones and tetracyclines 
presented higher recoveries when extraction was performed in most acidic 
conditions (1% formic acid) [64, 76, 87, 229]. Conversely, other veterinary drugs 
like sulfonamides, macrolides and NSAIDs provided the best recovery results 
when extracted with 0.1% formic acid [64, 76, 87, 230].  
After the solid-liquid extraction with the final combination of extraction solvents, 
an additional ultrasonic-assisted extraction was performed in order to obtain 
higher recovery yields. Ultrasound can be considered as a useful alternative for 
solid sample pretreatment because the energy imparted facilitates and 
accelerates some steps, such as dissolution, fusion, and leaching, among others 
[231]. In milk powder samples, the ultrasonic extraction was held in three 
different temperatures, 30 ºC, 50 ºC and 60 ºC in order to investigate the relation 
between extraction temperature and recovery of the analytes. For 102 out of 115 
compounds the recovery value was increased when the extraction temperature 
was set > 30 ºC, with the 72 of them presenting best results when the 
temperature was set at 60 ºC (Figure S5.4). Therefore, the temperature of 
choice for the extraction was 60 ºC. 
After ultrasonic – assisted extraction the samples were subjected in low-
temprature clean up. Low temperature clean up is a rather recently reported 
technique that amplifies the precipitation of proteins and fat from the sample [86, 
232]. In an effort to obtain even more clear extracts further defatting with hexane 
followed.  
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Finally, a preconcentration step was evaluated, in order to improve the sensitivity 
of the analytical method. To carry out this step, the extract was evaporated under 
a stream of nitrogen and the final residue was dissolved in 0.5 mL of a mixture of 
methanol/aqueous solution of formic acid, 0.05% (25:75 v/v). However, the result 
was more turbid samples and lower recoveries of the analytes due to the higher 
amount of matrix components which provoke severe matrix effects and interfere 
in the detection of analytes in the ESI source. 
Recovery values for the majority of the target compounds were satisfactory 
(>50%). The NSAIDs carprofen, diclofenac, mefenamic acid and tolfenamic acid 
presented low extraction recoveries in milk, with the two latter compounds having 
recovery values <50% also in butter. This comes as a verification of the fact that 
not always satisfactory correction occurs when analogue ILIS are used. Flunixin-
d3, used as the ILIS for carprofen and mefenamic acid, and meloxicam-d3, used 
for tolfenamic acid, did not manage to compensate for the recovery losses. Since 
NSAIDs are compounds that bind in proteins, low recoveries in some cases could 
come as a result for the lack of a hydrolysis step in the sample preparation [233]. 
Low recovery values for acidic NSAIDs in milk have been previously reported 
[92].  
The anthelmintic oxyclozanide, the antiparasitic drug coumaphos and the fibrate 
gemfibrozil have shown limited extraction from all three matrices tested. Previous 
reports have already pointed out the difficulty in oxyclozanide’s determination in 
milk reporting unacceptable recovery and precision values [223]. According to 
Caldow’s study, acetic acid 1% in acetone seems to be the most efficient 
extraction solvent for oxyclozanide [234].To the best of our knowledge, there are 
no previous references for the determination of gemfibrozil and coumaphos in 
butter, milk and egg. 
Triclabendazole’s poor recovery in butter is due to butters high content of fat in 
which the compound and its metabolites are strongly bound [235]. The same 
applies for ionophore coccidiostats (monensin, salinomycin and semduramycin) 
that also presented low recoveries in butter samples due to their hydrophobicity, 
which makes their separation from fatty samples nearly impossible [86]. 
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5.3.3 Method Validation 
 
5.3.3.1 Identification 
An analyte was considered as positively identified and confirmed in a sample 
when the criteria established in the EU Commission Decision 2002/657/EC were 
met: 
 the ratio of the relative (to the IS) retention time of the analyte to that of the 
same analyte in standard solution was within ± 2.5 % tolerance  
 the presence of a signal at each of the two SRMs for the analyte was 
achieved (the use of two selected precursor-product ion transition per 
compound counts for four identification points, which fulfill the EU 
identification points requirement) 
 the signal intensity ratios of the two MS/MS transitions (quantifier and 
qualifier) with those obtained using fortified blank samples was within the 
tolerance defined [54]. 
In the present work, when no Internal Standard (IS) is used (determination of 
analytes in positive ionization mode), the identification of the target compounds 
was carried out by searching in the appropriate Retention Time Windows (RTW), 
which were given by the mean retention time ± three standard deviations of the 
retention time of ten blank samples spiked at 100 μg kg−1 (VL) for each 
compound [68, 78]. The retention times of all target compounds is presented in 
Table 5.1. 
 
5.3.3.2 Selectivity 
The selectivity of the method was evaluated by the analysis of 10 control blank 
samples from all four matrices. The absence of any signal at the same elution 
time as the target veterinary drugs and pharmaceuticals indicated the absence of 
chemical or matrix interferences that may give a false positive signal. 
 
5.3.3.3 Linearity 
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The linearity of calibration curves was assessed by using an eight-point 
calibration curve of standards in pure solvent as well as in blank milk powder, fish 
tissue, egg and butter extracts at different concentrations (1 to 200 ng mL-1). This 
number of levels was chosen in order to achieve the optimal concentration range 
for each target analyte, considering the large differences in sensitivity between 
the single substances. Each calibration standard was injected in each batch in 
duplicate. Peak area was used as the analytical response versus concentration in 
all cases except from some NSAIDs (carprofen, flunixin, ibuprofen, mefenamic 
acid, meloxicam, naproxen and tolfenamic acid) for which the peak area ratio of 
the analyte/IS was used. Calibration curves were obtained by least-squares 
linear regression analysis and acceptable linear regression R2 values were 
obtained for all compounds over the concentration ranges. Determination 
coefficient values for standard solution curves were >0.997 (Table S3), and 
>0.990 for all standard solution calibration curves in extracts of all four matrices 
examined (4×115 curves). Based on these results, a good linearity was proven 
and allowed coverage of all drugs within the working range. 
 
5.3.3.4 Precision 
The precision of this method was demonstrated in term of repeatability (intra-day 
precision) and within-laboratory reproducibility (inter-day precision), which were 
expressed as the %RSD values of set of 6 replicate analysis at the VL in every 
matrix. Reproducibility experiments lasted three consecutive days. Repeatability 
results for milk powder, fish tissue, butter and egg spiked samples (n=6 for each 
matrix) are presented in Table 5.2 In butter the %RSDs range from 2.4% 
(morantel) to 15% (bacitracin), in fish tissue from 1.7% (meloxicam) to 17% 
(semduramycin), in milk powder from 2.2% (clenbuterol) to 18% 
(chlortetracycline) and in egg samples from 3.1% (triamterene) to 16% 
(colchicine).  
It can be observed that relative standard deviations were always lower than 20 
for all the veterinary drugs and pharmaceuticals and for all matrices assayed. 
Moreover, the obtained RSD values of the within-laboratory reproducibility did not 
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exceed in any case the acceptable values calculated from the Horwitz equation. 
These results indicate the good precision and reliability of the developed method. 
 
 
Table 5.2. %Recovery and repeatability (expressed as %RSD) results in the VL for all matrices tested.  
 Butter (n=6) Fish tissue (n=6) Egg (n=6) Milk powder (n=6) 
Compound % 
Recovery 
% RSD % 
Recovery 
% RSD % 
Recovery 
% RSD % 
Recovery 
% RSD 
Quinolones 
Ciprofloxacin 87.2 4.7 82.5 13 93.0 9.7 72.0 4.4 
Danofloxacin 93.8 5.5 84.9 13 107 9.7 101 6.5 
Difloxacin 109 5.0 86.8 9.6 63.5 13 84.9 7.4 
Enrofloxacin 103 6.2 91.1 12 107 6.3 87.2 7.6 
Flumequine 103 5.5 85.3 8.0 47.2 5.5 79.6 6.6 
Marbofloxacin 94.4 2.7 101 3.2 78.4 4.7 70.3 6.1 
Norfloxacin 98.3 4.9 96.4 5.5 84.8 5.7 71.1 6.1 
Ofloxacin 99.8 2.9 109 8.1 64.8 8.0 75.7 7.2 
Oxolinic acid 95.5 5.5 92 4.5 101 4.0 74.0 6.6 
Sarafloxacin 95.9 4.9 83.7 9.6 58.1 8.4 80.2 6.4 
Tetracyclines 
Chlortetracycline 86.5 5.6 59.6 8.9 74.2 4.3 70.4 18 
Doxycycline 78.7 11 74.8 11 52.9 10 64.2 13 
Oxytetracycline 83.7 6.3 84.0 6.2 80.7 10 59.5 9.5 
Tetracycline 66.3 5.5 80.4 7.1 28.3 8.8 53.1 7.1 
Cefalosporines 
Cefaclor 106 11 72.3 11 66.7 11 59.7 12 
Cefadroxil 94.2 10 73.7 13 41.5 5.0 41.8 8.6 
Penicillins 
Amoxicillin 69.8 12 95.6 12 59.4 11 74.6 11 
Ampicillin 90.9 7.8 68.3 11 62.2 6.7 113 15 
Macrolides 
Azithromycin 88.2 5.3 95.0 10 69.8 12 104 6.7 
Clarithromycin 84.8 4.8 88.2 10 85.7 7.5 109 4.5 
Erythromycin 71.1 6.7 94.5 5.2 56.9 12 88.3 6.4 
Tiamullin 93.7 3.1 95.4 5.9 58.8 5.5 99.1 9.7 
Tylosin 83.6 6.8 85.9 8.6 72.6 8.2 95.7 9.6 
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Tilmicosin 99.1 5.5 93.5 5.2 66.4 5.5 87.4 11 
Sulfonamides 
SClZ 104 3.2 99.1 9.5 50.3 6.7 69.2 14 
SCP 101 8.6 92.2 3.9 57.0 7.7 55.7 8.1 
SDD 92.2 5.8 85.9 7.5 71.3 10 50.7 8.8 
SDM 83.2 6.5 77.0 6.2 59.4 6.0 60.3 5.9 
SDX 85.1 6.2 76.4 3.2 64.5 8.3 51.6 6.9 
SDZ 86.7 7.7 99.6 6.0 63.3 3.6 44.0 7.3 
SGN 71.2 11 91.3 11 66.6 13 50.3 12 
SIX 80.0 7.2 93.1 3.0 36.9 11 55.2 11 
SMM 85.2 7.7 85.2 8.1 60.4 5.7 56.1 6.4 
 SMP 88.9 5.0 88.8 6.5 80.3 7.5 80.3 8.5 
SMR 86.4 6.7 82.9 10 67.2 7.3 65.6 10 
SMT 74.7 12 82.2 9.8 58.1 12 60.6 11 
SMTX 99.4 5.6 89.7 7.5 64.8 12 65.4 7.2 
SMX 96.3 6.7 98.7 3.5 45.8 7.3 62.2 8.1 
SPD 98.4 4.3 86.0 12 72.5 8.8 62.2 5.9 
SQX 84.2 6.6 81.1 4.6 52.5 4.1 58.1 12 
STZ 93.8 6.3 78.2 11 57.5 9.6 69.7 9.1 
Dapsone 81.0 11 87.1 8.8 54.2 9.2 82.1 9.2 
Other antibiotics 
Bacitracin 56.3 15 73.8 11 72.3 7.2 77.2 12 
Lincomycin 89.1 7.3 94.2 4.1 103 7.4 79.0 9.3 
Novobiocin 42.3 12 72.2 9.9 63.1 10 63.6 10 
Rifaximin 83.7 5.6 92.5 5.1 68.1 8.4 91.1 7.8 
Trimethroprim 98.1 8.1 95.2 5.4 63.6 7.1 66.8 6.4 
Benzimidazoles 
Albendazole 53.3 9.3 64.8 9.1 88.6 11 87.2 8.5 
Albendazole  
sulfone 
89.7 3.6 90.3 6.1 61.2 10 115 9.5 
Febantel 70.4 11 81.2 11 55.0 12 61.9 12 
Fenbendazole 63.6 13 32.4 15 41.8 8.8 18.0 10 
Flubendazole 79.2 8.8 90.8 8.1 57.7 13 61.8 4.7 
Mebendazole 95.9 7.4 91.5 6.2 53.8 6.7 70.1 4.3 
Oxfendazole 102 2.6 95.3 3.4 65.9 8.2 83.2 7.4 
Thiabendazole 101 4.9 94.8 5.9 56.1 6.8 74.8 4.0 
Triclabendazole 12.2 14 62.3 6.4 51.0 7.7 94.8 13 
Nitroimidazoles 
Dimetridazole 46.2 11 68.8 6.5 74.7 6.1 69.6 5.4 
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Metronidazole 110 7.0 75.9 13 60.1 7.1 68.6 14 
Ronidazole 109 5.6 91.7 8.0 63.9 13 77.2 8.5 
Ternidazole 115 6.6 96.2 11 74.4 6.0 82.7 4.0 
Coccidiostats 
Aprinocid 90.8 4.6 70.2 4.8 69.4 8.6 65.0 6.5 
Clopidol 97.1 6.8 91.0 9.0 57.2 11 78.0 13 
Diaveridine 77.7 11 105 4.9 60.4 6.4 77.2 7.6 
Ethopabate 89.8 4.0 90.0 5.3 72.4 6.5 83.3 5.0 
Halofuginone 82.4 9.0 78.7 10 37.6 9.4 76.1 11 
Monensin 41.4 5.6 72.9 12 72.0 6.5 50.1 5.9 
Salinomycin 29.0 14 87.2 9.8 85.2 5.9 62.0 11 
Semduramycin 44.2 13 78.6 17 94.7 13 101 8.7 
Other Anthelmintics 
Levamisol 88.4 13 90.8 2.7 48.2 3.9 75.5 5.5 
Morantel 99.3 2.4 82.9 8.5 61.6 6.6 78.3 8.2 
Nitroxinil 79.7 8.5 55.5 11 66.0 5.4 63.6 14 
Oxyclozanide 4.3 4.3 18.3 9.6 31.6 12 4.7 9.4 
NSAIDs 
Carprofen 66.0 12 62.6 9.1 44.9 13 37.8 6.9 
Diclofenac 63.4 11 59.5 10 51.0 10 36.8 13 
Flunixin 87.7 7.7 95.2 7.4 79.8 8.5 57.4 10 
Ibuprofen 60.7 10 54.9 11 62.2 13 98.7 11 
Ketoprofen 84.2 10 96.6 6.2 65.5 9.2 75.2 10 
Mefenamic acid 6.6 11 58.1 7.8 44.5 11 63.7 13 
Meloxicam 102 4.9 67.5 1.7 77.3 4.2 86.5 12 
Naproxen 106 8.6 86.9 13 76.8 12 92.6 12 
Niflumic acid 87.6 11 63.4 5.8 50.6 8.8 64.6 6.6 
Salicylic acid 82.1 7.7 80.9 5.9 83.8 12 60.2 9.6 
Tolfenamic acid 9.2 11 31.8 9.3 58.5 11 10.9 11 
Amphenicols 
Chloramphenicol 84.9 8.5 64.1 7.5 86.6 11 63.0 11 
Florfenicol 84.8 11 65.2 13 78.7 9.1 67.8 10 
Thiamphenicol 81.5 8.4 59.7 8.6 82.3 11 57.1 11 
beta-agonists 
Clenbuterol 92.7 7.4 88.8 10 58.5 3.7 96.3 2.2 
Beta-blockers 
Atenolol 84.8 6.4 100 4.2 68.2 9.8 100 2.3 
Metoprolol 109 12 88.5 9.6 67.0 9.1 73.1 6.2 
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Propanolol 85.8 5.5 84.3 11 47.2 9.2 68.2 13 
Steroids 
Betamethasone 
 acetate 
75.3 9.5 71.2 12 83.6 12 84.7 11 
Cortisol 82.7 6.7 73.3 11 63.5 7.6 78.6 8.0 
Cortisone 98.8 6.9 72.6 8.8 63.0 7.2 94.9 10 
Dexamethasone 70.3 11 97.0 14 76.8 7.3 53.0 11 
Methylprednisolone 105 4.8 88.9 7.5 62.6 9.8 70.4 14 
Prednisolone 92.4 9.2 76.6 13 74.7 3.9 86.9 6.8 
Progesterone 115 12 75.7 10 58.2 7.9 66.3 4.2 
Analgetics 
Caffeine 98.1 11 55.8 8.3 90.0 4.7 110 3.4 
Paracetamol 109 8.6 78.9 10 110 10 114 12 
Tramadol 107 7.2 83.2 11 60.1 10 94.6 8.7 
Diuretics 
Furosemide 64.8 3.8 77.8 5.3 71.3 7.4 44.6 10 
Hydrochlorthiazide 90.7 12 72.3 11 88.8 11 40.4 12 
Indapamine 91.7 2.9 58.2 4.7 74.8 6.5 68.9 9.9 
Triamterene 101 8.5 89.1 8.7 51.6 3.1 73.0 6.2 
Statins 
Atorvastatin 59.2 14 63.7 11 40.4 12 33.7 14 
Antiepileptic drugs 
Carbamazepine 104 6.2 114 9.9 63.9 9.6 74.2 8.6 
Antiulcer Drugs 
Cimetidine 80.2 9.2 92.6 7.9 114 9.2 77.8 7.6 
Omeprazole 68.6 13 95.9 3.1 98.6 7.0 100 4.9 
Ranitidine 63.6 13 84.5 7.3 67.2 7.1 84.0 9.2 
Fibrates 
Clofibric acid 51.5 5.84 65.2 6.8 59.7 9.6 85.2 5.9 
Gemfibrozil 10.3 11 22.3 10 62.2 7.3 22.4 13 
Others 
Colchicine 84.0 7.2 91.1 9.9 84.6 16 86.0 7.4 
Coumaphos 26.6 13 21.9 10 22.3 12 18.8 8.5 
Theophylline 96.5 8.2 95.2 11 57.7 14 95.8 9.3 
Valsartan 59.3 11 84.1 13 49.1 12 63.2 8.2 
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5.3.3.5 Trueness  
The trueness of the method was estimated through recovery studies. Average 
recoveries of each analyte at the Validation Level (100 μg kg−1) were calculated 
performing the analysis in 6 replicates for each matrix (Table 5.2). Overall 
recoveries for all target compounds in butter, fish tissue, egg and milk powder 
were also calculated. Overall recovery for each compound was assessed by 
comparing the slope of the the matrix-matched calibration curve (samples spiked 
before the extraction) (A) to the slope of the standard solution calibration curve in 
matrix extracts (B). 
OVERALL REC (%) = A/B × 100            (4) 
This parameter is of great value since it indicates the recovery of each analyte 
within the whole working range of concentrations for each matrix, separately. 
Overall recoveries for butter are presented in Table 5.3. For the other three 
matrices the results are presented in Electronic Supplementary Material 1 (ESM 
1) in Tables S5.4, S5.5, S5.6.    
 
Table 5.3: Performance and validation data of the analytical method in butter. 
Compound 
Slope matrix 
matched curve 
Slope standard 
solution curve in 
matrix extracts 
Overall 
recovery (%) 
Matrix 
effect (%) 
LOD 
(μg Kg
-1
) 
LOQ  
(μg Kg
-1
) 
Quinolones 
Ciprofloxacin 463480 460364 101 68 0.059 0.18 
Danofloxacin 65906 66527 99.1 83 0.30 0.91 
Difloxacin 989318 1092360 90.6 11 0.018 0.053 
Enrofloxacin 447855 445422 101 90 0.019 0.056 
Flumequine 1372960 1177780 117 -25 0.017 0.051 
Marbofloxacin 547875 512314 107 64 0.040 0.12 
Norfloxacin 425116 472336 90.0 73 0.064 0.19 
Ofloxacin 1083970 994331 109 73 0.034 0.10 
Oxolinic acid 1382460 1712640 80.7 162 0.017 0.051 
Sarafloxacin 522881 468447 112 -23 0.013 0.039 
Tetracyclines 
Chlortetracycline 210289 220660 95.3 105 0.094 0.28 
Doxycycline 866383 1185820 73.1 105 0.041 0.12 
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Oxytetracycline 562185 707888 79.4 63 0.028 0.084 
Tetracycline 287902 565617 50.9 91 0.040 0.12 
Cefalosporines 
Cefaclor  17010 13846 123 -55 0.48 1.4 
Cefadroxil 14708 12581 117 -61 0.29 0.86 
Penicillins 
Amoxicillin 8507 7507 113 -62 0.51 1.5 
Ampicillin 9444 8358 113 -52 0.38 1.2 
Macrolides 
Azithromycin 55968 88538 63.2 209 0.10 0.31 
Clarithromycin 162759 220562 73.8 14 0.074 0.22 
Erythromycin 4037 6887 58.6 11 0.49 1.46 
Tiamullin 910082 1085370 83.8 -9 0.010 0.030 
Tylosin 24300 38346 63.4 20 0.41 1.23 
Tilmicosin 44534 55723 79.9 94 0.30 0.91 
Sulfonamides 
SClZ 39715 42509 93.4 -48 0.20 0.61 
SCP 78270 86571 90.4 -46 0.12 0.36 
SDD 355019 455522 77.9 -15 0.086 0.26 
SDM 338416 532608 63.5 -3 0.10 0.30 
SDX 438945 617109 71.1 -2 0.094 0.28 
SDZ 71746 73728 97.3 -31 0.12 0.35 
SGN 48461 64305 75.4 -54 0.13 0.40 
SIX 199534 188372 106 -47 0.11 0.33 
SMM 119712 161653 74.1 -9 0.10 0.31 
 SMP 78289 109657 71.4 -9 0.073 0.22 
SMR 109450 122133 89.6 -26 0.092 0.28 
SMT 243914 288233 84.6 -44 0.13 0.38 
SMTX 207163 195599 106 -41 0.078 0.23 
SMX 201324 228083 88.3 -37 0.10 0.31 
SPD 175623 200245 87.7 -33 0.070 0.21 
SQX 89071 149645 59.5 -10 0.10 0.30 
STZ 214072 186111 115 -51 0.073 0.22 
Dapsone 257154 342391 75.1 -49 0.19 0.58 
Other antibiotics 
Bacitracin 10827 24013 45.1 33 0.15 0.45 
Lincomycin 720193 726292 99.2 -5 0.023 0.070 
Novobiocin  16210 44412 36.5 48 0.19 0.58 
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Rifaximin 574044 835486 68.7 20 0.015 0.046 
Trimethroprim 501502 453749 111 -26 0.025 0.076 
Benzimidazoles 
Albendazole 1122920 2364790 47.5 -8 0.017 0.052 
Albendazole sulfone 1283570 1462660 87.8 -11 0.011 0.033 
Febantel 388798 480591 80.9 82 0.075 0.22 
Fenbendazole 1529243 3623800 42.2 -8 0.020 0.059 
Flubendazole 2349500 3596740 65.3 0 0.024 0.072 
Mebendazole 2002800 1831910 109 -40 0.021 0.062 
Oxfendazole 1901900 2261780 84.1 -6 0.0083 0.025 
Thiabendazole 500017 557204 89.7 -13 0.074 0.22 
Triclabendazole 22223 964455 2.3 8 0.12 0.35 
Nitroimidazoles 
Dimetridazole 152643 284246 53.7 -39 0.11 0.34 
Metronidazole 562869 461290 122 -38 0.018 0.053 
Ronidazole 120646 86063 140 -47 0.017 0.050 
Ternidazole 696286 567108 123 -37 0.068 0.20 
Coccidiostats 
Aprinocid 1190690 1414240 84.2 -4 0.013 0.040 
Clopidol 27474 22565 122 -35 0.38 1.15 
Diaveridine 1467440 1445080 102 -25 0.037 0.11 
Ethopabate 791863 876555 90.3 -12 0.012 0.036 
Halofuginone 20750 26562 78.1 8 0.46 1.37 
Monensin 115342 465089 24.8 104 0.037 0.11 
Salinomycin 20775 262979 7.9 -11 0.26 0.77 
Semduramycin 137645 384548 35.8 -2 0.059 0.18 
Other Anthelmintics 
Levamisol 230640 207226 111 -30 0.17 0.52 
Morantel 107340 109004 98.5 -33 0.070 0.21 
Nitroxinil 25987 42101 61.7 108 0.060 0.18 
Oxyclozanide 695 18537 3.7 38 0.87 2.6 
NSAIDs 
Carprofen 0.0001294 0.0002640 49.0 22 0.30 0.90 
Diclofenac 76475 139046 55.0 -19 0.079 0.24 
Flunixin 0.0218276 0.0220700 98.9 -34 0.0064 0.019 
Ibuprofen 0.0000982 0.0001400 70.1 -49 0.33 1.00 
Ketoprofen 188048 233190 80.6 -25 0.14 0.42 
Mefenamic acid 0.0003020 0.0038700 7.8 6 0.26 0.78 
158 
 
Meloxicam 0.0553025 0.0557000 99.3 -5 0.018 0.053 
Naproxen 0.0023887 0.0021500 111.1 -12 0.11 0.32 
Niflumic acid 4303695 4342780 99.1 1 0.017 0.050 
Salicylic acid 28763 49774 57.8 167 0.071 0.21 
Tolfenamic acid 0.0005384 0.0191200 2.8 22 0.41 1.23 
Amphenicols 
Chloramphenicol 16348 20574 79.5 54 0.21 0.64 
Florfenicol 21134 27819 76.0 1 0.14 0.43 
Thiamphenicol 5494 8043 68.3 27 0.16 0.49 
beta-agonists 
Clenbuterol 503442 457563 110 -23 0.020 0.060 
Beta-blockers 
Atenolol 124444 121700 102 -17 0.10 0.29 
Metoprolol 75853 63606 119 -35 0.16 0.49 
Propanolol 134941 168315 80.2 0 0.075 0.23 
Steroids  
Betamethasone 
acetate 
16659 23123 72.0 6 0.54 1.6 
Cortisol 28676 34779 82.5 -20 0.45 1.3 
Cortisone 64570 57972 111 -40 0.46 1.4 
Dexamethasone 6284 7107 88.4 -16 0.46 1.4 
Methylprednisolone 25865 28129 92.0 -15 0.33 0.98 
Prednisolone 84454 87067 97.0 -25 0.13 0.38 
Progesterone 67647 66977 101 -22 0.40 1.19 
Analgetics 
Caffeine 94859 83209 114 -46 0.14 0.41 
Paracetamol 19532 16795 116 -35 0.52 1.6 
Tramadol 208993 165325 126 -37 0.10 0.31 
Diuretics 
Furosemide 6586 11048 59.6 32 0.26 0.79 
Hydrochlorthiazide 2517 2438 103 237 0.21 0.62 
Indapamine 11787 15043 78.4 -11 0.15 0.46 
Triamterene 1204680 1089870 111 -8 0.025 0.074 
Statins 
Atorvastatin 86594 200448 43.2 15 0.084 0.25 
Benzodiazepams 
Carbamazepine 210165 190884 110 -39 0.084 0.25 
Antiulcer Drugs 
Cimetidine 260820 262854 99.2 -1 0.13 0.39 
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Omeprazole 75595 182795 41.4 70 0.15 0.46 
Ranitidine 109095 211702 51.5 38 0.075 0.23 
Fibrates 
Clofibric acid 23073 34616 66.7 66 0.21 0.63 
Gemfibrozil 1872 13308 14.1 52 0.21 0.63 
Others 
Colchicine 99097 134873 73.5 20 0.068 0.20 
Coumaphos 107482 721359 14.9 -13 0.094 0.28 
Theophylline 60366 51157 118 -63 0.18 0.55 
Valsartan 25569 68128 37.5 0 0.090 0.27 
 
In butter, for over 90% of the analytes, recoveries were between 50% and 120%. 
Only 5 compounds presented recoveries lower than 50% in fish tissue 
(oxyclozanide, coumaphos, gemfibrozil, tolfenamic acid and fenbendazole) with 
the 61% of the veterinary drugs and pharmaceuticals giving recoveries >80%. In 
milk and egg the recoveries for the majority of the analytes lie between 50-80% 
(66 and 78 compounds, respectively).This is due to the complexity of these 
matrices which have a high protein and lipid content. The compounds may bind 
to the lipoproteins and not be sufficiently extracted from the matrix which in some 
cases also forms emulsions and foams with the extraction solvents [88, 68]. 
However, recovery values were > 50% for more than 85% of the analytes in both 
egg and milk powder. In conclusion, although for several compounds the 
recovery values were not close to 100%, they are considered acceptable since 
they were reproducible (Table 5.2). A schematic presentation of these results is 
demonstrated in Figure 5.1. 
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Figure 5.1: Schematic presentation of the recovery results of all target analytes in all studied 
matrices. 
Additionally, trueness was verified by analyzing test materials provided from 
proficiency testing. As it is not possible to obtain certified reference or proficiency 
test material containing all analytes simultaneously, the developed method was 
applied to proficiency testing material for several target compounds only. 
Sulfonamides, tetracyclines and quinolones were the compounds of choice.  
MI1320A and MI1321A test materials were obtained by Progetto Trieste, a 
proficiency testing service by Test Veritas S.r.l. They consisted of lyophilized 
bovine milk samples, blank, incurred and spiked, provided for performance 
evaluation of confirmatory techniques.  54 laboratories from 22 countries 
participated in this proficiency testing scheme and the compounds detected and 
quantified were three sulfonamides (sulfadimidine, sulfamerazine and 
sulfadiazine), one tetracycline (oxytetracycline) and one quinolone (enrofloxacin). 
In all cases, the z scores achieved were less than 2, fulfilling the proficiency test 
criteria for successful participation.  
Results are presented in Table 5.4. A diagram reflecting the dispersion of the 
calculated concentrations of all laboratories for sulfamerazine in test material 
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MI1320A-2 is shown in Figure S5.5. Figure S5.6 shows the chromatogram of a 
proficiency test lyophilized bovine milk sample containing three sulfonamides 
(MI1320A-2). For comparison, the chromatogram of the blank sample (MI1320A-
1) spiked with 35 μg kg−1 of all sulfonamide analytes is also presented (Figure 
S5.7). 
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Table 5.4: Results of the assessment of proficiency testing materials. 
Test material 
code 
Sample Analytes tested 
Analytes 
detected 
Assigned value  
(μg Kg-1) 
Calculated 
concentration 
(μg Kg-1) 
z-score 
MI1320A-1 blank 
sulfadimidine, sulfadimethoxine, sulfaquinoxaline, 
sulfamerazine, sulfadiazine, sulfamethoxypyridazine, 
sulfamonomethoxine, sulfathiazole 
none 
< 10 for all analytes 
except from 
sulfamonomethoxine 
< 12.1  
< LOQ for all 
analytes 
– 
MI1320A-2 incurred 
sulfadimidine, sulfadimethoxine, sulfaquinoxaline, 
sulfamerazine, sulfadiazine, sulfamethoxypyridazine, 
sulfamonomethoxine, sulfathiazole 
sulfadimidine 40.29 33.3 - 0.67 
sulfamerazine 34.39 36.0 0.18 
sulfadiazine 38.53 34.0 - 0.45 
MI1321A-1 incurred 
oxytetracycline, chlortetracycline , doxycycline, 
tetracycline, enrofloxacin, ciprofloxacin , flumequine, 
marbofloxacin, danofloxacin, sarafloxacin, oxolinic acid  
oxytetracycline 109.97 144.4 1.40 
MI1321A-2 spiked 
oxytetracycline, chlortetracycline , doxycycline, 
tetracycline, enrofloxacin, ciprofloxacin , flumequine, 
marbofloxacin, danofloxacin, sarafloxacin, oxolinic acid 
enrofloxacin 87.23 104.6 0.86 
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5.3.3.6 LODs & LOQs 
LODs and LOQs were calculated by analyzing blank samples spiked at 0.1, 0.5, 
2 or 10 μg kg-1, according to each analyte’s sensitivity, as described in the 
Experimental section. For instrumental LODs and LOQs standard solutions in the 
same concentrations were analyzed in quintuplicate. Instrumental LODs ranged 
from 0.0037 ng ml-1 (mebendazole) to 2.3 (hydrochlorthiazide). Results are 
shown in Table S5.7.  
In butter the lowest LODs and LOQs were achieved, ranging from 0.0064 μg 
kg−1 for flunixin (LOQ 0.019 μg kg−1) to 0.87 μg kg−1 for the anthelmintic 
oxyclozanide (LOQ 2.6 μg kg−1). All results are presented in Table 5.3.  
Similarly low values of LOD and LOQ were obtained also for egg samples, 
although eggs constitute a very complex matrix with high lipid and protein 
content. Results are shown in Table S5.4 and, as it can be seen, LOD values 
vary from 0.0028 μg kg−1 (tetracycline) to 3.2 μg kg−1 (hydrochlorthiazide) and 
LOQs from 0.0083 μg kg−1 (tetracycline) to 9.5 μg kg−1 (hydrochlorthiazide).To 
the best of our knowledge these are the lowest LODs and LOQs reported in 
literature for multi-residue/multi-analyte determination in egg. 
In fish tissue and in milk powder the LODs and LOQs were slightly elevated. In 
fish tissue LOQs were in all cases below 5 μg kg−1 except for hydrochlorthiazide 
and danofloxacin who’s LOQs were 6.7 and 5.6 μg kg−1, respectively. For these 
compounds there is no MRL established in fish tissue. Finally, LODs in milk 
powder ranged from 0.0033 μg kg−1 (flunixin) to 4.4 μg kg−1 (hydrochlorthiazide). 
All LODs and LOQs in fish tissue and milk powder are presented in Tables S5.5 
and S5.6.  
For some compounds, like azithromycin, lowest method LODs than instrumental 
LODs were obtained due to the severe matrix enhancement of these compound 
to the matrices examined (+208% in butter, +808% in egg, +462% in milk 
powder). The same applies for oxolinic acid and salicylic acid (+162% and 
+167% in butter, respectively, +181% and + 227% in egg, +116% & 107% in fish 
tissue and 103% & 82% in milk powder), for hydrochlorthiazide in butter (+ 237%) 
and carprofen in milk powder (+589%). 
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5.3.3.7 Matrix Effect 
When complex samples, such as milk, muscle or egg are analyzed, LC–MS/MS 
measurements, especially in the ESI mode, might significantly be influenced by 
matrix effects. Matrix effects derive from various physical and chemical 
processes and may be difficult or impossible to eliminate. They relate to the 
concentrations and protonation levels of co-extracted components and can be 
variable and unpredictable in occurrence. Matrix effects are co-dependent and 
can affect the ionization efficiency of the analytes, leading to suppression or 
enhancement of the signal depending on the analyte/matrix combination. 
Obviously, this affects the quantification, unless matrix effects are minimized or 
compensated [68, 236]. The best way to compensate the matrix effect is the use 
of isotope labeled internal standards (ILIS). However, these compounds are not 
available for many veterinary drugs, they increase severely the cost of the 
analysis and it is well known that an adequate correction is assured only when 
the own ILIS is used [237]. The use of analogue ILIS is not always satisfactory 
[236, 237]. Therefore, other approaches such as matrix-matched calibration or 
standard addition method can be used for proper quantification of the samples 
[68, 78, 87, 236]. 
To evaluate matrix effect, the slopes obtained in the matrix-matched calibration 
curves were compared with those obtained with solvent standards. Matrix effects 
(ME%) were calculated by subtracting 1 from the ratio between the standard 
solution calibration curve slope in matrix extracts (B) and in pure solvent (C) for 
each compound, and then multiplying by 100: 
ME (%) = ((B/C) – 1) × 100          (5)  
The signal is enhanced if the value is positive, whereas it is suppressed if the 
value is negative. A signal enhancement or suppression effect is considered as 
acceptable if the matrix effect values range from -20% to +20% (36).  
% Matrix effects higher than 20% or lower than -20% indicate a strong matrix 
effect. It can be observed that a significant matrix effect was noticed for 75 
compounds in butter, 100 compounds in fish tissue, 89 compounds in milk 
powder and 81 compounds in egg whereas tolerable matrix effect was observed 
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for the rest of compounds. The majority of the compounds in butter, fish tissue 
and milk powder were subjected to a signal suppression (72 in butter, 95 in fish 
tissue, 85 in milk powder) while a signal enhancement was observed for most of 
the compounds in egg samples (73 compounds). Matrix effect results for all 
compounds in each matrix are presented in Table 5.3 and 5.S4, 5.S5 and 5.S6. 
 Briefly, azithromycin and erythromycin were subjected to significant signal 
enhancement in all matrices examined, a fact that comes in agreement with other 
studies which indicate signal enhancement for macrolides [80, 87]. Tetracyclines 
presented severe signal enhancement in egg samples while for sulfonamides, 
especially in fish tissue, calibration curves in matrix were found to have a slope 
lower than the calibration curves in solvent, indicating signal suppression [81]. 
Amphenicols showed an increase of their signal when measured in standards 
prepared in fish tissue extracts and conversely, nitroimidazoles were subjected in 
extended signal suppression in all matrices studied in this work. Nitroimidazoles’ 
signal suppression is not an unprecedented phenomenon [238]. Steroids also 
reveal a decrease in their signal in butter, milk and fish matrix-matched standards 
compared to standards in solvent.   
 
5.4 Application to Real Samples 
To evaluate the applicability of the proposed method, seventy three (73) milk 
powder, five (5) butter, twenty two (22) fish tissue and eight (8) egg samples 
were analysed. A calibration standard (solvent standard), a matrix blank, a spiked 
blank sample at 50 μg kg−1 and a matrix-matched standard at the same 
concentration were included in the analysis of each batch of samples in order to 
check the reliability of the proposed method. 
The retention time, quantification and confirmation transitions and relative ion 
intensities of the detected ions in unknown samples were compared to those of 
corresponding spiked samples and matrix-matched calibration standards in the 
same batch to confirm the identity of the detected analytes using the criteria 
established by Decision Commission 657/2002/EC. The standard addition 
method was used for quantification. The application of the standard addition 
method with spiking standards to the samples pre-extraction is recommended to 
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get highly reliable quantitative results independently from correction factors both 
for recovery and matrix effects. 
Analysis of the samples showed that progesterone was repeatedly present in 
butter and milk powder samples since it has an endogenous origin [39].  Only few 
other compounds were detected in the samples. Oxfendazole and albendazone 
sulfone were detected in two milk powder samples at 1 μg kg−1 and 0.54 μg kg−1, 
respectively. These concentrations, although they are higher than LOQ, are very 
low and far below the MRL established for these benzimidazoles in milk (10 μg 
kg−1 and 100 μg kg−1). Several quinolones were detected in milk (ciprofloxacin at 
7.3 μg kg−1 and norfloxacin at 2.2 μg kg−1) and fish tissue samples (flumequine at 
4.6 μg kg−1 and enrofloxacin at 4.8 μg kg−1). Thiabendazole was detected and 
quantified at 9.7 μg kg−1 in one butter sample and, finally, caffeine was present in 
6 milk powder samples, at concentrations ranging from 2.4 to 32 μg kg−1. There 
was no compound detected and quantitated that would exceed the MRL 
established in Regulation 37/2010/EC. The obtained results are in agreement 
with other studies [78, 81, 83, 86, 92].  
 
5.5 Conclusions 
A simple, sensitive and efficient multi-residue and multi-class analytical method 
for the simultaneous determination of 115 veterinary drugs and pharmaceuticals 
in milk powder, butter, egg and fish tissue by HPLC–MS/MS has been 
developed. Among the different classes of veterinary drugs, the method allows 
also the determination of TCs, polar penicillins, cefalosporins and ionophores, 
whose simultaneous analysis in multiclass methods often presents a problem. 
 The proposed methodology allows the simultaneous extraction of veterinary 
drugs and pharmaceuticals with very different physicochemical properties from 
various matrices, employing a simple solvent extraction with 0.1% formic acid in 
aqueous solution of EDTA 0.1% (w/v) – acetonitrile (ACN) – methanol (MeOH) 
(1:1:1, v/v) and further ultrasonic-assisted extraction. The extraction procedure 
was fully optimized in terms of recovery for the three out of four matrices 
examined. 
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Good validation parameters such as linearity, recovery, precision and LOQs were 
obtained indicating the suitability of the proposed solvent extraction method for 
the analysis of veterinary drugs and pharmaceuticals. 
Only a few veterinary drugs and pharmaceuticals were detected in egg, milk 
powder and butter samples taken from different markets, and their concentrations 
were below the MRL established for each compound detected. Furthermore, the 
method was successfully applied in two proficiency test samples of lyophilized 
bovine milk containing several target analytes (sulfonamides, tetracyclines and 
quinolones). In all cases a z-score of <2 was achieved, indicating the excellent 
accuracy of the proposed method. 
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CHAPTER 6 
Multiresidue / Multiclass Determination Of 76 Veterinary Drugs 
And Pharmaceuticals In Bovine Muscle Tissue By Hydrophilic 
Interaction Liquid Chromatography-Tandem Mass Spectrometry  
 
 
6.1 Introduction   
 
Multi-residue methods reported in literature are mainly based on reversed phase 
(RP) separation due to its efficient separation of analytes within broad range of 
polarity. However, highly polar compounds undergo early elution on traditional 
RP stationary phases, leading to lower sensitivity of the mass spectrometric (MS) 
detection due to (1) high matrix effects and (2) high water percentage in the 
mobile phase at the beginning of the run resulting in lower ionization efficiency in 
the MS interface. The analysis of highly hydrophilic and polar compounds by 
hydrophilic interaction chromatography (HILIC) coupled to MS has been 
demonstrated as a valuable complementary approach to RPLC [239]. 
Several applications of HILIC in the analysis of veterinary drugs and 
pharmaceuticals in food products have been reported the last decade [69, 70, 
240-244]. Great attention has been paid in the determination of aminoglycoside 
antibiotics (AGs) with HILIC [70, 241, 243, 244] due to their extremely polar 
character which makes them practically unretainable  in RP coloums. The 
simultaneous determination of AGs and other veterinary drugs in one method 
and in a single chromatographic run, has only been reported once so far [69]. 
Chiaonchan et al. reported the development of a multi-residue method for the 
determination of 24 veterinary drugs, mainly antibiotics, in chicken muscle, 
without however including the most strongly retained AGs.  
In this study, a simple, rapid and sensitive multiresidue method for the 
simultaneous determination of 74 veterinary drugs and pharmaceuticals in bovine 
muscle tissue has been developed and validated according to the requirements 
of European Commission Decision 2002/657/EC. The analytes belong in 13 
169 
 
different classes, including strongly retained AGs like apramycin and neomycin 
which have never been previously included in a multi-residue method. The 
method combines a two-step extraction procedure (extraction with acetonitrile 
(ACN) followed by an acidic aqueous buffer extraction) with Hydrophilic 
Interaction Liquid Chromatography - Tandem Mass Spectrometry (HILIC-MS/MS) 
determination, allowing confirmation and quantification in a single 
chromatographic run. Further cleanup with solid phase extraction (SPE) using 
HLB cartridges was performed.  
A thorough ionization study of aminoglycosides was performed in order to 
increase their sensitivity and significant differences in the abundance of the 
precursor ions of the analytes were revealed, depending on the composition of 
the mobile phase tested. To the best of our knowledge, any similar study 
concerning aminoglycosides has not been reported previously. Further gradient 
elution optimization and injection solvent optimization were performed for all 
target analytes.  The chromatographic column used was an Acquity UPLC BEH 
HILIC and the mobile phase consisted of ACN, MeOH and ammonium formate 
1mM with 0.1% formic acid, using a ternary gradient. 
The method was validated according to the European Commission Decision 
2002/657. Quantitative analysis was performed using the standard addition 
method. Recoveries varied from 37.4% (bromhexine) to 106% (kanamycin) in the 
lowest validation level and only the 18% of the compounds showed recovery < 
70%. CCβ varied from 2.4 μg kg-1 (salinomycin) to 1302 (apramycin) 
 
6.2 Experimental  
 
6.2.1 Chemicals and reagents  
 
All the analytes studied are presented in Table 6.1. All veterinary drug and 
pharmaceutical standards were of high purity grade (>90%) and the majority of 
them was purchased from Sigma-Aldrich (Steinheim, Germany) along with six 
internal standards (IS, amikacin, decoquinate d5, fenbendazole d3, flubendazole, 
phenylbutazone - (diphenyl-13C12) and triclabendazole d3). Amikacin and 
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flubendazole are not regulated in bovine muscle tissue and thus were used as 
internal standards. Arprinocid, salinomycin, semduramicin, manduramycin, 
narasin, albendazole sulfone, flunixin and meloxicam and the IS nigericin, flunixin 
d3 and meloxicam d3 were donated by the Veterinary Drug Residues Laboratory 
of the State General Laboratory of Cyprus. Sulfadiazine d4, sulfadimidine d4 and 
sulfadimethoxine d4 were obtained from Toronto Research Chemicals (Toronto, 
Canada).  
Acetonitrile (ACN) and methanol (MeOH) LC–MS grade were purchased from 
Merck (Darmstadt, Germany). Formic acid 99% and ammonium formate (>90% 
purity) were purchased from Fluka (Buchs, Switzerland). All other solid reagents 
used were of analytical grade. Ethylenediaminetetraacetic acid disodium salt 
(EDTA), sodium hydroxide monohydrate (NaOH) and sodium chloride (NaCl) 
were purchased from Panreac (Barcelona, Spain) while trichloroacetic acid (TCA) 
and ammonium acetate from Fisher Scientific (Loughborough, UK). Distilled 
water was provided by a MilliQ purification apparatus (Millipore Direct-Q UV, 
Bedford, MA, USA). RC (Regenerated Cellulose) syringe filters (15 mm diameter, 
0.22 μm pore size) were provided from Phenomenex (Torrance, CA, USA). Solid 
phase extraction cartridges were Oasis HLB 6 cc (200 mg) from Waters (Millford, 
MA). 
Stock standard solution of individual veterinary drugs were prepared at a 
concentration of 1000 μg mL-1 by diluting the proper amount of each standard in 
the suitable dilution solvent. For apramycin a stock standard solution of 5000 μg 
mL-1 was constructed. Aminoglycosides and penicillins were dissolved in MilliQ-
water while all other analytes in methanol. In benzimidazole standard solutions, 
100 μL of NaOH were added to enhance solubility. Stock solutions were stored at 
−20 °C in brown glass in order to avoid photodegradation and new ones were 
prepared every six months, except for aminoglycosides which were prepared 
every 3 months.  
Four intermediate standard solutions were prepared, all in ACN. The first one 
contained only aminoglycosides and the second one consisted of the compounds 
prohibited in bovine tissue (dapsone, phenylbutazone, chlorpromazine and 
bromhexine). For dapsone and phenylbutazone a Recommended Concentration 
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(RC) in animal tissue is set [218]. All other veterinary drugs examined were 
included in the last two intermediate solutions. The final concentration of each 
analyte in these intermediate standards corresponded to 200-fold the MRL or ML 
established for each compound in bovine tissue or the Validation Concentration 
(VC) of choice for the compounds where no MRL is established. The MRLs, MLs, 
RCs and VCs for all the determined analytes are summarized in Table S6.1. 
Validation Levels (VLs), which represent the concentration that the validation was 
performed for each compound, are also presented in this Table. The intermediate 
standard solutions were also stored at −20 °C and were conserved for one month 
except for the one containing aminoglycoside antibiotics which was newly 
prepared every week. Another intermediate standard solution was prepared for 
the twelve internal standards at 10 μg mL-1 by dilution of their stock solutions in 
ACN. 
Working solutions were constructed by mixing the appropriate amounts of the 
intermediate standard solutions and diluting with ACN. One working solution of all 
analytes was obtained with variable concentrations equivalent with 50 times the 
MRL, ML or VC of each compound. For prohibited veterinary drugs a separate 
working solution was constructed at analogous concentration (50×VC). The 
working solution of internal standards was prepared at a concentration of 2.5 μg 
mL-1. New working solutions were prepared every day of analysis. 
 
6.2.2 Instrumentation. 
A Thermo Scientific TSQ Quantum Access Triple Quadrupole Instrument was 
connected to a Thermo UHPLC Accela system (Thermo, San Jose, CA, USA). 
An Acquity UPLC BEH HILIC (100 mm x 2.1 mm, 1.7 μm, Waters) column was 
used at a constant flow rate of 100 μL min-1. The determination was performed in 
positive ionization mode and the mobile phase consisted of ACN (solvent A), 
aqueous ammonium formate 1mM with 0.1 formic acid (v/v, solvent B) and 
MeOH (solvent C). The gradient profile started at 80% of solvent A and 20% B 
(0% C), and decreased linearly to 0% A and 95% B (5%C) in 10 min. This 
composition was held for additional 4 min before being returned to the initial 
conditions, in order for all strongly retained aminoglycosides to elute. A 6 min re-
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equilibration step gave a total run time of 20 min. This re-equilibration step is 
rather long for a UPLC column but the equilibration of the column is very 
significant in HILIC in order to achieve retention time reproducibility [245]. The full 
loop injection volume of the extract was set at 10 μL. Spray Voltage was set at 
4000 V, Seath Gas and Auxiliary Gas were set at 25 psi and 10 a.u respectively 
and Capillary temperature was set at 300 °C. 
Single Reaction Monitoring (SRM) was used and the selected transitions, 
collision energies and tube lenses are presented in Table 2. Two SRM transitions 
were monitored for identification and the most intense one was used for 
quantification.  
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Table 6.1: MS/MS parameters and retention times for all analytes and internal standards. 
Compounds 
Pseudo 
Molecular Ion 
(m/z) 
Quantifier 
Ion, Q (m/z) 
Collision 
Energy (eV) 
Qualifier 
ion, q, (m/z) 
Collision 
Energy (eV) 
Tube Lens (V) Internal Standard 
Aminoglycosides 
Apramycin (Q) 540 378 19   123 Amikacin 
Apramycin (2+) (q) 271 217 14   74  
Dihydrostreptomycin 584 262.5 31 246 35 132 Amikacin 
Gentamycin 478 322 15 167 22 119 - 
Kanamycin 485 163 27 324 16 120 Amikacin 
Neomycin 615 163 34 161 28 119 - 
Streptomycin 582 245.5 36 263 31 131 Amikacin 
Penicillins 
Ampicillin 350 106 25 174 17 89 - 
Cloxacillin 410 178 32 174 19 80 - 
Dicloxacillin 444 211 33 128 29 115 - 
Oxacillin 376 174 18 144 31 97 - 
Penicillin G 309 174 16 128 26 93 - 
Penicillin V 325 128 26 174 16 86 - 
Macrolides 
Azithromycin 750 158 37 591 29 127 - 
Clarithromycin 749 158 30 591 20 123 - 
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Erythromycin 734 158 30 576 20 130 - 
Tiamullin 494 192 21 119 33 101 - 
Tilmicosin 869 174 42 156 44 165 - 
Tylosin 917 174 36 772 28 148 - 
Sulfonamides 
Dapsone 249 156 14 108 22 79 sulfadimidine d4 
Sulfachloropyridazine 285 156 14 92 28 87 sulfadimethoxine d4 
Sulfadiazine 251 156 15 92 27 87 sulfadiazine d4 
Sulfadimethoxine 311 156 17 108 29 87 sulfadimethoxine d4 
Sulfadimidine 279 186 17 124 26 87 sulfadimidine d4 
Sulfaguanidine 215 156 14 92 14 87 sulfadiazine d4 
Sulfamerazine 265 172 16 156 16 87 sulfadimethoxine d4 
Sulfamethizole 271 156 14 92 28 87 sulfadimethoxine d4 
Sulfamethoxazole 254 156 16 108 25 87 sulfadimidine d4 
Sulfamonomethoxine 281 92 29 156 13 87 sulfadimethoxine d4 
Sulfapyridine 250 156 15 184 17 87 sulfadimethoxine d4 
Sulfaquinoxaline 301 156 18 92 30 87 sulfadimethoxine d4 
Sulfathiazole 256 156 15 92 26 87 sulfadimidine d4 
Sulfisoxazole 268 156 13 92 27 87 sulfadimethoxine d4 
Diaminopyrimidines 
Baquiloprim 309 171 29 123 28 113 - 
Trimethoprim 291 230 25 123 30 87 - 
Other antibiotics 
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Rifaximin 786 754 22 362 32 114 - 
Anthelmintics 
Albendazole 266 234 29 191 31 85 Flubendazole 
Albendazole sulfo(oxide) 282 240 13 208 24 99 Fenbendazole d3 
Albendazole sulfone 298 266 19 159 35 74 Fenbendazole d3 
Febantel 447 383 17 280 31 110 Flubendazole 
Fenbendazole 300 268 29 159 33 85 Fenbendazole d3 
Levamisole 205 178 29 123 31 87 - 
Mebendazole 296 264 31 105 35 90 Fenbendazole d3 
Morantel 221 123 31 111 26 96 - 
Oxfendazole 316 159 30 191 24 87 Flubendazole 
Thiabendazole 202 131 35 175 35 87 Flubendazole 
Triclabendazole 359 274 35 171 40 85 Triclabendazole d3 
Coccidiostats 
Amprolium 243 150 12 122 24 69 - 
Aprinocid 278 143 28 107 48 95 - 
Clopidol 192 101 27 87 31 99 - 
Decoquinate 418 204 41 232 35 119 Decoquinate d5 
Diaveridine 261 245 26 123 26 93 - 
Ethopabate 238 206 11 136 27 37 - 
Maduramycin (NH4
+) 935 629 30 647 17 129 Nigericin 
Monensin (Na+) 693 461 51 501 52 159 Nigericin 
Narasin (NH4
+) 782 747 19 373 30 99 Nigericin 
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Robenidine 334 155 20 138 27 81 Nigericin 
Salinomycin (NH4
+) 768 733 18 373 32 109 Nigericin 
Semduramycin (Na+) (Q) 895 833 28   116 Nigericin 
Semduramycin (NH4
+) (q) 890 629 22   117  
NSAIDs 
5-Hydroxyflunixin 313 295 23 227 30 96 Flunixin d3 
Flunixin 298 280 23 109 44 92 Flunixin d3 
Meloxicam 352 115 22 141 23 85 Meloxicam d3 
Phenylbutazone 309 160 20 211 16 94 
Phenylbutazone 
13C12 
Thyreostats 
6-phenyl-2-thiouracil 205 146 19 103 26 68 - 
Tranquilizers 
Chlorpromazine 319 86 20 246 23 69 - 
Pharmaceuticals 
Ambroxol 379 264 20 104 51 95 - 
Atenolol 267 145 26 190 18 94 - 
atorvastatin 559 440 22 250 42 123 - 
caffeine 195 138 18 110 22 87 - 
Carbamazepin 237 194 19 193 32 114 - 
Metropolol 268 191 17 133 25 96 - 
Propanolol 260 183 19 155 25 99 - 
Simvastatin 419 225 22 199 7 103 - 
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Tramadol 264 58 15 246 8 66 - 
Triamterene 254 237 26 104 36 93 - 
Valsartan 436 291 16 207 28 99 - 
Others 
Bromhexine 377 114 18 264 29 78 - 
Internal Standards 
Amikacin 586 424 20   87  
Decoquinate d5 423 377 25   87  
Fenbendazole d3 303 268 31   87  
Flubendazole 314 282 31   90  
Flunixin d3 300 282 25   91  
Meloxicam d3 355 115 25   132  
Nigericin (NH4
+) 742 461 28   101  
Phenylbutazone - 
(diphenyl-13C12) 
321 166 21   90  
Sulfadiazine d4 255 160 16   96  
Sulfadimethoxine d4 315 156 22   90  
Sulfadimidine d4 283 186 18   101  
Triclabendazole d3 364 201 29   130  
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Each chromatographic run comprised several scan events with a scan time of 20 
ms for each transition. Instrument control and data acquisition were carried out 
by using the Xcalibur software, Version 2.3, from Thermo. 
 
6.2.3 Samples 
Bovine tissue samples were obtained from local supermarkets. Upon arrival at 
the laboratory the samples were homogenized and refrigerated at -20 °C until 
analysis. 
 
6.2.4 Sample preparation 
A 5.0-g portion of bovine muscle was weighed into a 50-mL polypropylene 
centrifuge tube and 100 μL of the IS working solution were added to achieve a 
final concentration of 50 μg kg-1 of each internal standard. For fortified samples, 
aliquots of 50, 100 and 150 μL of the working solution standard containing all the 
analytes at a concentration of 50×VL were added to 5 g of sample. Spiked levels 
obtained were 0.5×VL, 1×VL and 1.5×VL, respectively. For prohibited 
compounds 100, 150 and 200 μL were added in order to aquire 1×VL, 1.5×VL 
and 2×VL concentration levels as indicated in European Commission 
2002/657/EC. 
When fortified, either with all analytes (fortified samples) or just with the IS mix, 
the samples are vortex-mixed for 30 s and allowed to stand for 10 – 15 min. After 
addition of 10 mL of ACN the samples are vortexed for 1 min and shaken for 30 
minutes using a mechanical shaker. Then, the sample tube is centrifuged at 4000 
rpm for 5 min and the supernatant is decanted in a glass tube. The acetonitrile 
extract is evaporated to final volume 1.0 mL under a stream of nitrogen at 30 °C. 
A volume of 20 mL of an aqueous extraction solvent is subsequently added to the 
sample. This extraction solvent, consisting of 10 mM ammonium acetate, 0.4 mM 
EDTA, 1% NaCl (w/v) and 2% TCA (w/v) in H2O, has been previously reported in 
literature to be adequate for aminoglycosides’ extraction [246]. The samples are 
vortexed for 1 min and shaken for 60 minutes using a mechanical shaker. 
Afterwards, the sample tube is centrifuged at 4000 rpm for 5 min and the 
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supernatant is decanted in a new polypropylene tube. The sample extract is 
adjusted to pH 6.5 by adding ammonia hydroxide 30% (w/v) and afterwards is 
loaded onto an OASIS HLB (200 mg, 6 mL) cartridge previously conditioned 
sequentially with 6 mL of MeOH and 6 mL of H2O. The sample is passed through 
the cartridge at a flow no faster than 1 drop/s and, then, it is vacuum-dried for 
approximately 15 min. The elution of the analytes was carried out with 2×0.5 mL 
of aqueous formic acid 10% (v/v) and 3×1 mL of ACN. The eluate is collected 
and combined with the 1-mL ACN extract. At this step proper volumes of working 
solutions were added to blank aliquots, to prepare the range of matrix-matched 
standards required. Finally, 500 μL of the combined extract were transferred in a 
vial and 10 μL was injected into the HILIC-MS/MS system. 
 
6.2.5 Method validation  
The method was validated in bovine tissue according to European Commission 
Decision 2002/657 at three concentration levels. Validation was performed at 
0.5×MRL – 1×MRL – 1.5×MRL and 0.5×ML – 1×ML – 1.5×ML where one exists. 
For prohibited compounds the VLs corresponded to 1×VC, 1.5×VC and 2×VC. 
For dapsone and phenylbutazone the VCs match the RC that has been set for 
them in animal tissues (5 μg kg-1). Finally, for compounds that no MRL or MRPL 
has been established the VCs chosen are presented in Table S1. When no MRL 
was specified for a particular compound in bovine tissue but there was an MRL 
established in another matrix (e.g. milk) this concentration was used as the VC. 
The VLs (Validation Levels) for these compounds corresponded to 0.5×VC, 
1×VC and 1.5×VC. Overall, the VL for each compound is the final concentration 
of choice in which the validation was performed. 
Identification and confirmation of the analytes were carried out by retention times, 
selected SRM transitions and the relative ion ratio of them as required by the EU 
validation criteria. The developed procedure was validated in terms of 
selectivity/specificity, linearity, accuracy through recovery studies, intra and 
interday precision, limits of detection (LODs) and quantification (LOQs), decision 
limit (CCα) and detection capability (CCβ). Matrix effects were also evaluated. 
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Since no certified reference materials (CRMs) were available, fortified blank 
bovine tissue samples were employed for the validation. 
The verification of the selectivity/specificity of the method was performed by 
analyzing 20 blank bovine tissue samples.  
Linearity was assessed both in standard solution calibration curves in pure 
solvent and in matrix extracts. For building up the calibration curves, pure solvent 
aliquots and blank bovine tissue extracts were fortified with the analytes in 6 
different levels, from 0.25×VL to 4×VL. Calibration curves were constructed by 
plotting the peak area against the concentration of the calibration standards 
except for analytes for which an internal standard is used for quantification (e.g 
sulfonamides etc). In this case the calibration curves were constructed by 
calculating the ratio of each peak area relative to the corresponding IS. Matrix 
matched calibration curves by spiking the analytes in the matrix before the 
extraction were also obtained in the same levels by fortifying blank muscle tissue 
samples with the target compounds and analyzing them with the sample 
preparation defined in Section 6.2.4. Overall matrix effects were calculated by 
comparing standard solution curves prepared in solvent and in blank bovine 
tissue extracts for all analytes. 
For accuracy estimation, three batches of 6 blank bovine tissue samples (n=18) 
were enriched with veterinary drugs and pharmaceuticals at 0.5, 1 and 1.5 times 
the VL (1, 1.5 and 2 times the VL for prohibited veterinary drugs). These samples 
were analyzed during three different laboratory days and recoveries in each 
concentration were determined by comparing samples spiked before and after 
the extraction. Intra-day precision (repeatability) was evaluated by analyzing six 
blank samples per validation level (n=6) in the same day and under the same 
conditions. Inter-day precision (reproducibility) was evaluated by analyzing six 
blank samples per validation level (n=6) during three different days. Precision in 
both cases is expressed as % Relative Standard Deviation (%RSD). 
Although not indicated in Commission Decision 2002/657/EC, limits of detection 
(LODs) and limits of quantification (LOQs) were also investigated. Blank bovine 
tissue samples enriched with all analytes before the extraction at descending 
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order were analysed and LODs and LOQs were determined based on Signal to 
Noise ratios (LOD S/N ≥ 3 and LOQ S/N ≥ 10). 
Finally, the method’s decision limit (CCα) and detection capability (CCβ) were 
calculated for all compounds examined as stated in Commission Decision 
2002/657/EC [54]. CCα is defined as the lowest concentration level of a certain 
compound at which it can be concluded that a sample is non compliant with an 
error probability α. For compounds with established MRLs and MLs CCα was 
calculated as the MRL (or ML) plus 1.64 times the standard deviation of the inter-
day precision at the MRL (or ML) level (1×VL). For compounds with no set MRL 
(or ML) the calibration curve approach was followed. CCα was calculated as the 
concentration at the y-intercept plus 2.33 times the standard deviation of the 
reproducibility at the lowest concentration level (1×VL for non-authorized 
compounds and 0.5×VL for other analytes).  
CCβ is the lowest concentration of the substance that may be detected, identified 
and/or quantified in a sample with an error probability of β. It is calculated as the 
decision limit plus 1.64 times the standard deviation of the reproducibility at the 
corresponding concentrations. 
 
6.3 Results and discussion 
 
6.3.1 LC-ESI-MS/MS determination  
 
6.3.1.1 ESI-MS/MS optimization – Ionization study of Aminoglycosides 
 
The ultimate goal of this study was the development of a multi-residue method for 
the determination of polar and non-polar veterinary drugs and pharmaceuticals, 
including aminoglycosides which have rarely been included in multi-residue/multi-
class analytical methods. Since aminoglycosides’ different physicochemical 
properties render their simultaneous determination with other veterinary drugs 
quite problematic, an extended investigation of the chromatographic behavior of 
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these antibiotics was performed in order to increase their sensitivity and make 
their simultaneous chromatographic detection with other drugs efficient.  
Initially, experiments for the determination and tuning of the precursor and 
product ions for the 6 aminoglycosides under HILIC conditions were carried out. 
Direct infusion of individual standards of each aminoglycoside at concentration of 
10 μg mL-1 in three different solvents – mobile phases was performed in positive 
ionization mode. The solvents tested were 
(A) ACN/aqueous ammonium formate 1 mM with 0.1 % formic acid (60/40, v/v),  
(Β) (ACN /aqueous ammonium formate 1 mM) with 0.1 % formic acid (60/40, v/v), 
(C) ACN/MeOH/aqueous ammonium formate 1 mM with 0.1 % formic acid 
(50/10/40, v/v),  
The mass spectra for all aminoglycosides were obtained in full-scan MS mode 
and the abundance of precursor ions was compared at the different mobile 
phases. The mass spectra of streptomycin and dihydrostreptomycin revealed 
monoprotonated ions [M+H]+ as base peaks. For streptomycin also the ion with 
m/z 600 was observed, which corresponds to the [Μ+Η2Ο+Η]
+ ion. For 
kanamycin, the sodiated ion [M+Na]+ appeared as the base peak with the 
monoprotonated ion at lower abundance. For apramycin and neomycin both 
single-charged [M+H]+ and double-charged [M+2H]2+ pseudomolecular ions were 
revealed in the mass spectra along with the formation of a strong sodium adduct 
of neomycin. 
Gentamicin, as it is well known, is not a single molecule but a complex of three 
major and several minor components [247]. Gentamicin’s forms C1 (C21H43N5O7, 
Mr: 477), C1a (C19H39N5O7, Mr: 449) and C2 (C20H41N5O7, Mr: 463) are the three 
major components of the drug complex. C2 form consists of two stereoisomers 
(C2 and C2a). In gentamicin’s mass spectra the ions [C2/C2a+Νa]+ (m/z 486), 
[C1a+Na]+ (m/z 472), [C1+ Na]+ (m/z 500) and [C1+ H]+ (m/z 478) were obtained. 
The solvent composition that presented the highest signal/noise ratio of the 
precursor ions of AGs was ACN/aqueous ammonium formate 1 mM with 0.1 % 
formic acid (60/40, v/v). Neither the addition of formic acid in the organic phase 
nor the addition of MeOH resulted in increasing the ionization efficiency. For 
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apramycin, gentamicin and neomycin the sensitivity acquired (abundance of 
precursor ion) was rather insufficient, especially bearing in mind the low MRL of 
gentamicin in muscle (50 μg kg-1). The low water content solvents are not 
suitable for these aminoglycosides which are not even well soluble in such 
solvents [248]. These compounds are the most strongly retained 
aminoglycosides in HILIC columns and they often need a very significant 
increase to the aqueous phase content in the mobile phase to be eluted (up to 
95% aqueous phase) [243, 248].  
Taking these facts into consideration a further optimization of the ionization 
efficiency of apramycin, gentamicin and neomycin was held. Direct infusion of 
AGs’ standards prepared in various solvents was performed and the abundance 
of precursor ions was compared. The aqueous/organic ratio of all the tested 
solvents was 95/5 (v/v) to match the eluting conditions of the analytes. Organic 
phase consisted of methanol or acetonitrile and the aqueous phase of water with 
different mobile phase additives, such as formic acid, acetic acid, ammonium 
acetate and ammonium formate at various concentrations. All solvents – mobile 
phases examined are summarized in Table S6.2 and the schematic results of the 
optimization are presented in Figures S6.1 – S6.3.  
Apramycin and gentamicin showed maximum abundance when ammonium 
formate 1mM with 0.1% formic acid – MeOH (95/5, v/v) was used as the mobile 
phase for the infusion experiments (standard solution solvent). Neomycin also 
gave satisfactory results in this mobile phase, mainly for the [M+H]+ ion. The 
optimum mobile phase for neomycin proved to be ammonium formate 1mM with 
0.0.5 % formic acid – ACN (95/5, v/v) (for [M+H]+ ion) but this was not suitable for 
the other aminoglycosides which did not present satisfactory ionization. In most 
cases MeOH as the organic solvent induced signal enhancement for the 
aminoglycosides, while the increase of the ionic strength (buffer concentration) 
caused signal suppression, as expected in ESI [243]. 
 Different percentages of formic acid (0.01–0.1 %) were also tested. A significant 
increase in the [M+H]+ abundance was observed when increasing the formic 
acid, favouring the formation of the charged species. Thus, ammonium formate 1 
mM with 0.1% formic acid – MeOH (95/5, v/v) was chosen as the optimum mobile 
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phase to elute these three compounds from HILIC columns achieving maximum 
ionization. 
Subsequently, collision energies for all analytes were optimized in order to find 
the most abundant product ions, selecting the most sensitive transition for 
quantification purposes and a second one for confirmation. For most of the 
compounds the [M+H]+ appeared to be the most abundant ion. Penicillins were 
monitored as their [(M+H2-CO)+H]
+ degradation products since they are 
subjected in a β-lactam ring-opening. 
Ionophores, such as monensin and semduramycin formed strong sodium 
adducts while for narasin, nigericin, manduramycin and salinomycin ammonium 
adducts where the most abundant ones. Sodium adducts of aminoglycosides 
showed very poor fragmentation with low abundance of product ions, which 
would decrease the sensitivity of the method. As a result, monoprotonated ions 
were selected as precursor ions for all aminoglycosides except for apramycin for 
which a product ion of the [M+2H]+ ion was selected as the qualifier. The 
precursor and product ions selected for all other target analytes, are presented in 
Table 6.1. 
 
6.3.1.2 LC-MS/MS optimization 
The lack of retention of highly hydrophilic compounds on reversed phase 
chromatography (RP) had at first been supplemented with ion exchange 
chromatography or ion paring on RP. However, these techniques were not 
suitable for the determination of strongly hydrophilic compounds which could not 
receive charge in solution and which had not been able to receive retention on 
any stationary phase [249]. The problem has been overcome in LC developing 
hydrophilic interaction chromatography (HILIC) [250].  
In the present study, HILIC was the technique of choice for the rapid and reliable 
determination of veterinary drugs and pharmaceuticals for two reasons: firstly 
because very polar compounds like aminoglycosides, sulfaguanidine and 
amprolium present lack of retention on reversed phase chromatographic 
columns. The second reason is that an increased MS sensitivity is generally 
observed in HILIC due to mobile phase’s high organic content which assures 
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high efficiency of spraying and desolvation techniques and, since for many of the 
target analytes MRLs on MLs are established at particularly low concentration 
levels (< 10 μg kg-1), low CCα and CCβ values must be achieved in order to meet 
EU requirements. 
Two chromatographic columns with different stationary phases were tested: bare 
silica (Acquity BEH HILIC, 2.1 × 100 mm, 1.7 μm, Waters) and aminopropyl 
(APS-2 Hypersil, 2.1 × 50 mm, 3 μm, Thermo). In aminopropyl stationary phase 
the functional group is an aminopropyl ligand with a primary amino group that is 
positively charged while bare silica the underivatised silanol groups act as the 
functional group and are themselves both acidic and hydrophilic in nature. Bare 
silica also belongs in the charged stationary phases (negatively charged) [249]. 
Strong electrostatic interactions can take place between the analytes and the 
charged stationary phases. The hydrophilic partition of the analytes and 
hydrogen bonding also contribute to the retention. 
The mobile phase that was used was a mixture of ACN (solvent A), ammonium 
formate 1mM with 0.1% formic acid (solvent B) and MeOH (solvent C), as chosen 
from the ionization optimization experiments. A gradient program of 80% A – 
20% B (t0) increasing linearly to 95% B – 5% C in 8 min and being held at this 
percentage for additional 5 min, at a flow rate of 100 μL min-1, was tested in both 
HILIC columns and the elution of all analytes was compared, in terms of peak 
area and peak shape. Most of the non polar or medium polarity analytes were 
adequately separated and determined in both stationary phases, showing low 
retention times, good peak shape and satisfactory sensitivity. However, the 
chromatographic behaviour of aminoglycosides was significantly different in 
these two HILIC columns.  
APS-2 Hypersil revealed very strong retention of AGs leading to bad peak shape 
with considerable peak tailing (symmetry > 1.4). Although AGs are positively 
charged compounds and the predominance of repulsion effects with the 
positevely charged aminopropyl phase would be expected, partitioning and 
hydrogen bonding seemed to be the preponderant retention mechanism leading 
to strong retention of the compounds in the column. The increase of the flow rate 
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to 300 μL min-1 resulted in a noticeable improvement of the peak shape but it 
could not compensate for the significant decrease in sensitivity. 
 On the other hand, when BEH HILIC bare silica column was tested, 
aminoglycosides were less retained and the peak shapes were improved. The 
use of mobile phase with pH <3 with silica stationary phase led to sharper and 
more symmetrical peaks due to minimised silanol interactions, as it has already 
been noted in previous studies [244]. Thus, BEH HILIC column was used for the 
simultaneous determination of 76 veterinary drugs and pharmaceuticals. 
Subsequently, different elution programs were tested in BEH HILIC and the 
sensitivity of each compound (peak area) along with the peak shape and signal 
to noise were compared for all target analytes. Due to the very different 
physicochemical properties of the target compounds (from polar aminoglycosides 
to hydrophobic ionophore coccidiostats), no isocratic elution program was 
feasible and so a gradient program was used in order to elute all compounds in 
one chromatographic run. Seven different gradient elution programs were tested 
and they are presented in Table S6.2. They all start with 80% ACN – 20% 
ammonium formate 1mM with 0.1% formic acid (t0) except for gradient 5 that 
starts with 75% ACN – 20% ammonium formate 1mM with 0.1% formic acid – 5% 
MeOH. 
 The elution of the analytes is held either in different isocratic steps in the same 
chromatogram (Gradients 1, 4, 5, 6) or in linear gradients (Gradients 2, 3, 7). In 
order to test the efficiency of the isocratic elution for all analytes, two different 
isocratic elution steps needed to be set in each chromatographic program. The 
first one was set in 80% organic - 20% aqueous phase for 8 min to elute all 
analytes except for aminoglycosides and then a sharp increase of the aqueous 
phase (in 0.1min) led to the second isocratic step (90% or 95% of the aqueous 
phase for 5 min). Aminoglycosides were eluted during the second isocratic step. 
Three different linear gradients were also tested, starting from 80% organic 
phase and coming up to a very high portion of aqueous mobile phase (90% or 
95%) in 10 min, a portion which is maintained constant for additional 4 min to 
complete the elution of even the most strongly retained analytes (neomycin and 
apramycin). 
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Aminoglycosides showed very interesting variations in their peak shape and 
sensitivity during these experiments. A mixture of 95% ammonium formate 1mM 
with 0.1% formic acid with 5% MeOH proved to be the most suitable mobile 
phase for the elution of apramycin, gentamycin and neomycin coming in 
agreement with the ionization optimization experiments. A significant increase in 
the sensitivity of those compounds is observed when linear gradient elution is 
performed, rather than isocratic elution; peak shape was also improved. A linear 
gradient starting from 80% ACN – 20% ammonium formate 1mM with 0.1% 
formic acid to 95% ammonium formate 1mM with 0.1% formic acid – 5% MeOH 
gave the most satisfactory results, with the sensitivity of apramycin, kanamycin 
and neomycin being almost two times higher than when isocratic elution is 
performed. Taking into consideration that these are the most strongly retained 
compounds in HILIC columns it is safe to conclude that a linear increase of the 
aqueous mobile phase reduces effectively the retention of the analytes, 
promoting their elution with maximum sensitivity. However, this does not seem to 
be the case for the other three aminoglycosides (streptomycin, 
dihydrostreptomycin and gentamycin) which presented insignificant differences in 
their sensitivity and chromatographic behaviour. Chromatograms of apramycin, 
kanamycin and neomycin obtained (A) with the linear gradient of choice and (B) 
with isocratic elution with 95% ammonium formate 1mM with 0.1% formic acid – 
5% MeOH are presented in Figure 6.1. As it can be seen, significant increase in 
the peak area as well as in the signal to noise ratio is achieved when the analytes 
are eluted using a linear gradient program. In addition, the retention times of the 
compounds when linear gradient is used are considerably reduced resulting in a 
smaller overall run time, ensuring the analysis of a larger number of samples in 
one laboratory day.  
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Figure 6.1: Chromatograms of apramycin, neomycin and kanamycin obtained  (A) 
with a linear gradient starting from 80% ACN – 20% ammonium formate 1mM with 
0.1% formic acid to 95% ammonium formate 1mM with 0.1% formic acid – 5% MeOH 
in 10 min and (B) with isocratic elution with 95% ammonium formate 1mM with 0.1% 
formic acid – 5% MeOH  
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All results for aminoglycosides in the optimization of the elution program 
experiments are presented in Figure S6.4. Each gradient program was tested by 
measuring three times a standard solution of all analytes at a concentration of 
2×VL. Results are presented as %Relative Peak Area where the first injection of 
gradient 1 represents 100%. Standard deviations are also calculated and shown 
in the chart. In addition,  %RSDs of the retention times of AGs in each gradient 
were calculated. %RSDs were in all cases <1.5%, indicating the excellent 
stability and repeatability of the chromatographic detection. 
Unlike aminoglycoside compounds, for most of the other analytes the differences 
in sensitivity were negligible when changing the gradient elution program. Figure 
S6.5 illustrates the compounds with the most noticeable variations in their 
sensitivity during elution program optimization experiments. 
Thus, the ternary linear gradient starting from 80% ACN – 20% ammonium 
formate 1mM with 0.1% formic acid, increasing to 95% ammonium formate 1mM 
with 0.1% formic acid – 5% MeOH in 10 min and remaining stable in this 
composition for additional 4 min was chosen as the final elution program for the 
determination of veterinary drugs and pharmaceuticals. Along with the re-
equilibration time needed, the overall run time was 20 min. This total run time is 
quite small for a multi-residue method including AGs, especially the strongly 
retained neomycin and apramycin. It should be noted that even specific HILIC 
methods for the determination of AGs which contain the strongly retained AGs 
report overall run times > 15 min [241, 243].  
Finally, the injection solvent composition was investigated and optimized in terms 
of sensitivity (peak area) and peak shape. Five different standard solutions of all 
analytes at a concentration of 2×VL were constructed in five different injection 
solvents and each one was measured in triplicate with the final gradient program 
(gradient 2). The injection solvents tested were (I) 50 MeOH:50 FA 0.1%, (II) 20 
MeOH:80 FA 0.1%, (III) 80 MeOH:20 FA 0.1%, (IV) 60 ACN:20 MeOH: 20 FA 
0.1% and (V) 80ACN: 20 FA 0.1%. The results of the optimization for all 
compounds are summarized in Figure S6.6. Results are presented as %Relative 
peak area with the first injection of the standard solution in solvent (I) 
representing 100%. Standard deviations of the measurements are displayed in 
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the graphs. %RSDs of the retention times were for all the target compounds 
<1.5%.  
The increase in the portion of ACN in the injection solvent resulted in a significant 
improvement in the peak shape of most of the compounds. The sensitivity was 
also increased in most cases, with the exception of streptomycin, 
dihydrostreptomycin and gentamycin which were favored by the presence of 
MeOH in the final injection solvent.  
Conclusively, in the developed  HILIC-MS/MS method  significantly low sensitivity 
is achieved for many compounds in a quite short total run time, comparing to 
other HILIC methods reported in the literature but also to reversed-phase 
chromatographic methods. Apart from aminoglycosides which were thoroughly 
investigated and optimized, many non-polar and hydrophobic compounds 
(ionophore coccidiostats, macrolides, statins) could be detected at very low 
concentration levels due to their affinity with the high organic portion of the 
mobile phase and the high ionization efficiency they presented in HILIC 
conditions. This has been very important in order to meet the EU Regulation 
requirements which in some cases (eg. for coccidiostats) has set MRLs and MLs 
at low-ppb levels. Further discussion about the sensitivity of the developed 
method is held in Method Validation Section (Section 6.3.3). 
   A HILIC–MS/MS chromatogram of a spiked bovine tissue sample at the 1×VL 
concentration (1.5×VL for prohibited substances) is presented in Figure 6.1 
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Sulfamethoxazole  254 > 156 
Sulfamonomethoxine  281 > 92 
Sulfapyridine  250 > 156 
Sulfaquinoxaline  301 > 156 
Sulfamethizole  271 > 156 
Sulfisoxazole  256 > 156 
196 
 
Diaminopyrimidines – Other antibiotics – Anthelmintics  
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Febantel  447 > 383 
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Anthelmintics (B) 
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mm_MRL
NL: 6.32E5
m/z= 158.50-159.50 F: + c ESI 
SRM ms2 316.000 
[158.800-159.200, 
190.800-191.200]  MS 
std_mrl_d
NL: 4.12E5
m/z= 130.40-131.40 F: + c ESI 
SRM ms2 202.000 
[130.700-131.100, 
174.700-175.100]  MS 
spike_2mrl_1
NL: 1.79E6
m/z= 273.40-274.40 F: + c ESI 
SRM ms2 359.000 
[170.800-171.200, 
273.700-274.100]  MS 
mm_MRL
Thiabendazole  202 > 131 
 
Oxfendazole  316 > 159 
 
Triclabendazole  359 > 274 
 
Morantel  221 > 123 
 
Mebendazole  296 > 264 
 
Levamisole  205 > 178 
 
Fenbendazole  300 > 268 
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Coccidiostats 
 
 
 
 
RT: 0.00 - 24.03 SM: 9G
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3.30
3.18
6.10
3.08
3.40
3.22
3.04
3.23
NL: 1.75E5
m/z= 149.40-150.40 F: + c ESI 
SRM ms2 242.900 
[121.700-122.100, 
149.700-150.100]  MS mm_MRL
NL: 1.67E4
m/z= 142.40-143.40 F: + c ESI 
SRM ms2 277.900 
[106.800-107.200, 
142.700-143.100]  MS 
spike_0,5mrl_1
NL: 7.03E2
m/z= 100.60-101.60 F: + c ESI 
SRM ms2 191.900 
[86.900-87.300, 
100.900-101.300]  MS mm_mrl_2
NL: 1.62E5
m/z= 203.50-204.50 F: + c ESI 
SRM ms2 418.000 
[203.800-204.200, 
231.800-232.200]  MS 
spike_2mrl_1
NL: 8.81E4
m/z= 244.40-245.40 F: + c ESI 
SRM ms2 261.000 
[122.800-123.200, 
244.700-245.100]  MS 
spike_mrl_2
NL: 5.10E4
m/z= 205.40-206.40 F: + c ESI 
SRM ms2 238.000 
[135.800-136.200, 
205.700-206.100]  MS 
spike_2mrl_1
NL: 1.35E4
m/z= 628.50-629.50 F: + c ESI 
SRM ms2 934.400 
[629.100-629.500, 
646.800-647.200]  MS 
spike_2mrl_1
NL: 1.10E4
m/z= 460.50-461.50 F: + c ESI 
SRM ms2 693.000 
[460.800-461.200, 
500.800-501.200]  MS 
spike_2mrl_1
Amprolium  243 > 150 
 
Arprinocid  278 > 143 
 
Clopidol  192 > 101 
 
Decoquinate  418 > 204 
 
Diaveridine  261 > 245 
 
Ethopabate  238 > 206 
 
Maduramycin (NH4
+
)  934 > 629 
 
Monensin (Na
+
)  693 > 461 
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Coccidiostats (B) – NSAIDs  
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NL: 4.28E3
m/z= 372.20-373.20 F: + c ESI 
SRM ms2 782.300 
[372.500-372.900, 
747.000-747.400]  MS mm_MRL
NL: 1.16E3
m/z= 137.40-138.40 F: + c ESI 
SRM ms2 333.900 
[137.700-138.100, 
154.700-155.100]  MS mm_MRL
NL: 2.27E3
m/z= 372.30-373.30 F: + c ESI 
SRM ms2 768.300 
[372.600-373.000, 
733.000-733.400]  MS 
std_mrl_d
NL: 7.32E3
m/z= 832.60-833.60 F: + c ESI 
SRM ms2 895.300 
[832.900-833.300]  MS 
spike_mrl_1
NL: 3.13E5
m/z= 294.60-295.60 F: + c ESI 
SRM ms2 313.000 
[227.000-227.400, 
294.900-295.300]  MS mm_MRL
NL: 3.08E4
m/z= 279.60-280.60 F: + c ESI 
SRM ms2 298.000 
[109.000-109.400, 
279.900-280.300]  MS mm_MRL
NL: 4.65E4
m/z= 114.50-115.50 F: + c ESI 
SRM ms2 351.900 
[114.800-115.200, 
140.700-141.100]  MS mm_MRL
NL: 6.90E2
m/z= 159.70-160.70 F: + c ESI 
SRM ms2 309.200 
[160.000-160.400, 
210.900-211.300]  MS mm_MRL
Narasin (NH4
+
)  782 > 747 
 
Salinomycin (NH4
+
)  768 > 733 
 
Semduramycin (Na
+
)  895 > 833 
 
5-Hydroxyflunixin 313 > 295 
 
Flunixin  298 > 280 
 
Meloxicam  352 > 115 
 
Phenylbutazone  309 > 160 
 
Robenidine  334 > 155 
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Thyreostats – Tranquilizers – Pharmaceuticals  
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NL: 3.70E3
m/z= 102.50-103.50 F: + c ESI 
SRM ms2 205.000 
[102.900-103.300, 
145.900-146.300]  MS mm_4mrl_2
NL: 3.18E4
m/z= 85.70-86.70 F: + c ESI SRM 
ms2 319.100 [86.000-86.400, 
245.600-246.000]  MS spike_mrl_2
NL: 2.47E4
m/z= 263.00-264.00 F: + c ESI 
SRM ms2 378.700 
[103.700-104.100, 
263.300-263.700]  MS spike_mrl_1
NL: 2.62E5
m/z= 144.50-145.50 F: + c ESI 
SRM ms2 267.200 
[144.800-145.200, 
189.800-190.200]  MS std_mrl_d
NL: 9.20E5
m/z= 439.60-440.60 F: + c ESI 
SRM ms2 559.400 
[249.800-250.200, 
439.900-440.300]  MS 
spike_2mrl_1
NL: 1.97E4
m/z= 137.70-138.70 F: + c ESI 
SRM ms2 195.100 
[110.000-110.400, 
138.000-138.400]  MS 
spike_2mrl_1
NL: 2.16E5
m/z= 193.60-194.60 F: + c ESI 
SRM ms2 237.100 
[192.900-193.300, 
193.900-194.300]  MS 
spike_2mrl_1
6-phenyl-2-thiouracil  205 > 146 
 
Chlorpromazine  319 > 86 
 
Ambroxol  379 > 264 
 
Atenolol  267 > 145 
 
Atorvastatin  559 > 440 
 
Caffeine  195 > 138 
 
Carbamazepin  237 > 194 
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Pharmaceuticals - Others 
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NL: 1.72E5
m/z= 190.60-191.60 F: + c 
ESI SRM ms2 268.200 
[132.900-133.300, 
190.900-191.300]  MS 
mm_4mrl_2
NL: 3.12E5
m/z= 182.60-183.60 F: + c 
ESI SRM ms2 260.000 
[155.000-155.400, 
182.900-183.300]  MS 
mm_4mrl_2
NL: 3.86E4
m/z= 198.50-199.50 F: + c 
ESI SRM ms2 419.300 
[198.800-199.200, 
225.100-225.500]  MS 
mm_4mrl_2
NL: 4.42E5
m/z= 57.90-58.90 F: + c ESI 
SRM ms2 264.300 
[58.200-58.600, 
245.800-246.200]  MS 
mm_4mrl_2
NL: 1.54E6
m/z= 236.50-237.50 F: + c 
ESI SRM ms2 254.100 
[103.900-104.300, 
236.800-237.200]  MS 
mm_4mrl_2
NL: 3.46E5
m/z= 206.50-207.50 F: + c 
ESI SRM ms2 436.200 
[206.800-207.200, 
290.800-291.200]  MS 
mm_4mrl_2
NL: 1.13E5
m/z= 263.50-264.50 F: + c 
ESI SRM ms2 376.900 
[113.900-114.300, 
263.400-263.800]  MS 
mm_4mrl_2
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Propanolol  260 > 183 
 
Simvastatin  419 > 225 
 
Tramadol  264 > 58 
 
Triamterene  254 > 237 
 
Valsartan  436 > 91 
 
Bromhexine  377 > 114 
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NL: 3.13E3
m/z= 423.80-424.80 F: + c ESI 
SRM ms2 586.100 
[162.700-163.100, 
424.100-424.500]  MS 
std_mrl_0,02_scan_time_b
NL: 8.92E5
m/z= 376.60-377.60 F: + c ESI 
SRM ms2 423.100 
[376.900-377.300]  MS 
mm_4mrl_2
NL: 2.11E5
m/z= 267.60-268.60 F: + c ESI 
SRM ms2 303.100 
[267.900-268.300]  MS 
mm_4mrl_2
NL: 4.42E5
m/z= 281.40-282.40 F: + c ESI 
SRM ms2 314.000 
[122.800-123.200, 
281.700-282.100]  MS 
mm_4mrl_2
NL: 2.58E5
m/z= 281.50-282.50 F: + c ESI 
SRM ms2 300.000 
[281.800-282.200]  MS 
mm_4mrl_2
NL: 3.03E4
m/z= 114.50-115.50 F: + c ESI 
SRM ms2 355.000 
[114.800-115.200]  MS 
mm_4mrl_2
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Decoquinate d5  423  > 377 
 
Fenbendazole d3  303 > 268 
 
Flubendazole  314 > 282 
 
Flunixin d3  300 > 282 
 
Meloxicam d3  355 > 115 
 
Amikacin  586 > 424 
 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 
203 
 
Internal Standards (B) 
 
 
 
 
Figure 6.2: SRM chromatogram of spiked bovine muscle tissue sample at a fortification 
level of 1×VL  for all target compounds (1.5×VL for prohibited veterinary drugs). 
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SRM ms2 321.000 
[165.900-166.300]  MS 
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NL: 1.37E5
m/z= 159.30-160.30 F: + c ESI 
SRM ms2 254.900 
[159.600-160.000]  MS 
std_mrl_0,02_scan_time_b
NL: 6.25E5
m/z= 155.40-156.40 F: + c ESI 
SRM ms2 314.900 
[155.700-156.100]  MS 
std_mrl_0,02_scan_time_b
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SRM ms2 282.900 
[185.600-186.000]  MS 
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Triclabendazole d3  364 > 201 
 
 
Sulfadimidine d4  283 > 186 
 
Sulfadimethoxine d4  315 > 156 
 
Sulfadiazine d4  255 > 160 
 
Phenylbutazone - (diphenyl-13C12)  321 > 166 
 
Nigericin (NH4+)  742 > 461 
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6.3.2 Sample Preparation 
Finding suitable extraction conditions for  the simultaneous extraction of the 
extremely polar aminoglycoside antibiotics along with a large number of other 
compounds with different physicochemical properties (lipophilicity, hydrophilicity, 
alcaline and acidic characteristics, etc) composes a great challenge in 
multiresidue analysis and has rarely been reported previously. An additional 
difficulty is presented in obtaining a final extract suitable for AGs’ determination 
and  HILIC-compatible ( >60% ACN) at the same time since AGs are not even 
well soluble at low water content solvents [248]. 
In this study, a two-step sample preparation protocol was used for the 
simultaneous extraction of the 76 veterinary drugs and pharmaceuticals, along 
with 12 internal standards, from bovine muscle tissue samples. The first step 
consists of a solvent extraction with ACN, employed in order to extract the 
medium polarity and non-polar compounds with high lipophilicity. ACN has been 
reported to effectively extract antibiotics, anthelmintics and coccidiostats from 
different matrices [75, 223, 228]. The ACN extract is evaporated to a final volume 
of 1.0 mL after the extraction. 
The second step consists of a solvent extraction with an aqueous buffer, in 
strong acidic conditions (2% TCA). The second extraction solvent consists of 
ammonium acetate, sodium chloride, EDTA and TCA and is mainly targeted in 
the extraction of aminoglycosides and other polar compounds like penicillins, 
thyreostats and sulfaguanidine. Aminoglycosides tend to bind to proteins and so 
strong acidic conditions are necessary for their extraction from tissue. EDTA is 
used as a chelating agent to improve the extraction recovery of aminoglycosides 
as it prevents their rapid chelation with metal ions [243]. After the extraction 
further clean up and preconcentration of the samples is performed using SPE 
with HLB cartridges. This copolymer of divinylbenzene and vinylpyrrolidone 
sorbent has broad applicability spectra due to its hydrophilic and lipophilic 
properties and has been widely used in the field of veterinary drug and 
pharmaceutical multiresidue analysis [75, 89, 90, 91, 224].  
After the extraction the pH of the extract was adjusted to 6.5 with NaOH 30%, 
w/v. Approximately 6 drops of NaOH solvent were needed to obtain the desired 
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pH value and the value was verified using a pH-meter device. Different pH values 
were tested (5.5, 6.5 and 7.5) with pH 6.5 proving to be optimum for 
aminoglycosides’ determination. The effect of pH value on other compounds’ 
recoveries was insignificant and thus this value was chosen and used in the final 
sample preparation protocol. Finally, for the elution of the analytes a mixture of 
aqueous formic acid 10 % (v/v) and ACN (1:4) was used. Strong acidic conditions 
are required in order to elute AGs [246, 248, 251] and 2×0.5 mL 10% of aqueous 
formic acid were used as indicated by Lehotay et al [246]. An organic solvent was 
also used since in the field of multiresidue analysis the vast majority of studies 
report the use of organic solvents for the elution of veterinary drugs and 
pharmaceuticals [75, 89, 90, 91, 224]. An organic solvent is also required for 
gentamicin’s elution [248]. 
The eluate (4.0 mL) was mixed with the remaining 1.0 mL of the ACN extract 
from the previous extraction step; the final extract consists of a 5-mL solution of 
80% ACN and 20% aqueous formic acid, a constitution that matches the 
optimum ACN/formic acid portion that has resulted from the injection solvent 
optimization (Section 6.3.1.2).  
 
6.3.3 Method Validation 
The method was validated according to European Commission Decision 
2002/657/EC. This Decision establishes criteria and validation procedures to 
ensure the quality and comparability of analytical results obtained. Some 
analytes are authorized, having corresponding MRL values, some are prohibited 
and some are not at all regulated, making the validation procedure for multi-
residue methods rather difficult to design.  
To the best of our knowledge, it is the first method reported in literature,  
including AGs, in which EU Regulation requirements are fulfilled for so many 
veterinary drugs with large variations in the established MRLs and MLs (from 
1000 μg kg-1 for apramycin to 2 μg kg-1 for some coccidiostats). 
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6.3.3.1 Identification, confirmation and quantification 
According to the criteria established in the EU Commission Decision 
2002/657/EC an analyte is considered as positively identified and confirmed in a 
sample when the relative retention time ratio of the analyte in the sample and in 
standard solution is within ± 2.5 % tolerance, both SRMs for the analyte are 
present in the sample and the ratio of the intensities of the two transitions 
(quantifier and qualifier) matches the one obtained using fortified blank samples 
within the defined tolerance [54]. The use of two selected precursor-product ion 
transition per compound counts for four identification points, which fulfill the EU 
identification point’s requirement. Ion Ratios for all compounds at the 1×VL level 
are presented in Table 6.2, along with the corresponding tolerances.  
The quantification procedure of a target analyte that is detected in an unknown 
sample involves the use of the standard addition method with calibration samples 
that were spiked with the analytes before extraction, in different concentrations. 
This quantification method  is recommended to get reliable quantitative results 
without the need for correction for recovery losses and for matrix effects. The use 
of isotopic analogue internal standards, where available, also ensures the 
reliability of the quantitation since their use can efficiently compensate for matrix 
suppression or enhancement as well as for recovery losses. 
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Table 6.2: Ion Ratios for all compounds in spiked samples at the 1×VL level. 
Compound (n=10) 
Ion Ratio 
(q/Q)  × 100% 
RSD % 
Tolerance levels  
(2002/657/ΕΕ) 
Compound (n=10) 
Ion Ratio 
(q/Q)  × 100% 
RSD % 
Tolerance levels  
(2002/657/ΕΕ) 
Aminoglycosides Febantel 33.2 6.7 ± 25 % 
Apramycin 67.1 8.4 ± 20 % Fenbendazole 84.0 6.0 ± 20 % 
Dihydrostreptomycin 57.0 7.6 ± 20 % Levamisole 36.5 14.4 ± 25 % 
Gentamycin 4.3 25.8 ± 50 % Mebendazole 29.7 9.9 ± 25 % 
Kanamycin 89.5 7.3 ± 20 % Morantel 85.7 4.9 ± 20 % 
Neomycin 70.6 12.8 ± 20 % Oxfendazole 29.3 17.0 ± 25 % 
Streptomycin 37.6 14.8 ± 25 % Thiabendazole 92.0 5.7 ± 20 % 
Penicillins Triclabendazole 6.1 3.3 ± 50 % 
Ampicillin 78.2 21.1 ± 20 % Coccidiostats 
Cloxacillin 92.2 5.3 ± 20 % Amprolium 16.7 10.3 ± 30 % 
Dicloxacillin 74.5 10.0 ± 20 % Aprinocid 13.4 16.3 ± 30 % 
Oxacillin 72.8 12.7 ± 20 % Clopidol 18.9 19.9 ± 30 % 
Penicillin G 88.5 4.5 ± 20 % Decoquinate 60.3 8.8 ± 20 % 
Penicillin V 90.5 15.7 ± 20 % Diaveridine 38.2 15.2 ± 25 % 
Macrolides Ethopabate 44.7 21.2 ± 25 % 
Azithromycin 24.2 17.7 ± 25 % Maduramycin (NH4
+) 32.4 18.7 ± 25 % 
Clarithromycin 29.4 18.7 ± 25 % Monensin (Na+) 24.8 20.5 ± 25 % 
Erythromycin 77.2 4.5 ± 20 % Narasin (NH4
+) 13.8 23.8 ± 30 % 
Tiamullin 13.5 3.8 ± 30 % Robenidine 76.7 14.7 ± 20 % 
Tilmicosin 21.7 20.2 ± 25 % Salinomycin (NH4
+) 39.8 18.0 ± 25 % 
Tylosin 57.9 16.8 ± 20 % Semduramycin (Na+) 26.1 6.8 ± 25 % 
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Sulfonamides NSAIDs 
Dapsone 45.4 21.3 ± 25 % 5-Hydroxyflunixin 2.3 12.1 ± 50 % 
Sulfachloropyridazine 34.9 12.1 ± 25 % Flunixin 4.3 13.1 ± 50 % 
Sulfadiazine 46.6 16.1 ± 25 % Meloxicam 59.0 10.6 ± 20 % 
Sulfadimethoxine 32.4 3.6 ± 25 % Phenylbutazone 44.6 22.5 ± 25 % 
Sulfadimidine 28.1 6.0 ± 25 % Thyreostats 
Sulfaguanidine 1.4 18.8 ± 50 % 6-phenyl-2-thiouracil 0.5 17.6 ± 50 % 
Sulfamerazine 92.0 9.3 ± 20 % Tranquilizers 
Sulfamethizole 32.9 12.0 ± 25 % Chlorpromazine 23.1 20.0 ± 25 % 
Sulfamethoxazole 50.5 6.2 ± 20 % Pharmaceuticals 
Sulfamonomethoxine 94.8 6.3 ± 20 % Ambroxol 5.3 29.2 ± 50 % 
Sulfapyridine 72.7 12.1 ± 20 % Atenolol 62.3 11.9 ± 50 % 
Sulfaquinoxaline 32.9 12.7 ± 25 % Atorvastatin 48.5 7.2 ± 25 % 
Sulfathiazole 40.5 15.5 ± 25 % Caffeine 46.8 12.3 ± 25 % 
Sulfisoxazole 31.8 11.2 ± 25 % Carbamazepin 24.8 10.5 ± 25 % 
Diaminopyrimidines Metropolol 64.4 8.4 ± 20 % 
Baquiloprim 33.4 15.7 ± 25 % Propranolol 34.5 8.2 ± 25 % 
Trimethoprim 25.1 6.8 ± 25 % Simvastatin 63.2 16.1 ± 20 % 
Other antibiotics Tramadol 11.0 3.7 ± 30 % 
Rifaximin 14.6 15.9 ± 30 % Triamterene 19.2 4.9 ± 30 % 
Anthelmintics Valsartan 81.3 5.1 ± 20 % 
Albendazole 98.0 3.4 ± 20 % Others 
Albendazole sulfo(oxide) 59.0 7.4 ± 20 % Bromhexine 67.8 17.3 ± 20 % 
Albendazole sulfone 65.5 9.2 ± 20 %     
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6.3.3.2 Selectivity/specificity 
The selectivity of the method was evaluated extracting and analyzing 20 control 
blank bovine tissue samples. No background peaks, above a signal-to-noise ratio 
of 3, were present at the same elution time as the target veterinary drugs and 
pharmaceuticals. This shows that the method is free of endogeneous 
interferences. 
 
6.3.3.3 Linearity 
The linearity of calibration curves was assessed by using a six-point standard 
solution calibration curve in pure solvents as well as in blank bovine mucle tissue 
extracts at different concentrations (0.25 to 4×VL for each target compound). The 
linear regression analysis was carried out by plotting the peak area versus the 
analyte concentrations for compounds with no corresponding IS and the peak 
area ratio of the analyte and I.S. versus the analyte concentrations, when an IS 
correction was used. The calibration parameters showed good linearity since 
correlation coefficients were >0.99 for all analytes. R2 ranged from 0.998 
(triamterene) to 0.9998 (erythromycin) for standard solution curves in pure 
solvent and from 0.998 (sulfamethizole) to 0.9999 (erythromycin) in matrix 
extracts. 
 
6.3.3.4 Precision 
The precision of this method was calculated as intra-day precision (repeatability) 
and inter-day precision (within-laboratory reproducibility), Repeatability and 
reproducibility were expressed as the %RSD values of set of 6 replicate analysis 
at the 3 concentration levels examined (0.5, 1 and 1.5 times the VL except for 
prohibited veterinary drugs for which the concentrations corresponded at 1, 1.5 
and 2 times the VL). Reproducibility experiments lasted three consecutive days. 
Precision results for all compounds in all concentration levels are presented in  
Table 6.3.
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Table 6.3: Precision, LOD, LOQ, CCα and CCβ values for target veterinary drugs and pharmaceuticals. 
 
Repeatability % RSD  Reproducibility % RSD 
LOD  
(μg kg-1) 
LOQ  
(μg kg-1) 
MRL  
(μg kg-1) 
CCα  
(μg kg-1) 
CCβ  
(μg kg-1) 
Compound 0.5 × VL  1× VL 1.5×VL 0.5 × VL  1× VL 1.5×VL      
Aminoglycosides  
Apramycin 8.8 10 6.7 13 10 8.9 22 74 1000 1151 1302 
Dihydrostreptomycin 15 12 10 16 15 9 9.8 32 500 594 688 
Gentamycin 16.1 12.0 5.9 14 9.3 6.8 7.0 23 50 58 66 
Kanamycin 9.4 11.0 4.3 12 10 6.1 17 56 100 118 135 
Neomycin 7.5 7.9 5.5 14 11 6.8 49 163 500 539 577 
Streptomycin 17 14 13 17 15 15 54 178 500 660 820 
           Penicillins 
Ampicillin 6.2 5.1 10 14 8.6 8.3 3.8 13 50 56 60 
Cloxacillin 12 10 9.0 18 15 9.8 1.1 3.5 300 355 389 
Dicloxacillin 12 11 4.3 11 14 15 2.4 8.0 300 340 364 
Oxacillin 8.8 6.9 6.6 12 7.7 13 1.5 4.9 300 325 340 
Penicillin G 10 14 11 13 7.0 15 2.1 7.0 50 55 58 
Penicillin V 5.2 9.3 9.1 12 16 12 3.5 12 - 5.4 8.5 
            Macrolides 
Azithromycin 9.7 5.9 3.4 14 12 12 0.48 1.6 - 13 21 
Clarithromycin 14 13 11 17 12 14 0.90 3.0 - 20 32 
Erythromycin 13 13 6.2 14 11 11 51 167 200 225 240 
Tiamullin 6.1 8.2 1.5 11 8.1 8.3 0.066 0.22 50 110 116 
Tilmicosin 11 6.5 5.4 12 6.7 13 0.56 1.9 100 54 56 
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Tylosin 12 4.2 9.2 13 13 11 2.2 7.3 100 115 125 
          Sulfonamides  
Dapsone* 8.9 8.9 8.2 18 17 6.0 0.11 0.37 prohibited 2.7 3.7 
Sulfachloropyridazine 7.1 9.6 12 17 12 14 0.16 0.52 100 116 126 
Sulfadiazine 11 9.0 5.1 11 14 12 1.9 6.3 100 122 135 
Sulfadimethoxine 7.9 4.2 2.1 12 14 4.3 0.053 0.18 100 119 130 
Sulfadimidine 7.7 5.5 6.5 7.5 5.4 12 0.022 0.072 100 109 114 
Sulfaguanidine 5.7 8.5 11.0 14 7.4 11 1.8 5.9 100 111 118 
Sulfamerazine 12 6.2 6.5 14 13 14 0.42 1.4 100 121 135 
Sulfamethizole 13 8.6 10.3 15 13 12 0.47 1.5 100 116 125 
Sulfamethoxazole 8.8 9.1 1.9 13 16 6.3 0.12 0.40 100 118 129 
Sulfamonomethoxine 8.9 7.7 2.3 15 4.5 8.8 0.49 1.6 100 107 112 
Sulfapyridine 12 5.0 6.6 9.7 14 14 0.74 2.4 100 124 138 
Sulfaquinoxaline 11 7.6 2.9 16 14 8.4 0.15 0.48 100 122 135 
Sulfathiazole 10 6.1 2.1 13 12 10 2.0 6.5 100 118 128 
Sulfisoxazole 6.9 8.6 5.0 11 13 6.1 0.26 0.86 100 119 131 
Diaminopyrimidines 
Baquiloprim 9.5 14 7.6 12 9.5 7.0 0.30 1.0 - 8.5 12 
Trimethoprim 9.5 10 6.4 15 11 13 0.072 0.24 50 57 61 
       Other antibiotics 
Rifaximin 6.1 7.0 4.1 13 12 15 0.18 0.59 - 8.4 13.0 
       Anthelmintics 
Albendazole 6.1 5.7 5.6 6.7 15 14 0.058 0.19 100 121 134 
Albendazole 
sulfo(oxide) 
13 11 7.6 12 11 6.1 0.14 0.46 100 120 132 
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Albendazole sulfone 12 7.0 4.3 14 15 11 0.14 0.45 100 124 138 
Febantel 8.5 8.0 4.4 10 13 11 0.017 0.056 50 60 66 
Fenbendazole 4.7 10 4.5 9.8 11 11 0.0092 0.030 50 57 62 
Levamisole 10 11 6.8 11 11 14 0.047 0.16 10 12 13 
Mebendazole 13 13 7.3 16 10 10 0.078 0.26 - 6.5 11 
Morantel 5.8 1.7 3.9 13 16 7.8 0.10 0.33 100 122 135 
Oxfendazole 13 14 9.4 17 12 15 0.078 0.26 50 59 65 
Thiabendazole 8.3 9.0 7.0 10 7.9 7.0 0.076 0.25 100 112 120 
Triclabendazole 7.2 6.6 11.8 17 8.7 8.6 0.027 0.088 225 252 269 
          Coccidiostats 
Amprolium 17 16 6.6 16 14 9.7 0.091 0.30 - 3.2 5.1 
Aprinocid 12 7.3 2.1 16 13 8.0 0.27 0.88 - 7.0 9.5 
Clopidol 11 8.1 8.5 10 10 15 0.97 3.2 - 4.7 7.2 
Decoquinate 6.5 7.4 6.9 9.0 10 13 0.044 0.15 20 3.8 4.9 
Diaveridine 5.1 5.5 3.7 9.6 9.9 6.3 0.028 0.093 - 2.4 3.4 
Ethopabate 16 13 5.7 14 11 6.5 0.11 0.36 - 4.2 6.1 
Maduramycin (NH4
+) 18 10 9.2 18 13 15 0.13 0.42 2 2.3 2.5 
Monensin (Na+) 14 15 15 13 19 9.7 0.095 0.31 2 2.4 2.6 
Narasin (NH4
+) 13 7.7 10 17 18 14 0.036 0.12 5 6.2 6.9 
Robenidine 10 12 5.6 15 15 10 0.081 0.27 5 6.1 6.7 
Salinomycin (NH4
+) 11 5.7 10 15 11 11 0.012 0.038 2 2.3 2.4 
Semduramycin (Na+) 6.7 8.0 8.3 9.4 12 10 0.025 0.082 2 2.3 2.5 
              NSAIDs 
5-Hydroxyflunixin  6.4 4.1 3.8 6.6 12 9.9 0.015 0.049 - 2.3 3.0 
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Flunixin  7.2 7.4 1.7 11 12 8.4 0.034 0.11 20 23 25 
Meloxicam 5.0 5.5 6.8 13 9.0 10 0.047 0.16 20 22 23 
Phenylbutazone* 10 4.7 3.1 17 13 6.9 0.33 1.1 - 2.2 3.0 
Thyreostats 
6-phenyl-2-thiouracil  7.8 6.2 2.1 9.5 5.6 7.2 1.2 3.9 - 2.5 3.2 
Tranquilizers 
Chlorpromazine* 9.3 6.8 7.0 17 12 6.8 0.054 0.18 prohibited 4.1 6.6 
Pharmaceuticals 
Ambroxol 6.7 8.0 1.8 18 6.4 12 0.36 1.2 - 8.6 13 
Atenolol 13 11 11 17 11 9.8 0.65 2.1 - 7.7 13 
Atorvastatin 5.2 5.7 4.1 15 15 9.8 0.21 0.68 - 13 17 
Caffeine 14 12 8.4 14 12 15 0.72 2.4 - 32 37 
Carbamazepin 8.5 6.8 6.5 16 13 8.1 0.32 1.1 - 14 19 
Metropolol 8.3 5.7 5.0 12 7.8 11 0.39 1.3 - 20 26 
Propranolol 8.4 6.8 2.3 10 6.3 6.6 0.086 0.28 - 27 30 
Simvastatin 13 5.5 8.2 16 11 14 0.43 1.4 - 18 25 
Tramadol 7.9 10 5.3 11 15 5.9 0.049 0.16 - 11 15 
Triamterene 4.9 4.3 2.7 16 9.7 17 0.024 0.081 - 11 16 
Valsartan 10 7.9 3.0 16 17 12 0.061 0.20 - 15 20 
Others 
Bromhexine* 14 14 4.5 14 14 8.6 0.068 0.22 prohibited 5.1 6.0 
* prohibited compounds for which the concentrations examined correspond in 1×VL, 1.5×VL and 2×VL 
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%Relative standard deviations were always < 20% for all the veterinary drugs 
and pharmaceuticals tested, indicating the good precision of the preposed 
methodology. Repeatability in the lowest validation level for all compounds varied 
from 4.7% (fenbendazole) to 18% (manduramycin).The obtained %RSDs under 
reproducibility conditions in the lowest validation level ranged from 6.6% (5-
hydroxyflunixin) to 19% (manduramycin).  
 
6.3.3.5 Accuracy 
The accuracy of the method was estimated through recovery studies, since there 
is a lack of certified reference material for all the target analytes in the examined 
matrix. Average recoveries of each analyte were calculated performing the 
analysis in 18 replicates at each validation level in three different days (6 
samples per day per validation level). These results of the recovery study are 
given in Table 6.4. Recoveries at the 0.5×VL varied from 37.4% (bromhexine) to 
106% (kanamycin). In spite that some compounds present recovery values not 
close to 100%, they are considered acceptable since they were reproducible 
(Table 6.3) 
 
6.3.3.6 LODs & LOQs 
LODs and LOQs were evaluated as described in the Experimental Section, 
showing the obtained results in Table 6.3. LOQs ranged from 0.030 μg kg-1 
(fenbendazole) to 178 μg kg-1 (streptomycin) and were in all cases lower than the 
corresponding MRL or ML where one established.  
 
6.3.3.7 Decision limit (CCα) and Detection capability (CCβ) 
CCα and CCβ calculation was performed following two different different 
procedures, based on whether there is an established MRL or ML for the target 
analyte, or not. All the compounds that do not have established MRLs were 
treated as banned compounds and the CCα and CCβ were calculated through 
the calibration curve procedure. Decision limits ranged from 2.3 μg kg-1 
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(salinomycin, ML: 2 μg kg-1) to 1151 μg kg-1 (apramycin, MRL: 1000 μg kg-1) and 
detection capability from 2.4 μg kg-1 (salinomycin) to 1302 (apramycin).
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Table 6.4: % Recoveries and % Matrix effect values for all target veterinary drugs and pharmaceuticals. 
 0.5 × VL 1× VL 1.5×VL % ME 
Compound Recoveries SD % RSD Recoveries SD % RSD Recoveries SD % RSD  
Aminoglycosides  
Apramycin 101.2 10.0 9.9 97.4 10.4 10.7 99.1 9.0 9.1 -61 
Dihydrostreptomycin 80.3 11.5 14.3 77.6 10.9 14.1 79.2 9.8 12.4 -74 
Gentamycin 64.3 11.3 17.6 64.3 10.1 15.7 65.5 9.4 14.4 -75 
Kanamycin 105.9 13.0 12.2 106.9 12.5 11.7 110.4 11.2 10.2 -34 
Neomycin 62.8 7.3 11.9 60.0 5.6 9.4 59.8 5.3 8.9 -53 
Streptomycin 97.4 12.8 13.1 98.0 11.4 11.7 96.9 8.2 8.5 -81 
           Penicillins 
Ampicillin 94.4 12 13 88.0 7.2 8.2 109 10 9.4 -95 
Cloxacillin 76.4 14 19 69.6 11 16 78.4 12 15 -99 
Dicloxacillin 74.3 12 16 61.1 9.0 15 73.4 13 17 -97 
Oxacillin 76.2 8.4 11 65.2 5.0 7.6 71.1 11 15 -99 
Penicillin G 90.6 14 16 93.0 7.6 8.2 63.7 9.8 15 -99 
Penicillin V 70.7 7.5 11 73.9 10 14 84.0 9.7 12 -99 
            Macrolides 
Azithromycin 69.8 13 18 78.5 8.9 11 92.5 10 11 -92 
Clarithromycin 75.2 12 16 73.7 8.8 12 77.9 12 15 -95 
Erythromycin 99.3 16 16 69.0 7.8 11 84.9 9.4 11 -97 
Tiamullin 76.1 7.6 10.0 71.9 6.5 9.0 100 8.0 8.0 -73 
Tilmicosin 70.1 8.5 12.1 72.4 4.4 6.1 90.2 12 13 -87 
Tylosin 76.6 12.4 16.2 70.5 8.3 12 85.0 8.5 10 -91 
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          Sulfonamides  
Dapsone* 70.8 12 17 58.9 9.2 16 55.0 4.6 8.5 27 
Sulfachloropyridazine 78.7 14 18 81.2 9.6 12 80.4 10 13 -40 
Sulfadiazine 79.3 9.6 12 94.7 12 13 94.7 12 13 -28 
Sulfadimethoxine 75.5 11 15 84.8 12 14 101 5.7 5.6 6 
Sulfadimidine 86.3 7.6 8.8 96.8 6.8 7.0 86.7 9.4 11 -89 
Sulfaguanidine 88.7 11 13 94.7 7.7 8.1 94.6 16 17 -58 
Sulfamerazine 96.3 12 13 103.8 12 12 85.0 10 12 -85 
Sulfamethizole 82.6 12 15 76.4 9.2 12 75.0 9.9 13 -78 
Sulfamethoxazole 83.0 13 16 68.6 9.7 14 78.6 7.0 8.8 5 
Sulfamonomethoxine 78.3 13 16 94.2 7.9 8.4 88.2 7.5 8.5 -77 
Sulfapyridine 102.7 8.5 8.2 102.6 11 11 78.7 11 14 -87 
Sulfaquinoxaline 80.8 15 19 99.9 15 15 100 11 11 -15 
Sulfathiazole 76.2 11 14 83.8 13 16 91.0 8.4 9.2 -95 
Sulfisoxazole 87.1 13.2 15.1 90.7 14 15 104 12 11 13 
Diaminopyrimidines 
Baquiloprim 71.3 6.9 9.6 74.5 9.1 12 81.6 7.7 9.4 -95 
Trimethoprim 85.8 14.9 17.3 77.9 13 17 80.2 10 12 -76 
       Other antibiotics 
Rifaximin 68.0 8.1 12 65.7 7.5 11 86.4 15 17 -95 
       Anthelmintics 
Albendazole 98.9 10.0 10 82.5 13 16 90.0 11 12 11 
Albendazole 
sulfo(oxide) 
84.8 11.4 13 109 14 13 75.7 7.9 10 -94 
Albendazole sulfone 78.5 11.0 14 95.8 12 12 91.9 10 11 -88 
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Febantel 86.7 9.2 10.6 87.9 12 14 91.4 13 15 48 
Fenbendazole 74.2 7.0 9.4 74.2 8.1 11 85.5 8.4 9.8 22 
Levamisole 92.2 11 12 87.4 12 14 86.2 12 14 -50 
Mebendazole 69.9 8.8 13 78.0 9.5 12 83.4 7.6 9.1 -70 
Morantel 89.0 12 13 86.0 14 16 91.1 6.6 7.3 -69 
Oxfendazole 95.7 15 16 90.7 12 14 85.0 12 14 -83 
Thiabendazole 101.8 8.4 8.3 93.0 7.9 8.5 89.1 6.8 7.6 42 
Triclabendazole 70.3 8.1 12 80.8 11 13 89.2 7.9 8.9 -22 
          Coccidiostats 
Amprolium 71.9 10 14 85.0 12 14 74.5 8.0 11 -79 
Aprinocid 77.3 8.8 11 82.4 11 13 106 14 13 -89 
Clopidol 73.9 10 14 76.7 9.5 12 88.7 12 14 -97 
Decoquinate 70.6 6.4 9.0 83.8 13 16 104 14 14 15 
Diaveridine 72.1 6.1 8.4 99.5 9.4 9.5 82.0 5.1 6.2 -55 
Ethopabate 88.2 12 14 89.7 9.1 10 95.4 5.7 5.9 -92 
Maduramycin (NH4
+) 79.1 15 19 77.0 8.8 11 77.3 12 15 -38 
Monensin (Na+) 54.7 7.9 14 56.7 10 18 69.0 9.7 14 100 
Narasin (NH4
+) 61.9 9.6 15 88.0 14 16 71.7 12 16 -55 
Robenidine 66.3 8.4 13 84.9 16 18 70.7 7.3 10 -26 
Salinomycin (NH4
+) 70.1 9.8 14 75.4 8.7 12 76.0 7.5 9.9 -39 
Semduramycin (Na+) 73.1 5.7 7.8 83.1 10 12 88.0 11 12 59 
              NSAIDs 
5-Hydroxyflunixin  63.0 5.4 8.5 74.7 9.8 13 102 11 10 117 
Flunixin  86.9 9.7 11 81.3 9.1 11 100 11 11 15 
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Meloxicam 67.9 8.7 13 69.4 9.8 14 97.8 9.4 9.6 1 
Phenylbutazone* 73.5 9.7 13 58.9 7.2 12 83.7 6.4 7.7 -97 
Thyreostats 
6-phenyl-2-thiouracil  89.6 8.0 8.9 80.9 4.8 5.9 102 8.8 8.6 -77 
Tranquilizers 
Chlorpromazine* 66.4 10 15 97.4 13 13 88.2 6.2 7.1 -65 
Pharmaceuticals 
Ambroxol 60.5 11 18 52.4 9.4 18 82.9 9.4 11 -93 
Atenolol 71.2 9.0 13 90.0 11 12 90.7 9.3 10 -96 
Atorvastatin 57.2 8.7 15 68.7 12 17 69.0 6.1 8.8 -36 
Caffeine 79.9 12 16 90.1 11 12 80.8 12 14 -97 
Carbamazepin 79.3 11 14 87.6 14 16 91.8 7.1 7.8 -93 
Metropolol 86.1 14 16 94.8 6.9 7.3 94.0 10 11 -21 
Propranolol 75.5 8.4 11 75.6 10 14 85.8 5.4 6.3 -36 
Simvastatin 84.2 15 18 74.4 10 14 79.4 10 13 -42 
Tramadol 79.8 12.7 16.0 88.2 11 13 93.1 5.4 5.8 -45 
Triamterene 67.1 12.0 17.9 86.4 9.0 10 95.4 14 15 53 
Valsartan 62.8 11.3 18.0 57.7 9.8 17 66.2 7.6 11 -57 
Others 
Bromhexine* 37.4 6.6 18 36.0 6.2 17 40.7 4.7 12 -61 
* prohibited compounds for which the concentrations examined correspond in 1×VL, 1.5×VL and 2×VL 
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6.3.3.8 Matrix Effect 
When complex samples, such as muscle are analyzed with LC–ESI-MS/MS 
significant matrix effects might influence the analysis. the ionization efficiency of 
the analytes is affect by matrix effects, leading to suppression or enhancement of 
the signal depending on the analyte/matrix combination. The use of isotope 
labeled internal standards (ILIS) and the standard addition quantification method 
can be used to compensate for matrix effect interferences. 
To evaluate matrix effect, the slopes obtained from the standard solution curves 
in solvent were compared with those obtained in matrix extracts. Matrix effects 
(ME%) were calculated by subtracting 1 from the ratio between the slope of the 
standard solution curve constructed in matrix extracts (A) and in pure solvent (B), 
and then multiplying by 100: 
ME (%) = ((A/B) – 1) × 100          (1)  
The signal is enhanced if the value is positive, whereas it is suppressed if the 
value is negative. Matrix effect values are presented in Table 6.4. Strong signal 
suppression was revealed for the vast majority of the analytes (63 out of 76 
compounds).The quantification of the samples was performed using a standard 
addition approach. 
 
6.4 Application to Real Samples 
To evaluate the applicability of the proposed method in routine analysis, 10 
bovine muscle tissue samples, obtained by local supermarkets, were tested. No 
positive results were found in any of these samples. 
 
6.5 Conclusions 
A rapid, sensitive and efficient multiresidue analytical method for the 
simultaneous determination of 6 AGs and 70 other veterinary drugs and 
pharmaceuticals in bovine muscle tissue by HILIC–MS/MS has been developed. 
The simultaneous determination of AGs with other veterinary drugs has only 
been reported once previously (69) and in much less extend (3 AGs and 21 other 
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compounds). Aminoglycosides present very different physicochemical properties 
compared to other drugs making their simultaneous chromatographic detection 
and matrix extraction quite challenging. The method includes ACN extraction 
followed by an acidic aqueous buffer extraction,  cleanup with HLB cartridges and 
HILIC-MS/MS determination in bare silica stationary phase (BEH HILIC).  
The strict EU legislation that sets MRLs and MLs for some veterinary drugs at the 
low ppb level ( <10 μg kg-1)  poses another significant obstacle in multi-
class/multiresidue analysis. The developed method was thoroughly optimized 
and validated fulfilling all European Commission Decision 2002/657 
requirements, revealing good validation parameters and thus indicating its great 
value in the veterinary drug and pharmaceutical analysis field. 
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ACN Acetonitrile 
AGs Aminoglycosides 
APCI Atmospheric Pressure Chemical Ionization 
ASE Accelerated solvent extraction 
 d-SPE Dispersive SPE 
ESI Electrospray Ionization 
GC Gas chromatography 
H2O Water 
HCl Hydrochloric acid 
HCOOH Formic acid 
HILIC  Hydrophilic Interaction Liquid Chromatography 
HPLC High Performance Liquid Chromatography 
HRMS High Resolution Mass Spectrometry 
IS Internal standard 
IT Ion Trap 
LC Liquid chromatography 
LC-MS Liquid Chromatography-Mass Spectrometry 
LC-MS/MS Liquid Chromatography-Tandem Mass Spectrometry 
LIT Linear Ion Trap 
LE Liquid Extraction 
LLE Liquid-Liquid Extraction 
LOD Limit of detection 
LOQ Limit of Quantification 
m/z Mass to charge ratio 
MeOH Methanol 
MIPs Molecularly imprinted polymers  
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
MSPD Matrix Solid Phase Dispersion  
PLE Pressurised liquid extraction 
QC Quality Control 
QqQ  Triple Quadrupole 
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RAMs Restricted access materials 
RP-LC Reversed phase-liquid chromatography 
RSD Relative standard deviation 
RT Retention time 
SAs Sulfonamides 
SE Solvent extraction 
SNR Signal to noise ratio 
SPE Solid Phase Extraction 
SRM Single reaction monitoring 
 TFC  Turbulent flow chromatography 
TOF Time-of-Flight 
UHPLC Ultra High Performance Liquid Chromatography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
224 
 
 
REFERENCES 
 
1 A.A.M. Stolker and U.A.Th. Brinkman, Analytical strategies for residue analysis of 
veterinary drugs and growth-promoting agents in food producing animals - a 
review, Journal of Chromatography A, vol. 1067, 2005, pp. 15-53. 
2 M.D. Marazuela and S. Bogialli, A review of novel strategies of sample 
preparation for the determination of antibacterial residues in foodstuffs using 
liquid chromatography–based analytical methods,  Analytica Chimica Acta, vol. 
645, 2009, pp. 5–17. 
3 T.A. McGlinchey, P.A. Rafter, F. Regan and G.P. McMahon, A review of 
analytical methods for the determination of aminoglycoside and macrolide 
residues in food matrices, Analytica Chimica Acta, vol. 624, 2008, pp. 1-15.  
4 A. Kaufmann, P. Butcher, K. Maden, S. Walker and M. Widmer, Quantification of 
anthelmintic drug residues in milk and muscle tissues by liquid chromatography 
coupled to Orbitrap and liquid chromatography coupled to tandem mass 
spectrometry, Talanta, vol. 85, 2011, pp. 991-1000. 
5 M. Moloney, L. Clarke, J. O’Mahony, A. Gadaj, R. O’Kennedy and M. Danaher, 
Determination of 20 coccidiostats in egg and avian muscle tissue using ultra high 
performance liquid chromatography–tandem mass spectrometry, Journal of 
Chromatography A, vol. 1253, 2012, pp. 94-104. 
6 A.E. Van den Bogaard and E.E. Stobberingh, Antibiotic usage in animals: impact 
on bacterial resistance and public health, Drugs, vol. 58, 1999, pp.  589-607. 
7 C.M. Lathers, Clinical pharmacology of antimicrobial use in humans and animals, 
Journal of Clinical Pharmacology, vol. 42, 2002, pp. 587-600. 
8 P.A. Beloeil, A. Battisti, J.T. Edo, K. Grave, O. Heuer, G. Moulin et al., Tackling 
Antibiotic Resistance from a Food Safety Perspective in Europe, World Health 
Organization Regional Office for Europe, Copenhagen 2011, pp. 1-65. 
9 N.A. Botsoglou and D.J. Fletouris, Drug Residues in Foods, Pharmacology, Food 
Safety and Analysis, Marcel Dekker, Inc., New York, 2001. 
225 
 
10 R. Gehring, S. R. Haskell, M. A. Payne, A. L. Craigmill, A. I. Webb and J. E. 
Riviere, Aminoglycoside residues in food of animal origin, Journal of the 
American Veterinary Medical Association, vol. 227, no. 1, 2005, pp. 63-66. 
11 S. B. Turnipseed and W. C. Andersen, Chapter 10: Veterinary Drug Residues, 
Comprehensive Analytical Chemistry, vol. 51, 2008, pp. 307-338. 
12 J.V. Samsonova, A. Cannavan and C.T. Elliott, A Critical Review of Screening 
Methods for the Detection of Chloramphenicol, Thiamphenicol, and Florfenicol 
Residues in Foodstuffs, Critical Reviews in Analytical Chemistry, vol. 42, 2012, 
pp. 50-78. 
13 M.E. Dasenaki, A.A. Bletsou and N.S. Thomaidis, Antibacterials (chapter 38) , 
Handbook of Food Analysis, Third Edition by Leo M.L. Nollet and Fidel Toldra, 
Eds., CRC Press, Boca Raton, FL, 2014, in press. 
14 K. Mastovska, “Multiresidue analysis of antibiotics in food of animal origin using 
liquid chromatography-mass spectrometry” (chapter 12), Mass Spectrometry in 
Food Safety: Methods and Protocols, by Jerry Zweigenbaum, Ed., Springer 
Verlag, New York, 2011. 
15 F.J. Lara, M. del Olmo-Iruela, C. Cruces-Blanco, C. Quesada-Molina and A.M. 
García-Campaña, Advances in the determination of b-lactam antibiotics by liquid 
chromatography, Trends in Analytical Chemistry, vol. 38, 2012, pp. 52–66. 
16 E.N. Evaggelopoulou and V.F. Samanidou, Development and validation of an 
HPLC method for the determination of six penicillin and three amphenicol 
antibiotics in gilthead seabream (Sparus Aurata) tissue according to the 
European Union Decision 2002/657/EC,  Food Chemistry,  vol. 136, 2013, pp. 
1322-1329. 
17 T. Tenson, M. Lovmar and M. Ehrenberg, The Mechanism of Action of 
Macrolides, Lincosamides and Streptogramin B Reveals the Nascent Peptide 
Exit Path in the Ribosome,  Journal of Molecular Biology, vol. 330, 2003, pp. 
1005-1014. 
18 W.H. Yu, T.S. Chin and H.T. Lai, Detection of nitrofurans and their metabolites in 
pond water and sediments by liquid chromatography (LC)-photodiode array 
detection and LC-ion spray tandem mass spectrometry, International 
Biodeterioration Biodegradation, vol. 85, 2013, pp. 517-526. 
226 
 
19 K.E. Brighty and T.D. Gootz, Chemistry and Mechanism of Action of the 
Quinolone Antibacterials (chapter 2), The Quinolones, V.T. Andriole, ed., 
Elsevier, Connecticut, U.S.A., 2000. 
20 C. Nebot, P. Regal, J.M. Miranda, C. Fente and A. Cepeda, Rapid method for 
quantification of nine sulfonamides in bovine milk using HPLC/MS/MS and 
without using SPE,  Food Chemistry, vol. 141, 2013, pp. 2294-2299. 
21 A. Önal, Overview on liquid chromatographic analysis of tetracycline residues in 
food matrices, Food Chemistry, vol. 127, 2011, pp. 197-203. 
22 R.G. Nelson and A. Rosowsky, Dicyclic and Tricyclic Diaminopyrimidine 
Derivatives as Potent Inhibitors of Cryptosporidium parvum Dihydrofolate 
Reductase: Structure–Activity and Structure–Selectivity Correlations, 
Antimicrobial agents and chemotherapy, vol. 45, 2001, pp. 3293–3303. 
23 G. Kesiūnaite, E. Naujalis and A. Padarauskas, Matrix solid-phase dispersion 
extraction of carbadox and olaquindox in feed followed by hydrophilic interaction 
ultra-high-pressure liquid chromatographic analysis, Journal of Chromatography 
A, vol. 1209, 2008, pp. 83-87. 
24 R. Novak, Are pleuromutilin antibiotics finally fit for human use?, Annals of the 
New York Academy of Sciences, vol. 1241, 2011, pp. 71–81.  
25 R. Romero-González, A. Garrido Frenich and J.L. Martínez Vidal, Veterinary 
Drugs Residues: Anthelmintics, Encyclopedia of Food Safety, Vol. 3: Foods, 
Materials, Technologies and Risks, Y. Motarjemi, ed., Elsevier Inc, 2014. 
26  P. Köhler, The biochemical basis of anthelmintic action and resistance, 
International Journal for Parasitology, vol. 31, no. 4, 2001, pp. 336-345. 
27 R.J Martin, Modes of action of anthelmintic drugs, Veterinary Journal, vol. 154, 
no. 1,1997, pp. 11-34.  
28 X.-D. Du, Y.-L. Wu, H.-J. Yang and T. Yang, Simultaneous  determination  of  10  
β2-agonists  in  swine  urine  using  liquid chromatography–tandem  mass  
spectrometry  and  multi-walled  carbon nanotubes  as  a  reversed  dispersive  
solid  phase  extraction  sorbent, Journal of Chromatography A, vol. 1260, 2012, 
pp. 25-32. 
29 E. Shishani, S.C. Chai, S. Jamokha, G. Aznar and M.K. Hoffman, Determination 
of ractopamine in animal tissues by liquid chromatography-fluorescence and 
227 
 
liquid chromatography/tandem mass spectrometry, Analytica Chimica Acta, 
vol.483, 2003, pp. 137-145. 
30 B. Shao, X. Jia, J. Zhang, J. Meng, Y. Wu, H. Duan and X. Tu, Multi-residual 
analysis of 16 β-agonists in pig liver, kidney and muscle by ultra performance 
liquid chromatography tandem mass spectrometry, Food Chemistry, vol. 114, 
2009, pp. 1115 – 1121. 
31 A. Anadón and M.R. Martínez-Larrañaga, Veterinary Drugs Residues: 
Coccidiostats, Encyclopedia of Food Safety, Vol. 3: Foods, Materials, 
Technologies and Risks, Y. Motarjemi, ed., Elsevier Inc, 2014. 
32 G. Kaklamanos, G. Theodoridis and T. Dabalis, Determination of anabolic 
steroids in bovine urine by liquid chromatography–tandem mass spectrometry, 
Journal of Chromatography B, vol. 877, 2009, pp. 2330–2336. 
33 R. Fraser, D.B. Gower, J.W. Honour, M.C. Ingram, A.T. Kicman, H.L.J. Makin 
and P.M. Stewart, Analysis of Corticosteroids, H.L.J. Makin and D.B. Gower, 
Eds. , Second ed., Springer, London, 2010 
34 R. Draisci, C. Marchiafava, L. Palleschi, P. Cammarata and S. Cavalli, 
Accelerated solvent extraction and liquid chromatography–tandem mass 
spectrometry quantitation of corticosteroid residues in bovine liver, Journal of 
Chromatography B, vol. 753, 2001, pp. 217-223. 
35 D. Courtheyn, B. Le Bizec, G. Brambilla, H.F. De Brabander, E. Cobbaert, M. 
Van de Wiele, J. Vercammen and K. De Wasch, Recent developments in the use 
and abuse of growth promoters, Analytica Chimica Acta, vol. 473, 2002, pp. 71–
82. 
36 J. Vanden Bussche, L. Vanhaecke, Y. Deceuninck, K. Verheyden, K. Wille, K. 
Bekaert, B. Le Bizec and H.F. De Brabander, Development and validation of an 
ultra-high performance liquid chromatography tandem mass spectrometry 
method for quantifying thyreostats in urine without derivatisation, Journal of 
Chromatography A, vol. 1217, 2010, pp. 4285-4293. 
37 D. C. Rankin, Tranquillizers (Chapter 14), Veterinary Anesthesia and Pain 
Management Secrets, S. A. Greene, ed., Hanley & Belfus, Inc, Philadelphia, 
USA, 2002. 
38 H.D. Belitz, W. Grosch, R. Schieberle, Food Chemistry, Springer–Verlag, Berlin, 
Heidelberg, 2009. 
228 
 
39 A.E. Van den Bogaard and E.E. Stobberingh, Antibiotic usage in animals: impact 
on bacterial resistance and public health, Drugs, vol.58, 1999, pp. 589-607. 
40 R. Prichard, Anthelmintic resistance, Veterinary Parasitology, vol. 54, 1994,  pp. 
259-268. 
41 J.F. Martínez-Navarro, Food poisoning related to consumption of illicit β-agonist 
in liver, The Lancet, vol. 336, 1990, pp. 1311. 
42 FAO/WHO, Joint FAO/WHO Technical Workshop on Residues of Veterinary 
Drugs without ADI/MRL, Bangkok, Thailand, 2004. 
43 S.-H. Jeong, D. Kang, M.-W. Lim, C. S. Kang and H. J. Sung, Risk Assessment 
of Growth Hormones and Antimicrobial Residues in Meat, Toxicology Research, 
vol. 26, no. 4, 2010, pp. 301-313. 
44 M.C. Lozano and M. Trujillo, Chemical Residues in Animal Food Products: An 
Issue of Public Health, Public Health – Methodology, Environmental and Systems 
Issues, (chapter 8), Maddock, J., ed, Intech, Croatia, 2012 
45 A. Passantino and C. Russo, Maximum Residue Levels of Veterinary Medicines 
in Relation to Food Safety: European Community Legislation and Ethical 
Aspects, Journal of Consumer Protection and Food Safety, vol.3, 2008, pp. 351–
358. 
46 Council Regulation (EEC) No. 2377/90, laying down a Community procedure for 
the establishment of maximum residue limits of veterinary medicinal products in 
foodstuffs of animal origin, Official Journal of the European Union, L 224, 1990, 
pp. 1-8. 
47 Council Regulation (EEC) No. 470/2009, laying down Community procedures for 
the establishment of residue limits of pharmacologically active substances in 
foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and 
amending Directive 2001/82/EC of the European Parliament and of the Council 
and Regulation (EC) No 726/2004 of the European Parliament and of the 
Council, Official Journal of the European Union, L152, 2009, pp. 11-22. 
48 Council Directive 96/22/EC, concerning the prohibition on the use in stockfarming 
of certain substances having a hormonal or thyrostatic action and of beta-
agonists, and repealing Directives 81/602/EEC, 88/146/EEC and 88/299/EEC, 
Official Journal of the European Union, L125, 1996, pp. 3-9. 
229 
 
49 Council Directive 96/23/EC, on measures to monitor certain substances and 
residues thereof in live animals and animal products and repealing Directives 
85/358/EEC and 86/469/EEC and Decisions 89/187/EEC and 91/664/EEC 
Official Journal of the European Union, L125, 1996, pp. 10-32. 
50 Regulation (EC) No 1831/2003, of the European Parliament and of the Council, 
on additives for use in animal nutrition, Official Journal of the European Union, 
L268, 2003, pp. 29-43. 
51 Commission Regulation (EC) No 124/2009, setting maximum levels for the 
presence of coccidiostats or histomonostats in food resulting from the 
unavoidable carry-over of these substances in non-target feed, Official Journal of 
the European Union, L40, pp. 7-11.  
52 Commission Regulation (EU) 37/2010, on pharmacologically active substances 
and their classification regarding maximum residue limits in foodstuffs of animal 
origin, Official Journal of the European Union, L15, 2010, pp. 1-72.  
53 Commission Implementing Regulation (EU) No 86/2012, amending the Annex to 
Regulation (EU) No 37/2010 on pharmacologically active substances and their 
classification regarding maximum residue limits in foodstuffs of animal origin, as 
regards the substance lasalocid, Official Journal of the European Union, L30, pp. 
6-7 
54 Commission Decision 2002/657/EC, implementing Council Directive 96/23/EC 
concerning the performance of analytical methods and the interpretation of 
results, Official Journal of the European Union, L221, 2002, pp. 8–36. 
55 Commission Decision 2003/181/EC, amending Decision 2002/657/EC as regards 
the setting of minimum required performance limits (MRPLs) for certain residues 
in food of animal origin, Official Journal of the European Union, L71, pp. 17-18. 
56 H. Li, P.J. Kijak, S.B. Turnipseed and W. Cui, Analysis of veterinary drug 
residues in shrimp: A multi-class method by liquid chromatography–quadrupole 
ion trap mass spectrometry, Journal of Chromatography B, vol. 836, 2006, pp. 
22-38. 
57 R. Yamada, M. Kozono, T. Ohmori, F. Morimatsu and M. Kitayama, 
Simultaneous determination of residual veterinary drugs in bovine, porcine and 
chicken muscle using liquid chromatography coupled with electrospray ionization 
230 
 
tandem mass spectrometry, Bioscience, Biotechnology, and Biochemistry, vol. 
70, 2006, pp. 54-65. 
58 D.N. Heller, C.B. Nochetto, N.G. Rummel and M.H. Thomas, Development of 
Multiclass Methods for Drug Residues in Eggs: Hydrophilic Solid-Phase 
Extraction Cleanup and Liquid Chromatography/Tandem Mass Spectrometry 
Analysis of Tetracycline, Fluoroquinolone, Sulfonamide, and β-Lactam Residues, 
Journal of Agricultural and Food Chemistry, vol. 54, 2006, pp. 5267-5278. 
59 B. Shao, X. Jia, Y. Wu, J. Hu, X. Tu, and J. Zhang, Multi-class confirmatory 
method for analyzing trace levels of tetracyline and quinolone antibiotics in pig 
tissues by ultra-performance liquid chromatography coupled with tandem mass 
spectrometry, Rapid Communications in Mass Spectrometry, vol. 21, 2007, pp. 
3487-3496. 
60 V. Carretero, C. Blasco and Y. Picó, Multi-class determination of antimicrobials in 
meat by pressurized liquid extraction and liquid chromatography–tandem mass 
spectrometry, Journal of Chromatography A, vol. 1209, 2008, pp. 162–173. 
61 J. Chico, A. Rϊbies, F. Centrich, R. Companyó, M.D. Prat and M. Granados, High-
throughput multiclass method for antibiotic residue analysis by liquid 
chromatography-tandem mass spectrometry, Journal of Chromatography A, vol. 
1213, 2008, pp. 189-199.  
62 Y. Hammel, R. Mohamed, E. Gremaud, M. LeBreton and P.A Guy, Multi-
screening approach to monitor and quantify 42 antibiotic residues in honey by 
liquid chromatography–tandem mass spectrometry, Journal of Chromatography 
A, vol. 1177, 2008, pp. 58–76. 
63 M.I. Lopez, J.S. Pettis, I.B. Smith and P. Chu, Multiclass Determination and 
Confirmation of Antibiotic Residues in Honey Using LC-MS/MS, Journal of 
Agricultural and Food Chemistry, vol. 56, 2008, pp. 1553-1559. 
64 M. Gaugain-Juhel, B. Delépine, S. Gautier, M.P. Fourmond, V. Gaudin, D. 
Hurtaud-Pessel, E. Verdon and P. Sanders, Validation of a liquid 
chromatography-tandem mass spectrometry screening method to monitor 58 
antibiotics in milk: a qualitative approach, Food Additives & Contaminants, vol. 
26, 2009, pp. 1459-1471. 
231 
 
65 K. Granelli, C. Elgerud, Ε. Lundstrӧm, A. Ohlsson and P. Sjӧberg, Rapid multi-
residue analysis of antibiotics in muscle by liquid chromatography–tandem mass 
spectrometry, Analytica Chimica Acta, vol. 637, 2009, pp. 87-91. 
66 D. A. Bohm, C. S. Stachel and P. Gowik, Multi-method for the determination of 
antibiotics of different substance groups in milk and validation in accordance with 
Commission Decision 2002/657/EC, Journal of Chromatography A, vol. 1216, 
2009, pp. 8217- 8223. 
67 J.L. Martínez Vidal, M. Del Mar Aguilera-Luiz, R. Romero-González and A. 
Garrido Frenich, Multiclass Analysis of Antibiotic Residues in Honey by 
Ultraperformance Liquid Chromatography-Tandem Mass Spectrometry, Journal 
of Agricultural and Food Chemistry, vol. 57, 2009, pp. 1760-1767. 
68 A. Garrido Frenich, M. Del Mar Aguilera-Luiz, J.L. Martínez Vidal and R. Romero-
González, Comparison of several extraction techniques for multiclass analysis of 
veterinary drugs in eggs using ultra-high pressure liquid chromatography-tandem 
mass spectrometry, Analytica Chimica Acta, vol. 661, 2010, pp. 150-160. 
69 C. Chiaochan, U. Koesukwiwat, S. Yudthavorasit and N. Leepipatpiboon, 
Efficient hydrophilic interaction liquid chromatography-tandem mass spectrometry 
for the multiclass analysis of veterinary drugs in chicken muscle, Analytica 
Chimica Acta, vol. 682, 2010, pp. 117-129. 
70 P.A. Martos, F. Jayasundara,J. Dolbeer, W. Jin, L. Spilsbury, M. Mitchell, C. 
Varilla and B. Shurmer, Multiclass, Multiresidue Drug Analysis, Including 
Aminoglycosides, in Animal Tissue Using Liquid Chromatography Coupled to 
Tandem Mass Spectrometry, Journal of Agricultural and Food Chemistry, vol. 58, 
2010, pp. 5932-5944. 
71 C. Blasco, and A. Masia, Comparison of the Effectiveness of Recent Extraction 
Procedures for Antibiotic Residues in Bovine Muscle Tissues, Journal of AOAC 
International, vol. 94, no. 3, 2011, pp. 991–1003. 
72 R.P. Lopes, D.V. Augusti, A.G.M. Oliveira, F.A.S. Oliveira, E.A. Vargas and R. 
Augusti, Development and validation of a methodology to qualitatively screening 
veterinary drugs in porcine muscle via an innovative extraction/clean-up 
procedure and LC-MS/MS analysis, Food Additives & Contaminants, vol. 28, 
2011, pp. 1667–1676. 
232 
 
73 V. Jiménez, A, Rubies, F. Centrich, R. Companyó and J. Guiteras, Development 
and validation of a multiclass method for the analysis of antibiotic residues in 
eggs by liquid chromatography - tandem mass spectrometry, Journal of 
Chromatography A, vol. 1218, 2011, pp. 1443-1451. 
74 D.A. Bohm, C.S. Stachel and P. Gowik, Validated Determination of Eight 
Antibiotic Substance Groups in Cattle and Pig Muscle by HPLC/MS/MS, Journal 
of AOAC International, vol.  94, no. 2, 2011, pp. 407-419. 
75 S.B. Clark, J.M. Storey and S.B. Turnipseed, Optimization and Validation of a 
Multiclass Screening and Confirmation Method for Drug Residues in Milk Using 
High-Performance Liquid Chromatography/Tandem Mass Spectrometry, Journal 
of AOAC International, vol.  94, no. 2, 2011, pp.383-393. 
76 S.J. Schneider, S.J. Lehotay and A.R. Lightfield, Evaluation of a multi-class, 
multi-residue liquid chromatography- tandem mass spectrometry method for 
analysis of 120 veterinary drugs in bovine kidney, Drug Testing and Analysis, vol. 
4, no. 1, 2012, pp. 91-102. 
77 A.L. Capriotti, C. Cavaliere, S. Piovesana, R. Samperi and A. Lagana, Multiclass 
screening method based on solvent extraction and liquid chromatography-
tandem mass spectrometry for the determination of antimicrobials and 
mycotoxins in egg, Journal of Chromatography A, vol. 1268, 2012, pp. 84-90. 
78 M.M. Aguilera- Luiz, J.L. Martínez Vidal, R. Romero-González and A. Garrido 
Frenich, Multiclass method for fast determination of veterinary drug residues in 
baby food by ultra - high performance liquid chromatography–tandem mass 
spectrometry, Food Chemistry, vol. 132, 2012, pp. 2171–2180. 
79 R. P. Lopes, R. C. Reyes, R. Romero-González, A. Garrido Frenich and J. L. 
Martínez Vidal, Development and validation of a multiclass method for the 
determination of veterinary drug residues in chicken by ultra high performance 
liquid chromatography–tandem mass spectrometry, Talanta, vol. 89, 2012, pp. 
201–208. 
80 Y.Y. Tang, H.F. Lu, H.Y. Lin, Y.C. Shih and D.F. Hwang, Multiclass analysis of 23 
veterinary drugs in milk by ultra performance liquid chromatography–electrospray 
tandem mass spectrometry, Journal of Chromatography B, vol. 881–882, 2012, 
pp. 12–19. 
233 
 
81 R.P. Lopes, R. C. Reyes, R. Romero-González, A. Garrido Frenich and J. L. 
Martínez Vidal, Multiresidue determination of veterinary drugs in aquaculture fish 
samples by ultra high performance liquid chromatography coupled to tandem 
mass spectrometry, Journal of Chromatography B, vol. 895-896, 2012, 39-47. 
82 D. A. Bohm, C. S. Stachel and P. Gowik, Validation of a multi-residue method for 
the determination of several antibiotic groups in honey by LC-MS/MS,  Analytical 
and Bioanalytical Chemistry, vol. 403, 2012, pp. 2943–2953. 
83 J. Zhan, X. Yu, Y. Zhong, Z. Zhang, X. Cui, J. Peng, R. Feng, X. Liu and Y. Zhu, 
Generic  and  rapid  determination  of  veterinary  drug  residues  and  other 
contaminants  in  raw  milk  by  ultra  performance  liquid  chromatography–
tandem mass  spectrometry, Journal of Chromatography B, vol. 906, 2012, pp. 
48-57. 
84 C. Nebot, A. Iglesias, P. Regal, J. Miranda, A. Cepeda and C. Fente, 
Development of a multi-class method for the identification and quantification of 
residues of antibiotics, coccidiostats and corticosteroids in milk by liquid 
chromatography-tandem mass spectrometry, International Dairy Journal, vol. 22, 
2012, pp. 78 – 85 
85 S. Biselli, U. Schwalb, A. Meyer and L. Hartig, A multi-class, multi-analyte 
method for routine analysis of 84 veterinary drugs in chicken muscle using simple 
extraction and LC-MS/MS, Food Additives & Contaminants, vol. 30, 2013, pp. 
921 - 939. 
86 J. Zhan, Y-Y Zhong, X-J. Yu, J-F. Peng, S. Chen, J-Y. Yin, J-J. Zhang and Y. 
Zhu, Multi-class method for determination of veterinary drug residues and other 
contaminants in infant formula by ultra performance liquid chromatography–
tandem mass spectrometry, Food Chemistry, vol. 138, 2013, pp. 827 – 834. 
87 K. Bousova, H. Senyuva and K. Mittendorf, Quantitative multi-residue method for 
determination antibiotics in chicken meat using turbulent flow chromatography 
coupled to liquid chromatography–tandem mass spectrometry, Journal of 
Chromatography A, vol. 1274, 2013, pp. 19 – 27.  
88 A. Freitas, J. Barbosa and F. Ramos, Development and validation of a multi-
residue and multiclass ultra-high-pressure liquid chromatography-tandem mass 
spectrometry screening of antibiotics in milk, International Dairy Journal, vol. 33, 
2013, pp. 38 – 43. 
234 
 
89 A.A.M. Stolker, P. Rutgers, E. Oosterink, J.J.P. Lasaroms, R.J.B. Peters, J.A. 
van Rhijn, and M.W.F. Nielen, Comprehensive screening and quantification of 
veterinary drugs in milk using UPLC - TOF – MS, Analytical and Bioanalytical 
Chemistry, vol. 391, 2008, pp. 2309-2322. 
90 A. Kaufmann, P. Butcher, K. Maden and M. Widmer, Quantitative multiresidue 
method for about 100 veterinary drugs in different meat matrices by sub 2 μm 
particulate high-performance liquid chromatography coupled to time of flight 
mass spectrometry, Journal of Chromatography A, vol. 1194, 2008, pp.66-79. 
91 R.J.B. Peters, Y.J.C. Bolck, P. Rutgers, A.A.M. Stolker and M.W.F. Nielen, Multi-
residue screening of veterinary drugs in egg, fish and meat using high-resolution 
liquid chromatography accurate mass time-of-flight mass spectrometry, Journal 
of Chromatography A, vol. 1216, 2009, pp. 8206- 8216. 
92 D. Ortelli, E. Cognard, P. Jan and P. Edder, Comprehensive fast multiresidue 
screening of 150 veterinary drugs in milk by ultra-performance liquid 
chromatography coupled to time of flight mass spectrometry, Journal of 
Chromatography B, vol. 877, 2009, pp. 2363-2374. 
93 S.B. Turnipseed, J.M. Storey, S.B. Clark and K.E. Miller, Analysis of Veterinary 
Drugs and Metabolites in Milk Using Quadrupole Time-of-Flight  Liquid 
Chromatography-Mass Spectrometry, Journal of Agricultural and Food 
Chemistry, vol. 59, 2011, pp. 7569–7581. 
94 X.J. Deng, H.Q. Yang, J.Z. Li, Y. Song, D.H. Guo, Y. Luo, X. N. Du and T. Bo, 
Multiclass residues screening of 105 veterinary drugs in meat, milk, and egg 
using ultra high performance liquid chromatography tandem quadrupole Time-Of-
Flight Mass Spectrometry, Journal of Liquid Chromatography & Related 
Technologies, vol. 34, 2011, pp. 2286–2303. 
95 M. Villar–Pulido, B. Gilbert–López, J.F. García–Reyes, N. Ramos–Martos and A. 
Molina–Díaz, Multiclass detection and quantitation of antibiotics and veterinary 
drugs in shrimps by fast liquid chromatography time–of–flight mass spectrometry, 
Talanta, vol. 85, 2011, pp. 1419–1427. 
96 D. Hurtaud-Pessel, T. Jagadeshwar-Reddy and E. Verdon, Development of a 
new screening method for the detection of antibiotic residues in muscle tissues 
using liquid chromatography and high resolution mass spectrometry with a LC-
235 
 
LTQ-Orbitrap instrument, Food Additives & Contaminants, vol. 28, 2011, pp. 
1340-1351. 
97 M.S. Filigenzi, N. Ehrke, L.S. Aston and R.H. Poppenga, Evaluation of a rapid 
screening method for chemical contaminants of concern in four food-related 
matrices using QuEChERS extraction, UHPLC and high resolution mass 
spectrometry, Food Additives & Contaminants, vol. 28, 2011, pp. 1324-1339. 
98 A. Kaufmann, P. Butcher, K. Maden, S. Walker and M. Widmer, Development of 
an improved high resolution mass spectrometry based multi-residue method for 
veterinary drugs in various food matrices, Analytica Chimica Acta, vol. 700, 2011, 
pp. 86-94. 
99 S.B. Turnipseed, S.B. Clark, J.M. Storey and J.R. Carr, Analysis of Veterinary 
Drug Residues in Frog Legs and Other Aquacultured Species Using Liquid 
Chromatography Quadrupole Time–of–Flight  Mass Spectrometry, Journal of 
Agricultural and Food Chemistry, vol. 60, 2012, pp. 4430-4439. 
100 A. Martínez-Villalba, L. Vaclavik, E. Moyano, M. T. Galceran and J. Hajslova, 
Direct analysis in real time high-resolution mass spectrometry for high-throughput 
analysis of antiparasitic veterinary drugs in feed and food, Rapid 
Communications in Mass Spectrometry, vol. 27, 2013, pp. 467-475. 
101 J. Nácher-Mestre, M. Ibáñez, R. Serrano, J. Pérez-Sánchez and F. Hernández , 
Qualitative Screening of Undesirable Compounds from Feeds to Fish by Liquid 
Chromatography Coupled to Mass Spectrometry, Journal of Agricultural and 
Food Chemistry, vol. 61, 2013, pp. 2077-2087. 
102 S. K. B. Freitas, A. P. S. Paim and P. T. D. S. Silva, Development of a LC-IT-TOF 
MS Procedure to Quantify Veterinary Drug Residues in Milk Employing a 
QuEChERS Approach, Food Analytical Methods, vol. 7, 2014, pp. 39–46. 
103 S.B. Turnipseed, J. J. Lohne, J. M. Storey, W. C. Andersen, S. L. Young, J. R. 
Carr and M. R. Madson, Challenges in Implementing a Screening Method for 
Veterinary Drugs in Milk Using Liquid Chromatography Quadrupole Time-of Flight 
Mass Spectrometry, Journal of Agricultural and Food Chemistry, vol. 62, 2014, 
pp. 3660-3674. 
104 H.G.J. Mol, P. Plaza-Bolaños, P. Zomer, T.C. de Rijk, A.A.M. Stolker and P.P.J. 
Mulder, Toward a Generic Extraction Method for Simultaneous Determination of 
236 
 
Pesticides, Mycotoxins, Plant Toxins, and Veterinary Drugs in Feed and Food 
Matrixes, Analytical Chemistry, vol. 80, 2008, pp. 9450–9459. 
105 Y. Babin and S. Fortier, A high–throughput analytical method for determination of 
aminoglycosides in veal tissues by liquid chromatography / tandem mass 
spectrometry with automated cleanup, Journal of AOAC International, vol. 90, 
2007, pp. 1418–1426. 
106 C. Kukusamude, R. Burakham, O. Chailapakul and S. Srijaranai, High 
performance liquid chromatography for the simultaneous analysis of penicillin 
residues in beef and milk using ion–paired extraction and binary water–
acetonitrile mixture, Talanta, vol. 92, 2012, pp. 38–44. 
107 M. Anastassiades, S.J. Lehotay, D. Stajnbaher and F.J. Schenck, Fast and easy 
multiresidue method employing acetonitrile extraction/partitioning and "dispersive 
solid–phase extraction" for the determination of pesticide residues in produce, 
Journal of AOAC International, vol. 86, 2003, pp. 412-431. 
108 G. Stubbings and T. Bigwood, The development and validation of a multiclass 
liquid chromatography tandem mass spectrometry (LC–MS/MS) procedure for 
the determination of veterinary drug residues in animal tissue using a 
QuEChERS (QUick, Easy, CHeap, Effective, Rugged and Safe) approach, 
Analytica Chimica Acta, vol. 637, 2009, pp. 68–78. 
109 H. Sun, X. Ge, Y. Lv and A. Wanh, Application of accelerated solvent extraction 
in the analysis of organic contaminants, bioactive and nutritional compounds in 
food and feed, Journal of Chromatography A, vol. 1237, 2012, pp. 1–23. 
110 J.A. Mendiola, M. Herrero, A. Cifuentes and E. Ibañez, Review: Use of 
compressed fluids for sample preparation: Food applications, Journal of 
Chromatography A, vol. 1152, 2007, pp. 234-246. 
111 D.M. Pavlovic, S. Babic, A.J.M. Horvat and M. Kastelan-Macan, Sample 
preparation in analysis of pharmaceuticals, Trends in Analytical Chemistry, vol. 
26, 2007, pp. 1062-1075. 
112 S. Herranz, M.C. Moreno-Bondi and M.D. Marazuela, Development of a new 
sample pretreatment procedure based on pressurized liquid extraction for the 
determination of fluoroquinolone residues in table eggs, Journal of 
Chromatography A, vol. 1140, 2007, pp. 63–70. 
237 
 
113 H. Berrada, F. Borrull, G. Font and R.M. Marcé, Determination of macrolide 
antibiotics in meat and fish using pressurized liquid extraction and liquid 
chromatography–mass spectrometry, Journal of Chromatography A, vol. 1208, 
2008, pp. 83-89. 
114 Y. Tao, G. Yu, D. Chen, Y. Pan, Z. Liu, H. Wei, D. Peng, L. Huang, Y. Wang and 
Z. Yuan, Determination of 17 macrolide antibiotics and avermectins residues in 
meat with accelerated solvent extraction by liquid chromatography–tandem mass 
spectrometry, Journal of Chromatography B, vol. 897, 2012, pp. 64-71. 
115 H. Yu, Y. Tao, D. Chen, Y. Wang and Z. Yuan, Development of an HPLC–UV 
method for the simultaneous determination of tetracyclines in muscle and liver of 
porcine, chicken and bovine with accelerated solvent extraction, Food Chemistry, 
vol. 124, 2011, pp. 1131–1138. 
116 G. Font, A. Juan-García and Y. Picó, Pressurized liquid extraction combined with 
capillary electrophoresis–mass spectrometry as an improved methodology for the 
determination of sulfonamide residues in meat, Journal of Chromatography A, 
vol. 1159, 2007, pp. 233–241. 
117 S. Bogialli, R. Curini, A. Di Corcia, A. Laganá, M. Mele and M. Nazzari, Simple 
confirmatory assay for analyzing residues of aminoglycoside antibiotics in bovine 
milk: hot water extraction followed by liquid chromatography–tandem mass 
spectrometry, Journal of Chromatography A vol. 1067, 2005, pp. 93–100. 
118 Y. Camel, Recent extraction techniques for solid matrices - supercritical fluid 
extraction, pressurized fluid extraction and microwave-assisted extraction: their 
potential and pitfalls, Analyst, vol. 126, 2001, pp. 1182–1193. 
119 L. Chen, D. Song, Y. Tian, L. Ding, A. Yu and H. Zhang, Application of on–line 
microwave sample–preparation techniques, Trends in Analytical Chemistry, vol. 
27, 2008, pp. 151–159. 
120 M.H. Akhtar, L.G. Croteau, C.Dani and K.A. ElSooud, Development and 
validation of microwave-assistied extraction of fortified and incurred 
chloramphenicol residues in egg albumen and yolk, Spectroscopy, vol 13, 1997, 
pp. 33-40. 
121 M.P. Hermo, D. Barrón and J. Barbosa, Determination of residues of quinolones 
in pig muscle. Comparative study of classical and microwave extraction 
techniques, Analytica Chimica Acta, vol. 539, 2005, pp. 77–82. 
238 
 
122 R. Fernandez-Torres, M.A. Bello Lopez, M. Olias Consentino, M. Callejon 
Mochon, M. Ramos Payan, Enzymatic-microwave assisted extraction and high-
performance liquid chromatography–mass spectrometry for the determination of 
selected veterinary antibiotics in fish and mussel samples, Journal of 
Pharmaceutical and Biomedical Analysis, vol. 54, 2011, pp. 1146-1156. 
123 B. Kinsella, J. O’Mahony, E. Malone, M. Moloney, H. Cantwell, A. Furey and M. 
Danaher, Current trends in sample preparation for growth promoter and 
veterinary drug residue analysis, Journal of Chromatography A, vol. 1216, 2009, 
pp. 7977–8015. 
124 M. Zougagh, M. Valcárcel and A. Ríos, Supercritical fluid extraction: a critical 
review of its analytical usefulness, Trends in Analytical Chemistry, vol. 23, 2004, 
pp. 399-405. 
125 J.H. Shim, M.H. Lee, M.R. Kim, C.J. Lee and I.S. Kim, Simultaneous 
Measurement of Fluoroquinolones in Eggs by a Combination of Supercritical 
Fluid Extraction and High Pressure Liquid Chromatography, Bioscience, 
Biotechnology and Biochemistry, vol. 67, 2003, pp. 1342–1348. 
126 J.H. Choi, M.I.R. Mamun, A.M.A. El- Aty, K. T. Kim, H.B. Koh, H.C. Shin, J.S. 
Kim, K.B. Lee and J.H. Shim, Inert matrix and Na4EDTA improve the 
supercritical fluid extraction efficiency of fluoroquinolones for HPLC determination 
in pig tissues, Talanta, vol. 78, 2009, pp. 348–357. 
127 M. Danaher, M. O’Keeffe and J. D. Glennon, Extraction and isolation of 
avermectins and milbemycins from liver samples using unmodified supercritical 
CO with in-line trapping 2 on basic alumina, Journal of Chromatography B, vol. 
761, 2001, pp. 115–123. 
128 E. Karageorgou and V. Samanidou, Application of ultrasound–assisted matrix 
solid–phase dispersion extraction to the HPLC confirmatory determination of 
cephalosporin residues in milk, Journal of Separation Science, vol. 33, 2010, pp. 
2862–2871. 
129 E. Karageorgou and V. Samanidou, Development and validation according to 
European Union Decision 2002/657/EC of an HPLC–DAD method for milk multi–
residue analysis of penicillins and amphenicols based on dispersive extraction by 
QuEChERS in MSPD format, Journal of Separation Science, vol. 34, 2011, pp. 
1893–1901. 
239 
 
130 M.A. García-Mayor, A. Gallego-Picó, R.M. Garcinuño, P. Fernández- Hernando 
and J.S. Durand-Alegría, Matrix solid–phase dispersion method for the 
determination of macrolide antibiotics in sheep’s milk, Food Chemistry, vol. 134, 
2012, pp. 553–558. 
131 G. Mu, H. Liu, L. Xu, L. Tian and F. Luan, Matrix Solid-Phase Dispersion 
Extraction and Capillary Electrophoresis Determination of Tetracycline Residues 
in Milk, Food Analytical Methods, vol. 5, 2012, pp. 148–153. 
132 S. Nász, L. Debreczeni, T. Rikker and Z. Eke, Development and validation of a 
liquid chromatographic-tandem mass spectrometric method for determination of 
eleven coccidiostats in milk, Food Chemistry, vol. 133, 2012, pp. 536–543. 
133 H. Yan, F. Qiao and K.H. Row, Molecularly Imprinted–Matrix Solid–Phase 
Dispersion for Selective Extraction of Five Fluoroquinolones in Eggs and Tissue, 
Analytical Chemistry, vol. 79, 2007, pp. 8242–8248. 
134 Y. Zhang, X. Xu, X. Qi, W. Gao, S. Sun, X. Li, C. Jiang, A. Yu, H. Zhang and Y. 
Yu, Determination of sulfonamides in livers using matrix solid–phase dispersion 
extraction high-performance liquid chromatography, Journal of Separation 
Science, vol. 35, 2012, pp. 45-52. 
135 L. Guo, M. Guan, C. Zhao and H. Zhang, Molecularly imprinted matrix solid– 
phase dispersion for extraction of chloramphenicol in fish tissues coupled with 
high– performance liquid chromatography determination, Analytical and 
Bioanalytical Chemistry, vol. 392, 2008, pp. 1431–1438. 
136 Y. Lu, Q. Shen, Z. Dai, H. Zhang and H. Wang, Development of an on-line matrix 
solid-phase dispersion/fast liquid chromatography/tandem mass spectrometry 
system for the rapid and simultaneous determination of 13 sulfonamides in grass 
carp tissues, Journal of Chromatography A, vol. 1218, 2011, pp. 929–937. 
137 K. Kishida, Quantitation and confirmation of six sulfonamides in meat by liquid 
chromatography–mass spectrometry with photodiode array detection, Food 
Control, vol. 18, 2007, pp. 301–305. 
138 S. Bogialli, G. D’Ascenzo, A. Di Corcia, G. Innocenti, A. Laganá and T. 
Pacchiarotta, Monitoring quinolone antibacterial residues in bovine tissues: 
extraction with hot water and liquid chromatography coupled to a single- or triple- 
quadrupole mass spectrometer, Rapid Communications in Mass Spectrometry, 
vol. 21, 2007, pp. 2833–2842. 
240 
 
139 S. Bogialli, G. D’Ascenzo, A. Di Corcia, A. Laganá and S. Nicolardi, A simple and 
rapid assay based on hot water extraction and liquid chromatography–tandem 
mass spectrometry for monitoring quinolone residues in bovine milk, Food 
Chemistry, vol. 108, 2008, pp. 354-360. 
140 S. Bogialli, G. D’Ascenzo, A. Di Corcia, A. Laganá and G. Tramontana, Simple 
assay for monitoring seven quinolone antibacterials in eggs: Extraction with hot 
water and liquid chromatography coupled to tandem mass spectrometry. 
Laboratory validation in line with the European Union Commission Decision 
657/2002/EC, Journal of Chromatography A, vol. 1216, 2009, pp. 794–800. 
141 E.M. Thurman and M.S. Mills, Solid-Phase Extraction: Principles and Practice, 
Wiley-Interscience, Inc, New York, 1998. 
142 J.S. Fritz, Analytical Solid-Phase Extraction, Wiley-VCH, Inc, New York, 1999. 
143 M. O’Keeffe, Residue Analysis in Food: Principles and Applications, Harwood 
Academic Publishers, Amsterdam, 2000. 
144 N. Fontanals, R.M. Marcé and F. Borrull, New hydrophilic materials for solid-
phase extraction, Trends in Analytical Chemistry, vol. 24, 2005, pp. 394-406. 
145 G. Stubbings, J. Tarbin, A. Cooper, M. Sharman, T. Bigwood and P. Robb, A 
multi-residue cation-exchange clean up procedure for basic drugs in produce of 
animal origin, Analytica Chimica Acta, vol. 547, 2005, pp. 262–268. 
146 A. Juan-García, G. Font and Y. Picó, Simultaneous determination of different 
classes of antibiotics in fish and livestock by CE-MS, Electrophoresis, vol. 28, 
2007, pp. 4180-4191. 
147 K. Mastovska and A.R. Lightfield, Streamlining methodology for the multiresidue 
analysis of β-lactam antibiotics in bovine kidney using liquid chromatography–
tandem mass spectrometry, Journal of Chromatography A, vol. 1202, 2008, pp. 
118–123. 
148 C.K. Fagerquist, A.R. Lightfield and S. J. Lehotay, Confirmatory and Quantitative 
Analysis of β–Lactam Antibiotics in Bovine Kidney Tissue by Dispersive Solid–
Phase Extraction and Liquid Chromatography–Tandem Mass Spectrometry, 
Analytical Chemistry, vol. 77, 2005, pp. 1473–1482. 
149 M.D. Hernando, M. Mezcua, J.M. Suárez–Barcena and A.R. Fernández-Alba, 
Liquid chromatography with time-of-flight mass spectrometry for simultaneous 
241 
 
determination of chemotherapeutant residues in salmon, Analytica Chimica Acta, 
vol. 562, 2006, pp. 176–184. 
150 C. Pan, H. Zhang, S. Chen, Y. Xu and S. Jiang, Determination of 
chloramphenicol residues in honey by monolithic column Liquid chromatography-
mass spectrometry after use of QuEChERS clean-up, Acta Chromatographica, 
vol. 17, 2006, pp. 320-327. 
151 G. Brambilla , M. Fiori , B. Rizzo , V. Crescenzi  and G. Masci, Use of molecularly 
imprinted polymers in the solid-phase extraction of clenbuterol from animal feeds 
and biological matrices, Journal of Chromatography B, vol. 759, 2001, pp. 27-32. 
152 T. Jing, X-D. Gao, P. Wang, Y. Wang, Y-F. Lin, X-Z. Hu, Q-L. Hao, Y-K. Hao and 
S-R. Mei, Determination of trace tetracycline antibiotics in foodstuffs by liquid 
chromatography–tandem mass spectrometry coupled with selective molecular–
imprinted solid–phase extraction, Analytical and Bioanalytical Chemistry, vol. 
393, 2009, pp. 2009-2018 
153 J. He, S. Wang, G. Fang, H. Zhu and Y. Zhang, Molecularly Imprinted Polymer 
Online Solid–Phase Extraction Coupled with High–Performance Liquid 
Chromatography–UV for the Determination of Three Sulfonamides in Pork and 
Chicken, Journal of Agricultural and Food Chemistry, vol. 56, 2008, pp. 2919-
2925. 
154 M. Lombardo-Agüí, A.M. García-Campãna, L. Gámiz-Gracia and C.C. Blanco, 
Laser induced fluorescence coupled to capillary electrophoresis for the 
determination of fluoroquinolones in foods of animal origin using molecularly 
imprinted polymers, Journal of Chromatography A, vol.1217, 2010, pp. 2237–
2242. 
155 R. Barreiro, M. Díaz-Bao, P. Regal, J.M. Miranda and A. Cepeda, Development 
of a HPLC-MS/MS confirmatory method for the simultaneous determination of 
amphenicols in baby formulas using molecularly imprinted polymers, Analytical 
Methods, vol. 5, 2013, pp. 3970-3976. 
156 R. Krebber, F.J. Hoffend and F. Ruttmann, Simple and rapid determination of 
enrofloxacin and ciprofloxacin in edible tissues by turbulent flow 
chromatography/tandem mass spectrometry (TFC-MS/MS), Analytica Chimica 
Acta, vol. 637, 2009, pp. 208-213. 
242 
 
157 P. Mottier, Y.A. Hammel, E. Gremaud and P.A. Guy, Quantitative High-
Throughput Analysis of 16 (Fluoro)quinolones in Honey Using Automated 
Extraction by Turbulent Flow Chromatography Coupled to Liquid 
Chromatography-Tandem Mass Spectrometry, Journal of Agricultural and Food 
Chemistry, vol. 56, 2008, pp. 35-43. 
158 J.A. Van Rhijn, J.J.P. Lasaroms, B.J.A. Berendsen and U.A.T. Brinkman, Liquid 
chromatographic-tandem mass spectrometric determination of selected 
sulphonamides in milk, Journal of Chromatography A, vol. 960, 2002, pp. 121-
133. 
159 N. Furusawa, Rapid high-performance liquid chromatographic determining 
technique of sulfamonomethoxine, sulfadimethoxine, and sulfaquinoxaline in 
eggs without use of organic solvents, Analytica Chimica Acta, vol. 481, 2003, pp. 
255–259. 
160 N. Furusawa, Determining the procedure for routine residue monitoring of 
sulfamethazine in edible animal tissues, Biomedical Chromatography, vol. 15, 
2001, pp. 235–239. 
161 N. Furusawa, Simplified Liquid–Chromatographic Determination of Residues of 
Tetracycline Antibiotics in Eggs, Chromatographia, vol. 53, 2001, pp. 47–50. 
162 N. Furusawa, Liquid Chromatographic determination/identification of residual 
penicillin G in food producing animal tissues, Journal of Liquid Chromatography & 
Related Technologies, vol. 24, 2001, pp. 161–172. 
163 T. Goto, Y. Ito, S. Yamada, H. Matsumoto and H. Oka, High–throughput analysis 
of tetracycline and penicillin antibiotics in animal tissues using electrospray 
tandem mass spectrometry with selected reaction monitoring transition, Journal 
of Chromatography A, vol. 1100, 2005, pp. 193–199. 
164 P. Sadílek, D. Satínský and P. Solich, Using restricted–access materials and 
column switching in high–performance liquid chromatography for direct analysis 
of biologically–active compounds in complex matrices, Trends in Analytical 
Chemistry, vol. 26, 2007, pp. 375–384. 
165 J. Chico, S. Meca, R. Companyó, M. D. Prat and M. Granados, Restricted access 
materials for sample clean-up in the analysis of trace levels of tetracyclines by 
liquid chromatography, Application to food and environmental analysis, Journal of 
Chromatography A, vol.1181, 2008, pp. 1-8. 
243 
 
166 M. Farré and D. Barcelo, Analysis of emerging contaminants in food, Trends in 
Analytical Chemistry, vol. 43, 2013, pp. 240–253. 
167 F. Wei and Y. Feng, Methods of sample preparation for determination of 
veterinary residues infood matrices by porous monolith microextraction–based 
techniques, Analytical Methods, vol. 3, 2011, pp. 1246-1256. 
168 Y. Wen, M. Zhang, Q. Zhao and Y-Q Feng, Monitoring of five sulfonamide 
antibacterial residues in milk by in–tube solid–phase microextraction coupled to 
high–performance liquid chromatography, Journal of Agricultural and Food 
Chemistry, vol. 53, 2005, pp. 8468–8473. 
169 M-M. Zeng, M-Y. Zhang, G-Y. Peng and Y-Q. Feng, Monitoring of sulfonamide 
antibacterial residues in milk and egg by polymer monolith microextraction 
coupled to hydrophilic interaction chromatography / mass spectrometry, Analytica 
Chimica Acta, vol. 625, 2008, pp. 160–172. 
170 J-F. Huang, B. Lin, Q-W. Yu and Y–Q. Feng, Determination of fluoroquinolones 
in eggs using in–tube solid–phase microextraction coupled to high-performance 
liquid chromatography, Analytical and Bioanalytical Chemistry, vol. 384, 2006, 
pp. 1228-1235. 
171 M–M. Zheng, G–D. Ruan and Y–Q. Feng, Evaluating polymer monolith in-tube 
solid-phase microextraction coupled to liquid chromatography/quadrupole time-
of-flight mass spectrometry for reliable quantification and confirmation of 
quinolone antibacterials in edible animal food, Journal of Chromatography A, 
vol.1216, 2009, pp. 7510-7519. 
172 Y. Wen, Y. Wang and Y-Q. Feng, Simultaneous residue monitoring of four 
tetracycline antibiotics in fish muscle by in–tube solid–phase microextraction 
coupled with high–performance liquid chromatography, Talanta, vol. 70, 2006, 
pp. 153–159. 
173 J-F. Huang, H-J. Zhang and Y-Q. Feng, Chloramphenicol Extraction from Honey, 
Milk, and Eggs Using Polymer Monolith Microextraction Followed by Liquid 
Chromatography–Mass Spectrometry Determination, Journal of Agricultural and 
Food Chemistry, vol. 54, 2006, pp. 9279-9286. 
174 M-M. Zheng, G-D. Ruan and Y-Q.Feng, Hybrid organic-inorganic silica monolith 
with hydrophobic/strong cation-exchange functional groups as a sorbent for 
244 
 
micro-solid phase extraction, Journal of Chromatography A, vol. 1216, 2009, pp. 
7739-7746. 
175 X. Huang, N. Qiu and D. Yuan, Simple and sensitive monitoring of sulfonamide 
veterinary residues in milk by stir bar sorptive extraction based on monolithic 
material and high performance liquid chromatography analysis, Journal of 
Chromatography A, vol.1216, 2009, pp. 8240–8245. 
176 F. David and P. Sandra, Stir bar sorptive extraction for trace analysis, Journal of 
Chromatography A, vol.1152, 2007, pp. 54–69. 
177 Y. Lu, Q. Shen, Z. Dai and H. Zhang, Multi-walled carbon nanotubes as solid-
phase extraction adsorbent for the ultra–fast determination of chloramphenicol in 
egg, honey, and milk by fused-core C18-based high-performance liquid 
chromatography-tandem mass spectrometry, Analytical and Bioanalytical 
Chemistry, vol. 398, 2010, pp. 1819–1826. 
178 X.L. Hou, Y.L Wu, T. Yang and X.D. Du, Multi–walled carbon nanotubes–
dispersive solid–phase extraction combined with liquid chromatography–tandem 
mass spectrometry for the analysis of 18 sulfonamides in pork, Journal of 
Chromatography B, vol. 929, 2013, pp.107–115. 
179 C. Cháfer-Pericás, Á. Maquieira, R. Puchades, Fast screening methods to detect 
antibiotic residues in food samples, Trends in Analytical Chemistry, vol. 29, 2010, 
pp. 1038 – 1049. 
180 V. Gaudin, C. Hedou, A. Rault, P. Sanders, E. Verdon, Comparative study of 
three screening tests, two microbiological tube tests, and a multi-sulphonamide 
ELISA kit for the detection of antimicrobial and sulphonamide residues in eggs, 
Food Additives & Contaminants, vol. 26, 2009, pp. 427 – 440. 
181 Z. Bargańska, M. Slebioda and J. Namieśnik, Determination of antibiotic residues 
in honey, Trends in Analytical Chemistry, vol 30, 2011, pp. 1035-1041. 
182 C. Cháfer-Pericás, A. Maquieira, R. Puchades, J. Miralles and A. Moreno, 
Multiresidue determination of antibiotics in feed and fish samples for food safety 
evaluation. Comparison of immunoassay vs LC-MS-MS, Food Control, vol. 22, 
2011, pp. 993-999. 
183 F. Opekar, P. Coufal and K. Stulνk, Rapid capillary zone electrophoresis along 
short separation pathways and its use in some hyphenated systems: A critical 
review, Chemical Reviews, vol. 109, 2009, pp. 4487–4499. 
245 
 
184 R.V. Robledo and W.F. Smyth, The application of CE–MS in the trace analysis of 
environmental pollutants and food contaminants, Electrophoresis, vol. 30, 2009, 
pp. 1647–1660. 
185 M. Castro–Puyana, A.L. Crego and M.L. Marina, Recent advances in the analysis 
of antibiotics by CE and CEC, Electrophoresis, vol. 31, 2010, pp.  229–250. 
186 F.J. Lara, A.M. García-Campaña, F. Alés-Barrero and J.M. Bosque-Sendra, In-
line solid-phase extraction preconcentration in capillary electrophoresis-tandem 
mass spectrometry for the multiresidue detection of quinolones in meat by 
pressurized liquid extraction, Electrophoresis, vol. 29, 2008, pp. 2117-2125. 
187 J.J. Soto-Chinchilla, A.M. García-Campaña and L. Gámiz-Gracia, Analytical 
methods for multiresidue determination of sulfonamides and trimethoprim in meat 
and ground water samples by CE-MS and CE-MS/MS, Electrophoresis,  vol. 28, 
2007, pp. 4164-4172. 
188 A. Juan-García, G. Font and Y. Picó, Simultaneous determination of different 
classes of antibiotics in fish and livestock by CE-MS, Electrophoresis, vol. 28, 
2007, pp. 4180-4191 
189 L. Vera–Candioti, A.C. Olivieri and H.C. Goicoechea, Development of a novel 
strategy for preconcentration of antibiotic residues in milk and their quantitation 
by capillary electrophoresis, Talanta, vol. 82, 2010, pp. 213–221. 
190 L. Santos, J. Barbosa, M.C. Castilho, F. Ramos, C.A. Fontes Ribeiro and M.I.N. 
da Silveira, Determination of chloramphenicol residues in rainbow trouts by gas 
chromatography-mass spectometry and liquid chromatography-tandem mass 
spectrometry, Analytica Chimica Acta, vol. 529, 2005, pp. 249-256. 
191 B. Le Bizec, G. Pinel and J-P. Antignac, Options for veterinary drug analysis 
using mass spectrometry, Journal of Chromatography A, vol. 1216, 2009, pp. 
8016-8034. 
192 J. Shen, X. Xia, H. Jiang, C. Li, J. Li, X. Li and S. Ding, Determination of 
chloramphenicol, thiamphenicol, florfenicol, and florfenicol amine in poultry and 
porcine muscle and liver by gas chromatography–negative chemical ionization 
mass spectrometry, Journal of Chromatography B, vol.  877, 2009, pp. 1523–
1529. 
193 T.M. Annesley, Minireview: Ion Suppression in Mass Spectrometry, Clinical 
Chemistry, vol. 49, no. 7, 2003, pp.1041–1044. 
246 
 
194 J.P. Antignac, K. de Wasch, F. Monteau, H. De Brabander, F. Andrea and B. Le 
Bizec, The ion suppression phenomenon in liquid chromatography–mass 
spectrometry and its consequences in the field of residue analysis, Analytica 
Chimica Acta, vol. 529, 2005, pp.129–136. 
195 H. Trufelli, P. Palma, G. Famiglini and A. Cappiello, An overview of matrix effects 
in liquid chromatography - mass spectrometry, Mass Spectrometry Reviews, vol. 
30, 2011:491-509 
196 S. Bogialli and A. Di Corcia, Recent applications of liquid chromatography–mass 
spectrometry to residue analysis of antimicrobials in food of animal origin, 
Analytical and Bioanalytical Chemistry, vol. 395, 2009, pp. 947–966 
197 M.E. Dasenaki and N.S. Thomaidis, Multi-residue determination of seventeen 
sulfonamides and five tetracyclines in fish tissue using a multi-stage LC–ESI–
MS/MS approach based on advanced mass spectrometric techniques, Analytica 
Chimica Acta, vol. 672, 2010, pp. 93-102. 
198 C. Huang B. Guo, X. Wang, J. Li, W. Zhu, B. Chen, S. Ouyang and S. Yao, A 
generic approach for expanding homolog-targeted residue screening of 
sulfonamides using a fast matrix separation and class-specific fragmentation-
dependent acquisition with a hybrid quadrupole-linear ion trap mass 
spectrometer, Analytica Chimica Acta, vol. 737, 2012, pp. 83-98. 
199 Y. Picó. And D. Barcelo, The expanding role of LC–MS in analyzing metabolites 
and degradation products of food contaminants, Trends in Analytical Chemistry, 
vol. 27, 2008, pp. 822–835. 
200 S.C. Brown, G. Kruppa and J.L. Dasseux, Metabolomics applications of FT–ICR 
mass spectrometry, Mass Spectrometry Reviews, vol. 24, 2005, pp. 223–231. 
201 A. Makarov, E. Denisov, A. Kholomeev, W. Balschun, O. Lange, K. Strupat and 
S. Horning, Performance Evaluation of a Hybrid Linear Ion Trap/Orbitrap Mass 
Spectrometer, Analytical Chemistry, vol. 78, 2006, pp. 2113-2120. 
202 J. Barbosa, S. Moura, R. Barbosa, F. Ramos and  M.I.N. da Silveira, 
Determination of nitrofurans in animal feeds by liquid chromatography–UV 
photodiode array detection and liquid chromatography–ionspray tandem mass 
spectrometry, Analytica Chimica Acta, vol. 586, 2007, pp. 359-365. 
203 R. D. Voyksner, C. S. Smith and P. C. Knox, Optimization and application of 
particle beam high-performance liquid chromatography/mass spectrometry to 
247 
 
compounds of pharmaceutical interest, Biomedical & Environmental Mass 
Spectrometry, vol. 19, 1990, pp. 523-534. 
204  K.-I. Harada, K. Masuda, M. Suzuki, H. Oka, Y. Ikai and J. Hayakawa, Fast Atom 
Bombardment Mass Spectral Study of Tetracycline Antibiotics, Organic Mass 
Spectrometry, vol. 28, 1993, pp. 1512-1515. 
205 H. Oka, Y. Ikai, J. Hayakawa, K.-I Harada, H. Asakabe, M. Suzuki, R. Himei, M. 
Horie, H. Nakazawa and J. D. MacNeil, Improvement of chemical analysis of 
antibiotics. 22. Identification of residual tetracyclines in honey by frit FAB/LC/MS 
using a volatile mobile phase, Journal of Agricultural and Food Chemistry, vol. 
42, 1994, pp. 2215-2219. 
206 V. H. Vartanian, B. Goolsby and J. S. Brodbelt, Identification of Tetracycline 
Antibiotics by Electrospray Ionization in a Quadrupole Ion Trap, Journal of the 
American Society for Mass Spectrometry, vol. 9, 1998, pp. 1089-1098. 
207 B. Shao, D. Dong, Y. Wu, J. Hu, J. Meng, X. Tu and S. Xu, Simultaneous 
determination of 17 sulfonamide residues in porcine meat, kidney and liver by 
solid-phase extraction and liquid chromatography–tandem mass spectrometry, 
Analytica Chimica Acta, vol. 546, 2005, pp. 174–181. 
208 Z. Cai, Y. Zhang, H. Pan, X. Tie and Y. Ren, Simultaneous determination of 24 
sulfonamide residues in meat by ultra-performance liquid chromatography 
tandem mass spectrometry, Journal of Chromatography A, vol. 1200, 2008, pp. 
144–155. 
209 V.K. Agarwal, High-performance liquid chromatographic methods for the 
determination of sulfonamides in tissue, milk and eggs, Journal of 
Chromatography, vol. 624, 1992,  pp. 411-423. 
210 A.D. Cooper, G.W.F. Stubbings, M. Kelly, J.A. Tarbin, W.H.H. Farrington and G. 
Shearer, Improved method for the on-line metal chelate affinity chromatography–
high-performance liquid chromatographic determination of tetracycline antibiotics 
in animal products, Journal of Chromatography A, vol. 812, 1998, pp. 321–326. 
211 N. Furusawa, Rapid and Simple Determination of Oxytetracycline in Chicken 
Products, Journal of AOAC International, vol. 82, 1999, pp. 770–772. 
212  K. Iwaki, N. Okumura and M. Yamazaki, Rapid determination of tetracycline 
antibiotics in serum by reversed-phase high-performance liquid chromatography 
248 
 
with fluorescence detection , Journal of Chromatography B, vol. 619, 1993, pp. 
319–323. 
213 Z. Qiang and C. Adams, Potentiometric determination of acid dissociation 
constants (pKa) for human and veterinary antibiotics, Water Research, vol. 38, 
2004, pp. 2874–2890. 
214 L.J. Leeson, J.E. Krueger and R.A. Nash, Concerning the structural assignment 
of the second and third acidity constants of the tetracycline antibiotics, 
Tetrahedron Letters, vol. 18, 1963, pp. 1155–1160. 
215  C.R. Anderson, H.S. Rupp and W.H. Wu, Complexities in tetracycline analysis—
chemistry, matrix extraction, cleanup, and liquid chromatography, Journal of 
Chromatography A, vol. 1075, 2005, pp. 23–32. 
216 C. Boix, M. Ibáñez, J. V. Sancho, N. León, V. Yusá and F. Hernández,  
Qualitative screening of 116 veterinary drugs in feed by liquid chromatography–
high resolution mass spectrometry: Potential application to quantitative analysis, 
Food Chemistry, vo. 160, 2014, pp. 313–320. 
217 R. Diaz, M. Ibáñez, J.V Sancho and F. Hernández,  Qualitative  validation  of  a  
liquid  chromatography–quadrupole-time  of  flight mass  spectrometry  screening  
method  for  organic  pollutants  in  waters, Journal of Chromatography A, vol. 
1276, 2013, pp. 47– 57. 
218 Guidelines for the validation of screening methods for residues of veterinary 
medicines, Community Reference Laboratories Residues (CRLs), 2010 
219 A. Gentili, D. Perret and S. Marchese, Liquid chromatography-tandem mass 
spectrometry for performing confirmatory analysis of veterinary drugs in animal-
food products, Trends in Analytical Chemistry, vol. 24, 2005, pp. 704-733. 
220 R. Nageswara Rao, N. Venkateswarlu and R. Narsimha, Determination of 
antibiotics in aquatic environment by solid-phase extraction followed by liquid 
chromatography–electrospray ionization mass spectrometry, Journal of 
Chromatography A, vol. 1187, 2008, pp. 151-164. 
221 W. F. Smyth and V. Rodriguez, Recent studies of the electrospray ionisation 
behaviour of selected drugs and their application in capillary electrophoresis–
mass spectrometry and liquid chromatography–mass spectrometry, Journal of 
Chromatography A, vol. 1159, 2007, pp. 159-174. 
249 
 
222 L. Grunwald and M. Petz, Food processing effects on residues: penicillins in milk 
and yoghurt, Analytica Chimica Acta, 483, 2003, pp. 73-79. 
223 B. Kinsella, S. J. Lehotay, K. Mastovska, A.R Lightfield, A. Furey and M. Danahe, 
New method for the analysis of flukicide and other anthelmintic residues in 
bovine milk and liver using liquid chromatography–tandem mass spectrometry, 
Analytica Chimica Acta,  vol. 637, 2009, pp. 196-207. 
224 W.W. Buchberger, Current approaches to trace analysis of pharmaceuticals and 
personal care products in the environment, Journal of Chromatography A, vol. 
1218, 2011, pp. 603–618. 
225 M. Sismotto, J. A.R. Paschoal, J. A. Teles, R. A.E. de Rezende and F. G.R. 
Reyes, A simple liquid chromatography coupled to quadrupole time of flight mass 
spectrometry method for macrolide determination in tilapia fillets, Journal of Food 
Composition and Analysis, vol. 34, 2014, pp. 153–162. 
226 A. Junza, A. Montané, J. Barbosa, C. Minguillón and D Barrón, High  resolution  
mass  spectrometry  in  the  identification  of transformation  products  and  
metabolites  from β-lactam  antibiotics  in thermally treated  milk, Journal of 
Chromatography A, vol. 1368, 2014, pp. 89–99. 
227 W. Horwitz, Protocol for the design, conduct and interpretation of collaborative 
studies, Pure and Applied Chemistry, vol. 60, 1988, pp. 855 – 864 
228 M. Olejnik, T. Szprengier-Juszkiewicz and P. Jedziniak, Multi-residue 
confirmatory method for the determination of twelve coccidiostats in chicken liver 
using liquid chromatography tandem mass spectrometry, Journal of 
Chromatography A, vol. 1216, 2009, pp. 8141 – 8148. 
229 A. Boscher, C. Guignard, T. Pellet, L. Hoffmann and T. Bohn, Development of a 
multi-class method for the quantification of veterinary drug residues in 
feedingstuffs by liquid chromatography-tandem mass spectrometry, Journal of 
Chromatography A, vol. 1217, 2010, pp. 6394 – 6404. 
230 A. Gadaj, V. di Lullo, H. Cantwell, M. McCormack, A. Furey and M. Danaher, 
Determination of nitroimidazole residues in aquaculture tissue using ultra high 
performance liquid chromatography coupled to tandem mass spectrometry, 
Journal of Chromatography B, vol. 960, 2014, pp. 105 – 115. 
231 M.D. Luque de Castro and M.P. da Silva, Strategies for solid sample treatment, 
Trends in Analytical Chemistry, vol. 16, 1997, pp. 16 – 24. 
250 
 
232 T. Payanan, N. Leepipatpiboon and P. Varanusupakul, Low-temperature cleanup 
with solid-phase extraction for the determination of polycyclic aromatic 
hydrocarbons in edible oils by reversed phase liquid chromatography with 
fluorescence detection, Food Chemistry, vol. 141, 2013, 2720 – 2726. 
233 T. Hu, T. Peng, X.-J. Li, D.-D. Chen, H.-H. Dai, X.-J. Deng, Z.-F. Yue, G.-M. 
Wang, J.-Z. Shen, X. Xia, S.-Y. Ding, Y.-N. Zhou, A.-L. Zhu and H.-Y. Jiang, 
Simultaneous determination of thirty non-steroidal anti-inflammatory drug 
residues in swine muscle by ultra-high-performance liquid chromatography with 
tandem mass spectrometry, Journal of Chromatography A, vol. 1219, 2012, pp. 
104 – 113. 
234 M. Caldow, M. Sharman, M. Kelly, J. Day, S. Hird and J.A. Tarbin, Multi-residue 
determination of phenolic and salicylanilide anthelmintics and related compounds 
in bovine kidney by liquid chromatography–tandem mass spectrometry, Journal 
of Chromatography A, vol. 1216, 2009, 8200 – 8205. 
235 C. Power, M. Danaher, R. Sayers, B. O’Brien, C. Clancy, A. Furey and K. Jordan, 
Investigation of the migration of triclabendazole residues to milk products 
manufactured from bovine milk, and stability therein, following lactating cow 
treatment, Journal of Dairy Science, vol. 96, 2013, 6223 – 6232. 
236 M. Becker, E. Zittlau and M. Petz, Residue analysis of 15 penicillins and 
cephalosporins in bovine muscle, kidney and milk by liquid chromatography–
tandem mass spectrometry, Analytica Chimica Acta, vol. 520, 2004, pp. 19-32. 
237 E. Gracia-Lor, M. Martínez, J. V. Sancho, G. Peñuela and F. Hernández, Multi-
class determination of personal care products and pharmaceuticals in 
environmental and wastewater samples by ultra-high performance liquid-
chromatography-tandem mass spectrometry, Talanta, vol. 99, 2012, pp. 1011-
1023. 
238 J. Wang, Determination of five macrolide antibiotic residues in honey by LC-ESI-
MS and LC-ESI-MS/MS, Journal of Agricultural and Food Chemistry, vol. 52, 
2004, pp. 171–181. 
239 A. L.N. van Nuijs, I. Tarcomnicu and A. Covaci, Application of hydrophilic 
interaction chromatography for the analysis of polar contaminants in food and 
environmental samples, Journal of Chromatography A, vol. 1218, 2011, pp. 5964 
– 5974. 
251 
 
240 M.M. Zheng, M.Y. Zhang, G.Y. Peng, Y.Q. Feng, Monitoring of sulfonamide 
antibacterial residues in milk and egg by polymer monolith microextraction 
coupled to hydrophilic interaction chromatography/mass spectrometry, Analytica 
Chimica Acta, vol. 625, 2008, pp. 160 – 172. 
241 D.A. Bohm, C.S. Stachel and P. Gowik, Validation of a method for the 
determination of aminoglycosides in different matrices and species based on an 
in-house concept, Food Additives and Contaminants, vol. 30, 2013, pp. 1037 – 
1043. 
242 H. Luo, L. Zhang, F. Xue, Y. Li, X. Wang, C. Fei and C. Zhang, Simultaneous 
Determination of Trimethoprim and Diaveridine in Tissues of Chicken, Porcine, 
and Fish by Hydrophilic Interaction Liquid Chromatography–Tandem Mass 
Spectrometry, Food Analytical Methods, vol. 7, 2014, pp. 308 – 317. 
243 É. Alechaga, E.Moyano and M. T. Galceran, Mixed-mode liquid chromatography 
coupled to tandem mass spectrometry for the analysis of aminoglycosides in 
meat, Analytical Bioanalytical Chemistry, vol. 406, 2014, pp. 4941 – 4953. 
244 P. Kumar, A. Rúbies, R. Companyó and F. Centrich, Determination of 
aminoglycoside residues in kidney and honey samples by hydrophilic interaction 
chromatography-tandem mass spectrometry, Journal of Separation Science, vol. 
35, 2012, pp. 2710–2717. 
245 L.-S. New, E.C.Y. Chan, Evaluation of BEH C18, BEH HILIC, and HSS T3 (C18) 
Column Chemistries for the UPLC–MS–MS Analysis of Glutathione, Glutathione 
Disulfide, and Ophthalmic Acid in Mouse Liver and Human Plasma, Journal of 
Chromatographic Science, vol. 46, 2008, pp. 209-214. 
246 S. J. Lehotay, K.Mastovska, A. R. Lightfield, A. Nuñez, T. Dutko, C. Ng, L. 
Bluhm, Rapid analysis of aminoglycoside antibiotics in bovine tissues using 
disposable pipette extraction and ultrahigh performance liquid chromatography–
tandem mass spectrometry, Journal of Chromatography A, vol. 1313, 2013, pp. 
103–112. 
247 N. Isoherranen, S. Soback, Determination of Gentamicins C1, C1a, and C2 in 
Plasma and Urine by HPLC, Clinal Chemistry, vol. 46, 2000, pp. 837-842. 
248 A. Kaufmann, P. Butcher, K. Maden, Determination of aminoglycoside residues 
by liquid chromatography and tandem mass spectrometry in a variety of matrices, 
Analytica Chimica Acta, vol. 711, 2012, pp. 46– 53. 
252 
 
249 J. Bernal, A. M. Ares, J. Pol, S. K. Wiedmer, Hydrophilic interaction liquid 
chromatography in food analysis, Journal of Chromatography A, vol. 1218, 2011, 
pp. 7438– 7452. 
250 A. J. Alpert, Hydrophilic-Interaction Chromatography for the separation of 
peptides, nucleic acids and other polar compounds, Journal of Chromatography, 
vol. 499, 1990, pp. 177-196. 
251 Y. Tao, D. Chen, H. Yu, L Huang, Z. Liu, X. Cao, C. Yan, Y. Pan, Z. Liu, Z. Yuan, 
Simultaneous determination of 15 aminoglycoside(s) residues in animal derived 
foods by automated solid-phase extraction and liquid chromatography–tandem 
mass spectrometry, Food Chemistry, vol. 135, 2012, pp. 676–683. 
 
